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Summary
Peptide posttranslational modiﬁcations have been shown to regulate multiple aspects
of cell signalling, thereby inﬂuencing cellular functions. The addition of O-linked N-
acetylglucosamine to serine or threonine residues (O-GlcNAcylation) of proteins has
only recently been characterized and its overall role in cell signalling remains elusive
to date. Recent studies suggest an essential role of O-GlcNAcylation on the viability
and pluripotency of mouse and human embryonic stem (ES) cells. Here we show that
increased levels of O-GlcNAcylation in response to speciﬁc inhibition of O-GlcNAc
hydrolase (Oga) hinder mouse ES cell diﬀerentiation. In addition to these ﬁndings, I
could also demonstrate that increased O-GlcNAcylation leads to expression of a gene
set normally epigenetically repressed in mouse ES cells and associated with a subpop-
ulation resembling cells in the 2-cell-stage embryo. I also extended our lab's investiga-
tions to human induced pluripotent stem (iPS) cells. While mesendodermal diﬀeren-
tiation remains unaﬀected by high O-GlcNAc levels, neural diﬀerentiation is severely
disrupted in these cells. Human iPS cells with elevated O-GlcNAcylation are unable
to commit to the ectodermal lineage and fail to organize in neural tube-like struc-
tures, so-called neural rosettes. Following these observations we performed mRNA
sequencing analysis on human iPS cells with high O-GlcNAc levels and found gene
expression to be signiﬁcantly altered. Genes aﬀected by increased O-GlcNAcylation
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include modulators of key neural developmental processes, for example components of
the bone morphogenic protein signalling cascade.
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1. Introduction
1.1. Pluripotent stem cells
1.1.1. Pluripotency and diﬀerentiation
Pluripotency can be described as the ability of a cell to specialize and become a cell
of any cell type of the mature organism. This process of specialisation is also termed
diﬀerentiation and it is a characteristic feature of embryonic stem cells (ES cells) or
induced pluripotent stem cells (iPS cells). Pluripotent stem cells can diﬀerentiate into
cells of the germ layers of the developing embryo as well as the germ line. During ver-
tebrate embryonic development three germ layers can be distinguished that develop
during gastrulation: ectoderm, endoderm and mesoderm (MacCord, 2013; Thomson
et al., 1998). Cells of the ectoderm lineage will ﬁnally diﬀerentiate into the nervous
system and the epidermis (contributing i.e. to skin and hair). Endoderm cells diﬀer-
entiate to form the digestive tract and inner organs, such as liver and pancreas. The
skeleton and skeletal muscle, as well as the heart are derived form the mesoderm layer
(Gilbert, 2013). In contrast to pluripotent cells, cell populations that are described as
totipotent can contribute to all embryonic, but also to extra-embryonic tissue like the
placenta. Multipotent cell types such as somatic stem cells have restricted potency
and will only diﬀerentiate within their lineage.
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There are two assays for assessing pluripotency. First, cells can be tested for their
ability to contribute to embryonic chimeras. Pluripotent cells will be capable of dif-
ferentiation into all tissues of these embryos (Robertson, 1986). The second assay
is teratoma formation, an in vivo method which describes the formation of benign
tumours in immunodeﬁcient or syngeneic mice upon injection of cells. In this case,
pluripotent cells will generate teratoma that contain fully diﬀerentiated cells of the
three germ layers (Stevens and Little, 1954). Besides their ability to diﬀerentiate into
the three germ layers, pluripotent stem cells exhibit unlimited self-renewal capacity
and are therefore immortal (Thomson et al., 1998).
The following sections will provide background information on the two pluripotent
stem cell models used in this study as well as on signalling pathways involved in
maintaining pluripotency and triggering diﬀerentiation.
1.1.2. Mouse embryonic stem cells
Early mouse embryonic development is characterised by multiple sequential cell divi-
sions of the fertilized zygote. In the ﬁrst 24 hours, one cleavage occurs from which
the 2-cell stage blastomere arises (Edwards and Gates, 1959). At this point, cells
retain a totipotent cell potential. Importantly, at this stage the zygote's transcription
is activated and the transcriptome undergoes a maternal-to-zygote switch. This pro-
cess is referred to as zygotic genome activation (Bensaude et al., 1983; Schultz, 1993).
The 2-cell stage of the developing embryo is also key for further development because
of the reprogramming process that transforms the highly diﬀerentiated oocyte into
totipotent blastomeres (Latham et al., 1992).
In the following the blastomeres undergo further divisions, mainly without cellular
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growth or an increase in total cell mass (Aiken et al., 2004). First lineage decisions
are made around embryonic day 2.75 (E2.75): Outer cells of the morula will become
trophectoderm and give rise to extraembryonic tissue (Lawson et al., 1999), while inner
cells will constitute the inner cell mass (ICM) of the early blastocyst (Boroviak and
Nichols, 2014). Cells of the ICM at E3.5 represent a naïve pluripotent cell population.
Those cells can be isolated and taken into monolayer culture where they represent an
immortal and self-renewing population of ES cells (Evans and Kaufman, 1981; Martin,
1981).
Mouse ES cells were originally co-cultured on mouse embryonic ﬁbroblasts. These
feeder cells produce leukaemia inhibitory factor (LIF) which promotes self-renewal and
aids to retain pluripotency of mouse ES cells. Today, standard culture conditions are
feeder-free and mouse ES cells are maintained using LIF and fetal calf serum (FCS)
as medium supplements (Smith et al., 1988; Williams et al., 1988). Instead of FCS,
medium can be supplemented with bone morphogenic protein (BMP)4 (Ying et al.,
2003b).
It is important to note that mouse ES cells cultured under those standard conditions
(serum/LIF) represent a mixture of both naïve pluripotent cells and cells that are in a
state that is more primed for diﬀerentiation (formative state) (Martin Gonzalez et al.,
2016; Kalkan and Smith, 2014; Kumar et al., 2014). While cells that are in a naïve
pluripotent state reﬂect molecular properties of the early pre-implantation blastocyst,
cells in a formative state are thought to functionally correspond to a slightly later de-
velopmental stage of the blastocyst. The two subpopulations can be distinguished by
marker gene expression (i.e. the naïve genes Zfp42 and Esrrb are not expressed in the
formative state) and they also diﬀer slightly regarding cell potency: Naïve pluripotent
stem cells contribute to blastocyst chimeras while this has not been reported to be the
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case for cells in the formative state (Davidson et al., 2015; Kalkan and Smith, 2014;
Hackett and Surani, 2014; Tesar et al., 2007; Guo et al., 2009). It is also possible to
isolate cells in a fully primed pluripotent state which represents the post-implantation
epiblast at around E5.5. Those primed pluripotent cells are called epiblast stem cells
(EpiSCs). Inhibition of glycogen synthase kinase 3 (GSK-3) and mitogen activated
protein kinase (MAPK) by small molecules has been shown to promote the mainte-
nance of a homogeneous naïve pluripotent mouse ES cell population (Silva et al., 2008;
Ying et al., 2008). The mouse ES cell culture condition using those two inhibitors is
commonly referred to as 2i condition.
Besides the previously described naïve-formative heterogeneity of mouse ES cell
cultures under serum/LIF condition, additional subpopulations have been proposed
to exist. Of particular interest is a small subset of cells that have been reported
to express genes characteristic for the 2-cell stage embryo (Macfarlan et al., 2012).
Another study hints towards the existence of a subpopulation of cells in 2i culture
conditions that express the extraembryonic endoderm marker Hex. This population
appears to be able to form extraembryonic tissue and might therefore represent a
totipotent cell type (Morgani et al., 2013).
1.1.3. Human induced pluripotent stem cells
Human iPS cells represent the second pluripotent stem cell model system used in
this study. Induction of pluripotency by reprogramming is a young method that has
become increasingly popular over the last decade (Takahashi and Yamanaka, 2016;
Chari and Mao, 2016). Mature, fully diﬀerentiated cells are reprogrammed by in-
troducing a combination of pluripotency related transcription factors. Initially, the
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Figure (1.1) Schematic of early mouse development and mouse embryonic stem cell derivation from
the blastocyst. The fertilized zygote undergoes sequential cleavage divisions. At E3.5 the embryo has developed into
the pre-implantation blastocyst. At this stage, mouse ES cells can be derived from the ICM (blue) and taken into
culture, where they represent a pluripotent, immortal cell population capable of self-renewal.
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set of factors consisted of Oct4, Sox2, Klf4 and Myc (often referred to as OSKM),
but diﬀerent combinations of pluripotency transcription factors have since been used
successfully to establish iPS lines (Takahashi and Yamanaka, 2006; Takahashi et al.,
2007; Yu et al., 2007; Nakagawa et al., 2008; Jiang et al., 2008). These factors are
simultaneously introduced into diﬀerentiated cells and will then orchestrate key re-
programming events on both transcriptional and epigenetic level. Molecular details
for the mechanism underlying reprogramming are not yet understood, but cells will
eventually revert to a pluripotent cell type whose functional characteristics closely
resemble those of embryonic stem cells (Takahashi and Yamanaka, 2006; Takahashi
et al., 2007). Respectively, iPS cells can diﬀerentiate into all mature cell types found in
the adult organism. When reprogramming is complete, the ectopically expressed tran-
scription factors are silenced and the cell will switch to expressing them endogenously
(Brambrink et al., 2008; Papapetrou et al., 2009). The principle of reprogramming
has been described for both mouse and human cells (Takahashi and Yamanaka, 2006;
Takahashi et al., 2007; Yu et al., 2007). Importantly, generation of iPS cells is possible
using diﬀerent starting material, for example patient cells or cells from mutant mice,
which allows investigations into multiple genetic backgrounds.
Human iPS cells are maintained in a pluripotent state by using the BMP antagonist
noggin and basic ﬁbroblast growth factor (bFGF) (Xu et al., 2005; Wang et al., 2005).
These culture conditions bear the advantages of a feeder- and xeno-free environment
with chemically well-deﬁned culture conditions.
Induced pluripotent stem cells obtained by transcription factor mediated repro-
gramming have been demonstrated to be highly similar to ES cells. The two cell types
appear to be indistinguishable in terms of their morphology, marker gene expression,
global gene expression pattern and cell potency tested by teratoma formation assays
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(Takahashi and Yamanaka, 2006; Takahashi et al., 2007). Nonetheless, the question
whether ES cells and iPS cells are comparable model systems has been conversely
debated. While several studies argue that iPS and ES cells exhibit identical proper-
ties and can not be reliably distinguished (Guenther et al., 2010; Wernig et al., 2007;
Boland et al., 2009; Kang et al., 2009; Zhao et al., 2009), there are numerous reports
of discrepancies between both cell types. Doi et al. (2009); Deng et al. (2009); Lis-
ter et al. (2011) and Kim et al. (2009) describe diﬀerences in deoxyribonucleic acid
(DNA) methylation patterns. Furthermore, copy number variations (Hussein et al.,
2011) and divergence in global gene expression proﬁling (Chin et al., 2009; Marchetto
et al., 2009; Ghosh et al., 2010) have been reported. Several of these studies describe
similarities of iPS cells with their donor cells (Ghosh et al., 2010; Marchetto et al.,
2009; Doi et al., 2009).
1.1.4. Signalling pathways relevant for pluripotency
Maintenance of pluripotency and the process of diﬀerentiation are both orchestrated
by multiple signalling cascades. In the following sections selected pathways will be
introduced regarding their role in pluripotent stem cells. The focus will be on signalling
pathways that are particularly relevant for maintenance of the undiﬀerentiated state
and that can be manipulated in order to trigger directed diﬀerentiation of pluripotent
cells.
Wnt pathway
The Wnt signalling pathway is highly conserved and known to play a key role in embry-
onic development, cell signalling and cancer. The central component of this pathway
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is β-catenin, a cytoplasmic protein that is ubiquitilated and degraded upon absence
of Wnt ligands by a complex of adenomatous polyposis coli (APC), axin and GSK-3.
Activation of Wnt is mediated by binding of the Wnt ligand to its receptors Frizzled
(Fz) and LDL receptor related protein 5/6 (LRP5/6) which leads to GSK-3 inactiva-
tion and disruption of the β-catenin destruction complex. β-catenin will consequently
accumulate and travel to the nucleus were it binds to the T-cell factor/lymphoid en-
hancer factor (TCF/LEF) transcription factors and initiates target gene expression
(reviewed by Holland et al. (2013)).
In ES cells the Wnt pathway has been shown to promote pluripotency. In 2002,
Aubert et al. (2002) demonstrated that Wnt activity attenuates neural diﬀerentia-
tion by inhibiting GSK-3 using lithium chloride. Consistent results were obtained
by Sato et al. (2004), who reported that active Wnt signalling is suﬃcient to sustain
pluripotency in both human and mouse ES cells.
LIF-mediated JAK/STAT signalling
Janus kinase/signal transducers and activators of transcription (JAK/STAT) sig-
nalling activity can be initiated by binding of the cytokine LIF to its receptor con-
stituted by leukaemia inhibitory factor receptor (LIFR) and gp130. Consequently,
several intracellular signalling cascades are activated including the JAK/STAT path-
way. LIF binding results in phosphorylation of the receptor heterodimer, followed by
recruitment of STAT1 and STAT3. Both STAT proteins undergo JAK-mediated phos-
phorylation activation and thereupon dimerize and translocate to the nucleus where
they act as transcriptional activators (Okita and Yamanaka, 2006).
Concerning mouse ES cell culture conditions, the addition of recombinant LIF to
culture media containing serum or BMP4 has been shown to inhibit diﬀerentiation,
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Figure (1.2) The canonical Wnt pathway. A: In absence of Wnt ligand β-catenin is bound by a complex
containing APC, axin and GSK-3. GSK-3 phosphorylates β-catenin which is consequently degraded. B: Upon ligand
binding axin is relocated to the plasma membrane. As a result the destruction complex is disrupted and GSK-3 no
longer marks β-catenin for degradation. β-catenin accumulates and translocates to the nucleus where it acts as a
co-activator of TCF/LEF transcription factors.
rendering the previously common feeder layers gratuitous (Smith et al., 1988; Williams
et al., 1988). This eﬀect has been reported to be due to LIF-induced STAT1/3 sig-
nalling activity, as proven by several independent studies (Boeuf et al., 1997; Niwa
et al., 1998; Matsuda et al., 1999; Raz et al., 1999). These studies indicate that
STAT1/3 signalling plays a key role in pluripotency maintenance, however it has been
shown to not be suﬃcient to protect mouse ES cells from diﬀerentiation (Ying et al.,
2003a). In contrast to its role in mouse ES cells, LIF-mediated STAT1/3 activity has
been reported to be dispensable in human and monkey ES cells (Sumi et al., 2004;
Humphrey et al., 2004). Taken together, these results indicate that while STAT1/3
activity makes a major contribution to maintaining mouse ES cells in an undiﬀer-
entiated state, pluripotency maintenance in human ES is achieved by a LIF/STAT3
independent mechanism (Humphrey et al., 2004; Sumi et al., 2004).
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Figure (1.3) LIF-mediated STAT signalling. Binding of LIF to the heterodimer LIFR/gp130 results in receptor
phosphorylation which recruits STAT1/3. JAK tyrosine kinases are bound to LIFR/gp130 and phosphorylate STAT1/3
which dimerizes and translocates to the nucleus where it acts as a transcriptional activator for pluripotency genes and
thereby supports self-renewal of ES cells.
TGF-β pathway and BMP signalling
The transforming growth factor (TGF)-β superfamily has been demonstrated to inﬂu-
ence many aspects of embryonic development as well as stem cell signalling (reviewed
by Wu and Hill (2009) and Oshimori and Fuchs (2012)). Multiple ligands can activate
the signalling cascade: TGF-β 1-3, Activins, Nodal, BMPs and growth diﬀerentiation
factors (GDF). Receptors are constituted of two subunits which are brought together
upon ligand binding and act as transmembrane serine-threonine kinases (Derynck,
1994). The cellular eﬀectors that become phosphorylated in this process are termed
regulatory Smads (R-Smads). Phosphorylated R-Smads can then form a complex with
Smad4 which translocates to the nucleus where it acts as a transcription factor (Oshi-
mori and Fuchs, 2012). Depending on the ligand that activated the pathway, diﬀerent
receptors and combinations of R-Smads are aﬀected downstream: TGF-β 1-3, Activin
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or Nodal binding induces phosphorylation of Smad2/3, while BMP-mediated path-
way activation results in Smad1/5/8 phosphorylation (Oshimori and Fuchs, 2012).
Smad6/7 are prevent phosphorylation of R-Smads and are therefore termed inhibitory
Smads (I-Smads) (Nakao et al., 1997; Imamura et al., 1997).
With a view to maintaining pluripotent stem cells in an undiﬀerentiated state, sig-
nalling through BMP4 is of particular importance. In mouse ES cells, BMP4 maintains
a pluripotent state and is therefore used as a supplement of the culture medium to
replace serum (Ying et al., 2003b; Qi et al., 2004). Besides Smad1/5/8 phosphoryla-
tion, BMP4 can inhibit mitogen-activated kinase pathways which has been suggested
to be the underlying mechanism for its role in maintaining pluripotent cells (Qi et al.,
2004). Strikingly, BMP4 signalling has been show to have an opposing eﬀect in human
ES cells: Instead of maintaining pluripotency it initiates diﬀerentiation and blockage
of BMP4 signals by the antagonist noggin is necessary to preserve an undiﬀerentiated
state (Xu et al., 2002; Wang et al., 2005; James et al., 2005; Kurek et al., 2015).
Directed diﬀerentiation of pluripotent stem cells
Modulation of the above mentioned pathways can be used in order to stimulate dif-
ferentiation into speciﬁc lineages and cell types. For the study at hand, directed
diﬀerentiation assays into cells of ectoderm, mesoderm and endoderm lineage have
been performed. There are a multitude of respective protocols and diﬀerentiation can
be driven until late stages of cell maturation. Therefore, the subsequently presented
protocols only represent three examples of how pathway manipulation can be used to
steer pluripotent stem cell diﬀerentiation in human iPS or ES cells.
Neural diﬀerentiation has been demonstrated to be successfully driven by inhibition
of TGF-β signalling through activin/nodal (Smith et al., 2008). The protocol used
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Figure (1.4) Overview of TGF-β signalling. TGF-β signalling is activated by ligand binding to respective
receptor pairs which act as kinases phosphorylating R-Smads (Smad2/3 or Smad1/5/8). Phosphorylation can be
blocked by inhibitory Smads (Smad6/7). After complex formation with Smad4, Smad2/3 or Smad1/5/8 enter the
nucleus and drive transcription.
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for neural diﬀerentiation in the study applies inhibition of two routes of the TGF-
β pathway by blocking both signalling through activin/nodal and BMP (Chambers
et al., 2009). The small molecule SB431542 blocks phosphorylation of the receptor
subtypes activin receptor-like kinase (ALK)4, ALK5 and ALK7, which in turn results
in inhibition of Smad2/3 phosphorylation (Laping et al., 2002). At the same time,
the BMP antagonist LDN-193189 inhibits the type I receptors ALK2, ALK3 and
ALK6 and thereby blocks phosphorlyation of Smad1/5/8 (Cuny et al., 2008). It is
not entirely clear how this dual-Smad-inhibition acts synergistically to promote neural
diﬀerentiation in human pluripotent stem cells. However, it has been proposed that
TGF-β signalling through activin directly acts on the pluripotency network (Xu et al.,
2008) and blockage of this pathway could release the cells from their pluripotent state.
Parallel inhibition of BMP signalling could then hinder diﬀerentiation into trophoblast
(Xu et al., 2002) or mesendoderm (D'Amour et al., 2005; Laﬂamme et al., 2007) and
therefore steer diﬀerentiation towards a neural fate.
Diﬀerentiation into deﬁnitive endoderm can be achieved by combined modulation of
Wnt and activin signalling (D'Amour et al., 2006). According to the protocol used for
the present study, cells are subjected to high doses of Activin A in order to activate
TGF-β signalling and to support diﬀerentiation towards mesendoderm (Medine et al.,
2011). In addition, the Wnt signalling pathway is activated by supplementing the
culture medium with Wnt3a. Alternatively, Wnt pathway activation can be achieved
by using a small molecule inhibitor targeting GSK-3 (Kunisada et al., 2012). Further
studies have demonstrated that Wnt signalling can be substituted for by adding BMP
(Teo et al., 2012; Vallier et al., 2009). How exactly the cooperation of Activin signalling
with Wnt or BMP acts on a molecular level to drive deﬁnitive endoderm diﬀerentiation
has not been resolved to date.
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In order to achieve diﬀerentiation of human pluripotent stem cells into mesoderm,
modulation of the Wnt signalling cascade can be used. For this study, diﬀerentiation
into cardiomyocytes was performed according to the protocol described by Burridge
et al. (2014). Initially, the Wnt pathway is stimulated by blocking GSK-3 using a
small molecule inhibitor. After a deﬁned period (i.e. two days), the Wnt pathway is
blocked by adding the Protein-serine O-palmitoleoyltransferase porcupine (PORCN)
inhibitor Wnt-C59 (Proﬃtt et al., 2013) for another two days. Successful derivation
of cardiomyocytes is also depending on composition of the basal medium and can be
promoted by providing an extracellular matrix (Zhang et al., 2012).
Overall it is important to note that multiple factors interact during directed diﬀer-
entiation of pluripotent stem cells. The previously described examples illustrate the
impact of signalling pathways and possibilities of manipulating these in order to favour
commitment to certain lineages. However, successful diﬀerentiation is also highly de-
pending on cell density, extracellular matrices provided and composition of the basal
medium used during the assay.
1.2. O-GlcNAc: a dynamic posttranslational modiﬁcation
Protein posttranslational modiﬁcations (PTMs) have been shown to regulate multiple
aspects of cell signalling, thereby inﬂuencing cellular functions. A wide range of PTMs
are known to date and many of them, i.e. phosphorylation, methylation or ubiqui-
tination, have been extensively studied. O-linked N-acetylglucosamine (O-GlcNAc)
describes the addition of a single, uncharged N-acetylglucosaminyl residue to hydroxyl
groups of serine or threonine by an O-glycosidic linkage. This PTM has been char-
acterized around 30 years ago (Torres and Hart, 1984) and has been demonstrated
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Figure (1.5) Overview of signalling modulation used for this study in order to direct pluripotent stem
cell diﬀerentiation. Ectoderm (neural) diﬀerentiation can be achieved by dual inhibition of Smad phosphorylation.
Diﬀerentiation into deﬁnitive endoderm can be triggered through activation of both TGF-β (through Activin A) and
Wnt signalling. With the aim of diﬀerentiating into mesoderm the Wnt pathway is initially activated and subsequently
blocked.
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to be distinct from other forms of glycosylation in terms of kinetics, substrates and
characteristics of its regulators. For example, O-GlcNAc does not occur extracellu-
larly and is not usually elongated by additional molecules (Hart and Akimoto, 2009).
Furthermore, O-GlcNAc is a dynamic and highly abundant, intracellular modiﬁcation
that has been found in the nucleus and cytoplasm of all eukaryotes examined so far
(Kreppel et al., 1997; Lubas et al., 1997). Interestingly, there is reported interplay
between O-GlcNAcylation and phosphorylation as most O-GlcNAc modiﬁed proteins
are also phophoproteins. Both modiﬁcations occur on Ser/Thr residues and have been
shown to occasionally compete. Respective sites are therefore often termed Yin-Yang
sites (Rexach et al., 2010). In contrast to phosphorylation, which is mediated by more
than 500 protein kinases (Manning et al., 2002) and about 200 phosphatases (Sacco
et al., 2012), O-GlcNAc cycling is catalysed by only two enzymes. While the addition
of O-GlcNAc is administered by the O-GlcNAc transferase Ogt, its removal is regu-
lated by the hydrolase Oga (also known as Mgea5) (Gao et al., 2001; Kreppel et al.,
1997; Lubas et al., 1997).
O-GlcNAc has a key function as nutrient sensor: The product of the nutrient-
sensitive hexosamine biosynthetic pathway, the nucleotide monosaccharide uridine
diphosphate (UDP)-GlcNAc, acts as a substrate for the O-GlcNAc transferase Ogt.
Availability of UDP-GlcNAc is therefore depending on nutritional input and the abun-
dance of the substrate can directly impact on O-GlcNAc levels (reviewed in Wells et al.
(2003)). While O-GlcNAc has been implicated to play a major role in metabolism,
diabetes and Alzheimer's (Dias and Hart, 2007) very little is known to date about its
function in stem cell signalling and maintenance. The following sections will introduce
basic regulation of O-GlcNAc and provide information on stem cell relevant molecular
mechanisms that are inﬂuenced by the modiﬁcation.
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1.2.1. Regulating enzymes
Both enzymes that are responsible for mediating attachment and removal of the mod-
iﬁcation are highly abundant in the cell. Importantly, both have also been shown to
be highly conserved throughout species (Kreppel et al., 1997). In addition, Ogt and
Oga are themselves targets of O-GlcNAcylation, but also phosphorylation and most
likely regulated by those modiﬁcations (Lubas and Hanover, 2000; Beausoleil et al.,
2004; Khidekel et al., 2007).
Ogt: the O-GlcNAc transferase
The O-GlcNAc transferase Ogt mediates the attachment of O-GlcNAc to target pro-
teins (Haltiwanger et al., 1990). The gene encoding the transferase is located on the X
chromosome in both mouse and human and contains two potential promoter sequences
that could lead to the generation of four transcripts, however, only three isoforms have
been reported to date (Shaﬁ et al., 2000; Hanover et al., 2003). The enzyme is highly
abundant in most cells. Importantly, the expression of the three diﬀerent isoforms
varies in a tissue-dependent manner (Kreppel et al., 1997). The largest Ogt isoform
(116 kDa) is the nucleo-cytoplasmic Ogt (ncOgt), followed by a mitochondria-speciﬁc
103 kDa protein (mOgt) and a small isoform with 78 kDa (sOgt) (Lubas et al., 1997;
Love et al., 2003; Hanover et al., 2003). The N-terminal domain of Ogt contains mul-
tiple tetratricopeptide (TPR) repeats and the three isoforms are mainly distinguished
by variation in TPR number: ncOgt contains 12 TPRs, mOgt 9 TPRs and sOgt only 2
TPRs (Hanover et al., 2003). A potential function of the Ogt N-terminus is mediating
protein-protein interactions (Kreppel and Hart, 1999; Kreppel et al., 1997; Jinek et al.,
2004), but it is also to some extent required for the enzymatic activity of the protein
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(Lubas and Hanover, 2000). The C-terminal domain of Ogt harbours the active site of
the enzyme that binds UDP-GlcNAc and catalyses the attachment to target proteins
(Lazarus et al., 2011; Kreppel and Hart, 1999).
Ogt appears to be regulated on multiple levels, but full mechanistic details remain
largely elusive. First of all, the protein has been shown to exhibit autoglycosylation
ability and can be O-GlcNAc modiﬁed both within the catalytic domain and the TPR
repeats (Kreppel et al., 1997; Lubas and Hanover, 2000; Tai et al., 2004). Ogt can also
be tyrosine-phosphorylated (Kreppel et al., 1997), potentially within the TPR region
(Kreppel and Hart, 1999). The role of these modiﬁcations has not yet been elucidated.
Furthermore, Ogt is regulated by nutrient input through the availability of UDP-
GlcNAc (Kreppel et al., 1997; Kreppel and Hart, 1999). Increasing UDP-GlcNAc levels
also increase Ogt's aﬃnity to the substrate, while free UDP has an inhibitory eﬀect
(Haltiwanger et al., 1990; Kreppel et al., 1997; Kreppel and Hart, 1999). Moreover,
Kreppel and Hart (1999) found that Ogt can form multimers (both homotrimers and
heterotrimers of diﬀerent isoforms). Interestingly, multimerisation does not impact on
speciﬁc catalytic activity, but can alter substrate aﬃnity.
Ogt also interacts with numerous proteins via the TPR domain. These protein-
protein interactions are likely to inﬂuence the activity of Ogt, its localization as well
as its ability to bind to further interaction partners and contribute to complex for-
mation (Jinek et al., 2004; Lubas and Hanover, 2000). For example, Ogt has been
demonstrated to form a complex with Sin3A which can repress transcription. In this
context, it has been proposed that Sin3A acts to anchor Ogt to relevant promoters
(Yang et al., 2002). Interestingly, Ogt has also been shown to form a complex with its
opposite, the O-GlcNAc hydrolase Oga (Whisenhunt et al., 2006). This phenomenon
is biologically highly unusual, however, its eﬀects have not been further studied to
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date.
Figure (1.6) The O-GlcNAc transferase Ogt. Structure of the three Ogt isoforms: nucleo-cytoplasmic (nc),
mitochondria-speciﬁc (m) and small (s) Ogt.
Oga: the O-GlcNAc hydrolase
As previously mentioned the O-GlcNAc hydrolase Oga catalyses the removal of O-
GlcNAc from target proteins. The gene encoding Oga has been ﬁrst characterized as
meninginoma expressed antigen 5 (MGEA5) and resides on chromosome 10 (Heckel
et al., 1998). An alternative splicing event can result in the expression of a smaller
variant of Oga (Oga-SV) (Heckel et al., 1998). While full-length Oga is located mainly
in the cytoplasm, Oga-SV has been demonstrated to primarily accumulate in the nu-
cleus (Gao et al., 2001; Comtesse et al., 2001). The splicing variant is truncated on
the C-terminus and lacks a region that has been proposed to harbour a histone acetyl-
transferase (HAT) domain (Schultz, 2002). While it has been reported that this HAT
domain is functional (Toleman et al., 2004), there are also opposing reports (including
the data presented in this study) that indicate that the domain is catalytically inactive
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and represents a pseudo-HAT domain (He et al., 2014; Rao et al., 2013). The catalytic
centre responsible for the hexosaminidase activity of Oga is located at the N-terminus
of the enzyme (Schultz, 2002).
It remains elusive to what extent and under which mechanisms the activity of Oga
can be regulated. There has been a report describing cleavage of Oga by caspase
3, however, the cleaved enzyme fragments retain O-GlcNAcase activity (Butkinaree
et al., 2008). Oga has also been demonstrated to be subject to both phosphorylation
(Ser 364) and O-GlcNAcylation (Ser 405), but no functional consequences have been
associated with these modiﬁcations (Beausoleil et al., 2004; Khidekel et al., 2007).
The activity of Oga is apparently also regulated by substrate availability as GlcNAc
acts as competitive inhibitor of the hexosaminidase (Gao et al., 2001). Furthermore,
Oga could be regulated by interaction and complex formation with other proteins.
However, this aspect has been poorly studied and the most prominent interaction
partner of Oga appears to be Ogt. Whisenhunt et al. (2006) report that O-GlcNAcase
activity of Oga is reduced when in complex with Ogt in in vitro assays.
Figure (1.7) The O-GlcNAc hydrolase Oga. Structure of the two Oga variants. The full-length protein contains
a pseudo-HAT domain at the C-terminus which is truncated in a natural splicing variant.
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1.2.2. O-GlcNAc in pluripotent stem cells
With a view to elucidating the role of O-GlcNAc in pluripotent stem cells, its eﬀects
on the diﬀerentiation capability of these cells and their pluripotency can be proclaimed
as the most crucial element in this ﬁeld. Surprisingly, this has so far been a poorly
studied aspect.
Nevertheless, a few studies provide evidence that O-GlcNAc modiﬁcations play a
major part in diﬀerentiation. For instance, Kim et al. (2009) describe a progressive
reduction of O-GlcNAc levels during cardiomyocyte diﬀerentiation of mouse ES cells.
Moreover, their results indicate that an increase in O-GlcNAcylation impairs cardio-
genesis. In accordance to this study, Speakman et al. (2014) conﬁrm that O-GlcNAc
levels decrease during mouse ES cell diﬀerentiation. In addition, this study indicates
that Oga inhibition using the highly speciﬁc small molecule inhibitor GlcNAcstatin
(GNS) C hinders diﬀerentiation of mouse ES cells into all lineages. However, early
transition from a naïve state of pluripotency to a primed state appears to be unaf-
fected by inhibition of Oga. The respective data is partly included in the thesis at
hand. Only one study has so far focused on the eﬀects of O-GlcNAc in human pluripo-
tent stem cell diﬀerentiation: Maury et al. (2013) used both human ES and iPS cells
to investigate eﬀects of Oga inhibition using the hexosaminidase inhibitors PUGNAc
and Thiamet G in undiﬀerentiated cultures and during diﬀerentiation. Their ﬁndings
indicate that pluripotency is not aﬀected by Oga inhibitor treatments under standard
culture conditions. When investigating spontaneous diﬀerentiation in embryoid bodies
they report that some lineage markers are deregulated in cells treated with PUGNAc
or Thiamet G. The ectoderm marker genes Pax6 and Msx1 appear to be downregu-
lated, while the adipose-related (endoderm) markers PPAR γ and C/EBP α seem to
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be upregulated at some point of diﬀerentiation as a consequence of Oga inhibition.
In conclusion, it seems likely that the removal of O-GlcNAc from some proteins is
required for correct ES cell diﬀerentiation. It might be speculated that the removal of
O-GlcNAc from key pluripotency transcription factors plays a role in this context.
Interestingly, some of these transcription factors have previously been reported to be
O-GlcNAc modiﬁed. In 1995, Chou et al. (1995) showed that c-Myc is O-GlcNAcylated
at T58. However, no functional consequences of this modiﬁcation have so far been
addressed, although the site is also subject to phosphorylation by GSK3 and therefore
appears to be a site of competition between the two modiﬁcations. In addition to this,
three O-GlcNAyclation sites of Sox2 have been identiﬁed (S248, T258, S259) (Myers
et al., 2011; Jang et al., 2012). Again, no functional consequences have been assigned.
Of special interest is the modiﬁcation of Oct4 by O-GlcNAc. Two diﬀerent sites of Oct4
have been demonstrated to be O-GlcNAc modiﬁed (T228, S229) (Jang et al., 2012).
Strikingly, the O-GlcNAc modiﬁcation of T228 appears to have a major impact on
pluripotency. By using a mutant form of Oct4 that was defective for O-GlcNAcylation,
Jang et al. (2012) could demonstrate that O-GlcNAc modiﬁcation of Oct4 is essential
to maintain pluripotency and has a key role regarding reprogramming eﬃciency. To
date, no reports of O-GlcNAcylation of Nanog or Klf4 have been published. However,
recent unpublished data from our lab indicate that Klf4 is an O-GlcNAc target.
O-GlcNAc in stem cell relevant pathways
Wnt pathway In ES cells the Wnt pathway has been shown to maintain pluripo-
tency. In 2002, Aubert et al. (2002) demonstrated that Wnt activity attenuates neural
diﬀerentiation in mouse ES cells by inhibiting GSK-3 using lithium chloride. Con-
sistent results were obtained by Sato et al. (2004), who reported that active Wnt
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signalling is suﬃcient to sustain pluripotency in human and mouse ES cells. To date,
the exact mechanism by which O-GlcNAcylation of Wnt signalling molecules inﬂuences
ES cell signalling is still not fully understood. So far only β-catenin has been shown
to be O-GlcNAc modiﬁed (Sayat et al., 2008) and the consequences for pluripotent
stem cell functions are currently still under debate. While Sayat et al. (2008) report
that O-GlcNAc-modiﬁcation of β-catenin in human CaP cells is inversely correlated
to its nuclear localization levels and therefore decreases its transcriptional activity,
our more recent results clearly indicate increased Wnt signalling and elevated tran-
scriptional activity of β-catenin upon Oga inhibition (Marios Stavridis, unpublished
data). These results are consistent with a recent study in mice and various cell lines
demonstrating an increase in β-catenin protein levels upon elevation of O-GlcNAc con-
tent (Olivier-Van Stichelen et al., 2012). Taken together these results might implicate
a role of O-GlcNAc in pluripotency maintenance via Wnt signalling activity which
could possibly be mediated by the modiﬁcation of β-catenin. However, the underlying
mechanism remains elusive.
LIF-mediated STAT3 signalling In 2004, Gewinner et al. (2004) reported for the
ﬁrst time that STAT3 is O-GlcNAcylated and that interaction of STAT family proteins
with transcriptional co-activators can be inﬂuenced by their O-GlcNAcylation, imply-
ing a role of O-GlcNAc in regulation of the transcriptional activity of STATs. Several
years later, Whelan et al. (2008) conﬁrmed the O-GlcNAc modiﬁcation of STAT3.
Furthermore, they were able to show that Ogt activity increases in response to ele-
vated insulin levels in adipocytes. In contradiction to these results, data from our lab
indicate no changes in STAT3 activating phosphorylation upon increased O-GlcNAc
levels in mouse ES cells (Speakman et al., 2014). As our study is the ﬁrst to address
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the impact of O-GlcNAc on STAT3 signalling in ES cells, this result could implicate
that there are no direct eﬀects of O-GlcNAc on STAT3. Nonetheless, O-GlcNAc might
modify targets downstream of STAT3. As an example, it has been shown that c-Myc,
a STAT3 target gene, is O-GlcNAcylated (Chou et al., 1995). Overall, the role of O-
GlcNAc in ES cells STAT3 signalling is poorly understood and further work is required
to clarify the eﬀect of O-GlcNAcylation on this pathway.
TGF-β and BMP signalling Overall, very little is known about potential crosstalk
between O-GlcNAcylation and TGF-β/BMP signalling. Only a single study has so
far described an interaction on the levels of R-Smads: Herhaus (2014) described Ogt
as a potential interaction partner of the R-Smad Smad2 in HeLa cells. Furthermore,
this study indicated that Smad4 can be O-GlcNAc modiﬁed in HEK293 or HeLa cells.
However, functional consequences of the modiﬁcation for respective cellular signalling
have not been addressed.
O-GlcNAc in transcriptional regulation and epigenetics
Recent studies on O-GlcNAcylation put emphasis on its role in epigenetic regulation.
While consequences of the epigenetic functions of O-GlcNAc for ES cells remain elu-
sive, ﬁrst hints indicate a key role in transcriptional regulation as well as in repression
mechanisms and are therefore likely to have an impact on ES cell self-renewal and
pluripotency.
Histone code Apart from its interaction with chromatin remodelling factors, O-
GlcNAc modiﬁcation is also part of the histone code. By using mass spectrometry,
Sakabe et al. (2010) identiﬁed sites of O-GlcNAcylation of H2A, H2B and H4. More
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recently, further studies by Zhang et al. (2011) and Fong et al. (2012) indicated that H3
is also modiﬁed by O-GlcNAc. Overall, the following sites of O-GlcNAc modiﬁcation
of histones have been identiﬁed: H2AT101, H2BS36, H2BS112, H3S10 and H4S47
(Sakabe et al., 2010; Zhang et al., 2011; Fujiki et al., 2011; Fong et al., 2012). The
consequences of O-GlcNAcylation of many of the identiﬁed sites remain elusive to
date. Nonetheless, it has been shown that the O-GlcNAc sites H3S10, H2BS36 and
H4S47 are also subject to phosphorylation, implying that both PTMs might compete
in this context (Sakabe et al., 2010). Overall, histone modiﬁcations inﬂuence chromatin
accessibility by aﬀecting its conﬁguration or by mediating the recruitment of enzymes
(Kouzarides, 2007). In pluripotent stem cells, the chromatin conﬁguration appears to
be in an accessible state, displaying a decrease of repressive and an increase in active
histone modiﬁcations in comparison to diﬀerentiated cells (Hawkins et al., 2010; Wen
et al., 2009; Krejci et al., 2009). Some of the O-GlcNAc modiﬁcations on histones
mentioned above are likely to have a function in pluripotent stem cell maintenance
associated with respective inﬂuences on the chromatin conﬁguration. Firstly, H3S10
is a site that has been previously implicated to mediate both repressive and active
chromatin status (Zhang et al., 2011). In addition, O-GlcNAc modiﬁcation of H2BS112
has been shown to facilitate this histone's monoubiquitination at K120 which has been
implicated with transcriptional activation (Fujiki et al., 2011). These results indicate
a possible function of O-GlcNAc in regulating transcriptional activity by modifying
histones which might contribute to an open chromatin status in pluripotent stem cells.
O-GlcNAcylation of RNA polymerase II The C-terminal domain (CTD) of
RNA polymerase II (PolII) is known to be modiﬁed by several kinases with major ef-
fects on its function as a transcriptional regulator, but also on complex formation with
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mRNA capping enzymes, splicing and polyadenylation factors (Hirose and Manley,
2000; Comer and Hart, 2001). In 1993, Kelly et al. (1993) demonstrated that the un-
phosphorylated CTD of PolII is also subject to O-GlcNAcylation. Findings presented
in this study also indicate that, in this case, phosphorylation and O-GlcNAcylation are
mutually exclusive. Further studies suggest that diﬀerent PTMs on the CTD might
give rise to functionally distinct forms of PolII (Comer and Hart, 2001). However,
detailed consequences on epigenetic functions are not yet fully understood. PolII is an
essential regulation element in development. Subsequent to transcription initiation,
PolII can pause directly downstream of transcription initiation sites and remain in
a poised state. Poised PolII can be found at developmental control genes and has
recently been suggested to prepare genes for rapid expression in the course of de-
velopment as demonstrated by Gaertner et al. (2012). Interestingly, this study also
implicates an interplay between temporally regulated poised PolII and tissue-speciﬁc
Polycomb repression. These ﬁndings are in line with results obtained by Chopra et al.
(2011) suggesting that poised PolII levels are regulated by polycomb group (PcG)
repressors in the Drosophila embryo. Strikingly, the Drosophila homologue for O-
GlcNAc transferase Ogt, super sex combs (sxc), is a member of the polycomb group
(Sinclair et al., 2009) (see section 1.2.2). Taken together the aforementioned results
imply a key role of O-GlcNAc in regulation of PolII functional states and thereby in
gene expression at diﬀerent developmental stages. Although not yet proven, an eﬀect
on pluripotent stem cells is probable as PolII epigenetic regulation mechanisms are
known to be highly conserved.
O-GlcNAc and epigenetic repression DNA methylation is another essential epi-
genetic mechanism to regulate gene expression. Ten-eleven translocation (Tet) pro-
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teins have recently been reported to play a crucial role in DNA methlyation. The
mammalian family of Tet proteins comprises three members: Tet1, Tet2 and Tet3
(Iyer et al., 2009). Tet proteins mediate the conversion of 5-methylcytosine (5-mC) to
5-hydroxymethylcytosine (5-hmC), eventually leading to DNA demethylation (Tahil-
iani et al., 2009; Guo et al., 2011) and all three Tet family members have recently been
reported to interact with Ogt (Deplus et al., 2013; Ito et al., 2013; Shi et al., 2013).
Interestingly, Tet-mediated demethylation is vital for the recruitment of the polycomb
repressive complex (PRC)2 (compare section 1.2.2) (Wu and Zhang, 2011). Several
recent studies connect O-GlcNAc to both Tet protein function and pluripotent stem
cell epigenetics. Vella et al. (2013) identiﬁed both Tet1 and Tet2 as stable partners
of Ogt in mouse ES cells. Furthermore, the results obtained in this study indicate
that Ogt and Tet1 associate at CpG-rich promoter regions and imply that Tet1 might
exhibit an anchor-like function thereby mediating Ogt recruitment to chromatin. In-
triguingly, further results obtained by Vella et al. (2013) also suggest the existence of
a multiprotein complex consisting of Ogt, Tet1, Tet2, Sin3A and histone deacetylase
(HDAC)1. As both Sin3A and HDAC1 are known to mediate gene repression, this
represents an interesting link toward the repressive function of Ogt in ES cells. An-
other study in mouse ES cells by Shi et al. (2013) further stresses the role of Ogt/Tet1
interaction in gene repression. Besides conﬁrming the interaction of Tet1 and Ogt,
they also presented evidence that Tet1 is O-GlcNAcylated. This modiﬁcation of Tet1
appears to have an eﬀect on its stability. Further results obtained in this study in-
dicate that O-GlcNAcylation positively regulates Tet1 protein levels. On the other
hand, loss of O-GlcNAcylation was shown to reduce both Tet1 and 5-hmC levels.
Knockdown of Ogt or Tet1 in ES cells appears to result in loss of pluripotency and
in an increase in diﬀerentiated cells. Data presented in this study implies that Tet1
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can recruit repressive complexes, thereby maintaining pluripotency of ES cells. This
mechanism might possibly be inﬂuenced by O-GlcNAcylation of Tet1. Two further
studies indicate an interaction between Ogt and Tet3 (Zhang et al., 2014; Ito et al.,
2013). In addition, Zhang et al. (2014) propose that the O-GlcNAcylation of Tet3
regulates its localisation as well as its enzymatic activity. Nonetheless, further studies
on the detailed mechanisms by which Tet-mediated repression inﬂuences pluripotency
are essential at this stage of research.
PcG proteins are known to form multiprotein complexes exhibiting repressive func-
tion. Overall, PcG proteins are regulators of gene expression during embryonic devel-
opment, in stem cells and in somatic cell reprogramming (reviewed by Aloia et al.
(2013)). In pluripotent stem cells, PcG complexes have been shown to maintain
pluripotency by repressing genes involved in diﬀerentiation. Furthermore, the PRC2
component Pcl2 interacts with key members of the pluripotency network (Walker
et al., 2010), while Pcl3 was shown to promote self-renewal (Hunkapiller et al., 2012).
In addition, PcG complexes play a crucial role in ES cell diﬀerentiation. Ezh2, the
enzymatically active component of PRC2 is essential for mesodermal diﬀerentiation
(Shen et al., 2008) and loss of Ring1B, an enzyme in PRC1, hinders the expression
of diﬀerentiation markers (Leeb and Wutz, 2007). Reprogramming of somatic cells
into pluripotent cells has also been shown to be inﬂuenced by Polycomb repression.
Zhang et al. (2011) reported that overexpression of PRC2 components facilitates re-
programming of into iPS cells. The role of PcG proteins in reprogramming was further
underlined by the results of Buganim et al. (2012) who suggest Ezh2 to function as a
part of a novel reprogramming transcription factor cocktail.
First results hinting to a role of O-GlcNAc in Polycomb repression where obtained
in 2009, when two independent studies showed that the Drosophila Ogt enzyme is
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encoded by supersexcombs (sxc) which is a PcG gene (Sinclair et al., 2009; Gambetta
et al., 2009). Gambetta et al. (2009) also reported an enrichment of O-GlcNAcylated
proteins at Polycomb response elements in Drosophila. In 2011, Myers et al. (2011)
provided ﬁrst evidence for the connection between Ogt and PcG proteins in mouse ES
cells. Their ﬁndings indicate that PRC2 is necessary to maintain normal levels of Ogt
and O-GlcNAc distribution. However, this study also indicates no disruption of PRC2
function upon Ogt knockdown. In contrast to the ﬁndings of Myers et al. (2011),
Tet1-mediated demethylation of CpG islands was shown to be essential for PRC2 re-
cruitment to chromatin (Wu and Zhang, 2011; Aloia et al., 2013). As described above,
this process was reported to be inﬂuenced by Ogt and O-GlcNAcylation of Tet1. It is
therefore surprising, that Ogt knockdown in mouse ES cells does not appear to have
any signiﬁcant eﬀect on PRC2 recruitment and function. A recent study by Maury
et al. (2015) further stresses the correlation between O-GlcNAcylation and polycomb-
mediated gene repression: Data presented in this study reveals that the catalytic
subunit of PRC1, Ring1B, is subject to O-GlcNAcylation at three sites. More im-
portantly, O-GlcNAcylation appears to regulate DNA-binding of Ring1B. In addition,
O-GlcNAc modiﬁed Ring1B was preferentially detected in proximity of genes related to
neural diﬀerentiation. Maury et al. (2015) suggest that with a loss of O-GlcNAcylation
occuring with progressing diﬀerentiation, PRC1 is lost at diﬀerentiation-relevant genes
providing an on-switch for those genes.
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1.2.3. Key reagents for investigating O-GlcNAcylation
Detection methods
Global O-GlcNAcylation can be investigated using conventional immunoblotting tech-
niques. There are two commercially available pan-speciﬁc antibodies that are widely
used for this purpose: CTD 110.6 (Covance) and RL2 (Sigma) (Comer et al., 2001;
Snow, 1987). It is important to note that both antibodies recognize a subset of O-
GlcNAcylated proteins. While CTD 110.6 has been demonstrated to detect a wider
range of O-GlcNAc modiﬁed peptides it also binds to N-GlcNAc(2)-modiﬁed glyco-
proteins (Isono, 2011). Therefore, further investigations using alternative detection
methods or upstream sample treatments are generally recommended in order to avoid
false positives. Alternative detection methods available for O-GlcNAc are chemoenzy-
matic or metabolic labelling techniques (Khidekel et al., 2003; Vocadlo et al., 2003).
Enzyme inhibitors
With the aim of studying the function O-GlcNAcylation means of manipulating the
O-GlcNAc system are of major importance. This can be achieved by modulation of the
two key regulators, Oga and Ogt. Knockdown of both enzymes is possible to a certain
degree, but technically challenging and knockdown of Ogt largely impairs cell viability
in our hands. Several inhibitors are available for both Ogt and Oga. As inhibition
of Ogt also leads to cell death in ES cells (Speakman et al., 2014), modulating the
activity of Oga is a useful way of deregulating O-GlcNAcylation and there are several
inhibitors commercially available.
PUGNAc is an inhibitor of hexosaminidases that can be used to increase ﬂux through
the O-GlcNAc cycle by blocking Oga activity and thereby increasing global O-GlcNAc
49
levels (Haltiwanger, 1998). In addition to inhibiting Oga, PUGNAc also inactivates
lysosomal hexosaminidases due to their structural similarity with Oga (Dorfmueller
et al., 2010). Thiamet-G was designed as a selective inhibitor of human Oga that
mimics O-GlcNAc (Yuzwa et al., 2008). GlcNAcstatins (GNS) apply a similar ap-
proach, but are also characterized by their additional ability to penetrate cells even at
nanomolar concentrations thereby minimizing potential oﬀ-target eﬀects (Dorfmueller
et al., 2010). By targeting a conserved cystein within the catalytically active site of
Oga GNS acts as a suicide inhibitor providing an irreversible blockage of the enzyme
(Dorfmueller et al., 2010).
1.3. Research objective
This study aims to investigate the function of O-GlcNAcylation in diﬀerentiation us-
ing diﬀerent pluripotent stem cell model systems. The role of O-GlcNAc in pluripo-
tent stem cell diﬀerentiation has so far been poorly studied, especially regarding
human pluripotent stem cells which have become an essential tool for translational
and medical research approaches over the last decade. The eﬀects of deregulated O-
GlcNAcylation can be studied either by treatment with an Oga inhibitor or by knock-
down/overexpression studies of O-GlcNAc-regulating enzymes. Using these tools, O-
GlcNAc functions during diﬀerentiation into diﬀerent lineages will be studied. These
investigations aim to give hints towards potential eﬀects on lineage commitment in
the early mammalian embryo, thereby providing starting points for further studies on
embryonic development. In addition, the study will focus on the underlying molecular
mechanisms of any possible eﬀects of O-GlcNAc on diﬀerentiation. Together, these
investigations will contribute signiﬁcantly to current knowledge on how pluripotent
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stem cell diﬀerentiation, lineage commitment and early developmental processes are
regulated by the posttranslational modiﬁcation. With a view to the eﬀects of dereg-
ulation of O-GlcNAc levels on diﬀerentiation, two well-established stem cell models,
mouse ES cells and human iPS cells, will be compared. This will provide further
understanding of diﬀerences and similarities of those model systems.
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2. Materials and Methods
2.1. Chemicals
Table (2.1) Chemicals
Chemical Manufacturer Order number
2-propanol Sigma I9516
4,6-Diamidino-2-phenylindole dihydrochloride Sigma D9542
Amersham ECL Western Blotting Detection
Reagent
GE Healthcare RPN2106
Bovine Serum Albumin Fraction V Sigma BSAV-RO
Ethanol absolute VWR 20821.330
Ethylene glycol-bis(2-aminoethylether)-
N,N,N',N'-tetraacetic acid
Sigma E3889
Ethylenediaminetetraacetic acid Sigma EDS
Glycine VWR 101194M
Methanol VWR 20847.307
milk powder Marvel -
Paraformaldehyde Sigma 158127
Phosphate buﬀered saline without Ca++ Mg++
or phenol red
Lonza 17-516F
Sodium azide 0.1 M solution Sigma 8591
Sodium chloride Sigma S3014
Sodium dodecyl sulfate Sigma L3771
Tris base Calbiochem 648310-2.5
Triton X-100 Sigma T8787
Tween 20 Sigma P9416
UltraPure Agarose Invitrogen 16500-100
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2.2. Cells and general cell culture
2.2.1. Mouse embryonic stem cells
For this study, the mouse ES cell lines E14Tg2aIV and 46C were used. 46C ES
cells are an E14Tg2aIV-derived Sox1-GFP knock-in reporter cells (Ying et al., 2003b).
All mouse ES cells were cultured on 0.1% gelatin-coated dishes in Glasgow Minimal
Essential Medium (GMEM) (Life Technologies) with 10% FCS and LIF (for detailed
medium composition see table 2.2). These culture conditions are often referred to as
serum/LIF culture and are used to grow mouse ES cells as a mixture of naïve and
formative state pluripotent cells. For standard passaging, the cells were dissociated
using 0.05% Trypsin-EDTA (Life Technologies) and plated at a density of 40 000
cell/cm2 on gelatin-coated dishes. Cells were maintained at 37 ◦C and 5% CO2.
Table (2.2) GMEM complete
component supplier amount/
concentration
Glasgow MEM (BHK-21) ThermoFisher Scientiﬁc 500 ml
Sodium Pyruvate (100 mM) ThermoFisher Scientiﬁc 1 mM
MEM Non-essential Amino
Acids Solution (100 ×)
ThermoFisher Scientiﬁc 1 ×
2-Mercaptoethanol (≥ 99%) Sigma 0.1 mM
Leukemia-induced Factor recombinantly generated 1:1000
Fetal Calf Serum (batch-tested) obtained from University of
Cambridge
10%
2.2.2. Human induced pluripotent stem cells
ChiPS4 human induced pluripotent stem cells used for diﬀerentiation experiments
were maintained using DEF-CS (Cellartis AB) and provided by Lindsay Davidson,
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Human Pluripotent Stem Cell Facility, University of Dundee.
2.2.3. Inhibitors and growth factors
The inhibitors and growth factors given in table 2.3 were added as a direct supplement
to cell culture medium.
Table (2.3) Overview inhibitors and chemicals
Name Function Supplier Final concentration
GlcNAcstatin C/G Oga inhibitor GlycoBioChem 1 µM
CT99021 GSK-3 inhibitor Sigma 3 µM (assay-
dependent)
PD0325901 Sigma 1 µM
LDN193189 antagonist of BMP
receptor isotypes
ALK2 and ALK3
100 nM (assay-
dependent)
SB431542 inhibitor of ALK4,
ALK5 and ALK7
10 µM
Y-27632 ROCK inhibitor 10 µM
Trichostatin A histone deacetylase
inhibitor
Sigma 300 nM
Wnt-C59 PORCN inhibitor 2 µM
Dimethyl sulfoxide control Sigma 1:1000
bFGF (recombinant
human)
growth factor Peprotech 30 ng/ml
noggin (recombi-
nant human)
BMP4 antagonist Peprotech 10 ng/ml
Activin A (recombi-
nant human)
R & D Systems 100 ng/ml
Oncostatin M (re-
combinant human)
growth and diﬀeren-
tiation factor
Preprotech 20 ng/ml
Human HGF growth factor Peprotech 10 ng/ml
BMP4 (recombi-
nant human)
Peprotech assay-dependent
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2.2.4. Cell culture coating
Prior to plating of cells, respective culture dishes were coated. For mouse ES cell
culture, dishes were coated with 0.1 % gelatin for ﬁve minutes at room temperature.
For standard culture of undiﬀerentiated human iPS cells dishes were coated with ﬁ-
bronectin for at least one hour at 37◦C. Geltrex-coated dishes (at least one hour at
37◦C) were used for diﬀerentiation assays using human iPS cells. Relevant concentra-
tions and coating reagents are listed in table 2.4.
Table (2.4) Reagents for coating of cell culture dishes
Name Supplier Final concentration
Gelatin from porcine skin Sigma 80 µl of 0.1% gelatin/cm2
Fibronectin (human plasma) Millipore 5 µg/cm2
Geltrex (stem cell-qualiﬁed LDEV-
free growth factor reduced)
Life Technologies 10 µg/cm2
Poly-l-ornithine Sigma 15 µg/cm2
Laminin Life Technologies 1 µg/cm2
2.2.5. Diﬀerentation assays
Spontaneous diﬀerentiation of mouse ES cells in embryoid bodies
Upon LIF withdrawal mouse ES cells diﬀerentiate spontaneously. In this assay, cells
were cultured in multicellular aggregates termed embryoid bodies (EBs) and medium
without LIF which allows them to diﬀerentiate into multiple lineages.
Mouse ES cells (46C or E14Tg2aIV) were detached enzymatically using StemPro
Accutase (Thermo Fisher Scientiﬁc) described and resuspended in GMEM (Life Tech-
nologies) with 10% FCS (GMEM/FCS) but without LIF and with either GNS G (1
µM) or DMSO (1:1000). The cell suspension was adjusted to a concentration of 1×105
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cell/ml. Cells were then plated as hanging drops of 25 µl volume onto the lid of a petri
dish. In order to avoid evaporation the petri dish was ﬁlled with 1× PBS and the lid
with the hanging drops was placed on top. The hanging drop culture was incubated
for three days to allow the cells to form EBs. Subsequently, EBs were either harvested
for gene expression analysis in RLT lysis buﬀer or transferred to a non-adherent petri
dish with GMEM/FCS and GNS G/DMSO. Cells were then cultured for another 2
days before they were lysed in RLT lysis buﬀer for RT-qPCR (reverse transcriptase
quantitative polymerase chain reaction).
Neural diﬀerentiation of ChiPS4 (high-density protocol)
For neural diﬀerentiation, we applied a dual SMAD inhibition protocol as described
by Chambers et al. (2009). Before diﬀerentiation was initiated, ChiPS4 cells were
plated on geltrex-coated dishes (10 µg/cm2) at a density of 4 × 104 cells per cm2.
The cells were grown until they formed a uniform monolayer (approximately 3 d).
During this time medium was changed daily. Diﬀerentiation was then initiated by
changing the culture medium to serum replacement medium (Knockout DMEM, 20
% knockout serum replacement, 1x glutamax, 1x non-essential amino acids, 100 M
2-mercaptoethanol, all from Life Technologies) supplemented with 10 µM SB431542
and 100 nM LDN193189. Cells were kept under these conditions with daily medium
changes for 5 days. On day 5 of the diﬀerentiation medium was changed to 75%
Knockout serum replacement (KOSR)/25% neurobasal medium with 1 × N2, 1 ×
B27 and LDN193189. The medium was subsequently changed to increasing amounts
of neurobasal/N2B27 (50%, 75% and 100%) every other day while maintaining 100
nM of the inhibitor LDN193189. Protein and ribonucleic acid (RNA) lysates were
obtained at various timepoints throughout the diﬀerentiation.
56
Neural diﬀerentation of ChiPS4 in embryoid bodies
Neural diﬀerentiation of ChiPS4 in EBs was performed based on the protocol described
by Koch et al. (2009). In order to generate EBs, a cell suspension with a concentration
of 2 × 105 cells/ml in DEF base medium with bFGF (30 ng/ml), noggin (10 ng/ml)
and Y-27632 (10 µM) was prepared. This equates to 10,000 cells per 50 µl drop. The
cell suspension was then dispensed onto a non-adhesive 96-well v-bottom plate (50 µl
per well). Plates were centrifuged at 500 × g for 5 min. This leads to the formation
of cell aggregates in the bottom of the wells which will then form EBs within the next
48 h.
EBs were then transferred into 10 cm dishes with knockout Dulbecco's minimal es-
sential medium (DMEM) containing SB-431542 (10 µM) and LDN-193189 (0.5 µM)
(Day 1 of diﬀerentiation). Over the course of the coming days the medium was sequen-
tially changed from knockout DMEM to neurobasal/N2B27: Every other day, half of
the medium was replaced by neurobasal/N2B27 while the inhibitors were maintained
at the previously stated concentrations. On day 9 of diﬀerentiation the medium was
changed completely to neurobasal/N2B27/SB-431542/LDN-193189 and the EBs were
plated out onto poly-l-ornithine (15 µg/cm2 in sterile water) and laminin (1 µg/cm2
in phosphate buﬀered saline (PBS)) coated dishes. The medium was then changed
every 48 h for another 6 days.
On day 15 of the diﬀerentiation neuroectodermal islands (three-dimensional cell ag-
gregates with neural-tube-like structures) can be isolated in order to remove potential
contamination with other lineages. For this, neural islands were dislodged using a
p1000 pipette. The cells were then transferred to a 50 ml tube and centrifuged at
300 × g for 2 min. Neural islands were resuspended in fresh neurobasal/N2B27/SB-
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431542/LDN-193189 medium and plated on matrigel (20 µg/cm2) coated dishes. Cells
were maintained for another 9 days with media changes every other day. On day 24
of the diﬀerentiation cells were ﬁxed and analysed by immunoﬂuorescence.
Hepatocyte diﬀerentiation of ChiPS4
Human iPS cell were diﬀerentiated into a hepatocyte-like cell type using a protocol
which was based on Medine et al. (2011). This three-step protocol starts with deﬁnitive
endoderm diﬀerentiation during the ﬁrst four days. This is followed by a hepatic
diﬀerentiation step (ﬁve additional days) and a hepatic maturation (nine days).
Cells were initially plated at a density of 4 × 104 cells per cm2 on matrigel (10
µg/cm2) coated plastics. When cells had grown to conﬂuence, diﬀerentiation was
initiated by changing the medium to RPMI/B27 (RPMI-1640 with 1 × B27, 1 × Glu-
tamax and penicillin/streptomycin, all from Thermo Fisher Scientiﬁc) supplemented
with Activin A (100 ng/ml) and Wnt3a (50 ng/ml). Medium was changed every 25
hours for the next three days. On day four of diﬀerentiation, the medium was changed
to serum replacement medium (Knockout DMEM, 20 % knockout serum replacement,
1x glutamax, 1x non-essential amino acids, 100 mM 2-mercaptoethanol, all from Life
Technologies) supplemented with 1% dimethylsulfoxide (DMSO). Cell were kept in
this medium for an additional ﬁve days with medium changes every 48 hours. On day
eight of the diﬀerentiation, medium was changed to L-15 maturation medium (Lei-
bovitz L-15 medium with tryptose phosphate broth (ﬁnal concentration 8.3%, Sigma),
FCS (ﬁnal concentration 8.3 %), 10 µM hydrocortisone 21-hemisuccinate, Insulin (1
µM), 1 × Glutamax, 0.2% ascorbic acid, from ThermoFisher Scientiﬁc unless oth-
erwise stated) supplemented with hepatocyte growth factor (HGF) (10 ng/ml) and
oncostatin M (20 ng/ml). Medium was again renewed every other day for another
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nine days. Protein and RNA lysates were obtained at various timepoints throughout
the diﬀerentiation.
Cardiomyocyte diﬀerentiation of ChiPS4
Cardiomyocyte diﬀerentiation of ChiPS4 was carried out according to the protocol
described by Burridge et al. (2014). First, cells plated in DEF medium (including
noggin (10 ng/ml), bFGF (30 ng/ml) and Y-27632 (10 µM)) at a density of 50,000
cells/cm2 on matrigel (10 µg/cm2) coated plastics. Medium was changed the next
day to DEF medium without Y-27632. Approximately 48 h after plating medium was
changed to RPMI/B27-ins with CT99021 (5 µM) (D0 of diﬀerentiation). Cells were
kept in this medium for two days. On day 2 of the diﬀerentiation medium was changed
to RPMI/B27-ins with Wnt-C59 (2 µM). The medium was changed to RPMI/B27-ins
on day 4 of the assay and cells were maintained in this medium with medium changes
every other day. The cells were kept until day 10 of cardiomyocyte diﬀerentiation.
Lysates for RNA extraction and Western Blot were generated at relevant timepoints
during this assay.
2.2.6. BMP pathway stimulation
ChiPS4 were plated at a density of 30 000 cells/cm2 on geltrex-coated dishes. The cells
were kept in standard culture conditions (DEF medium supplemented with bFGF and
noggin) including relevant drugs (i.e. DMSO, GNS) for three days. Medium was then
changed to DMEM/FCS (DMEM, 10% FCS, 1 × glutamax) and diﬀerent amounts
of BMP4 were added (between 0.1 to 100 ng/ml). After overnight stimulation with
BMP4, RNA was harvested.
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2.2.7. RNAi
siRNA-induced knockdown in mouse ES cells
For small inhibitory RNA (siRNA)-induced knockdown of Oga or Ogt cells were
plated into 6-well dishes at a concentration of 2 × 105 cells/well. While the cells
were still in suspension, they were reversely transfected with siRNAs targeting either
Oga or Ogt (50 pmol per well) (ON-TARGETplus SMARTpool against mouse Ogt or
mouse Mgea5; Thermo Fisher Scientiﬁc). As a control, cells were transfected with a
non-targeting siRNA pool (50 pmol per well) (ON-TARGETplus non-targeting pool;
Thermo Fisher Scientiﬁc). For each well both siRNAs and 5 µl of the transfection
reagent Lipofectamine RNAiMAX (Life Technologies) were diluted in 250 µl Opti-
MEM (Thermo Fisher Scientiﬁc) each. The two dilutions were then combined and
incubated for 5 min before they were added to the cells. Using the same protocol cells
were transfected again after 24 h. Lysates for RNA puriﬁcation and Western blotting
were obtained after another 24 h in culture.
2.2.8. Transfections
For overexpression of full length Oga and a shorter splicing variant, E14 mouse ES
cells were transfected with the plasmids pCAG-IP-Oga-full length or pCAG-IP-Oga-
splicing variant respectively. One million cells were plated in 6 cm dishes and reversely
transfected using 4.5 µg DNA and 9 µl Lipofectamine 2000 (Life Technologies) in 1000
µl OptiMEM (Life Technologies). After 24 hours, the transfection was repeated. Cells
were then incubated for another day before being harvested respective to the desired
subsequent analysis method.
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2.3. Molecular biology methods
2.3.1. DNA extraction
For some of the methods described in the following sections genomic DNA was ex-
tracted. As a ﬁrst step, medium was removed and cells were washed with PBS before
being harvested in 250 µl DNA lysis buﬀer (75 mM NaCl, 25 mM Ethylenediaminete-
traacetic acid (EDTA), 1% sodium dodecyl sulfate (SDS)). RNAse A (Sigma) was
added at a ﬁnal concentration of 50 µg/ml and samples were incubated for 30 minutes
at 37 ◦C Subsequently, 10 µl of proteinase A (10 mg/ml stock, Sigma) was added and
incubation was continued at 55 ◦C for one hour. To each sample 365 µl chloroform and
78.5 µl 5 M sodium chloride were added. The samples were then incubated on a rotat-
ing wheel for 45 minutes. Samples were centrifuged at 16 000 × g for 10 minutes. The
upper aqueous phase was transferred to a new tube with 250 µl isopropanol. Samples
were mixed, incubated for ﬁve minutes and then centrifuged again for another twelve
minutes. After this, a pellet had formed at the bottom of the tube. The supernatant
was discarded and pellets were dried for approximately 15 minutes. The DNA pellet
was then dissolved in an appropriate volume of Tris-EDTA buﬀer.
2.3.2. Real time quantitative PCR
Reverse transcription
In order to generate cDNA (complementary DNA), RNA was reversely transcribed
using the qScript cDNA synthesis kit (Quanta Biosciences) according to the manu-
facturer's instructions. Reverse transcription was performed on 1000-500 ng of RNA.
The temperature proﬁle for the reverse transcription reaction is depicted in table 2.5.
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Table (2.5) Temperature proﬁle for cDNA synthesis
22 ◦C 5 min
42 ◦C 30 min
85 ◦C 5 min
2.3.3. RNA extraction
Cells were harvested in 350 µl RLT buﬀer supplemented with 3.5 µl beta-mercaptoethanol
(Qiagen). Subsequently, RNA extraction including on-column DNase digest was per-
formed using the NucleoSpin RNA kit (Macherey-Nagel) according to the manufac-
turer's instructions. RNA was eluted in RNase-free water (40-50 µl) and RNA con-
centrations were determined using a Nanodrop 1000 Spectrophotometer (Thermo Sci-
entiﬁc).
Real-time PCR
Firstly, cDNA was diluted to a total volume of 80 µl with nuclease-free water. Reaction
mixes were prepared by combining SooFast EvaGreen Supermix (BioRad), nuclease-
free water and primers according to table 2.6. Mastermix was then pipetted into the
respective wells and 3 µl of diluted cDNA were added per well. The plate was sealed
and spun down. Subsequently, the reaction was performed using a CFX384 Touch
Real-Time PCR Detection System (BioRad). The temperature proﬁle used for this
reaction is depicted in table 2.7. All reactions were performed as technical triplicates.
Relevant primer sequences for human cells are listed in table 2.8.
Table (2.8) RT-qPCR primers, human
primer name sequence (5' to 3') primer bank ID/
publication
beta-actin, forward CATGTACGTTGCTATCCAGGC 4501885a1
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beta-actin, reverse CTCCTTAATGTCACGCACGAT 4501885a1
Oct4, forward CTTGAATCCCGAATGGAAAGGG 4505967a1
Oct4, reverse GTGTATATCCCAGGGTGATCCTC 4505967a1
Nanog, forward AAGGTCCCGGTCAAGAAACAG 153945815c2
Nanog, reverse CTTCTGCGTCACACCATTGC 153945815c2
Pax6, forward AGTGCCCGTCCATCTTTGC 189083679c2
Pax6, reverse CGCTTGGTATGTTATCGTTGGT 189083679c2
Sox1, forward ATGCACCGCTACGACATGG D'Amour et al. (2005)
Sox1, reverse CTCATGTAGCCCTGCGAGTTG D'Amour et al. (2005)
Pax7, forward ACCCCTGCCTAACCACATC 207029245c1
Pax7, reverse GCGGCAAAGAATCTTGGAGAC 207029245c1
FoxG1, forward GAGCGACGACGTGTTCATC 375151583c1
FoxG1, reverse GCCGTTGTAACTCAAAGTGCTG 375151583c1
Sox17, forward CTCCGGTGTGAATCTCCCC 145275218c2
Sox17, reverse CACGTCAGGATAGTTGCAGTAAT 145275218c2
FoxA2, forward GGAGCAGCTACTATGCAGAGC 194363755c1
FoxA2, reverse CGTGTTCATGCCGTTCATCC 194363755c1
AFP, forward CTTTGGGCTGCTCGCTATGA 4501988c1
AFP, reverse GCATGTTGATTTAACAAGCTGCT 4501988c1
albumin, forward TGCAACTCTTCGTGAAACCTATG 215982788c1
albumin, reverse ACATCAACCTCTGGTCTCACC 215982788c1
Brachyury, forward TATGAGCCTCGAATCCACATAGT 19743811c1
Brachyury, reverse CCTCGTTCTGATAAGCAGTCAC 19743811c1
GATA5, forward CTTCGTGTCCGACTTCTTGGA 157952217c1
GATA5, reverse CCGAGGCATTCCTTGTGGA 157952217c1
cTNT, forward ATGATGCATTTTGGGGGTTA Fonoudi et al. (2013)
cTNT, reverse CAGCACCTTCCTCCTCTCAG Fonoudi et al. (2013)
Hand1, forward GAGAGCATTAACAGCGCATTCG 196259809c2
Hand1, reverse CGCAGAGTCTTGATCTTGGAGAG 196259809c2
Klf2, forward CTACACCAAGAGTTCGCATCTG 49574523c2
Klf2, reverse CCGTGTGCTTTCGGTAGTG 49574523c2
FoxJ1, forward GTGCTTCATCAAAGTGCCTCG 260764002c2
FoxJ1, reverse GCCTCGGTATTCACCGTCA 260764002c2
MAPK12, forward AGTGGCTTTTACCGCCAGG 48255969c1
MAPK12, reverse GACTGGAAGGGCCGATACAG 48255969c1
Klf8, forward GTCAGTCTGCCAAATAAGATGGG 226530794c2
Klf8, reverse ATGGAGGTGGGGTCAACTTTC 226530794c2
Smad7, forward TTCCTCCGCTGAAACAGGG 299890804c1
Smad7, reverse CCTCCCAGTATGCCACCAC 299890804c1
TGFBI, forward CACTCTCAAACCTTTACGAGACC 170650698c1
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TGFBI, reverse CGTTGCTAGGGGCGAAGATG 170650698c1
SEMA3A, forward GTGCCAAGGCTGAAATTATCCT 100913215c1
SEMA3A, reverse CCCACTTGCATTCATCTCTTCT 100913215c1
BMPR1B, forward ATTTGCAGCACAGACGGATATT 377823722c2
BMPR1B, reverse GAGGCAGTGTAGGGTGTAGGT 377823722c2
GDNF, forward GCAGACCCATCGCCTTTGAT 299473777c2
GDNF, reverse CCACACCTTTTAGCGGAATGC 299473777c2
Cdx2, forward GACGTGAGCATGTACCCTAGC 372624391c1
Cdx2, reverse GCGTAGCCATTCCAGTCCT 372624391c1
Quantiﬁcation
Relative quantiﬁcation was performed according to the method described by Pfa
(2001). Beta-actin was used as reference gene.
2.3.4. Cloning of Oga overexpression plasmids
With the aim of generating plasmids for overexpression of Oga, cDNA was generated
from RNA extracted from E14 mouse ES cells according to the procedure described
in section 2.3.3 and section 2.3.2. The relevant sequences for cloning were then am-
pliﬁed by polymerase chain reaction (PCR) using the primers in table 2.10. For
ampliﬁcation, PrimeSTAR HS DNA Polymerase (Clonetech) was used according to
the manufacturer's instructions.
The ampliﬁed sequences were then cloned into the pCAG-IP vector (Niwa et al.,
2002) using the XhoI and NotI restriction sites. Plasmid preparations were performed
using the QIAprep Spin Miniprep Kit (Qiagen) or the PureLink HiPure Plasmid Filter
Midiprep Kit (ThermoFisher Scientiﬁc).
Maps of the generated plasmids are depicted in ﬁgure 2.1 and ﬁgure 2.2.
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Table (2.6) Reaction for RT-qPCR
5 µl SooFast EvaGreen Supermix
1 µl primer mix (10 pmol/µl each)
1 µl nuclease-free water
3 µl cDNA
10 µl total volume
Table (2.7) Temperature proﬁle for RT-qPCR
95 ◦C 5 min
95 ◦C 15 sec
57 ◦C 32 sec 40 ×
65-95 ◦C 5 s melt curve, increment 0.5 ◦C
Figure (2.1) pCAG-IP-Oga full length
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Table (2.9) RT-qPCR primers, mouse
primer name sequence (5' to 3') primer bank ID/
publication
beta-actin, forward GGCTGTATTCCCCTCCATCG 6671509a1
beta-actin, reverse CCAGTTGGTAACAATGCCATGT 6671509a1
Ogt, forward GACGCAACCAAACTTTGCAGT 20982829a1
Ogt, reverse TCAAGGGTGACAGCCTTTTCA 20982829a1
MGEA5, forward GGGTTATGGAGCAGAGAAAAGAG 15011884a1
MGEA5, reverse CCTGGCGAAATAGCATAGATGAA 15011884a1
BMP2, forward GGGACCCGCTGTCTTCTAGT 6680794a1
BMP2, reverse TCAACTCAAATTCGCTGAGGAC 6680794a1
Eomesodermin, forward GGCCCCTATGGCTCAAATTCC 258645095c1
Eomesodermin, reverse CCTGCCCTGTTTGGTGATG 258645095c1
Brachyury, forward GCTTCAAGGAGCTAACTAACGAG 6678203a1
Brachyury, reverse CCAGCAAGAAAGAGTACATGGC 6678203a1
FGF5, forward AAGTAGCGCGACGTTTTCTTC 3721900a1
FGF5, reverse CTGGAAACTGCTATGTTCCGAG 3721900a1
Tdpoz3, forward TCTCCAATGTCCAATGCTTTCTG 157057187c1
Tdpoz3, reverse ACGGTTCCAACTATGCTCACC 157057187c1
Zfp352, forward AAGTCCCACATCTGAAGAAACAC 23821036a1
Zfp352, reverse GGGTATGAGGATTCACCCACA 23821036a1
Zscan4, forward CAGATGCCAGTAGACACCAC -
Zscan4, reverse GTAGATGTTCCTTGACTTGC -
AthoI, forward GAGTGGGCTGAGGTAAAAGAGT 6680742a1
AthoI, reverse GGTCGGTGCTATCCAGGAG 6680742a1
Sp110, forward ATGAAGGTGAACATCGCCTATG 30425106a1
Sp110, reverse GGACAGAGGGACCAGATTTTG 30425106a1
Table (2.10) Oga cloning primers
primer name sequence (5' to 3')
Oga full length, forward CTCGAGCGGCAGGAGGATGGTG
Oga full length, reverse GCGGCCGCAGTCAACTGGCTGATCTGCT
Oga, splicing variant, forward CTCGAGCGGCAGGAGGATGGTG
Oga, splicing variant, reverse CTAGTGCGGCCGCCTACAGCAAACGCT

GGAACTCTC
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Figure (2.2) pCAG-IP-Oga splicing variant
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2.4. Protein biochemistry
2.4.1. Western Blot
Lysate generation
In order to generate whole cell lysates, cells were ﬁrst washed twice with 1 × PBS.
An appropriate volume of lysis buﬀer (20 mM Tris, pH 7.5; 150 mM NaCl; 1 mM
EDTA; 1 mM EGTA; 1 µM GNS G; cOmplete Tablets, Mini, EDTA-free (Roche))
was then added to the cells and they were scraped oﬀ using a cell scraper. The lysate
was transferred to a tube and centrifuged in a tabletop centrifuge at maximum speed
for ten minutes. Subsequently, the supernatant was transferred to a new tube.
Bradford assay
Total protein concentration was determined using a photometric assay according to
Bradford (1976). For each sample, 2 µl of lysate were pipetted into a 96-well plate
and 200 µl of Bradford reagent Pierce Coomassie (Bradford) Protein Assay Kit (Ther-
moFisher Scientiﬁc) were added to the sample. Absorption at 625 nm was determined
after brief incubation using a Multiskan Spectrum (ThermoFisher Scientiﬁc) plate
reader.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
Three parts of protein lysate were mixed with one part 4 × NuPAGE LDS Sample
Buﬀer (ThermoFisher Scientiﬁc). Samples were then boiled for ﬁve minutes. Both for
SDS-PAGE and transfer Novex NuPAGE (ThermoFisher Scientiﬁc) tanks were used.
Novex NuPAGE Tris-Glycine gels were washed and inserted into the tank which was
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then ﬁlled with 1 × NuPAGE MOPS SDS Running Buﬀer (ThermoFisher Scientiﬁc).
SeeBlue Plus2 Prestained Standard (Thermo Fisher Scientiﬁc) (5 µl for a gels with
1 mm thickness) and samples were loaded (5-15 µg total protein). Gels were run at
100-200 V at constant voltage.
Transfer
Subsequently, proteins were transferred to a Polyvinylidene diﬂuoride (PVDF) mem-
brane (Immobilon-P, Millipore). For this, PVDF membranes were ﬁrst activated by
incubation in methanol. Filter paper and sponges were soaked in transfer buﬀer (ta-
ble 2.11). In order to prepare the transfer sandwich, a soaked sponge was placed into
the transfer cassette ﬁrst, followed by ﬁlter paper, the gel, the membrane, a second
ﬁlter paper and ﬁnally a second sponge. The cassette was then inserted into the tank
and ﬁlled with transfer buﬀer. The rest of the tank was ﬁlled with ice and cold water.
As a last step the transfer was performed at 50-45 V for 1.5 h.
Table (2.11) Transfer buﬀer
2.9 g glycine
5.8 g Tris base
0.37 g SDS
ad 800 ml water
200 ml methanol
Antibody incubation and development
After the transfer, the membrane was incubated in blocking buﬀer (TBS-T (table 2.12)
with either 5 % milk powder, 3% BSA or 1 % BSA corresponding to the blocking buﬀer
the antibody was diluted in). Subsequently, the membrane was incubated in primary
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antibody dilution overnight at 4 ◦C The next day, the membrane was washed three
times with TBS-T for approximately ﬁve minutes. Secondary antibodies were diluted
in 5 % milk in TBS-T according to table 2.14 and incubated for 45 minutes at room
temperature. The membrane was then washed again as previously described. To de-
velop membranes that had been incubated with a HRP-coupled secondary antibodies
ECL was used according to the manufacturer's instruction. Blots were then devel-
oped using Amersham Hyperﬁlm and an autodeveloper. When ﬂuorochrome-coupled
antibodies had been used, detection was performed using a Odyssey CLX scanner
(LI-COR Biotechnology) and Image Studio (LI-COR Biotechnology) software.
Table (2.12) TBS-T
10 mM Tris-HCl (pH 7.3)
100 mM NaCl
0.1 % Tween 20
Table (2.13) Primary antibodies for Western Blot
target supplier product number dilution blocking/dilution in
beta-actin Abcam ab6276 1:10000 3 % BSA
O-GlcNAc (CTD110.6) Covance MMS-248R 1:5000 1 % BSA
Oga Abcam ab124807 1:1000 5 % milk
Ogt Abcam ab50271 1:500 3 % BSA
2.4.2. Immunoﬂuorescence staining and analysis
In order to prepare cells for immunoﬂuorescence staining, medium was aspirated and
cell were washed twice with 1 × PBS. Cells were then ﬁxed using a 4 % formaldehyde
solution (paraformaldehyde solved in 1 × PBS) for 20 minutes at room temperature.
Subsequently, cell were again washed with 1 × PBS.
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Table (2.14) Secondary antibodies for Western Blot
Antibody supplier product number dilution
Goat anti-mouse IgM Dy-
Light 680
ThermoFisher Scientiﬁc SA5-10154 1:15000
Anti-mouse IgG (H+L),
DyLight 680
Cell Signaling Technology 5470 1:15000
Donkey anti-mouse IgG,
HRP conjugated
Millipore AP192P 1:10000
Goat anti-mouse IgM - mu
chain, HRP conjugated
Abcam ab97230 1:5000
Anti-rabbit IgG, HRP
conjugated
Cell Signalling Technol-
ogy
7074 1:1000
Cells that would be stained with antibodies against Oct4, Nanog or HNF-III-β
were treated with 90 % ice-cold methanol for ﬁve minutes on ice before permeabili-
sation/blocking. For combined permeabilisation and blocking, cells were then treated
with 4% BSA in PBS/0.2% Triton-X-100. Cells that would subsequently be stained
with antibodies for detecting extracellular markers (TRA-1-60, TRA-1-80) were not
permeabilized and blocked using 4% BSA in PBS without any detergent. Cells were
then washed again with 1 × PBS and primary antibodies were incubated overnight
at 4 ◦C All primary antibody dilutions were made up in 4 % BSA/PBS according to
table 2.15.
After primary antibody incubation cells were washed four times with 1 × PBS (ap-
proximately ten minutes per wash). Secondary antibody dilutions were then prepared
in 4 % BSA/PBS (see table 2.16, all antibodies diluted 1:500) and incubated for 20
minutes on the cells at room temperature (protected from light). For nuclear staining
DAPI (4',6-diamidino-2-phenylindole) (ﬁnal concentration: 300 nM) was added to the
secondary antibody dilution.
Subsequently, secondary antibodies were taken oﬀ and the cells were again washed
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Table (2.15) Primary antibodies for immunoﬂuorescence
target supplier product number dilution
Oct-3/4 Antibody (C-10) Santa Cruz sc-5279 1:100
Nanog (D73G4) XP R©
Rabbit mAb
Cell Signaling Technology 4903 1:200
TRA-1-60 antibody Santa Cruz sc-21705 1:50
TRA-1-81 (TRA-1-80)
antibody
Santa Cruz sc-21706 1:50
HNF-3-β antibody (MC-
20)
Santa Cruz sc-6554 1:100
ZO-1 / TJP1 Antibody ThermoFisher Scientiﬁc 40-2200 1:300
N-cadherin / CDH2 Anti-
body (NCD-2)
ThermoFisher Scientiﬁc 13-2100 1:300
Monoclonal Anti-β-
Tubulin III (neuronal)
antibody produced in
mouse
Sigma T8578 1:600
Sox2 (D6D9) XP Rabbit
mAb
Cell Signaling Technology 3579 1:400
Table (2.16) Secondary antibodies for immunoﬂuorescence
Antibody supplier product number
Goat anti-mouse IgG / IgM (H+L),
Alexa Fluor 488
Thermo Fisher Scientiﬁc A-10680
Donkey anti-rabbit, Alexa Fluor 488 Thermo Fisher Scientiﬁc A-12206
Donkey anti-mouse, Alexa Fluor 568 Thermo Fisher Scientiﬁc A-10037
Donkey anti-mouse, Alexa Fluor 647 Thermo Fisher Scientiﬁc A-31571
Donkey anti-Rat IgG (H+L), Alexa
Fluor 488
Thermo Fisher Scientiﬁc A-21208
Donkey anti-goat IgG (H+L), Alexa
Fluor 488
Thermo Fisher Scientiﬁc A-11055
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four times with 1 × PBS. Cells were then analyzed using a DeltaVision Microscopy
Imaging System (GE Healthcare) and softWoRkx (AppliedPrecision).
2.5. Epigenetic methods
2.5.1. Histone extraction
Histone extracts were generated for as starting material for analysis of histone modi-
ﬁcations, i. e. by Western Blot or enzyme-linked immunosorbent assay (ELISA) (see
below). First, cells were detached with accutase (Life Technologies) and resuspended
in 1 × PBS. The cell suspension was spun down at 1000 rpm and 4◦C for ﬁve minutes.
The supernatant was discarded, the cell pellet was resuspended in TEB buﬀer (107
cells per 1 ml buﬀer; PBS + 0.5 % Triton + 0.02 % sodium azide + Pefabloc SC (0.1
mM, Roche)) and samples were left to lyse on ice for ten minutes with gentle stirring.
Subsequently, samples were centrifuged (3000 rpm for ﬁve minutes for volumes over 1.5
ml, 10 000 rpm for 1 minute for volumes up to 1.5 ml). The supernatant was removed
and the pellet was resuspended in extraction buﬀer (200 µl buﬀer per 107 cells; 0.5 N
hydrochloric acid + 10 % gylcerol) and incubated on ice for 30 minutes. Samples were
then centrifuged again at 12 000 rpm at 4◦C for ﬁve minutes. The supernatant was
transferred to a new vial and acetone was added (600 µl per 107 cells). After mixing
the samples they were incubated overnight at -20◦C.
The next day, samples were centrifuged at 12 000 rpm for ﬁve minutes, the super-
natant was discarded and the pellets were air-dried. As a last step the pellet was
dissolved in distilled water (30-50 µl per 107 cells).
73
2.5.2. Histone 3 acetylation: enzyme-linked immunosorbent
assay
Analysis of histone 3 acetylation levels by ELISA was performed using the Histone H3
Acetylation Assay Kit (Abcam: ab115102) according to the manufacturer's instruc-
tions. Colorimetrc readout was performed using a Multiskan Spectrum (ThermoFisher
Scientiﬁc) plate reader.
2.5.3. Bisulﬁte sequencing
DNA methlyation was analysed by bisulﬁte sequencing. Genomic DNA was extracted
from E14 mouse ES cells according to the procedure for DNA extraction described
above (section 2.3.1). Subsequently, DNA samples were bisulﬁte converted using the
Epitect Bisulﬁte Conversion kit (Qiagen) according to the manufacturer's instructions.
For each sample, 2 µg of total DNA were converted.
Bisulﬁte-converted DNA (1 µl of the conversion mix) was then ampliﬁed using Epi-
Taq HS polymerase (Clonetech) according to the manufacturer's standard protocol
and primers designed for the ampliﬁcation of bisulﬁte-converted templates (table 2.17,
designed using MethPrimer by Li Lab, Peking Union Medical College Hospital). Fol-
lowing ampliﬁcation, 25 µl of the PCR reaction were treated with 6 U Klenow fragment
for 20 minutes at room temperature. Samples were then cleaned up using the Qiaquick
Gel Extraction kit (Qiagen) according to the kit instructions from step four onwards.
DNA was eluted in 25 µl EB buﬀer.
PCR products were then cloned into a pSC-B vector. For this, the Stratclone
Blunt Cloning (Agilent Technologies) kit was used according to the respective instruc-
tions. Transformed cells were plated onto X-Gal- and ampicillin-containing LB agar
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Table (2.17) bisulﬁte-speciﬁc primers
primer name sequence (5' to 3')
beta-actin, forward GTTTTTTTTGTTTTTTGAGTTTGG
beta-actin, reverse TCACCCACATAAAAATCCTTCTAAC
REST, forward AAAAGAAAGAAGGATGTTGAGGTTTA
REST, reverse AAAATCTAAAAACACCCCCACTTA
Sp110, forward TGAATGTAGTTAAGGAGAGGTATAGTT
Sp110, reverse ATCAAAAAAAACCACAAATAAATAC
Klf4, forward TGTTTTTTTATGTGTAAGGTAAGGTG
Klf4, revers CTTCTAACAATAACTTCAACAACCC
Xist, forward GTAATTGGTTGTTTTTATTTAGTT
Xist, reverse CCTAAAATATCTATACCTCTTATTTAC
Rex1, forward TATTTTGGTATTTTGGATTGGTTTT
Rex1, reverse AATCACTTTCTCACCATAAACTCTC
plates. Per reaction, ﬁve white colonies were picked for plasmid preparation. Plasmid
minipreps were performed using the QIAprep Spin Miniprep Kit (Qiagen). Plasmids
were then send for sequencing using M13 forward and reverse primers. Analysis of the
sequencing results was performed using BiQ Analyzer v2.0 (Bock et al., 2005).
2.5.4. Sample preparation for HPLC-MS
High-performance liquid chromatography-mass spectrometry (HPLC-MS) analysis of
genomic DNA for E14 and ChiPS4 cells was performed by Dr Rachel Amouroux in
the group of Petra Hajkova (Imperial College, London). Genomic DNA was extracted
using the ZR-Duet DNA/RNA miniprep kit form Zymo Research (Cambridge) ac-
cording to the manufacturer's instructions. DNA was eluted in LC-MS grade water
(Fisher Scientiﬁc, order number W/0112/17).
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2.6. Flow Cytometry
Flow cytometry was performed using an LSRFortessa cytometer (BD Biosciences,
Belgium). Data analysis was performed using FlowJo (FlowJo, USA).
Viability assay
To determine viability of live cells by ﬂow cytometry approximately 2×106 cells were
detached using 1× TrypLE Select Enzyme (ThermoFisher Scientiﬁc, USA). The en-
zyme was inhibited by adding standard culture medium (at least four times the volume
of the TrypLE Select volume). The cell suspension was subsequently transferred to 5
ml polystyrene round-bottom tubes (Falcon, USA) and cells were pelleted by centrifu-
gation (200× g, 2 min). After discarding the supernatant the cells were resuspended
in 300 µl 5 µg/ml DAPI (Sigma-Aldrich, USA) in PBS containing 1 % FCS (PBS/1%
FCS). Subsequently, the cells were analysed for DAPI staining as an indicator of dead
cells.
Cell cycle analysis
For analysing cell cycle, approximately 2×106 cells were detached by the method
described above. Again, the cells were transferred into standard culture medium in
5 ml polystyrene round-bottom tubes (Falcon, USA) and pelleted by centrifugation
(200× g, 2 min). The supernatant was discarded and cells were resuspended in the
small volume remaining. Per tube, 1 ml of PBS/1% FBS was added. Cells were
pelleted again by centrifugation. Subsequently, the supernatant was poured oﬀ and
the pellet was resuspended in the volume remaining in the tube. While vortexing, 1
ml of ice-cold 90% methanol was added to the cells. The cells were then incubated
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in the ﬁxative for at leat 30 min at room temperature. After this, the cells were
washed twice with 1 ml PBS/1% FBS. Following the last centrifugation step, the
supernatant was removed completely and cells were resuspended in 300 µl of staining
buﬀer (50 µg/ml propidium iodide (PI) (Sigma-Aldrich, USA), 50 µg/ml RNase A
(Sigma-Aldrich, USA) in PBS/1% FBS). The cell suspension was then incubated for 20
min at room temperature protected from light. Analysis of propidium iodide staining
was performed by ﬂow cytometry and cell cycle analysis was carried out using FlowJo
with a Watson Pragmatic algorithm.
Analysis for RFP or EGFP expression
In order to analyse the expression of RFP or EGFP of relevant reporter cell lines, cells
were dissociated and stained with DAPI using the method described above. The cells
were then analysed for their ﬂuorescence properties and DAPI was used to exclude
dead cells from the analysis.
2.7. RNA sequencing
2.7.1. Cell treatments and sample preparation
ChiPS4 were plated in 6-well-plates at a density of 30 000 cells/cm2 and treated with 1
mM GNS or the equivalent volume of DMSO. Cells were kept under standard culture
conditions for three days and RNA lysates were then generated. RNA extraction
was performed as described in section 2.3.3 and the RNA was handed over to the
Genetics Core Services Unit at Ninewells Hospital and Medical School in Dundee
where ribosomal depletion, library preparation and sequencing were carried out.
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2.7.2. Bioinformatic analysis
Bioinformatic analysis was performed in collaboration with Pieta Schoﬁeld (Data Anal-
ysis Group, University of Dundee).
Alignment against the human genome reference (GRCh38) was carried out using
STAR2.5 (Dobin et al., 2013). Diﬀerential gene expression analysis was then performed
using the Bioconductor package edgeR (Robinson et al., 2010). The Bioconductor
packages biomaRt (Durinck et al., 2009) and StringDB (Franceschini et al., 2013) were
used for further analysis of the data, i.e. gene ontology and kegg pathway analysis.
The relevant R code sections are provided in the appendix (section A.1.3).
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3. O-GlcNAc function in pluripotent stem cells and
diﬀerentiation
3.1. Eﬀects of GlcNAcstatin on mouse embryonic stem cells
3.1.1. GlcNAcstatin G treatment does not aﬀect viability or
cell cycle
GlcNAcstatins have been reported to inhibit Oga in a highly speciﬁc manner by bind-
ing to the active site of the enzyme and preventing substrate glycosylation. Further-
more, these inhibitors have been shown to induce hyper-O-GlcNAcylation in human
cell lines. (Dorfmueller et al., 2006, 2009) In order to investigate the eﬀects of in-
creased global levels of O-GlcNAc in pluripotent stem cells, GlcNAcstatin G (GNS G)
was added to the culture medium at a concentration of 1 µM.
With the aim of ruling out potential oﬀ-target eﬀects of GNS G on pluripotent stem
cells, I set out to validate that cell viability and cell cycle are unaﬀected by treatment
with GNS G. This was essential as eﬀects on viability or cell cycle might impact
on the cells ability to diﬀerentiate into diﬀerent lineages. Therefore, ﬂow cytometry
experiments on E14Tg2aIV (E14) mouse ES cells were carried out.
In order to determine potential eﬀects on viability cells were treated with GNS
G for approximately 48 h and stained with DAPI. This allows determination of the
number of dead cells within the population by inclusion of the dye. The ﬁndings of
these ﬂow cytometry experiments are illustrated in Figure 3.1 A and B. The overall
percentage of dead cells was low (less than 8 %) and no signiﬁcant diﬀerences could be
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detected between GNS G treated cells and those that had been treated with a DMSO
vehicle control. It is evident from these results that GNS G treatment does not impair
viability of E14 mouse ES cells.
Previously obtained data on mouse 46C ES cell proliferation suggest that the cell
cycle of mouse ES cells is also not aﬀected by GNS G treatment (Speakman et al.,
2014). To extend and validate those ﬁndings, cell cycle analysis using PI staining and
ﬂow cytometry was performed. This method allows a precise determination of the
number of cells in G1-, S- and G2-phase by assessing the cell's DNA content. Again,
cells were treated for at least 48 h with GNS G before being submitted to the analysis.
It becomes clear from Figure 3.1 C, D and E that GNS G has no eﬀect on the cell
cycle. Taken together these results are consistent with our previous ﬁndings showing
that GNS G does not impair cell proliferation.
It is apparent from the results described above that GNS G does not exhibit any
unintended eﬀect on the viability and cell cycle of mouse ES when used at a ﬁnal
concentration of 1 µM. It can therefore be concluded that the observed eﬀects described
below are unrelated to any impact of GNS G treatment on proliferation or viability.
3.1.2. Inhibition of Oga by GlcNAcstatin increases global
O-GlcNAc levels and leads to a feedback upregulation of
Oga
To further characterize the eﬀects of GNS treatment on mouse ES cells, previously
reported eﬀects of GNS C on global O-GlcNAcylation as well as on protein levels of
Oga and Ogt (Speakman et al., 2014) had to be validated. With the aim of describing
the eﬀects of GNS treatment on O-GlcNAc levels and the two regulators, Western
Blotting was performed using protein lysates obtained from E14 mouse embryonic
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Figure (3.1) GNS G treatment does not aﬀect viability or cell cycle of E14Tg2aIV mouse ES cells.
A, B: Flow cytometry of DAPI stained cells showing that viability is not aﬀected by GNS G treatment. A: Gating
strategy excluding debris and cell duplets. Numbers in the boxes indicate percentage of total counts. B: Percentages
of single cells after exclusion of debris and duplets with high DAPI (dead cells) and low DAPI (live cells) staining. C,
D: Flow cytometry of propidium iodide stained cells indicate no changes in cell cycle. E: Representative cell cycle
proﬁles of control treated (left graph) and GNS G treated (right) cells. (n=3 independent biological repeats for all
experiments, errorbars represent standard error of the mean (SEM))
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Figure (3.2) GNS G increases O-GlcNAcylation and leads to feedback regulation of Oga and Ogt in
mouse ES cells. A: Whole cell lysates obtained from E14 mouse ES cells treated with various concentrations of
GNS G show increased O-GlcNAcylation, feedback upregulation of Oga and downregulation of Ogt protein levels. A
representative Western Blot is shown.
stem cells treated with GNS G at three diﬀerent concentrations (0.5 µM, 1 µM and 2
µM) for 48 h. As shown in Figure 3.2, treatment with GNS G dramatically increases
global O-GlcNAc levels even at 0.5 µM. In addition, inhibition of Oga by GNS G could
be demonstrated to aﬀect total protein levels of Oga and Ogt. While Ogt protein levels
decrease with increasing GNS G concentration, Oga protein levels become elevated.
These ﬁndings demonstrate a feedback regulation of the two enzymes by global O-
GlcNAcylation levels. It can also be seen from this result that a further increase in
GNS concentration from 1 µM to 2 µM only has little eﬀect on global O-GlcNAcylation
as well as on Ogt and Oga proteins levels.
Those results are in good agreement with the eﬀects of Oga inhibitors described for
other models as well as with previous data from our group (Speakman et al., 2014).
As expected, treatment with GNS G leads to elevated O-GlcNAc levels and feedback
regulation of Oga and Ogt. However, it is important to note that modulation of this
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system is only possible to a certain extent and the addition of GNS at concentrations
above 1 µM does not aﬀect O-GlcNAcylation any further.
3.1.3. Elevated O-GlcNAc levels delay spontaneous
diﬀerentiation into mesodermal and endodermal lineage
The key feature of pluripotent stem cells is their ability to diﬀerentiate into cells of
all three germ layers as well as the germline. In order to understand the function
of O-GlcNAcylation in early development and pluripotent stem cells it is essential to
elucidate potential roles of the modiﬁcation in mouse ES cell diﬀerentiation. Overall
very little work has been done on this subject. Kim et al. (2009) describe a progressive
reduction of O-GlcNAc levels and Ogt protein during cardiomyocyte diﬀerentiation.
Moreover, their results indicate that excessive O-GlcNAcylation in response to treat-
ment with the Oga inhibitor PUGNAc impairs cardiogenesis. In accordance to this
study, recent results conﬁrm that O-GlcNAc levels decrease during mouse ES cell
diﬀerentiation (Speakman et al., 2014). In addition, a delay in the onset of neural
diﬀerentiation has been shown in response to Oga inhibition by GNS C (Speakman
et al., 2014). In order to extend previous ﬁndings the eﬀects of increased protein
O-GlcNAcylation on the ability of mouse ES cells to diﬀerentiate spontaneously in
embryoid bodies were investigated. In contrast to lineage-speciﬁc diﬀerentiation pro-
tocols, this assay allows the cells to diﬀerentiate into cells of any lineage rather than
directing diﬀerentiation towards a speciﬁc fate by changes of culture medium or ad-
dition of growth factors. Due to this undirected nature of spontaneous diﬀerentiation
the resulting cell population contains cells of all three lineages which allows the as-
sessment of potential eﬀects on each lineage by observing the expression of speciﬁc
marker genes (Martin et al., 1977; Coucouvanis and Martin, 1995). For this assay 46C
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cells were cultured in embryoid bodies using standard culture medium without LIF,
but supplemented with either GNS C or DMSO. Cells were diﬀerentiated for ﬁve days
and quantitative RT-PCR for marker genes was performed on mRNA extracted from
undiﬀerentiated cells as well as from cells at day 3 and day 5 of diﬀerentiation. Fig-
ure 3.3 A, B and C illustrate the results of the analysis for the endoderm marker BMP2
and the mesoderm markers Eomesodermin and Brachyury. The expression of all three
genes is reduced in GNS treated cells when compared to cells treated with a vehicle
control. This indicates a delay in diﬀerentiation into both endodermal and meso-
dermal lineage. Combined with previously obtained data on ectoderm diﬀerentiation
(Speakman et al., 2014) these results clearly indicate a crucial role of O-GlcNAcylation
during mouse ES cell diﬀerentiation which appears to be lineage-independent.
Surprisingly, the expression of the transient epiblast marker Fgf5 appears to be
unchanged by GNS treatment (Figure 3.3 D). This ﬁnding implies that while lin-
eage speciﬁcation is impaired by GNS treatment transition from naïve to formative
pluripotency remains unaﬀected. Further experiments have also demonstrated that
expression of naïve pluripotency markers like Nanog, Rex1 (Zfp42), Esrrb and Dppa3
are unaltered by GNS induced Oga inhibition supporting the conclusion that naïve to
formative transition is not modulated by O-GlcNAc levels (Speakman et al., 2014).
These data clearly demonstrate that elevated O-GlcNAc levels aﬀect diﬀerentiation
of mouse ES cells in a lineage-independant manner. The data also implies that early
onset of diﬀerentiation remains largely unaﬀected as both the marker expression lev-
els at early timepoints in diﬀerentiation (day three) and expression of Fgf5 remain
unchanged by GNS treatment.
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Figure (3.3) Endoderm and mesoderm diﬀerentiation is hindered by GNS C treatment while naïve to
formative transition is unchanged. RT-qPCR analysis of marker genes for endoderm (A), mesoderm (B, C) and
the epiblast (D) during spontaneous diﬀerentiation in embryoid bodies. n=3 independent biological repeats, errorbars
indicate SEM; ***: p ≤ 0.001; **: p ≤ 0.01; *: p ≤ 0.05; n.s.: p > 0.05 (Student's t-test, unpaired)
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3.2. Eﬀects of GlcNAcstatin on human iPS cells
3.2.1. GlcNAcstatin G treatment does not aﬀect viability or
cell cycle
Human iPS cells represent an excellent system to study diﬀerentiation in a human
pluripotent cell type without the need of using ES cells and a multitude of targeted
diﬀerentiation assays for those cells have been developed over the last years (Takahashi
et al., 2007; Taura et al., 2009; Hirami et al., 2009; Tanaka et al., 2009). In order to
extend the ﬁndings in mouse ES cells to another model system, ChiPS4 human iPS
cells generated by the human pluripotent stem cell facility of the University of Dundee
were used for the experiments described in the following.
In order to ensure that GNS treatment would not interfere with cell viability or cell
cycle a similar set of ﬂow cytometry experiments as described in section 3.1.1 were
performed. In contrast to the experiments done with mouse ES cells, human iPS cells
were treated with GNS G for three days instead of 48 h. The reason for this prolonged
treatment is the fact that human iPS cells divide slower than mouse ES cells and
potential eﬀects could otherwise be masked by a too brief treatment.
Again, cells were analysed by ﬂow cytometry for inclusion of DAPI in order to
determine the number of viable cells. The gating strategy and the result of this
experiment are depicted in Figure 3.4 A and B. As can be seen from Figure 3.4 B,
the percentage of living cells was very high (more than 80 % of single cells) and there
were no detectable diﬀerences between cells that had been treated with GNS and the
vehicle control. It can therefore be concluded that GNS G does not aﬀect human iPS
cell viability.
With the aim of ruling out any possible eﬀects of GNS on the cell cycle of ChiPS4
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Figure (3.4) GNS G treatment does not aﬀect viability or cell cycle of ChiPS4 cells. A, B: Flow
cytometry of DAPI stained cells showing that viability is not aﬀected by GNS G treatment. A: Gating strategy
excluding debris and cell duplets. Numbers in the boxes indicate percentage of total counts. B: Percentages of single
cells after exclusion of debris and duplets with high DAPI (dead cells) and low DAPI (live cells) staining. C, D: Flow
cytometry of propidium iodide stained cells indicate no changes in cell cycle. E: Representative cell cycle proﬁles of
control treated (left graph) and GNS G treated (right) cells. (n=3 independent biological repeats for all experiments,
errorbars represent SEM)
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cells we performed PI staining for DNA content on living cells followed by ﬂow cy-
tometry analysis (gating strategy in Figure 3.4). The results of this experiment are
illustrated in Figure 3.4 D and E. As can be seen from the cell cycle proﬁles there
were no diﬀerences between ChiPS4 treated with GNS and those cells that had been
treated with a DMSO control. Interestingly, when comparing the cell cycle proﬁles of
ChiPS4 with our previous experiment using mouse ES cells (see Figure 3.1 D, E) it
is clear that there are more ChiPS4 cells in G2 than mouse ES cells. This increase in
the G2-population for human iPS cells corresponds to their slower cell cycle. To sum-
marize, GNS G does not have any detectable eﬀect on either human iPS cell viability
or cell cycle. Any eﬀects of GNS treatment on diﬀerentiation are therefore unlikely to
be caused by cell death or reduced proliferation of the cells.
3.2.2. Inhibition of Oga by GlcNAcstatin increases global
O-GlcNAc levels and leads to a feedback regulation of
Oga and Ogt
As described in section 3.1.2 GNS treatment leads to an increase in global O-GlcNAc
levels and respective feedback regulation of Oga and Ogt in mouse ES cells. As to
ensure that these eﬀects can be reproduced in human iPS cells, ChiPS4 were treated
with two diﬀerent concentrations of GNS G for three days and whole cell lysates were
harvested and analysed by Western Blot. As illustrated in Figure 3.5 O-GlcNAcylation
was found to be signiﬁcantly increased at 1 µM GNS. In addition, Ogt protein lev-
els were dramatically decreased in GNS treated cells due to the expected feedback
mechanism. Interestingly, the amount of Oga protein did not seem to be as strongly
aﬀected. It is also important to note that an increase in GNS concentration to 2 µM
did not elevate O-GlcNAc levels any further and had very little additional eﬀect on
88
Figure (3.5) GNS G increases O-GlcNAcylation and leads to feedback regulation of Oga and Ogt
in human iPS cells. A: Whole cell lysates obtained from ChiPS4 cells treated with various concentrations of
GNS G show increased O-GlcNAcylation, feedback upregulation of Oga and downregulation of Ogt protein levels. A
representative Western Blot is shown.
Oga and Ogt protein levels. These ﬁndings are consistent with our results in mouse
ES cells and demonstrate clearly that GNS G concentrations of beyond 1 µM do not
have an additional eﬀect in modulating O-GlcNAcylation.
3.2.3. GNS does not aﬀect pluripotent stem cell markers
Data by Maury et al. (2013) had suggested that while excess O-GlcNAcylation can
modify diﬀerentiation of human ES cells it does not aﬀect these cells in their undif-
ferentiated state. In order to determine whether ChiPS4 can be maintained in an
undiﬀerentiated state when treated with GNS G, cells were analysed for their ex-
pression of pluripotency markers. As illustrated in Figure 3.6 A gene expression of
Nanog and Oct4 remain unchanged in ChiPS4 that had been treated with GNS G
for three days. In order to further validate those ﬁndings, immunoﬂuorescence stain-
ing and analysis was performed on ChiPS4 (again after three days of treatment with
GNS). It can be observed that both the transcription factor Nanog (Figure 3.6 B)
and the extracellular stem cell marker TRA-1-60 (Figure 3.6 C) are expressed in the
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Figure (3.6) GNS G treatment does not aﬀect pluripotent stem cell markers in ChiPS4. A: Gene
expression of Nanog and Oct4 remain unaﬀected by GNS G treatment (n=6 independent biological replicates, errorbars
represent SEM; n.s.: p > 0.05 (Student's t-test, paired).). B, C: Pattern and intensity of staining for the transcription
factor Nanog and the extracellular stem cell marker TRA-1-60 are unaﬀected by GNS G treatment. Representative
images are shown. scalebar: 40 µm
same pattern and quantity when comparing GNS treated ChiPS4 to the respective
control. These data indicate that pluripotency markers of ChiPS4 is not aﬀected by
high O-GlcNAcylation and that undiﬀerentiated cells are maintained under GNS G
treatment.
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3.3. The role of O-GlcNAc during diﬀerentiation of human iPS
cells
Data presented in the previous sections provides validation of the eﬀects of GNS
treatment on global O-GlcNAc levels and their regulating enzymes in undiﬀerentiated
pluripotent stem cells. I then set out to investigate potential eﬀects of elevated O-
GlcNAcylation on diﬀerentiation of human iPS cells into diﬀerent lineages. Therefore,
one directed diﬀerentiation assay per lineage was chosen and the dynamics of global
O-GlcNAc levels as well as expression of lineage marker genes were investigated with
the aim of determining potential consequences of GNS treatment.
3.3.1. O-GlcNAc functions in hepatocyte diﬀerentiation of
ChiPS4
In order to investigate the diﬀerentiation into endoderm an assay for generation of
hepatocytes from human iPS cells was chosen based on the protocol described by
Medine et al. (2011). A brief overview of the three main steps of this protocol is il-
lustrated in Figure 3.7 A. Cells are ﬁrst diﬀerentiated into deﬁnitive endoderm which
is achieved by supplementing the medium with Activin A and the GSK-3 inhibitor
CT99021. After three days all cells are expected to have committed to endodermal
lineage and can be further diﬀerentiated into hepatocytes in two following steps: hep-
atocyte diﬀerentiation and hepatic maturation (Medine et al., 2011).
Initially, lysates for RNA extraction were generated at diﬀerent timepoints during
the hepatocyte diﬀerentiation which were then analysed for the expression of relevant
marker genes by RT-qPCR. Lysates were obtained from both cells treated with GNS
and control cells treated with DMSO. A set of markers consisting of pluripotency
markers (Oct4, Nanog), deﬁnitive endoderm markers (Sox17, FoxA2 ) and hepatocyte
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Figure (3.7) RT-qPCR analysis of marker gene expression during hepatocyte diﬀerentiation A: Time-
course of the hepatocyte diﬀerentiation protocol; B: mRNA levels of the pluripotency markers Oct4 and Nanog; C:
gene expression proﬁles of the deﬁnitive endoderm markers Sox17 and FoxA2 ; D: expression of the hepatocyte marker
genes alpha-fetoprotein (AFP) and albumin. n=3 independent biological repeats, errorbars represent SEM
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markers (alpha-fetoprotein (AFP), albumin) was chosen in order to obtain detailed
information about the diﬀerentiation process. The results of the RT-qPCR analysis
are shown in Figure 3.7 B-D. As expected, the expression of the pluripotency markers
Oct4 and Nanog drops very quickly with the onset of diﬀerentiation within the ﬁrst two
days of this assay (Figure 3.7 B). For both pluripotency markers there are no diﬀerences
in gene expression when comparing GNS treated and untreated cells. Figure 3.7 C
illustrates the timecourse of the expression of the transient markers Sox17 and FoxA2.
Both genes are transiently expressed during the deﬁnitive endoderm priming step (day
2 to day 8) and experience a sharp drop in expression as cells progress towards a
hepatic fate. Again, there are no signiﬁcant diﬀerences between cells that had been
treated with GNS and the vehicle control indicating that diﬀerentiation onset and
lineage speciﬁcation to endoderm are not aﬀected by Oga inhibition. For the two
mature hepatocyte markers AFP and albumin mRNA levels begin to increase steadily
from day 10 onwards as cells begin to complete diﬀerentiation into hepatocytes (see
Figure 3.7 D). Interestingly, high variations in the magnitude of expression of these
genes between experiments were observed. These are most likely caused by biological
diﬀerences between individual experiments which will impact on the cells' ability to
fully diﬀerentiate into mature hepatocytes (i.e. plating density). It can be summarized
from the data presented above that both lineage commitment to endoderm and hepatic
maturation remain unaﬀected by Oga inhibition in response to GNS treatment in this
assay.
With the aim of further validating these observations, the expression of marker pro-
teins for deﬁnitive endoderm diﬀerentiation was investigated. Therefore, the same dif-
ferentiation assay as previously described was applied but the experiment was stopped
after completion of the deﬁnitive endoderm priming step (day 4). Cells were then ﬁxed
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Figure (3.8) Immunoﬂuorescence staining for markers of pluripotency (Oct4) and deﬁnitive endoderm
diﬀerentiation (HNF3-β). Oct4 (A) and HNF3-β (B) expression in undiﬀerentiated ChiPS4; C, D: Expression of
Oct4 and HNF3-β after 4 days of diﬀerentiation in DMSO treated cells; E, F: Expression of Oct4 and HNF3-β after
4 days of diﬀerentiation in GNS treated cells. Representative images are shown. Scalebar: 50 µm.
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Figure (3.9) Variations in global O-GlcNAc levels during hepatocyte diﬀerentiation of ChiPS4. Left
panel: O-GlcNAcylation of ChiPS4 treated with DMSO. Right panel: O-GlcNAcylation of GNS treated cells. A
representative Western Blot is shown.
and subjected to immunoﬂuorescence staining and microscopy. The samples were then
analysed for the expression of Oct4 as a marker of pluripotency and HNF3-β as endo-
derm marker. The respective results are presented in Figure 3.8. As expected Oct4 was
highly expressed in undiﬀerentiated ChiPS4 cells, whereas HNF3-β was not expressed
(Figure 3.8 A and B). After four days of diﬀerentiation into deﬁnitive endoderm only
few cells remained Oct4-positive in the DMSO control (Figure 3.8 C). For cells that
had been treated with GNS Oct4 expression was reduced even more than in the ve-
hicle control (Figure 3.8 E). However, both DMSO and GNS treated cells displayed
high levels and a uniform expression pattern of HNF3-β after deﬁnitive endoderm dif-
ferentiation (Figure 3.8 D and F). These ﬁndings underline the previous results and
demonstrate that GNS treated cells successfully diﬀerentiate into deﬁnitive endoderm.
In addition to the analysis of marker expression it is important to understand how
O-GlcNAc levels change over the course of diﬀerentiation. For this experiment whole
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cell lysate was harvested at diﬀerent timepoints of the diﬀerentiation and Western
Blot analysis was performed using an antibody that detects O-GlcNAc. As illustrated
in Figure 3.9 the overall levels of O-GlcNAcylation change little over the course of this
assay. Strikingly, O-GlcNAcylation exhibits a very dynamic pattern which is most
likely caused by the modiﬁcation being removed from certain proteins and attached to
others. At day 10 and 18 of the assay a strong shift of O-GlcNAcylation from proteins
of low molecular weight towards those with high molecular weight can be observed. At
those timepoints only very few proteins below a molecular weight of 51 kDa appear to
be weakly modiﬁed. The right panel of Figure 3.9 displays the respective analysis of O-
GlcNAcylation for GNS treated cells. In comparison to the vehicle control O-GlcNAc
levels are clearly increased. Interestingly, the levels appear to be ﬂuctuating more in
the GNS treated cells than in the DMSO control. It appears that O-GlcNAcylation
is reduced for day two and three of the diﬀerentiation followed by an increase on
day four. On day eight O-GlcNAcylation drops again dramatically whereas both day
10 and 18 are characterized by very high O-GlcNAc levels. However, the pattern
of O-GlcNAcylation remains dynamic with a shift towards more modiﬁcation of high
molecular weight proteins at the ﬁnal stage of the diﬀerentiation assay. Taken together,
the O-GlcNAcylation pattern and levels are dynamic during hepatocyte diﬀerentiation.
These ﬁndings imply that while the levels of the modiﬁcation appear to be of minor
importance for successful diﬀerentiation, the addition and removal of O-GlcNAc from
certain proteins might be essential as the pattern of O-GlcNAcylation is maintained
even in GNS treated cells.
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3.3.2. O-GlcNAc functions in cardiomyocyte diﬀerentiation of
ChiPS4
With the aim of investigating potential eﬀects of elevated O-GlcNAc levels on ChiPS4
diﬀerentiation into mesodermal lineage a cardiomyocyte diﬀerentiation protocol was
applied. In brief, ChiPS4 were diﬀerentiated according to the protocol described
by Burridge et al. (2014) and the Wnt signalling pathway was modulated in order
to trigger the lineage commitment. Again, RNA lysates were obtained at diﬀerent
timepoints during the diﬀerentiation and these were subsequently analysed for relevant
marker genes by RT-qPCR.
As detailed in Figure 3.10 A, both Oct4 and Nanog expression decreases rapidly with
the onset of diﬀerentiation with no signiﬁcant diﬀerences between GNS G treated cells
and the DMSO control. As transient marker of the diﬀerentiation process Brachyury
and GATA5 were investigated (Figure 3.10 B). Brachyury gene expression peaks early
in diﬀerentiation around day 1. When comparing GNS G and DMSO treated cells, it
becomes clear that there is a slight increase in Brachyury expression in GNS G treated
cells on day 1. However, the overall expression pattern of the marker is maintained. For
GATA5, there are no signiﬁcant diﬀerences between cells with elevated O-GlcNAc lev-
els and the control. As late markers of this diﬀerentiation, cardiac troponin T (cTNT )
and HAND1 were chosen (Figure 3.10 C). Both markers are induced to a comparable
degree in both GNS G treated cells and the control. However, slight diﬀerences can
be observed at intermediate stages of the diﬀerentiation, i.e. for HAND1 expression
on day 7. Taken together these results demonstrate that ChiPS4 diﬀerentiation into
the mesodermal lineage remains largely unaﬀected by increase O-GlcNAcylation in
response to GNS G.
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Figure (3.10) RT-qPCR analysis of marker gene expression during cardiomyocyte diﬀerentiation. A:
mRNA levels of the pluripotency markers Oct4 and Nanog; B: gene expression proﬁles of the transient diﬀerentiation
markers Brachyury and GATA5 ; C: expression of the cardiomyocyte markers cTNT and HAND1. n=3 independent
biological repeats, errorbars represent SEM.
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In addition to the analysis of marker gene expression, global O-GlcNAcylation at
diﬀerent timepoints during cardiomyocyte diﬀerentiation was analysed by Western
Blot. The result of this is displayed in Figure 3.11. It is clear that O-GlcNAcylation
initially decreases with the onset of diﬀerentiation. Throughout the diﬀerentiation
process, O-GlcNAc levels remain at a low level and only increase again at late stages
of the diﬀerentiation (day 10). Overall the pattern of O-GlcNAcylation displays lit-
tle dynamics. Interestingly, treatment with GNS G appears to not only raise total
O-GlcNAcylation, but it also induces peaks of high O-GlcNAcylation at intermedi-
ate timepoints of diﬀerentiation (i.e. day 5). These ﬁndings might suggest a role
of O-GlcNAc that modiﬁes intermediate diﬀerentiation processes in this assay. How-
ever, cells appear to be able to commit to the mesodermal lineage regardless of those
modiﬁcations.
3.3.3. O-GlcNAc functions in ectodermal diﬀerentiation of
ChiPS4
GNS treatment hinders neural diﬀerentiation of ChiPS4
Previous experiments in mouse ES cells had shown a pronounced eﬀect of GNS treat-
ment on neural diﬀerentiation (Speakman et al., 2014). Therefore, a neural diﬀeren-
tiation assay was chosen to test for eﬀects of GNS on diﬀerentiation into ectodermal
lineage. The diﬀerentiation was performed according to the well-established protocol
published by Chambers et al. (2009). The protocol is based on high density culture of
human iPS cells which are subjected to dual inhibition of SMAD signalling in order
to direct their diﬀerentiation to a neural fate (Chambers et al., 2009). In accordance
with the previously described experiments on endodermal and mesodermal diﬀeren-
tiation, ChiPS4 cells were treated with GNS or DMSO and the expression of marker
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Figure (3.11) Variations in global O-GlcNAc levels during cardiomyocyte diﬀerentiation of ChiPS4.
Analysis of O-GlcNAcylation on whole cell lysates of ChiPS4 treated with GNS G or DMSO at various timepoints
during cardiomyocyte diﬀerentiation. A representative Western Blot is shown.
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genes at various timepoints over the course of diﬀerentiation were examined. Initially,
RT-qPCR analysis of the pluripotency genes Oct4 and Nanog as well as the ectoderm
markers Pax6, Sox1, FoxG1 and Pax7 was performed.
As can be seen from Figure 3.12 A, both Oct4 and Nanog gene expression levels
decrease rapidly with advancing diﬀerentiation. This quick drop in the expression of
pluripotency markers is consistent throughout all the diﬀerentiation assays performed
and no diﬀerences can be noted between cells that were treated with the vehicle control
and GNS-treated cells.
Strikingly, dramatic diﬀerences between GNS treated cells and controls can be ob-
served with regard to the expression of neural markers (Figure 3.12 B). Expression
of Sox1, FoxG1 and Pax7 is strongly induced as a consequence of the cell's neural
diﬀerentiation for DMSO treated cells. In sharp contrast, GNS treated cells do not
exhibit expression of these neural marker genes. For GNS treated cells, Sox1 and
FoxG1 gene expression remains at a basal level throughout the diﬀerentiation and is
not induced at any stage. Pax7 mRNA levels increase initially (until day ﬁve of the
assay) and experience a sharp drop afterwards in GNS. Interestingly, Pax6 expression
does not appear to be aﬀected by GNS treatment and is induced equally for control
and GNS treated cells. These ﬁndings implicate that while GNS treated ChiPS4 loose
their pluripotency, they are unable to commit to a neural fate as respective marker
genes are mostly not expressed even at late stages of neural diﬀerentiation.
O-GlcNAcylation during neural diﬀerentiation
Analysis of global O-GlcNAcylation over the course of neural diﬀerentiation was again
performed by Western Blot (Figure 3.13). It can be observed that O-GlcNAcylation
during neural diﬀerentiation appears to be very dynamic. Overall levels of the mod-
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Figure (3.12) RT-qPCR analysis of marker gene expression during ectoderm diﬀerentiation. A: mRNA
levels of the pluripotency markers Oct4 and Nanog; B: gene expression proﬁles of the ectoderm markers Pax6, Sox1,
FoxG1 and Pax7. n=4 independent biological repeats for Nanog, Oct4 and FoxG1 ; n=3 independent biological repeats
for Pax6, Sox1 and Pax7 ; for FoxG1 and Pax7 weighted means are shown. ***: p ≤ 0.001; **: p ≤ 0.01; *: p ≤ 0.05
(Student's t-test, unpaired); errorbars represent SEM
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Figure (3.13) Variations in global O-GlcNAc levels during neural diﬀerentiation of ChiPS4. Left panel:
O-GlcNAcylation of ChiPS4 treated with DMSO. Right panel: O-GlcNAcylation of GNS treated cells. A representative
Western Blot is shown.
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iﬁcation initially increase until day ﬁve. O-GlcNAc levels then decrease again and at
day 15 of diﬀerentiation the level of the modiﬁcation has returned to a similar level
as before the start of diﬀerentiation. In addition, the pattern of O-GlcNAcylation
varies signiﬁcantly with a number of bands appearing and disappearing. For GNS
treated cells the pattern appears to remain comparable to the DMSO controls and O-
GlcNAc levels are respectively elevated in response to the drug treatment. It can be
concluded from this analysis that during neural diﬀerentiation both O-GlcNAc levels
and the pattern of O-GlcNAcylation are very dynamic underlining the importance of
the modiﬁcation for neural diﬀerentiation.
GNS hinders neural diﬀerentiation in embryoid bodies
The previously described observations were based on a high-density diﬀerentiation
protocol. Therefore it is not possible to assess morphological abnormalities that might
occur in GNS treated cells that can not complete neural diﬀerentiation. With the
aim of circumventing this issue an additional neural diﬀerentiation assay was chosen
which allows a close observation of cell morphology. The assay is based on initial
diﬀerentiation of ChiPS4 in embryoid bodies (EBs) followed by plating at a stage at
which cells should have diﬀerentiated to neuroectoderm (see Figure 3.14). Importantly,
cells were treated with GNS at from two diﬀerent stages of diﬀerentiation (day one
and day nine) in order to determine at which stage abnormalities occur. As illustrated
in Figure 3.14 B, cells of the vehicle control have generated distinct neural structures
at day 15 of the assay. This is characterized by the honeycomb-like structure of neural
rosettes. A very similar morphology can be observed for cells that had been treated
with GNS only from day nine on (GNS D9). These cells as well exhibit a characteristic
neural morphology. In contrast, cells that had been treated with GNS from the start
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Figure (3.14) GNS G hinders neural diﬀerentiation in embryoid bodies. A: Schematic of the diﬀerentiation
protocol for neural diﬀerentiation of ChiPS4 in embryoid bodies. B: Brightﬁeld images of ChiPS4 at day 15 and 24 of
the diﬀerentiation assay. C: Immunoﬂuorescence analysis of the neuron marker β-III-tubulin at day 24. Representative
images are shown. Scalebar = 90 µm
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of diﬀerentiation do not show any organized morphology and appear to be randomly
clustered together.
This phenotype is even more pronounced at day 24 as cells have ﬂattened out
further and structures are less compact: Both the DMSO control and GNS D9 cells
demonstrate a very organized morphology and between neural tube-like structures
cells have started to form mature and polarised neural rosettes. For cells that had
been treated with GNS throughout the assay, it can also be observed that the cell
layer has become ﬂatter. However, cells remain largely unorganized and completely
lack neural morphology.
In addition, the ability of the cells to generate neurons was assessed. Generally,
neurons form in the periphery of EBs in this assay. To determine neuron formation
ability, cells were ﬁxed, immunostained and analysed for the neuron marker β-III-
tubulin. As illustrated in Figure 3.14 C, DMSO treated control cells generate a large
number of neurons that extend from the original EB (left image). The same observa-
tion can be made for cells that had only had GNS from day nine of the diﬀerentiation
assay, although they appear to generate slightly fewer neurons (right image). When
comparing to cells that had been treated with GNS from the beginning of the assay,
it is clear that those cells are largely unable to diﬀerentiate into β-III-tubulin-positive
neurons.
These observations underline the previously described ﬁndings and emphasize that
GNS treatment inhibits neural diﬀerentiation. Importantly, if GNS is added at a later
stage of diﬀerentiation cells progress normally. This implies that early events of neural
diﬀerentiation are strongly aﬀected by GNS, but that there is no impact at later stages
of diﬀerentiation.
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GNS treatment disrupts neural rosette formation
During neural diﬀerentiation, human iPS cells show certain morphological character-
istics, i.e. the formation of neural rosettes. These are two-dimensional structures of
neural progenitors in which the cells exhibit strong polarity towards the centre of the
rosette. More mature neurons are then usually found to expand from the central point.
With the aim of analysing rosette formation ability, cells were diﬀerentiated accord-
ing to the EB diﬀerentiation protocol above. At day 20 cells were ﬁxed and stained
for diﬀerent markers. Staining for β-III-tubulin and Sox2 was performed in order to
analyse for neuron formation as well as for commitment to a neural progenitor fate.
Representative images of the analysis are depicted in Figure 3.15. Figure 3.15 A illus-
trated that ChiPS4 of the DMSO control form distinct rosettes. As can be seen from
the β-III-tubulin staining (A') several neuron extend from the centre of the rosette.
Most cells are Sox2-positive (A) conﬁrming their neural progenitor identity. When
comparing to cells that were treated with GNS from day nine onwards (Figure 3.15
B), it is clear that these cells are also organized in rosettes. However, fewer neurons
can be found and Sox2 expression appears to be slightly weaker than in the DMSO
control. Strikingly, ChiPS4 that were treated with GNS throughout the diﬀerentiation
did not show any organized structure at all (Figure 3.15 C). In addition, these cells are
also not able to generate mature neurons. Even commitment to a neural fate appears
to be severely obstructed as most cells are negative for Sox2.
Neural rosette formation can also be evaluated by investigating cell polarity. There-
fore, staining was performed for ZO-1 and N-Cadherin. Both proteins mediate cell
polarity in the centre of rosettes. From Figure 3.16 A it becomes apparent that both
ZO-1 and N-Cadherin are localized in the centre of neural rosettes in DMSO treated
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Figure (3.15) Immunoﬂuorescence analysis of ChiPS4 after neural diﬀerentiation in embryoid bodies.
Immunoﬂuorescence staining for β-III-tubulin and Sox2 demonstrates that neural diﬀerentiation is hindered by GNS
(C) whereas control cells (A) or cell treated at a later timepoint (B) diﬀerentiate normally. Representative images are
shown. Scalebar = 20 µm
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Figure (3.16) Immunoﬂuorescence analysis of ChiPS4 after neural diﬀerentiation in embryoid bodies.
Immunoﬂuorescence staining for ZO-1 and N-Cadherin indicates that polarity of neural rosettes is disrupted by GNS
treatment (C) in comparison to control cells (A) or cell treated at a later timepoint (B). Representative images are
shown. Scalebar = 20 µm
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ChiPS4 demonstrating central polarity of the cells. The same is true for GNS D9 cells
which also exhibit cell polarity to the rosette's centre as shown by the co-expression
of ZO-1 and N-Cadherin (Figure 3.16 B). In contrast, GNS treated cells are devoid of
any central polarity and neither ZO-1 nor N-Cadherin are expressed to a high level
(Figure 3.16 C). These ﬁndings underline the previously presented observations with
regard to the strong impact of GNS in ectodermal diﬀerentiation.
GNS addition at early diﬀerentiation stages impairs ectoderm
diﬀerentiation and neurogenesis
As the previously described results demonstrate that high O-GlcNAc levels impair
ectodermal diﬀerentiation, further experiments were performed to investigate if these
eﬀects are restricted to a certain stage of diﬀerentiation.
Monolayer neural diﬀerentiation was performed, in order to determine if ectoderm
diﬀerentiation was still hindered if GNS G was added at later stages. ChiPS4 were dif-
ferentiated for ten days and GNS G was added at diﬀerent timepoints. Cells were then
harvested for RNA and RT-qPCR analysis for the marker Sox1 was performed. Fig-
ure 3.17 illustrates the result of this analysis. It can be observed that Sox1 expression
is higher the later during diﬀerentiation GNS G was added to the cells. Cells that had
only been treated with GNS G from day 3 of the diﬀerentiation onwards express Sox1
to an extent comparable with cell that had been treated with a DMSO control. This
ﬁnding demonstrated clearly that increased O-GlcNAcylation only impairs ectoderm
diﬀerentiation if it occurs during early stages.
With the aim of validating these data, neural diﬀerentiation of ChiPS4 in EBs
was performed and GNS was again added at diﬀerent timepoints. In contrast to the
previously described method, cells were treated with BDNF and GDNF at the later
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stages of diﬀerentiation (day 15 onwards) to induce neurogenesis. At day 24, cells
were ﬁxed and analysed by immunoﬂuorescence staining for the neuron marker β-III-
tubulin. These results are depicted in Figure 3.17. Cells that were treated with GNS
G before day 3 exhibit a massively decreased ability of neuron formation. However, if
GNS G had been added after day 2, neurogenesis is no longer impaired and the neuron
formation of those cells is comparable to the DMSO control.
Taken together this ﬁndings illustrate that high levels of O-GlcNAc only impair
ectodermal diﬀerentiation if they persist at early stages of diﬀerentiation. Addition
of GNS G after the initial stages of commitment to this lineage have no eﬀect on
diﬀerentiation and neurogenesis.
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Figure (3.17) GNS G treatment impairs ectodermal diﬀerentiation of ChiPS4 only if added at initial
stages. A: RT-qPCR analysis of the ectoderm marker gene Sox1 (n=3 independent biological repeats, errorbars
represent SEM; **: p ≤ 0.01; *: p ≤ 0.05; n.s.: p > 0.05 (Student's t-test, unpaired)). A Immunoﬂuorescence staining
for β-III-tubulin on ectoderm diﬀerentiation in EBs indicates that neurogenesis is disrupted if GNS G is added before
day 3 of diﬀerentiation. Representative images are shown. Scalebar = 20 µm
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4. The role of O-GlcNAc in transcriptional regulation
The previously described ﬁndings highlight the importance of O-GlcNAc in pluripotent
stem cell diﬀerentiation. Diﬀerentiation of ES or iPS cells is a tightly regulated process
which is mediated by changes in the epigenetic landscape and gene expression. In order
for a cell to make the transition from a pluripotent cell to a mature somatic cell it
is vital that some genes are increasingly expressed while other are downregulated or
entirely repressed. With the aim of deciphering the eﬀects of O-GlcNAcylation on gene
expression, microarray analysis was performed on 46C mouse ES cells treated with
GNS C or DMSO as a vehicle control (Speakman et al., 2014). Gene set enrichment
analysis (GSEA) on this data indicated that two gene sets that are typically silenced
by epigenetic mechanisms are reexpressed in GNS treated cells. These two gene sets
are the Polycomb repressive complex repressed genes (PRCR) and the two-cell (2C)
stage gene set which is characteristic for the early developmental stage of the two-cell
embryo. The following experiments were performed with the aim of validating and
extending the microarray data presented in Speakman et al. (2014).
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Figure (4.1) Polycomb repressive complex repressed genes and 2C genes are upregulated by GNS
treatment. A: RT-qPCR analysis of selected genes of the PRCR geneset, n=6 independent biological repeats. B:
RT-qPCR analysis of selected 2C genes; n=3. ***: p ≤ 0.001; **: p ≤ 0.01; *: p ≤ 0.05; n.s.: p > 0.05 (Student's
t-test, paired); errorbars represent SEM.
114
4.1. Oga inhibition or knockdown causes reexpression of
epigenetically silenced genes
In order to validate the ﬁndings of the GSEA, the expression of selected candidate
genes from the 2C and PRCR geneset in cells with high O-GlcNAc levels was de-
termined. For this, E14 cells were treated with GNS G or the respective vehicle for
two days and subjected to RT-qPCR analysis. The ﬁndings of these experiments are
depicted in Figure 4.1. With a view to the expression of genes that are repressed
by polycomb repressive complexes, mRNA levels of AthoI, Sp110 and FGF5 were
analysed (Figure 4.1 A). It is clear from these data that expression of AthoI and
Sp110 is signiﬁcantly increased in GNS treated cells when compared to the DMSO
control. However, FGF5 expression appears to be more variable with only a small
trend towards upregulation in GNS treated cells. Zfp352, Zscan4 and Tdpoz3 have
been described as characteristic for the 2C subpopulation. All three genes experience
a signiﬁcant increase in their mRNA levels in cells with elevated O-GlcNAcylation in
response to GNS treatment. Again it remains to be noted that the described eﬀect
appears to be more variable for some genes (e.g. Tdpoz3 ). In summary, the RT-qPCR
data is in good agreement with the previous observations based on GSEA and it can
be concluded that the expression of selected 2C and PRCR genes is upregulated by
GNS treatment.
4.2. Knockdown of Oga leads to upregulation of 2C genes
With the aim of substantiating the previously described ﬁndings, knockdown experi-
ments with siRNAs were applied in combination with gene expression analysis of 2C
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genes. Using pools of siRNAs targeting Oga or Ogt it was possible to dramatically
decrease protein levels of the respective protein. Figure 4.2 A illustrates the eﬀect of
siRNA mediated knockdown over a period of four days. It can be observed that a suc-
cessful knockdown of Oga or Ogt can be achieved for as long as 72 hours. However, this
eﬀect is partially lost approximately 96 hours post-transfection. Importantly, in both
cases a direct feedback downregulation of the antagonizing enzyme can be observed,
i.e. knockdown of Oga leads to a feedback decrease in Ogt protein levels and vice versa.
In addition the eﬀects on mRNA levels of Oga/Ogt under knockdown conditions were
investigated (Figure 4.2 B and C). Levels of Oga mRNA decrease rapidly in response
to both Oga and Ogt knockdown. For Ogt, mRNA levels drop sharply after siOgt
transfection (Figure 4.2C). Interestingly, after transfection with siOgt a rise in Ogt
mRNA levels could be observed. This might hint at a compensatory transcriptional
eﬀect in response to the feedback regulation that can be observed at protein level.
Following the validation of the siRNA mediated knockdown for both enzymes, ex-
pression of 2C genes after a 48 h knockdown of Oga was monitored. As illustrated in
Figure 4.2 D cells transfected with siOga exhibit an increased expression of the three
selected 2C genes in comparison to cells transfected with a non-targeting control.
However, an increase in variability between independent experiment was observed
compared to the analysis that had been performed on GNS treated cells (compare
Figure 4.1 B). These ﬁndings support the previous observations and demonstrate that
both Oga inhibition and knockdown lead to a re-expression of genes characteristic for
the 2C subpopulation.
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Figure (4.2) Knockdown of Oga using siRNAs induces re-expression of 2C genes. A: Oga and Ogt protein
levels at diﬀerent timepoints after siRNA transfection show a decrease in respective protein levels. A representative
Western Blot is shown. B, C: mRNA levels of Oga and Ogt in response to siOga/siOgt; n=2 independent biological
repeats, mean values are shown. D: Gene expression of 2C genes is elevated in siOga; n=3 biological repeats; *: p ≤
0.05, n.s.: p > 0.05 (Student's t-test, paired); errorbars represent SEM.
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4.3. GNS G treatment induces 2C promoter activity
With the aim of further validating the previously described results on the 2C subpop-
ulation, the activity of the 2C promoter in response to GNS G treatment was inves-
tigated. For this purpose, two MERVL (Mouse endogenous retrovirus with a leucine
tRNA primer binding site) reporter cells were generated (cell lines generated by Marios
Stavridis). To generate the reporter, the 5'LTR of the MERVL retrovirus-like element,
the primer binding site and a portion of the Gag gene was cloned upstream of EGFP
(enhanced green ﬂuorescent protein) or RFP (red ﬂuorescent protein) as described by
Macfarlan et al. (2012) and stable E14 mouse ES cell lines expressing the respective
reporter were generated.
Cells were treated for 48 hours with GNS G, DMSO as a negative control or the
histone deacetylase inhibitor trichostatin A (TSA) (treatment for 2-4 hours) as a
positive control and were then analysed by ﬂow cytometry. The respective results
are depicted in Figure 4.3 and Figure 4.4. Both reporter lines indicate a small but
signiﬁcant increase in 2C promoter activity. It is also important to note that the
induction of the 2C promoter by GNS G appears to be comparable to treatment with
TSA. Interestingly the number of reporter-expressing cells varied between the two
reporter cell lines with a higher percentage of cells that were positive for the reporter
in the 2C:EGFP line (∼ 19 % EGFP-positive cells in DMSO) than in the 2C:RFP line
(∼ 11 % RFP-positive cells in DMSO). Regardless of these diﬀerences between the two
lines the result remained consistent and clearly supports the previously presented data
by indicating that GNS G treatments leads to an increase in 2C promotor activity.
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Figure (4.3) GNS G induces 2C promoter activity in E14 2C:RFP reporter cells. A: Gating strategy to
exclude debris. B: Gating to exclude duplets. C: Gating to select RFP-positive cells while excluding autoﬂuorescent
cells. D: Percentage of RFP+ single cells. n=4 independent biological repeats, **: p ≤ 0.001 (Student's t-test, paired).
Errorbars represent SEM.
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Figure (4.4) GNS G induces 2C promoter activity in E14 2C:EGFP reporter cells. A: Gating strategy
to exclude debris. B: Gating to exclude duplets. C: Gating strategy to exclude dead cells (= DAPI-positive). D:
Gating to select EGFP-positive cells while excluding autoﬂuorescent cells. D: Percentage of EGFP+ live cells. n=3
independent biological repeats, *: p ≤ 0.001 (Student's t-test, paired), errorbars represent SEM.
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4.4. Eﬀects of GNS G on total histone acetylation
The data above suggested that eﬀects of GNS G on mouse ES cells might to some ex-
tend be comparable to TSA treatment. TSA is a broad inhibitor of histone deacetlyases
and therefore increases histone acetylation in a global manner in the cells. Elevated hi-
stone acetylation leads to an open chromatin conformation and therefore to an increase
in transcriptional activity. It remains to be clariﬁed to which degree the re-expression
of 2C and PRCR gene sets by GNS G could be the results of a global mechanism
such as histone acetylation. Previous studies suggest that the C-terminus of Oga con-
tains a domain which can exhibit histone acetyltransferase (HAT) activity (Toleman
et al., 2004). As GNS G treatment results in a feedback upregulation of Oga (sec-
tion 3.1.2), further investigations aimed to clarify whether this would also correlate
with an increase in histone acetylation and therefore global transcriptional activity.
Initially, histone extracts were generated from E14 mouse ES cells treated with GNS
G for 48 hours. These extracts were then analysed by Western Blot using an antibody
against acetylated lysine. As illustrated in Figure 4.5 A a strong increase in lysine
acetylation of histone 3 can be observed. However, it needs to be noted that those
results were highly variable between diﬀerent experiments.
In order to directly relate those ﬁndings to Oga protein levels, knockdown and
overexpression of Oga was performed and histone extracts were again analysed for
levels of lysine acetylation. The results of these experiments are depicted in Figure 4.5
B. Upon knockdown of Oga or Ogt no signiﬁcant diﬀerences in lysine acetylation could
be observed when comparing to the respective control. In contrast, overexpression
of Oga appears to lead to a small increase in lysine acetylation of histone 3, but
not histone 4. Again, results from these experiments were highly variable with low
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Figure (4.5) GNS G increases global histone 3 lysine acetylation. A: Western Blot analysis of total lysine
acetylation of histone 3 on histone extracts after GNS G treatment (left panel). Right panel: Western Blot quantiﬁca-
tion. B: Western Blot analysis of panAcK on histone 3 on histone extracts after knockdown or overexpression of Oga.
Both Western Blots were selected to demonstrate a possible eﬀect of GNS on lysine acetylation.
reproducibility and therefore diﬃcult to interpret. For these reasons it was decided to
analyse histone acetylation by another method.
Therefore, global histone 3 acetylation was investigated by ELISA. E14 mouse ES
cells were transfected with two Oga overexpression plasmids: Oga full-length (Oga
FL) and a naturally occurring splicing variant (abbreviated Oga SV) which is devoid
of the majority of the potential HAT domain. The respective results are illustrated in
Figure 4.6. It is evident from the data obtained that there is a slight trend towards an
increase in histone 3 acetylation in cells that overexpress full-length Oga. This eﬀect
is lost when the splicing variant that lacks the potential HAT domain is overexpressed.
However, it is also clear that there is a very high variability between diﬀerent experi-
ments which make it diﬃcult to interpret the result. These issues appear to be due to
a technical problem that could be linked with batch eﬀects of the ELISA kit that was
used. Due to the high variability of both the Western Blot analysis and also the results
obtained from the histone 3 acetylation ELISA it is unclear if GNS G treatment or
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Figure (4.6) Analysis of histone 3 acetylation by ELISA. A: Overexpression of EGFP (negative control), Oga
splicing variant devoid of the potential HAT domain (Oga SV) and full-length Oga (Oga FL). B: ELISA of histone 3
acetylation. n=5 independent biological repeats, p=0.124 (Student's t-test, paired).
Oga overexpression lead to an increase in histone acetylation. Overall the observed
eﬀects appear to be insigniﬁcant and are most likely not the main mechanism leading
to the previously described re-expression of silenced genes.
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4.5. Eﬀects of GNS G on DNA methylation
A number of recent publications suggest an interplay of O-GlcNAcylation and its reg-
ulators with Tet proteins (Shi et al., 2013; Deplus et al., 2013; Chen et al., 2013; Ito
et al., 2013). Tet proteins mediate changes in DNA methylation, an important epige-
netic mark involved in gene silencing. For these reasons the DNA methylation status
of cells under high O-GlcNAc conditions was investigated using multiple approaches
and the respective results are presented in the following sections.
4.5.1. Eﬀects of GNS G on selected DNA methylation sites
Initial investigations were focussed on determining potential eﬀects of high O-GlcNAc
on DNA methylation at speciﬁc sites of selected genes. For this purpose, bisulﬁte
sequencing on DNA of E14 mouse ES cells was performed. This method allows de-
tection of methylated DNA by conversion of cytosine to uracil. Methylated sites are
protected from the conversion which can be detected during the following sequencing.
The genes investigated were the housekeeping gene beta-actin, the pluripotency-related
genes Rex1 and Klf4 as well as the silenced gene Rest and the long non-coding RNA
Xist. The respective results are illustrated in Figure 4.7, Figure 4.8, Figure 4.9, Fig-
ure 4.11 and Figure 4.10.
For beta-actin it can be observed that the number of methylated sites is slightly
increased in GNS treated cells. However, a proportion of sites were lost during the
sequencing (depicted as 'not present') which impose limitations in interpreting these
data.
For Rex1 (Figure 4.8) and Klf4 (Figure 4.9) no major diﬀerences in DNA methy-
lation can be observed when comparing DNA of GNS G treated cells to DNA of the
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Figure (4.7) Bisulﬁte sequencing of beta-actin. A: Illustration of the region investigated by bisulﬁte sequencing.
B: Methylation of CpG islands within the selected region in DMSO (upper panel) and GNS G (lower panel).
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Figure (4.8) Bisulﬁte sequencing of Rex1. A: Illustration of the region investigated by bisulﬁte sequencing. B:
Methylation of CpG islands within the selected region in DMSO (upper panel) and GNS G (lower panel).
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Figure (4.9) Bisulﬁte sequencing of Klf4. A: Illustration of the region investigated by bisulﬁte sequencing. B:
Methylation of CpG islands within the selected region in DMSO (upper panel) and GNS G (lower panel).
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Figure (4.10) Bisulﬁte sequencing of Rest. A: Illustration of the region investigated by bisulﬁte sequencing. B:
Methylation of CpG islands within the selected region in DMSO (upper panel) and GNS G (lower panel).
control.
The data depicted in ﬁgure 4.7 illustrates that the investigated methylation sites
on the gene body of beta-actin are largely unmethylated which corresponds to active
transcription of this gene. No signiﬁcant changes can be observed in response to GNS
G treatment. The pluripotency-related gene Rex1 (ﬁgure 4.8) exhibits a comparable
behaviour with overall low methylation in both DMSO and GNS G treated cells.
Surprisingly, the second pluripotency gene that was investigated, Klf4, appears to be
highly methylated at the investigated sites (compare ﬁgure 4.9) with no signiﬁcant
changes when cells were treated with GNS G. It remains unclear why Klf4 exhibits
such high levels of methylation as the gene is actively transcribed in ES cells. However,
it could be speculated that this methylation status is restricted to the respective site
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Figure (4.11) Bisulﬁte sequencing of Xist. A: Illustration of the region investigated by bisulﬁte sequencing. B:
Methylation of CpG islands within the selected region in DMSO (upper panel) and GNS G (lower panel).
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and could be overridden by low DNA methylation levels on other exons or promoter
regions. When investigating the DNAmethylation status for Rest which is expressed at
very low level in mouse ES cells, it becomes clear that DNA methylation of this gene is
also not aﬀected by GNS G treatment (see Figure 4.10). As expected, Rest is strongly
methylated which corresponds to its silenced state. Investigation of the methylation
status of the lncRNA Xist indicates no changes in GNS G treated cells in comparison
to the control (Figure 4.11). Similar to Rest, Xist is also heavily methylated in mouse
ES cells.
Taken together the results obtained by bisulﬁte sequencing of selected candidate
genes suggest that GNS G does not aﬀect DNA methylation on gene bodies in the
respective cases.
130
Figure (4.12) Schematic of DNA demethylation. DNAmethylation is achieved by addition of a methyl group to
cytosine (5-mC). In the progress of demethylation Tet proteins mediated conversion of 5-mC to hydroxymethylcytosine
(5-hmC), formylcytosine (5-fC) and carboxycytosine (5-caC). During ﬁnal step of DNA demethylation 5-caC is reverted
to cytosine through thymine DNA glycosylase (TDG)-dependent base excision repair (BER).
4.5.2. Eﬀects of GNS G on global DNA methylation in mouse
ES and human iPS cells
The results obtained by bisulﬁte sequencing indicate no eﬀect of GNS on overall methy-
lation of the gene bodies of the analysed genes. Nevertheless, this analysis does not
allow to distinguish between diﬀerent DNA methylation variants that occur as in-
termediate during DNA methylation. The variants that have been characterised are
5-methylcytosine (5-mC), 5-hydroxymethylcytosine (5-hmC), 5-formylcytosine (5-fC)
and 5-carboxymethylcytosine (5-caC). In order to investigate if GNS G treatment
could shift the ratios between those methylation variants, we initially tried to analyse
DNA from GNS G treated E14 mouse ES cells and ChiPS4 human iPS cells using dot
blots. However, there were technical issues using this method and we found it might
not entirely suitable for obtaining reliable results in our hands. With the aim of over-
coming those limitations, it was decided to perform a more quantitative measurement
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of DNA methylation by HPLC-MS.
The combination of liquid chromatography (HPLC) and mass spectrometry (MS) is
a very sensitive tool for the quantiﬁcation of nucleotides (modiﬁed and unmodiﬁed).
For this experiment, HPLC-MS was used for the quantiﬁcation of 5-mC and 5-hmC
content of DNA from E14 mouse ES cells and ChiPS4 human iPS cells after GNS G
treatment.
As can be seen from Figure 4.13 A there is no signiﬁcant diﬀerence in the 5-mC
content of E14 cells that had been treated with the inhibitor in comparison to the
respective control. Treatment with 2i results in the expected decrease in 5-mC in
those cells. Regarding the 5-hmC quantiﬁcation it can again be observed that GNS
G has no eﬀect and levels are comparable to those of the DMSO control (Figure 4.13
B).
The quantiﬁcation of 5-mC and 5-hmC content in ChiPS4 DNA also shows no
diﬀerences between cells that had been treated with GNS G and the control (see
Figure 4.14). It should be noted that the overall 5-hmC content in ChiPS4 is lower
than in E14 cells.
Taken together these results clearly demonstrate that treatment with GNS G does
not impact on 5-mC or 5-hmC content of E14 mouse ES cells or ChiPS4 human iPS
cells. It is therefore unlikely, that the previously observed eﬀects on gene expression
is due to a global change in DNA methylation.
132
Figure (4.13) Quantiﬁcation of cytosine methylation of DNA from E14 mouse ES cells by HPLC-MS.
A: Quantiﬁcation of 5-methylcytosine as percentage of total cytosine. B: Quantiﬁcation of 5-hydroxymethylcytosine.
n=8 independent biological repeats for all, ***: p ≤ 0.0001, n.s.: p > 0.05 (Student's t-test, paired), errorbars represent
SEM..
Figure (4.14) Quantiﬁcation of cytosine methylation of DNA from ChiPS4 human iPS cells by HPLC-
MS. A: Quantiﬁcation of 5-methylcytosine percentage of total cytosine. B: Quantiﬁcation of 5-hydroxymethylcytosine.
n=8 independent biological repeats for all, n.s.: p > 0.05 (Student's t-test, paired); errorbars represent SEM.
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5. Eﬀects of high O-GlcNAc on gene expression of
human iPS cells
The eﬀects of Oga inhibition by GNS G treatment on ectoderm diﬀerentiation of
human iPS cells described in chapter 3 represent a striking phenotype that has not been
described before. Yet the detailed mechanisms that lead to the observed hindrance
of ectoderm diﬀerentiation remain elusive. Therefore it was decided to perform a
messenger RNA (mRNA) sequencing experiment on undiﬀerentiated ChiPS4 human
iPS cells with the aim of elucidating the eﬀects of GNS G treatment on gene expression
in detail. Results of the sequencing and subsequent bioinformatic analysis will be
described in the following sections.
5.1. GNS G induces a feedback regulation of gene expression
of Oga and Ogt
In advance to sending samples for RNA sequencing the eﬀect of GNS G was validated
by investigating the expression of two known target genes: Ogt and Oga. Previous
experiments had demonstrated a feedback regulation of protein levels of the two O-
GlcNAc regulating enzymes in GNS G. Hence, it would be expected that a similar
eﬀect could be observed on mRNA level. Therefore, ChiPS4 were treated with GNS
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Figure (5.1) Expression of Oga and Ogt after three days of GNS G treatment. Gene expression analysed
by RT-qPCR prior to sending samples for RNAseq. n=6 independent biological repeats. ***: p ≤ 0.001; **: p ≤ 0.01;
*: p ≤ 0.05; n.s.: p > 0.05 (Student's t-test, paired), errorbars represent SEM. (Results for individual experiments are
shown in Figure A.1 and Figure A.2.)
G for three days, RNA was extracted, reversely transcribed and analysed for the
expression of Ogt and Oga by RT-qPCR. In total, seven independent experiments
were performed. Single results for each experiment are given in section A.1. Based
on these results, experiment number six was excluded as it the expected feedback was
weaker than in the other experiments performed. Combined results of experiments
one to ﬁve and seven are depicted in Figure 5.1. As can be seen from these data, GNS
G treatment induces a pronounced downregulation of Ogt mRNA. On the other hand
Oga expression increases. However, it should be noted that the increase in Oga mRNA
is a lot more variable between diﬀerent experiments, whereas the order of magnitude
of feedback downregulation of Ogt expression is very consistent between experiments.
Overall these results represent an initial validation of the GNS G treatment in regard
to its eﬀect on the expression of known targets and RNA samples of experiment one
to ﬁve and seven were submitted to RNA sequencing.
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5.2. Analysis of gene expression in high O-GlcNAc by RNA
sequencing
5.2.1. Quality control of the RNA sequencing
In order to determine the quality of the sequencing results analysis of the reads was
performed using FastQC (Andrews, 2010). Depicted in Figure 5.2 are representative
results of the FastQC analysis focussing on sequencing quality and GC content of
the samples. From Figure 5.2 A it can be seen that the quality of the sequencing
was very good as throughout the sequencing all reads reached high quality scores
(> 28). Importantly, those results were almost identical for GNS G treated samples
and the respective DMSO control. Figure 5.2 B illustrates the results of the FastQC
analysis for GC content per sequence. The mean GC content should ideally resemble
a normal distribution (indicated by the blue line in the graph) and discrepancies can
indicate contaminations. In this case, a slight shift of the curve towards a higher GC
content can be observed. This indicates a systematic bias which is independent of the
base position. As this observation can be made for both GNS G and DMSO treated
samples, the curve shift merely indicates a generic feature of the library as the GC
content of the experimental library varies from the reference distribution applied by
the FastQC module. Overall, the results of the FastQC analysis demonstrate that the
sequencing was successful and the data obtained is of high quality.
5.2.2. Diﬀerential gene expression
The obtained sequencing data was analysed for genes that are diﬀerentially expressed
in GNS G when comparing to the DMSO samples. In brief, sequences were aligned to
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Figure (5.2) FastQC analysis results. A: Sequence quality analysis with FastQC. Red central line: median value.
Yellow boxes represent the inter-quartile range. Blue line indicates the mean quality. B: Per sequence GC content.
The blue line indicates a theoretical reference distributions, the experimental distribution is depicted in red.
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the human reference genome (GRChg38) using STAR 2.5 (Dobin et al., 2013) and dif-
ferential gene expression analysis was performed using EdgeR (Robinson et al., 2010).
Cut-oﬀ values used to generate a list of diﬀerentially expressed genes were set accord-
ing to the values obtained for the known target genes Ogt and Oga. Respectively,
genes are considered signiﬁcantly diﬀerentially expressed when the log fold change
(logFC) is greater than or equal to 0.25 and the false discovery rate (FDR) is smaller
than 0.01. The distribution of diﬀerentially expressed genes analysed by EdgeR is
illustrated in Figure 5.3. In total, of 60,975 genes were identiﬁed. Of those genes
592 genes were signiﬁcantly upregulated in GNS G treated cells, while 341 genes were
downregulated. The volcano plot illustrates that while a high number of genes are
diﬀerentially expressed, the log fold changes for these genes are low. This indicates
that the expression of a large number of genes changes to a small extent in GNS G
treated cells. In addition, sample relations were explored by multidimensional scaling
using EdgeR's plotMDS. As can be seen from Figure 5.3 B, samples cluster together by
biological coeﬃcient of variation (BCV) according to treatments (DMSO or GNS G).
This illustrates again that there are signiﬁcant diﬀerences in gene expression between
the two treatments.
The full result of the diﬀerential gene expression (DGE) is given in table A.1.1. A
shortened list with genes with the highest log fold change (|logFC|>1.3) in this analysis
is given in table 5.2.2. Positive fold changes indicate genes that have higher expression
in GNS G than in DMSO. Negative fold changes indicate genes with lower expression in
GNS G than in DMSO. As illustrated in table 5.2.2 the genes that are aﬀected by GNS
G treatment include a huge variety of diﬀerent gene types. The list comprises genes
coding for transcription factors, growth factors, transmembrane receptors, histone
variants, potential oncogenes and also non-coding RNAs. Interestingly, two known
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Figure (5.3) Analysis of diﬀerential gene expression using EdgeR. A: Volcano plot showing all identiﬁed
diﬀerentially expressed genes. Green lines indicate cut-oﬀ for logFC > 0.25. Blue line indicates FDR cut-oﬀ (FDR <
0.01), green line indicates cut-oﬀ for log fold changes. Genes that were considered signiﬁcantly diﬀerentially expressed
are depicted in red. B: Multidimensional scaling plot of the fold-changes of biological coeﬃcient of variation (BCV)
using EdgeR's plotMDS function.
pluripotency-related genes are found in this list. Klf2 has been described to sustain a
naïve-state pluripotency in human ES cells (Takashima et al., 2014) and is also known
to be a Wnt target gene (Qiu et al., 2015). Fbxo15 is a transcriptional target of Oct4
that is speciﬁcally expressed in the early embryo and in mouse ES cells, however, it is
dispensable for self-renewal (Tokuzawa et al., 2003). The broad variety of this result
indicates a global eﬀect of GNS G and implies that deregulation of O-GlcNAcylation
impacts on a multitude of genes involved in many diﬀerent cellular processes.
Table (5.1) Diﬀerentially expressed genes with EdgeR (logFC>1.3)
external gene name description logFC FDR
1 RP11-261N11.8 -4.22 0.00
2 GALNT9 polypeptide N-acetylgalactosaminyltransferase 9 -2.59 0.00
3 NPTX1 neuronal pentraxin I -2.40 0.00
4 ESPNP espin pseudogene -1.92 0.00
5 KLF2 Kruppel-like factor 2 -1.92 0.00
6 FEZF1 FEZ family zinc ﬁnger 1 -1.91 0.00
7 RP11-482M8.1 -1.90 0.00
8 MYADML2 myeloid-associated diﬀerentiation marker-like 2 -1.79 0.00
9 LHX5 LIM homeobox 5 -1.72 0.00
10 TMEM88B transmembrane protein 88B -1.71 0.00
11 GNA15 guanine nucleotide binding protein (G protein), alpha 15 (Gq class) -1.69 0.00
12 ZNF781 zinc ﬁnger protein 781 -1.65 0.00
13 FEZF1-AS1 FEZF1 antisense RNA 1 -1.55 0.00
14 RAB33A RAB33A, member RAS oncogene family -1.51 0.01
15 SPEF1 sperm ﬂagellar 1 -1.51 0.00
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16 CALY calcyon neuron-speciﬁc vesicular protein -1.48 0.00
17 MIAT myocardial infarction associated transcript (non-protein coding) -1.47 0.00
18 FBXO15 F-box protein 15 -1.44 0.00
19 ATP6AP1L ATPase, H+ transporting, lysosomal accessory protein 1-like -1.44 0.00
20 CABP7 calcium binding protein 7 -1.42 0.00
21 TMEM151A transmembrane protein 151A -1.41 0.00
22 SLC16A11 solute carrier family 16 member 11 -1.41 0.00
23 LINC01234 long intergenic non-protein coding RNA 1234 -1.41 0.00
24 CCDC184 coiled-coil domain containing 184 -1.39 0.00
25 TTBK1 tau tubulin kinase 1 -1.37 0.00
26 RAB3C RAB3C, member RAS oncogene family -1.36 0.00
27 ASTL astacin-like metallo-endopeptidase (M12 family) -1.34 0.00
28 MAPK8IP2 mitogen-activated protein kinase 8 interacting protein 2 -1.32 0.00
29 DRD4 dopamine receptor D4 -1.31 0.00
921 RASSF9 Ras association (RalGDS/AF-6) domain family (N-terminal) mem-
ber 9
1.31 0.00
922 SLC40A1 solute carrier family 40 (iron-regulated transporter), member 1 1.33 0.00
923 HIST1H2BA histone cluster 1, H2ba 1.35 0.00
924 FOLR1 folate receptor 1 (adult) 1.39 0.00
925 CITED1 Cbp/p300-interacting transactivator, with Glu/Asp rich carboxy-
terminal domain, 1 [Source:HGNC Symbol;Acc:HGNC:1986]
1.47 0.00
926 AC007682.1 1.49 0.00
927 VIT vitrin 1.61 0.00
928 KDM4E lysine (K)-speciﬁc demethylase 4E 1.93 0.00
929 GDF6 growth diﬀerentiation factor 6 2.05 0.00
930 TNFSF10 tumor necrosis factor superfamily member 10 2.09 0.00
931 HIST1H2AA histone cluster 1, H2aa 2.09 0.00
932 TFEC transcription factor EC 2.33 0.01
933 PHKA1-AS1 PHKA1 antisense RNA 1 4.35 0.00
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5.2.3. Gene ontology analysis
With the aim of determining underlying processes and pathways that are inﬂuenced
by GNS G treatment the previously obtained list of diﬀerentially expressed genes
was used as an input for further analysis. Gene ontology (GO) enrichment analysis
provides a tool for assessing in which biological processes the respective genes and
their products are involved. Gene sets are associated with GO terms that underlie
a hierarchical system. The three root terms are "cellular component", "biological
process" and "molecular function". Each of those root terms holds a large number of
subordinated terms which increase in speciﬁcity and therefore give hints to the aﬀected
cellular mechanisms.
Overall, GO analysis indicates that the eﬀects of GNS G treatment are widely spread
and a large number of GO hits are found in all three root terms. Selected results of
the GO analysis for the two root terms "biological process" and "cellular component"
are described in the following. Full results of GO analysis are given in the appendix
(table A.1.2, table A.1.2, table A.1.2).
The analysis on biological processes revealed that some important feedback mech-
anisms of O-GlcNAcylation are aﬀected by GNS G treatment (see table 5.2). The
GO term hits include "negative regulation of phosphorylation" and "negative regula-
tion of protein phosphorylation". These hits are most likely linked to the competition
between O-GlcNAcylation and phosphorylation and therefore represent an important
control of the drug treatment with the Oga inhibitor. In addition, three GO terms
come up in this analysis that are linked to nutrition and the response to nutrient lev-
els. As O-GlcNAc functions as a metabolic sensor this is another major mechanism
that would have been expected to be aﬀected. Therefore, these results provides an
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important control and underline the reliability of the data obtained.
Table (5.2) GO Process
GO term ID Description Proteins Hits p-value
GO:0042326 negative regulation of phosphorylation 359 26 0.00092
GO:0001933 negative regulation of protein phosphory-
lation
326 24 0.00114
GO:0031669 cellular response to nutrient levels 183 16 0.00131
GO:0031667 response to nutrient level 397 30 0.00019
GO:0007584 response to nutrient 164 16 0.00040
When investigating in which cellular compartments the products of genes aﬀected
by GNS G treatment are localised, it becomes clear that the eﬀect is widely spread
throughout the cell (compare table A.1.2). Enrichment analysis for the GO parent
term "biological process" revealed that products of genes that are diﬀerentially ex-
pressed in GNS G are also involved an a large number of varied biological processes
(compare table A.1.2). Figure 5.4 illustrates these ﬁndings and provides an overview of
the multitude of GO processes that are aﬀected by GNS G treatment according to GO
enrichment. This graph was obtained using REViGO for reduction and visualization
of GO results (Supek et al., 2011). In the light of the previously described data on
ectoderm diﬀerentiation it is of particular interest that many GO term hits are closely
related to central nervous system and brain development as well as to neurogenesis.
These ﬁndings indicate that O-GlcNAcylation might not only play a role in ectodermal
diﬀerentiation, but it could potentially impact strongly on early neural development.
In addition, two hits were identiﬁed for GO terms related to growth factor response.
The appropriate response to growth factor stimuli is essential for driving diﬀerentia-
tion and embryonic development. It might therefore be possible that O-GlcNAcylation
hinders diﬀerentiation by impairing the cell's reaction to relevant factors.
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Figure (5.4) Visualization of gene ontology results using REViGO. REViGO analysis indicates a broad
eﬀect of GNS G treatment on GO process terms. Colours correspond to log10 p-values of the previously performed GO
analysis, circle sizes are correlated to the frequency of the GO term in the underlying GOA database (more general
terms are shown as larger circles).
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5.2.4. Interaction network analysis
Another tool for extending the information of diﬀerential gene expression analysis
is StringDB (Franceschini et al., 2013). It allows investigations into interactions of
products of the genes that are diﬀerentially expressed. A network of predicted pro-
tein interactions is build based diﬀerent levels of evidence, i.e. textmining, database
or textmining evidence. For this analysis, the diﬀerentially expressed gene list was
restricted to the genes that had an absolute log fold change of 0.85 or higher.
The results of StringDB is shown in Figure 5.5. The networks illustrates that a
large number of proteins that are aﬀected by GNS G treatment could potentially
interact. Overall, 307 possible interactions were detected between the 200 proteins
that were analysed. It becomes clear that there are a large proportion of the depicted
interactions are based on neighbourhood evidence (green lines) only and the respective
proteins very often only show a single line of connection.
There appear to be two clusters of interacting proteins that are both highly dereg-
ulated by GNS G treatment and also strongly connected by various lines of evidence.
The smaller cluster contains (amongst others) the proteins BMPR1B, GDF6, TN-
FSF10, CITED1, LEFTY1 and GDNF. Within the cluster especially BMPR1B is
connected by experimental evidence to LEFTY1 and GDF8. This smaller cluster is
again linked to a second, bigger cluster which contains for example KLF2, CDK5,
ZIC5, FOXJ1, MAPK11 and FEZF1. Within this cluster, proteins are connected by
diﬀerent lines of evidence. On the periphery of the second cluster, two histone vari-
ants (HIST1H2BA and HIST1H2AA), two zinc ﬁnger proteins are found (ZNF781,
ZNF436) and two transcription factors (TFEB, TFEC) are found. This might pos-
sibly suggest an eﬀect on transcriptional regulation. However, it is diﬃcult to draw
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conclusions with a view to the molecular function of high O-GlcNAc levels from this
data. The interaction network demonstrates that the eﬀects of GNS G aﬀect a large
number of proteins with diﬀerent functions and there is a high likelihood for crosstalk
between them.
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Figure (5.5) StringDB protein interaction network. Spheres represent the respective proteins, halos around
spheres indicate the degree of up- (green) or downregulation (red) in GNS G. Lines represent evidence of connection:
Red line - fusion evidence; Green line - neighbourhood evidence; Blue line - co-occurrence evidence; Purple line -
experimental evidence; Yellow line - textmining evidence; Light blue line - database evidence; Black line - co-expression
evidence.
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5.3. Validation of selected hits of DGE analysis
In order to validate the data obtained by RNA sequencing with another method, RT-
qPCR was performed. Therefore, a set of genes were selected that would span a range
of diﬀerent log fold changes with the aim of analysing the correlation between both
methods. As representative genes with a high log fold change Klf2 and GDNF were
analysed. FoxJ1 and Sema3A represent genes with a intermediate log fold change
whereas MAPK21 and Klf8 have a small log fold change.
The respective results are illustrated in Figure 5.6. The data obtained by RNA
sequencing is in most cases closely mimicked by the RT-qPCR data. Genes that were
detected with a high log fold change in the diﬀerential gene expression analysis also
show a signiﬁcant diﬀerence by RT-qPCR (i.e. Klf2 ). Interestingly, for GDNF and
Sema3A the results from RNA sequencing do not quiet correlate with those obtained
by RT-qPCR: While GDNF has a higher log fold change than Sema3A, Sema3A
appears to be more upregulated by RT-qPCR. It is also important to note that the
two genes with small log fold changes (around |0.35|), namely MAPK21 and Klf8, still
show signiﬁcant up- or downregulation by RT-qPCR. Altogether, these data support
the results of the RNA sequencing experiment very well and indicate that in most
cases RT-qPCR data and diﬀerential gene expression data correspond closely.
5.4. GNS G treatment interferes with signal transduction of
the BMP signalling pathway
From the results obtained by diﬀerential gene expression analysis several hits stood out
that were linked to the BMP signalling cascade. An overview of those hits and their
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Figure (5.6) Validation of diﬀerential gene expression results. RT-qPCR analysis of gene expression on
selected hits obtained by diﬀerential gene expression analysis. ***: p ≤ 0.001; **: p ≤ 0.01; *: p ≤ 0.05; n.s.: p >
0.05 (Student's t-test, paired); n=6 independent biological repeats for all, errorbars represent SEM.
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function within the BMP pathway is depicted in Figure 5.7 C (hits are highlighted in
green). First, the gene coding BMP receptor subtype BMPR1B (also known as Alk6)
is upregulated in GNS G treated ChiPS4 cells. In addition, the inhibitory Smad7 is
upregulated in GNS G in the diﬀerential gene expression analysis. Furthermore, the
gene TGFBI (TGF-β induced) exhibits an increase in expression in GNS G treated
cells. TGFBI is linked to the BMP signalling pathway via the crosstalk between
Smads and TGF-β signalling.
In order to investigate whether BMP4 signalling was modiﬁed in GNS G treated
human iPS cells, the ﬁndings of the RNA sequencing experiment were ﬁrst validated by
RT-qPCR (Figure 5.7 A). Both BMPRB1 and TGFBI show a strong increase in gene
expression in response to GNS G treatment which validates the previous ﬁndings. For
Smad7, a trend towards upregulation of gene expression in GNS G could be observed.
However, this result is not statistically signiﬁcant.
The increase in expression of the BMP receptor subtype BMPRB1 might imply
that the cells are more susceptible to BMP4 stimulation. In the interest of testing
this hypothesis, the pathway was stimulated with BMP4 and the expression level of
Cdx2, a transcriptional target of the BMP4 cascade, were determined by RT-qPCR.
ChiPS4 were treated with GNS G for three days prior to overnight stimulation with
diﬀerent concentrations of BMP4. The respective result from RT-qPCR is shown in
Figure 5.7 B. The data demonstrate a pronounced increase in expression levels of
Cdx2 in GNS G treated cells in comparison to the untreated and DMSO control. This
eﬀect can already be observed at very low concentrations of BMP4 and even without
BMP4 stimulation. The result suggests that the BMP4 signalling pathway might
become more active in GNS G treated cells. As the BMP4 pathway has an inhibitory
impact on neural diﬀerentiation and embryogenesis in various model systems (LaVaute
149
et al., 2009; Khokha et al., 2005; Wilson et al., 1997; Dosch et al., 1997) it might be
speculated that its increased activity could hinder diﬀerentiation and therefore provide
a molecular mechanism for the previously described eﬀects on neural diﬀerentiation.
However, it needs to be noted that this result is preliminary and future work should
therefore be targeted on validating this data and investigating further eﬀects on BMP4
signalling.
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Figure (5.7) GNS G treatment aﬀects the BMP4 signalling pathway in ChiPS4. A: RT-qPCR validation
of diﬀerential gene expression hits related to BMP4 signalling; **: p ≤ 0.01; *: p ≤ 0.05; n.s.: p > 0.05 (Student's
t-test, paired); n=6 independent biological repeats for all, errorbars represent SEM. B: RT-qPCR analysis of the BMP4
target gene Cdx2 in response to stimulation with BMP4; n=1 biological repeat, errorbars represent technical error of
the RT-qPCR (3 technical repeats of RT-qPCR). C: Schematic of the BMP4 signalling cascade, hits from diﬀerential
gene expression analysis are highlighted in green.
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6. Discussion
6.1. Results summary
The aim of this study was to investigate the role of O-GlcNAc on pluripotent stem
cell diﬀerentiation into diﬀerent lineages and to explore the molecular mechanisms of
any eﬀects discovered. These ﬁndings would then provide valuable starting points
for future research in the ﬁeld and contribute to the overall understanding of the
molecular functions of this posttranslational modiﬁcation in pluripotent stem cells,
lineage commitment and early mammalian development.
The ﬁndings presented in the previous chapters illustrate that O-GlcNAc plays a
vital role in the diﬀerentiation of both mouse ES cells and human iPS cells. Ele-
vated O-GlcNAc levels impair diﬀerentiation in both pluripotent stem cell models.
Importantly, this eﬀect is lineage independent in mouse ES cells, but restricted to
ectodermal diﬀerentiation in human iPS cells. Experiments on human iPS cells have
shown that the early stages of lineage commitment are strongly aﬀected by deregula-
tion of O-GlcNAcylation. At advanced stages, elevated O-GlcNAc levels do not impair
ectodermal diﬀerentiation, neurogenesis or the maintenance of neurons.
With a view on potential molecular mechanisms underlying the described eﬀect on
diﬀerentiation, several approaches were taken. For mouse ES cells, data previously
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obtained by microarray analysis suggested that gene sets that are normally silenced
get re-expressed upon GNS C treatment. Following up on these data, it was possible
to validate the microarray ﬁndings on the gene sets of polycomb repressive complex
repressed genes and 2C genes, a gene set characteristically expressed during the two-
cell-stage of mouse embryonic development. When investigating potential molecular
mechanisms that might cause the re-expression of those genes, the focus lay on global
mechanisms that could be linked to both O-GlcNAc and transcriptional activation
from previous studies. It was found that both histone acetylation and DNA methyla-
tion are not aﬀected by high O-GlcNAc levels to a degree that would explain the eﬀect
on silenced genes. For human iPS cells, a RNA sequencing experiment was performed
to elucidate potential mechanisms that cause the observed hindrance of ectodermal
diﬀerentiation in high O-GlcNAc conditions. This experiment and the subsequent
data analysis revealed that elevated O-GlcNAc levels impact on a multitude of genes.
Overall, it could be observed that many genes were aﬀected to a small extent by high
O-GlcNAc levels, suggesting a multitude of small eﬀects that orchestrate a global cel-
lular response. The data suggest that underlying mechanisms are complex and most
likely interacting on multiple levels. Regardless of those ﬁndings, it was possible to
reveal one signalling cascade that responds to elevated O-GlcNAc levels by an in-
crease in activity: the BMP pathway. One previous study has described potential
crosstalk between O-GlcNAc and BMP signalling, however this has not been linked to
pluripotent stem cells and their diﬀerentiation before (Herhaus, 2014). These ﬁndings
provide a good starting point for future studies that could, for example, focus on the
link between the function of O-GlcNAc in BMP signalling and neurogenesis in the
mammalian embryo.
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6.2. GNS G treatment: diﬀerences between high O-GlcNAc
and Oga inhibition
When evaluating the results represented in this thesis it is essential to keep in mind
the nature of Oga inhibitor treatment used for the majority of experiments. Both in
mouse ES and human iPS cells treatment with GNS G has multiple eﬀects. First,
O-GlcNAc levels get elevated globally as a consequence of inhibition of the hydrolase
Oga. In addition, protein levels of the two O-GlcNAc regulators Oga and Ogt are
aﬀected by feedback mechanisms. The excess of O-GlcNAcylation results in an upreg-
ulation of Oga while its counterpart, the transferase Ogt, is downregulated. Therefore,
treatment with GNS G has three distinct eﬀects and each of them could trigger var-
ious molecular mechanisms. An increase in O-GlcNAc modiﬁcation on proteins will
most likely impact on their function in cellular signalling. This could happen through
multiple mechanisms. For example, O-GlcNAcylated proteins could be functionally
distinct from their unmodiﬁed counterparts as has been proposed for RNA polymerase
II (Comer et al., 2001). Increased O-GlcNAcylation does also impact on phosphory-
lation as both modiﬁcations compete. Although data from our lab suggests that the
global elevation of O-GlcNAc levels does not lead to an overall decrease in phospho-
rylation, it is likely that selected proteins can be aﬀected in such a manner (Bauer
et al., 2015; Speakman et al., 2014). The feedback regulation of Oga and Ogt will have
further eﬀects on cell signalling that might act in concert or independently from glob-
ally increased O-GlcNAcylation. Especially Ogt has been proposed to complex with
numerous other enzymes and in many cases the detailed functions of Ogt therein have
not been revealed. However, a downregulation of Ogt in response to GNS G might
well lead to a decrease in the formation of Ogt-containing regulatory complexes. As an
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example, disruption of the previously proposed Ogt/Tet1/2/Sin3A/HDAC1 complex
(Vella et al., 2013) could result in a loss of repression on certain genetic elements.
For these reasons, it is important that the eﬀects of GNS G treatment are not lim-
ited to an increase in O-GlcNAcylation levels. In order to decipher the diﬀerences
between feedback eﬀects and high O-GlcNAc it would be vital to use a combination of
inhibitor treatment, knockdown and overexpression experiments of Ogt and Oga. Un-
fortunately, there are technical limitations that prevented me from conducting some
of those experiments in mouse ES and human iPS cells. In mouse ES cells, transient
knockdown of Ogt and Oga could be successfully performed for a short period using
siRNAs. However, siRNA-mediated knockdown of Ogt strongly disrupted the viability
of mouse ES cells in our hands. Transient overexpression of Oga and Ogt in mouse
ES cells was also possible, although the overexpression of Ogt remained at a very low
level and might therefore not have a biological eﬀect. Eﬀorts were made to generate
inducible knockdown cells from both mouse ES and human iPS cells. In both cases,
an eﬃcient knockdown of either Oga or Ogt have not be achieved to date. Conse-
quently, experiments had to be limited to using GNS G treatment in human iPS cells.
Where mouse ES cells were used, transient knockdown and overexpression of Oga were
conducted during short-term experiments.
6.3. O-GlcNAc in mouse ES cells and human iPS cells: eﬀects
on diﬀerentiation
With a view to extending current knowledge regarding the role of O-GlcNAcylation
in pluripotent stem cells, the data in this thesis has made a signiﬁcant contribution
for both mouse ES and human iPS cells. For mouse ES cells, only an eﬀect of treat-
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ment with the hexosaminidase inhibitor PUGNAc on cardiomyocyte diﬀerentiation
had previously been demonstrated by Kim et al. (2009). Data presented in the study
at hand has contributed to extending these observations by showing that all lineages
are aﬀected by treatment with GNS G. Further data from our lab demonstrates a
prominent eﬀect of elevated O-GlcNAc levels on neural lineage commitment and adds
to the signiﬁcance of the data presented in this thesis (Speakman et al., 2014). How-
ever, it remains to be clariﬁed at what stage diﬀerentiation and lineage commitment
can be disrupted by modiﬁed O-GlcNAcylation. The data at hand implies that the
transition from a naïve to formative pluripotency is not impaired by GNS G treatment.
For example, correct O-GlcNAcylation might only be important for the regulation of
lineage-speciﬁc transcription factors which are commonly expressed at an advanced
stage of diﬀerentiation. Consequently, the transition to a formative stage would not
be aﬀected, whereas further diﬀerentiation would be blocked, possibly through a mech-
anism controlling transcription of relevant genes and factors. It would therefore be
important to elucidate during which stages of diﬀerentiation deregulation of O-GlcNAc
hinders the correct progression of the cells towards a certain lineage and whether dif-
ferences between the three lineages could be observed in this aspect. Investigations
into the expression proﬁle of naïve, primed and relevant lineage markers would be of
particular importance to provide a good understanding on this matter.
Intriguingly, while a lineage-independent eﬀect was observed in mouse ES cells,
treatment with the Oga inhibitor GNS G only disrupts diﬀerentiation into ectoderm
when using human iPS cells. Prior to the experiments conducted for this study, only
one report had linked O-GlcNAcylation and diﬀerentiation in human pluripotent stem
cells: Maury et al. (2013) describe that the maintenance of pluripotent stem cells is not
disrupted by treatment with PUGNAc/Thiamet G, an observation that is in agreement
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with the data presented in this thesis using GNS G. Using a spontaneous diﬀerentia-
tion assay, Maury et al. (2013) concluded that some lineage markers were diﬀerently
expressed when cells had been treated with PUGNAc/Thiamet G. In particular, they
describe downregulation of the ectoderm markers Pax6 and Msx1 and upregulation of
two endoderm markers. However, in particular with a view to their results regarding
the endoderm markers it should be noted that the apparently signiﬁcant diﬀerences
can only be observed at one intermediate timepoint of the diﬀerentiation assay. At
later stages, PUGNAc/Thiamet G treated cells do not show an impact of inhibitor
treatment on the expression pattern of those markers. Although the data presented by
Maury et al. (2013) also hints towards an eﬀect of Oga inhibition on ectoderm diﬀeren-
tiation the detailed results are not consistent with data presented in this thesis. While
Maury et al. (2013) report a prominent eﬀect on Pax6 gene expression, Pax6 is the
only investigated ectoderm marker that was not deregulated during the experiments
presented in the study at hand. It is unclear why Pax6 appears to be unaﬀected in
GNS G treated cell during ectoderm diﬀerentiation while all other neuroectodermal
lineage markers that were investigated, i.e. Sox1, are strongly downregulated in GNS
G treated cells. Data provided by Chambers et al. (2009) suggests that Pax6 is in-
duced at a slightly later timepoint in diﬀerentiation than Sox1 which could explain
the diﬀerences in behaviour of those two markers as the eﬀect of GNS G appears to
be aﬀecting early timepoints predominantly. However, data presented in this thesis
does not support this hypothesis as both markers appear to be expressed in a similar
temporal pattern in control cells. Diﬀerences in the behaviour of Pax6 and Sox1 have
also been reported by other groups (Neely et al., 2012), although the reasons have
not been elucidated. As an eﬀect of O-GlcNAc has been established in relationship
with transcriptional and epigenetic regulation, it might also be speculated that GNS
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G treatment leads to repression of selected transcription factors and thereby hinders
neuroectodermal lineage commitment. This could explain why some markers are en-
tirely repressed, while others like Pax6 are induced normally. Furthermore, expression
of Pax6 and Pax7 is responsive to BMP signalling during development of the neural
tube. While Pax7 is expressed in the dorsal region (high BMP), Pax6 is found more
ventrally (low BMP) (Timmer et al., 2002; Briscoe and Small, 2015). Therefore, in-
creased sensitivity towards BMP4 in GNS might aﬀect Pax7 expression, but not the
induction of Pax6.
The discrepancies between the report from Maury et al. (2013) and the data in this
thesis could have several potential reasons. Firstly, the data presented by Maury et al.
(2013) is limited to spontaneous diﬀerentiation assays in EBs. While carrying out
similar experiments I found that marker gene expression at ﬁnal stages of spontaneous
diﬀerentiation is diﬃcult to investigate in human iPS cells. Due to the characteristics
of this type of diﬀerentiation the cell population harvested at the endpoint of the as-
say consists of numerous diﬀerent cell types and lineages. Analysis of gene expression
requires investigating the whole cell population with the result that speciﬁc lineage
markers are only expressed in a small subset of cells and therefore diﬃcult to detect
in meaningful quantities. Secondly, the eﬀects of PUGNAc and Thiamet G might be
diﬀerent from those observed when using GNS G as they are known to also target
other hexosaminidases than Oga. Moreover, diﬀerences in the ﬁnal analysis step by
RT-qPCR, i.e. primers used, also might contribute to the observed divergence. The
investigations presented in this thesis also extend the previous knowledge by providing
morphological evidence that demonstrates a strong disruption of in vitro neurogenesis.
As rosette formation bears close similarity to the establishment of the neural tube, this
observation puts further impact on the data and hints that O-GlcNAcylation might
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directly aﬀect early developmental steps in the mammalian embryo. Furthermore, it
could be clearly demonstrated, that GNS G treatment only disrupts ectoderm diﬀer-
entiation when added at early stages of the process. O-GlcNAcylation might therefore
be essential for early lineage decisions, but not necessarily for neuron formation or
maintenance once the cells have committed to their ectodermal fate.
6.3.1. Diﬀerences in model systems: Mouse ES cells vs. human
iPS cells
From the data previously presented it becomes clear that deregulation of O-GlcNAc
levels by GNS G treatment has very diﬀerent eﬀects in mouse ES cells and human iPS
cells. Most importantly, GNS G treatment impairs diﬀerentiation into all lineages in
mouse ES cells but only has an eﬀect on neuroectoderm diﬀerentiation of human iPS
cells. In addition, diﬀerentiation appears to be retarded in mouse ES cells whereas the
data at hand suggests that ectoderm diﬀerentiation of human iPS cells can be entirely
blocked by GNS G treatment. It should also be noted at this point that human iPS cells
treated with GNS G loose expression of pluripotency markers (Oct4, Nanog) at the
same rate as control treated cells. Therefore, the cells appear to become arrested after
switching oﬀ expression of pluripotency genes, but before expressing lineage markers.
The identity of those cells is therefore unclear. In comparison, mouse ES cells treated
with GNS G retain Oct4 expression longer than cells treated with a vehicle control
which implies that the complete diﬀerentiation process is retarded (Speakman et al.,
2014). From these diﬀerences in eﬀects of GNS G treatment on diﬀerentiation of mouse
ES and human iPS cells the question arises whether the discrepancies between those
two cell models are species-dependent (mouse versus human) or due to diﬀerences in
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the pluripotency model (ES versus iPS).
Current knowledge strongly suggests that mouse and human ES/iPS cells represent
diﬀerent developmental stages: While mouse ES cells are in a state of naïve pluripo-
tency, human ES cells bear more similarity with a primed pluripotent state in mouse
and can therefore be compared to mouse epiblast stem cells (EpiSCs) derived from the
postimplantation embryo (Tesar et al., 2007; Brons et al., 2007). Selected molecular
diﬀerences between mouse ES and human ES/iPS cells are summarized in table 6.1.
Very recently, several reports have claimed the that cells of a naïve pluripotent state
can be derived from human embryos (Guo et al., 2016; Warrier et al., 2016). In ad-
dition, multiple studies have undertaken approaches to "revert" human ES cells to a
state resembling the naïve ground state of mouse ES cells using combinations of multi-
ple cytokines and small molecule inhibitors (Theunissen et al., 2014; Ware et al., 2014;
Takashima et al., 2014; Chan et al., 2013; Gafni et al., 2013). Although these studies
indicate that human ES/iPS cells can exist in a state that shares most understood
molecular and epigenetic characteristics of the murine ground state pluripotency it can
be argued to what extent these naïve human ES/iPS cells actually mirror the in vivo
situation within the human embryo. For example, Pastor et al. (2016) point out that
maintaining human ES cells in a naïve state results in the loss of DNA methylation
at key imprints and those cells therefore lack the epigenetic memory of the human
embryo. An earlier study by Huang et al. (2014) also demonstrates that the transcrip-
tome of naïve human ES cells holds little resemblance with the ground-state mouse
ES cell transcriptome. However, both have been shown to clearly correspond to their
respective preimplantation epiblasts in this study.
Apart from species-dependent discrepancies, there are also reports on diﬀerences
between ES and iPS cells (compare section 1.1.3). iPS cells are cultured and diﬀeren-
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Table (6.1) Diﬀerences between mouse ES cells and human ES/iPS cells (Gafni et al., 2013; Marks et al., 2012;
Hanna et al., 2010)
Feature mouse ES cells human ES/iPS cells
Oct4 expression through distal enhancer proximal enhancer
X-chromosome active tendency to inactivation
DNA methylation very low increased
H3K27me3 on lineage-regulatory genes not deposited deposited
tiated under the same conditions as ES cells and have been demonstrated to demon-
strate a comparable level of cell potency (Takahashi and Yamanaka, 2006; Takahashi
et al., 2007). Regardless, it appears highly plausible that iPS cells can to some de-
gree retain a "somatic memory" after reprogramming which is most likely reﬂected by
diﬀerences in DNA methylation patterns between ES and iPS cells (Doi et al., 2009;
Kim et al., 2009; Ghosh et al., 2010; Lister et al., 2011).
Both interspecies diﬀerences and divergence between ES and iPS cells are found on
the level of gene regulation and expression. Numerous of these regulatory processes
have reported interaction with O-GlcNAc and its regulators which might be the rea-
son why deregulation of the modiﬁcation impacts diﬀerently on mouse ES and human
iPS cells. For example, human ES/iPS cells already show deposition of the histone
mark H3K27me3 on lineage-dependent genes which is mediated by PRC2. For recruit-
ment of PRC2, Tet1-mediated demethylation is essential (Wu and Zhang, 2011; Aloia
et al., 2013) which can again be inﬂuenced by O-GlcNAcylation of Tet1 and regulation
through Ogt (Vella et al., 2013). It could consequently be speculated that if H3K27me3
had already been deposited on some lineage-regulating genes in iPS cells, the eﬀect of
O-GlcNAc deregulation (decrease in Ogt protein levels) would be restricted to certain
genes that would not carry this methylation mark. Hence, this could explain why a
lineage-restricted eﬀect can be observed in iPS cells, but a lineage-independent eﬀect
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in ES cells. However, the most probable cause for the observed diﬀerences between
mouse ES cells and human iPS cells is a combination of small eﬀects of GNS G treat-
ment on multiple transcriptional regulatory mechanisms. As those mechanisms are
in a diﬀerent starting position when the cells are subjected to treatment and diﬀer-
entiation, the outcome diﬀers between the two model systems. Ideally, experiments
should have been repeated using both mouse iPS cells and human ES cells in order
to provided insight into the comparability of both species and pluripotent stem cell
model systems. In addition, diﬀerentiation experiments using mouse EpiSCs which
are in developmental state that is thought to be similar to the one of human iPS cells
(primed pluripotency) could be performed. Due to time restrictions such experiments
have not been subject of the thesis at hand and are therefore strongly recommended
for future work on the project.
6.4. O-GlcNAc in epigenetics
6.4.1. Reexpression of 2C genes and implications for cell
potency
Experiments on mouse ES cells presented in the thesis at hand provide proof of re-
expression genes that is normally silenced when treated with GNS G section 4.2. These
genes have previously been described to be characteristic for the early developmen-
tal stage of the two-cell embryo (Macfarlan et al., 2012). Expression of 2C genes is
correlated with retroviral activity as their transcription is initiated from long termi-
nal repeats (LTRs) of murine endogenous retroviruses. As the embryo progresses in
its development those retroviral elements and respective transcripts become silenced
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through epigenetic mechanism. Thus, expression of 2C genes can be seen as an indica-
tor of this early developmental two-cell stage at which cells are still totipotent. Mac-
farlan et al. (2012) suggest, that within every mouse ES cell population a totipotent
subset exists that can be identiﬁed by expression of 2C genes. Furthermore, they sug-
gest that ES cells cycle in and out of the totipotent state. Data presented in the thesis
at hand clearly indicates that treatment with GNS G as well as knockdown of Oga in-
creases transcription of 2C genes. Flow-cytometry experiments using MERVL reporter
cells have demonstrated that the ampliﬁcation in expression of 2C genes observed when
investigating the bulk population is due to a increase of MERVL-expressing subpopula-
tion. Therefore, GNS G treatment leads to an enlargement of a potentially totipotent
subpopulation. In order to elucidate whether MERVL-expressing cells are actually
a cycling population as suggested by Macfarlan et al. (2012) several attempts were
made to sort the cells. Unfortunately, cell viability was greatly impaired in response
to the sorting. For this reason the results are not included in this thesis. However,
data obtained with the few surviving cells suggested that the MERVL subpopulation
does cycle.
It remains to be clariﬁed an increase in the number of cells that express 2C genes
can be correlated with an eﬀect on total cell potency. If so, this would indicate that
GNS G treatment or knockdown of Oga could shift the cells towards a totipotent state.
Macfarlan et al. (2012) have used morula injection of the sorted 2C-subpopulation in
order to validate that those cells are able to contribute to the formation of extraem-
bryonic tissue. Due to the above mentioned technical restriction, similar experiments
have not been conducted as part of this thesis. Nonetheless, preliminary experiments
have been carried aiming to diﬀerentiate GNS G treated mouse ES cells into tro-
phoblast. However, results from those experiments were inconclusive. Furthermore,
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we tested whether cells treated with GNS G would also show an increased expression
of Hex, an extraembryonic endoderm marker that had been linked with totipotency
(Morgani et al., 2013). Preliminary data did not indicate an increase in Hex expres-
sion upon GNS G treatment. Consequently, it remains elusive whether deregulation
of O-GlcNAcylation can be linked with totipotency. In the light of data obtained to
date, it could be speculated that GNS G treatment exhibits a broad de-repressive
function on an epigenetic level that happens to include 2C genes amongst other gene
sets, rather than providing a switch from a pluripotent to a totipotent state.
6.4.2. Polycomb repression
The previously presented results indicated that in addition to 2C genes a second gene
set becomes re-expressed in mouse ES cells in response to GNS G treatment. This
set is composed of genes that are normally silenced by polycomb repressive complexes
(Speakman et al., 2014; Brookes et al., 2012). It should be noted that detailed in-
vestigations on the function of O-GlcNAc in polycomb repression were not subject
of this thesis at any point. Nevertheless, the validation of gene set enrichment data
presented by Speakman et al. (2014) can provide a starting point for future investi-
gations. The following discussion will therefore aim to reveal potential links between
the observations provided by the study at hand regarding pluripotent stem cell dif-
ferentiation and gene regulation in order to stimulate further research. As described
in section 1.2.2 O-GlcNAc and its regulating enzymes have been shown to crosstalk
with polycomb repression in multiple studies. Nonetheless, it remains largely elusive
to which extent O-GlcNAcylation aﬀects the two complexes and how this could im-
pact on diﬀerentiation and pluripotency. A very recent study provides insight into
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potential mechanisms by which O-GlcNAc modiﬁcation could regulate the activity of
PRC1: In 2015, Maury et al. (2015) used human ES cells to provide evidence that the
catalytical subunit of PRC1, Ring1B, can be modiﬁed by O-GlcNAc. Interestingly,
the modiﬁcation could be shown to correlate with localization of Ring1B on chromatin
as the O-GlcNAcylated enzyme is preferentially found on genes that are related to the
neural diﬀerentiation process. In addition, O-GlcNAc levels appear to decrease during
diﬀerentiation. It is important to note that this observation is not entirely consistent
with the data presented in this thesis. The observed discrepancies might be due to
methodological diﬀerences. However, if O-GlcNAcylation of Ring1B decreases with
the progress of diﬀerentiation, a loss of the modiﬁcation could provide an important
on-switch of neural genes. Therefore, GNS G treatment could artiﬁcially stabilize O-
GlcNAcylation of Ring1B and might thereby hinder neural diﬀerentiation as relevant
genes remain in a silenced state. Of note, the data presented by Maury et al. (2015)
was obtained using human ES cells. As part of this thesis, transcriptome analysis
of human iPS cells treated with GNS G was performed and this data does not sug-
gest a signiﬁcant deregulation of polycomb repression. Moreover, gene set enrichment
analysis of microarray data on mouse ES cells performed in Speakman et al. (2014)
indicate no signiﬁcant enrichment for two additional gene sets that consist of target
genes of PRC1 or PRC2. Myers et al. (2011) also demonstrate that knockdown of
Ogt, which corresponds with decreasing levels of O-GlcNAcylation, does not impair
PRC2 function. It is therefore unclear how pronounced the reported upregulation
of polycomb repressed genes is and to what extent it impacts on cellular signalling.
Potential eﬀects could be limited to certain genes or loci and biological consequences
would then be diﬃcult to predict. An additional possibility is that the observed de-
repression of polycomb targets in GNS G is a secondary eﬀect that follows other gene
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regulatory mechanisms, i.e. histone modiﬁcation or DNA methylation. As an exam-
ple, recruitment of PRC2 requires preceding demethylation of CpG islands which can
be mediated by Tet1 which has been shown to interact with Ogt (Wu and Zhang,
2011; Aloia et al., 2013; Vella et al., 2013).
6.4.3. Histone acetylation
The previously described impact of O-GlcNAcylation on transcriptional regulation of
2C and polycomb repressive complex repressed genes might suggest an underlying
more global mechanism. One candidate mechanism that has been investigated as a
part of this thesis is a potential eﬀect of O-GlcNAc on histone acetylation. An increase
in histone acetylation is commonly understood to lead to a more open chromatin
conformation, hence elevating transcriptional activity. O-GlcNAc is part of the histone
code and therefore capable of interfering with respective histone modiﬁcations (Sakabe
et al., 2010; Zhang et al., 2011; Fujiki et al., 2011; Fong et al., 2012). More importantly,
there have been reports that the C-terminus of Oga harbours a domain that exhibits
HAT activity (Schultz, 2002; Toleman et al., 2004). However, it has also been argued
that this domain is catalytically inactive Rao et al. (2013); He et al. (2014). Thus,
its function is still under debate. In the present study global histone acetylation
was investigated using various methods. Initial experiments indicated an increase
of lysine acetylation of H3 when investigated by Western Blot of histone extracts.
However, strong variations were observed between individual experiments and overall
reproducibility was low. Detailed records of cell morphology, density and viability for
each experiments were kept, but did not help to elucidate these issues. As previously
discussed, GNS G treatment has multiple eﬀects and the feedback upregulation of
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Oga protein levels is only one of them. Therefore, we decided to set up an experiment
using knockdown and overexpression of Oga. Again, high variability was observed
and the data was diﬃcult to interpret. As a consequence, a diﬀerent method was
chosen for investigating H3 acetylation levels: A commercial ELISA kit was used on
histone extracts of cells that had been transfected with overexpression plasmids of
full-length Oga and a naturally occurring splicing-variant devoid of the major part
of the HAT domain (Oga-SV). Independent experiments were performed and again
records were kept on the cells' density and health status. There appears to be a
minor trend towards an increase in H3 acetylation when cells were transfected with
full-length Oga. However, results were again highly variable. It was observed, that
the signal intensity of the colorimetric ELISA readout varied strongly with diﬀerent
batches of the kit regardless of the fact that consistent amounts of histone extracts
were used. These observed batch eﬀects make it even more diﬃcult to conﬁdently
interpret the results obtained. Nonetheless, it appears that overexpression of Oga
does not strongly impact on global H3 acetylation. Therefore, our results support the
ﬁndings presented by Rao et al. (2013) and He et al. (2014) which indicate that Oga's
HAT domain is catalytically inactive and can consequently be termed a pseudo-HAT
domain. Regardless of the ﬁndings that Oga might not act as a HAT itself it might be
speculated that the protein is involved in the regulation of histone modiﬁcation. For
example, the pseudo-HAT domain it might have a function in targeting other enzymes
to histones or mediate complex formation of histone modiﬁers. If Oga acts on histones
through interaction with other proteins it would be possible that upregulation of Oga
alone is not suﬃcient to induce a eﬀect that would be recognized by the methods
applied in this study. Moreover, it should be noted that mouse ES cells represent a
heterogeneous cell population and it has been proposed that a subpopulation with
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extended cell potency exists. Therefore, a potential eﬀect of Oga upregulation might
be restricted to a certain subset within the mouse ES cell population. Consequently,
eﬀects on a small subpopulation may be partially masked when analysing the mouse
ES cell bulk.
6.4.4. DNA methylation
Even though numerous previous studies indicate crosstalk between O-GlcNAcylation
and Tet proteins which regulate DNA demethylation, the results presented in the thesis
at hand do not suggest a major role of O-GlcNAc as a regulator of DNA methylation.
Potential eﬀects on DNA methylation were investigated using multiple approaches.
Initial experiments were performed using bisulﬁte sequencing of CpG islands on gene
bodies of selected genes and the respective results indicate no changes in DNA methy-
lation of the investigated regions when cells were treated with GNS G. However, it
can not be ruled out that the pattern of DNA methylation is modiﬁed on speciﬁc
regulatory elements or genes that were not included in our analysis. In order to rule
out an impact on few selected regions it would be recommended to perform a whole-
genome bisulﬁte sequencing experiment which was beyond the scope of the present
study. Instead, further experiments were performed investigating global DNA methy-
lation using a dot blot method. Unfortunately, several technical issues impaired the
interpretability of these experiments. The dot blot method appear to be very prone
to error as the signal was often very low and therefore diﬃcult to detect and interpret
conﬁdently. Moreover, results appeared to be highly variable, even within the tech-
nical dilutions performed for each experiment. Re-blotting of previously investigated
DNA often lead to a diﬀerent outcome that could not be explained by diﬀerences in
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DNA storage or processing. Nonetheless, several consecutive repeats could be per-
formed successfully and the results indicated an eﬀect of GNS G treatment on DNA
methylation. As we had little conﬁdence in the dot blot method itself, we decided
to perform a highly quantitative HPLC-MS experiment. Strikingly, results from this
investigation very clearly indicate that levels of 5-mC and 5-hmC are not aﬀected by
GNS G treatment in mouse ES or human iPS cells.
These results are particularly surprising the in light of current knowledge on inter-
actions of O-GlcNAc with Tet proteins. All three Tet proteins have been shown to
be O-GlcNAc targets (Deplus et al., 2013; Ito et al., 2013; Shi et al., 2013) and at
least Tet1 and Tet3 are regulated by the modiﬁcation (Shi et al., 2013; Zhang et al.,
2014). Moreover, Ogt interacts with both Tet1 and Tet3 and a role for this inter-
action in formation of repressive complexes has been proposed (Vella et al., 2013).
GNS G treatment leads to a downregulation of Ogt protein levels. If Tet1/Ogt in-
teract to recruit repressive complexes to chromatin, a loss of Ogt could correspond
to a loss of repressive function. Similarly, Ogt promotes the nuclear export of Tet3
and thereby hinders conversion from 5-mC to 5-hmC (= demethylation) (Zhang et al.,
2014). Less Ogt would allow more nuclear Tet3 which mediates demethylation and
consequently leads to a loss of gene repression by DNA methylation. Both scenarios
would correspond with the previously presented data on re-expression of silence gene
sets. Intriguingly, our investigations of DNA methylation by bisulﬁte sequencing, dot
blots and HPLC-MS do not support these theories. It could still be speculated that
GNS G treatment has eﬀects on DNA methylation that are restricted to single genes
or selected regulatory elements. Therefore, whole-genome bisulﬁte sequencing might
be a possibility to ﬁnally determine whether the crosstalk between O-GlcNAc and Tet
proteins has any functional relevance regarding DNA methylation.
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6.5. Implications from transcriptome analysis
Results obtained from transcriptome analysis using RNA sequencing have provided
several important insights into the transcriptional changes in response to GNS G
treatment. The key observation from this experiment is that O-GlcNAc appears to be
globally involved in multiple cellular processes as a large number of transcripts with
various functions are diﬀerentially expressed. In addition, GNS G treatment appears
to have relatively small, yet signiﬁcant eﬀects on diﬀerentially expressed transcripts,
meaning many genes are up- or downregulated, but only to a small extent. Consistent
with our observations in mouse ES cells, there are more genes up- than downregulated
which suggests a derepressive eﬀect also in human iPS cells (Speakman et al., 2014).
These observations underline that O-GlcNAc is a global player within the cell's sig-
nalling network that orchestrates multiple processes through precise transcriptional
regulation. This "ﬁne-tuning" function of O-GlcNAc might also be the reason why we
could not determine a function of O-GlcNAc regarding selected transcriptional regu-
lation mechanisms, such as histone acetylation or DNA methylation. The eﬀects of
deregulated O-GlcNAcylation could possibly be too small and coordinated very closely
with others that investigations of single mechanisms might not allow for conﬁdent con-
clusions to be drawn. Despite the fact that this global eﬀect makes it diﬃcult to make
predictions regarding a molecular mechanism that explains the impairment of neural
diﬀerentiation, results obtained by gene ontology analysis provide validation current
knowledge and reveal potential areas important for future research. For example, the
analysis' results validate the inhibitor treatment as well as more general functions
of O-GlcNAc by impacting on transcripts linked with phosphorylation and nutrition.
More importantly, the analysis indicates a strong role of O-GlcNAc regarding neural
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development. In the light of the previously obtained data on ectoderm diﬀerentiation
this may appear little surprising. However, the deregulation of transcripts that are
involved in processes like neural tube and brain development, neurogenesis and axon
guidance strongly suggest a function of O-GlcNAcylation that stretches beyond stem
cell diﬀerentiation. It would be most valuable to uncover the functions of O-GlcNAc
in the development of the mammalian central nervous system. As O-GlcNAc is a key
nutrient sensor, it may even provide a link to how the nutritional status of an organism
impacts on its neural development or, through epigenetic imprints, even on that of its
oﬀspring.
Even though the results indicate multiple global mechanisms through which O-
GlcNAc may impact on neural diﬀerentiation it was possible to identify a potential
signalling pathway that appears to be aﬀected by GNS G treatment. Analysis of dif-
ferential gene expression identiﬁed a set of genes involved in BMP signalling to be
diﬀerentially regulated in GNS G. Preliminary data suggests that human iPS cells
which have been treated with GNS G exhibit increased sensitivity towards BMP4
stimulation. BMP signalling is part of the TGF-β cascade and plays a key role in the
regulation of pluripotency and diﬀerentiation. In human ES cells, BMP signalling is
blocked to maintain a pluripotent state and stimulation of the pathway is correlated
with initiation of diﬀerentiation. However, in our experiments ectodermal diﬀerentia-
tion was hindered when cells were treated with GNS G. Therefore, it remains unclear
how increased sensitivity towards BMP signalling blocks diﬀerentiation rather than
driving it. Interestingly, there are multiple studies underlining the importance of
BMP4 signalling during embryogenesis of various vertebrate model systems. For ex-
ample, BMP4 acts as a morphogen and is essential for dorso-ventral patterning in
Xenopus laevis (Wilson et al., 1997; Dosch et al., 1997). Importantly, Khokha et al.
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(2005) showed that inhibition of BMP signalling is required for formation of the neural
plate in Xenopus tropicalis. Using zebraﬁsh Koshida et al. (2002) demonstrated that
blockage of BMP4 activity through FGF promotes neurogenesis. LaVaute et al. (2009)
extended these ﬁndings to human ES cells: Their study conﬁrms that inhibition of
BMP signalling is necessary for neural diﬀerentiation. The data presented by LaVaute
et al. (2009) support my ﬁndings in human iPS cells treated with GNS G: Inhibition
of BMP signalling as required for neural speciﬁcation might diminished due to an in-
crease in the cells' sensitivity towards BMP stimulation. This hypothesis would also
explain why the cells are capable of exiting the pluripotent state but unable to attain
a neural identity. In addition, the previously presented data also indicates that GNS
G no longer blocks neural diﬀerentiation when added at a later timepoint. The impact
of BMP signalling might vary depending on how far the diﬀerentiation has progressed.
Moreover, it is also likely that the cells require a certain period of time in GNS G to
acquire an elevated sensitivity to BMP4. It is clear that detailed investigations on the
role of O-GlcNAc in BMP/TGF-β signalling during diﬀerentiation are needed for a
complete understanding this mechanism.
6.6. Future directions
The project at hand provides many important insights into the function of O-GlcNAc
in pluripotent stem cells. Yet, many questions remain and provide various potential
directions for further research on this topic. Results presented in this thesis clearly
indicate discrepancies between the two pluripotent stem cell models used. It remains
unclear to what extent those diﬀerences are species-speciﬁc or model-speciﬁc. There-
fore, it would be highly recommended to perform additional experiments on diﬀeren-
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tiation of human ES cells and mouse iPS cells to provide clariﬁcation on this matter.
Most experiments performed for this study used GNS G as Oga inhibitor to elevate
global O-GlcNAc levels. As previously discussed, GNS G treatment has the additional
feature of inducing feedback regulatory eﬀects on the two O-GlcNAc regulators, Oga
and Ogt. These additional feedback eﬀects make it diﬃcult to determine molecular
mechanisms as both Oga and Ogt have been implied with additional functions on the
level of gene regulation. Therefore, it is essential to conduct a set of experiments
using knockdown or overexpression of the two enzymes, ideally through an inducible
and stable system. The generation of respective lines has been attempted, but was
so far unsuccessful. Some of the diﬃculties of deregulating levels of Ogt and Oga
are most likely due to the fact that the O-GlcNAc system is tightly regulated and
disruptions are in many cases not tolerated by the cell. It might be worthwhile to
apply a genetic engineering approach in order to generate ES/iPS cells lines with a
monoallelic deletion which could even be limited to the catalytic domain if necessary.
Ideally, an additional set of RNA sequencing experiments using Ogt/Oga knock-
down or overexpression lines could be performed to provide an understanding of the
molecular reasons behind some of the eﬀects in GNS G treated human iPS cells. If
further transcriptome analysis would be performed, it might also prove insightful to
investigate mouse and human pluripotent cells in direct comparison, ideally using
mouse and human ES cells rather than iPS cells. Our lab has previously performed
microarray-based analysis of gene expression of mouse ES cells in GNS C. Unfortu-
nately, RNA sequencing and microarray analysis provide approaches for transcriptome
analysis that are highly divergent on a technical level and therefore not suitable for
direct comparison. Gene ontology of RNA sequencing data in GNS G treated human
iPS cells revealed that many genes which are directly associated with development of
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the central nervous system are aﬀected by GNS G treatment. A potential approach
to investigate further would be to study the functions of O-GlcNAc in neural develop-
ment using a mammalian model organism like the mouse. Such investigations would
obviously require the laborious generation of respective mouse lines but could still be
worthwhile as several very recent studies imply an essential role of O-GlcNAc in the
brain (Lagerlof et al., 2016; Gong et al., 2016).
Finally, additional experiments should be undertaken to build on the preliminary
data suggesting a function of O-GlcNAc in the regulation of BMP signalling. First
of all, the preliminary data that indicates an elevated sensitivity of GNS G treated
cells towards BMP4 stimulation should be repeated. Additional experiments could
then focus on revealing the consequences on the entire signalling pathway, but also
investigate a potential eﬀect on the whole TGF-β cascade. When studying the impact
on BMP signalling it is essential to perform these experiments both in pluripotent
cells and diﬀerentiating cells, ideally using a detailed timecourse of neural diﬀerentia-
tion. In addition, the question arises whether key components of the BMP signalling
pathway are modiﬁed and regulated by O-GlcNAc in human iPS cells. A proteomic
approach could provide the respective information. It would also be interesting to
investigate how the landscape of O-GlcNAcylated proteins changes over the course of
diﬀerentiation and to what extent removal or addition of the modiﬁcations aﬀects the
cell's ability to diﬀerentiate.
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A. Appendix
A.1. Supplementary RNA sequencing data
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Figure (A.1) RT-qPCR analysis of RNA sequencing samples for Ogt expression.
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Figure (A.2) RT-qPCR analysis of RNA sequencing samples for Oga expression.
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A.1.1. Diﬀerential gene expression with EdgeR
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Table (A.1) Diﬀerentially expressed genes with EdgeR (logFC ≥ 0.25, FDR<0.01)
ensembl_gene_id external_gene_name description logFC FDR
1 ENSG00000203900 RP11-261N11.8 -4.22 0.00
2 ENSG00000182870 GALNT9 polypeptide N-acetylgalactosaminyltransferase 9 [Source:HGNC Sym-
bol;Acc:HGNC:4131]
-2.59 0.00
3 ENSG00000171246 NPTX1 neuronal pentraxin I [Source:HGNC Symbol;Acc:HGNC:7952] -2.40 0.00
4 ENSG00000268869 ESPNP espin pseudogene [Source:HGNC Symbol;Acc:HGNC:23285] -1.92 0.00
5 ENSG00000127528 KLF2 Kruppel-like factor 2 [Source:HGNC Symbol;Acc:HGNC:6347] -1.92 0.00
6 ENSG00000128610 FEZF1 FEZ family zinc ﬁnger 1 [Source:HGNC Symbol;Acc:HGNC:22788] -1.91 0.00
7 ENSG00000260750 RP11-482M8.1 -1.90 0.00
8 ENSG00000185105 MYADML2 myeloid-associated diﬀerentiation marker-like 2 [Source:HGNC Sym-
bol;Acc:HGNC:34548]
-1.79 0.00
9 ENSG00000089116 LHX5 LIM homeobox 5 [Source:HGNC Symbol;Acc:HGNC:14216] -1.72 0.00
10 ENSG00000205116 TMEM88B transmembrane protein 88B [Source:HGNC Symbol;Acc:HGNC:37099] -1.71 0.00
11 ENSG00000060558 GNA15 guanine nucleotide binding protein (G protein), alpha 15 (Gq class) [Source:HGNC
Symbol;Acc:HGNC:4383]
-1.69 0.00
12 ENSG00000196381 ZNF781 zinc ﬁnger protein 781 [Source:HGNC Symbol;Acc:HGNC:26745] -1.65 0.00
13 ENSG00000230316 FEZF1-AS1 FEZF1 antisense RNA 1 [Source:HGNC Symbol;Acc:HGNC:41001] -1.55 0.00
14 ENSG00000134594 RAB33A RAB33A, member RAS oncogene family [Source:HGNC Symbol;Acc:HGNC:9773] -1.51 0.01
15 ENSG00000101222 SPEF1 sperm ﬂagellar 1 [Source:HGNC Symbol;Acc:HGNC:15874] -1.51 0.00
16 ENSG00000130643 CALY calcyon neuron-speciﬁc vesicular protein [Source:HGNC Symbol;Acc:HGNC:17938] -1.48 0.00
17 ENSG00000225783 MIAT myocardial infarction associated transcript (non-protein coding) [Source:HGNC Sym-
bol;Acc:HGNC:33425]
-1.47 0.00
18 ENSG00000141665 FBXO15 F-box protein 15 [Source:HGNC Symbol;Acc:HGNC:13617] -1.44 0.00
19 ENSG00000205464 ATP6AP1L ATPase, H+ transporting, lysosomal accessory protein 1-like [Source:HGNC Sym-
bol;Acc:HGNC:28091]
-1.44 0.00
20 ENSG00000100314 CABP7 calcium binding protein 7 [Source:HGNC Symbol;Acc:HGNC:20834] -1.42 0.00
21 ENSG00000179292 TMEM151A transmembrane protein 151A [Source:HGNC Symbol;Acc:HGNC:28497] -1.41 0.00
22 ENSG00000174326 SLC16A11 solute carrier family 16 member 11 [Source:HGNC Symbol;Acc:HGNC:23093] -1.41 0.00
23 ENSG00000249550 LINC01234 long intergenic non-protein coding RNA 1234 [Source:HGNC Sym-
bol;Acc:HGNC:49757]
-1.41 0.00
24 ENSG00000177875 CCDC184 coiled-coil domain containing 184 [Source:HGNC Symbol;Acc:HGNC:33749] -1.39 0.00
25 ENSG00000146216 TTBK1 tau tubulin kinase 1 [Source:HGNC Symbol;Acc:HGNC:19140] -1.37 0.00
26 ENSG00000152932 RAB3C RAB3C, member RAS oncogene family [Source:HGNC Symbol;Acc:HGNC:30269] -1.36 0.00
27 ENSG00000188886 ASTL astacin-like metallo-endopeptidase (M12 family) [Source:HGNC Sym-
bol;Acc:HGNC:31704]
-1.34 0.00
28 ENSG00000008735 MAPK8IP2 mitogen-activated protein kinase 8 interacting protein 2 [Source:HGNC Sym-
bol;Acc:HGNC:6883]
-1.32 0.00
29 ENSG00000069696 DRD4 dopamine receptor D4 [Source:HGNC Symbol;Acc:HGNC:3025] -1.31 0.00
30 ENSG00000187902 SHISA7 shisa family member 7 [Source:HGNC Symbol;Acc:HGNC:35409] -1.30 0.01
31 ENSG00000106018 VIPR2 vasoactive intestinal peptide receptor 2 [Source:HGNC Symbol;Acc:HGNC:12695] -1.29 0.00
32 ENSG00000165495 PKNOX2 PBX/knotted 1 homeobox 2 [Source:HGNC Symbol;Acc:HGNC:16714] -1.29 0.00
33 ENSG00000176182 MYPOP Myb-related transcription factor, partner of proﬁlin [Source:HGNC Sym-
bol;Acc:HGNC:20178]
-1.28 0.00
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34 ENSG00000186891 TNFRSF18 tumor necrosis factor receptor superfamily member 18 [Source:HGNC Sym-
bol;Acc:HGNC:11914]
-1.28 0.01
35 ENSG00000177807 KCNJ10 potassium channel, inwardly rectifying subfamily J, member 10 [Source:HGNC Sym-
bol;Acc:HGNC:6256]
-1.28 0.00
36 ENSG00000130427 EPO erythropoietin [Source:HGNC Symbol;Acc:HGNC:3415] -1.25 0.00
37 ENSG00000125388 GRK4 G protein-coupled receptor kinase 4 [Source:HGNC Symbol;Acc:HGNC:4543] -1.25 0.00
38 ENSG00000138311 ZNF365 zinc ﬁnger protein 365 [Source:HGNC Symbol;Acc:HGNC:18194] -1.24 0.00
39 ENSG00000132016 C19orf57 chromosome 19 open reading frame 57 [Source:HGNC Symbol;Acc:HGNC:28153] -1.24 0.00
40 ENSG00000182566 CLEC4G C-type lectin domain family 4 member G [Source:HGNC Symbol;Acc:HGNC:24591] -1.21 0.00
41 ENSG00000159167 STC1 stanniocalcin 1 [Source:HGNC Symbol;Acc:HGNC:11373] -1.21 0.00
42 ENSG00000125285 SOX21 SRY-box 21 [Source:HGNC Symbol;Acc:HGNC:11197] -1.21 0.00
43 ENSG00000063015 SEZ6 seizure related 6 homolog (mouse) [Source:HGNC Symbol;Acc:HGNC:15955] -1.20 0.00
44 ENSG00000078967 UBE2D4 ubiquitin conjugating enzyme E2D 4 (putative) [Source:HGNC Sym-
bol;Acc:HGNC:21647]
-1.19 0.00
45 ENSG00000198720 ANKRD13B ankyrin repeat domain 13B [Source:HGNC Symbol;Acc:HGNC:26363] -1.18 0.00
46 ENSG00000161149 TUBA3FP tubulin alpha 3f pseudogene [Source:HGNC Symbol;Acc:HGNC:24067] -1.17 0.00
47 ENSG00000184524 CEND1 cell cycle exit and neuronal diﬀerentiation 1 [Source:HGNC Sym-
bol;Acc:HGNC:24153]
-1.16 0.00
48 ENSG00000196169 KIF19 kinesin family member 19 [Source:HGNC Symbol;Acc:HGNC:26735] -1.13 0.00
49 ENSG00000162639 HENMT1 HEN1 methyltransferase homolog 1 (Arabidopsis) [Source:HGNC Sym-
bol;Acc:HGNC:26400]
-1.12 0.00
50 ENSG00000122641 INHBA inhibin beta A [Source:HGNC Symbol;Acc:HGNC:6066] -1.11 0.00
51 ENSG00000104332 SFRP1 secreted frizzled-related protein 1 [Source:HGNC Symbol;Acc:HGNC:10776] -1.11 0.00
52 ENSG00000132141 CCT6B chaperonin containing TCP1, subunit 6B (zeta 2) [Source:HGNC Sym-
bol;Acc:HGNC:1621]
-1.11 0.00
53 ENSG00000102981 PARD6A par-6 family cell polarity regulator alpha [Source:HGNC Symbol;Acc:HGNC:15943] -1.08 0.00
54 ENSG00000249853 HS3ST5 heparan sulfate-glucosamine 3-sulfotransferase 5 [Source:HGNC Sym-
bol;Acc:HGNC:19419]
-1.07 0.00
55 ENSG00000196155 PLEKHG4 pleckstrin homology and RhoGEF domain containing G4 [Source:HGNC Sym-
bol;Acc:HGNC:24501]
-1.07 0.00
56 ENSG00000189410 SH2D5 SH2 domain containing 5 [Source:HGNC Symbol;Acc:HGNC:28819] -1.06 0.00
57 ENSG00000138400 MDH1B malate dehydrogenase 1B [Source:HGNC Symbol;Acc:HGNC:17836] -1.06 0.00
58 ENSG00000159761 C16orf86 chromosome 16 open reading frame 86 [Source:HGNC Symbol;Acc:HGNC:33755] -1.06 0.00
59 ENSG00000215644 GCGR glucagon receptor [Source:HGNC Symbol;Acc:HGNC:4192] -1.05 0.00
60 ENSG00000145882 PCYOX1L prenylcysteine oxidase 1 like [Source:HGNC Symbol;Acc:HGNC:28477] -1.05 0.00
61 ENSG00000184208 C22orf46 chromosome 22 open reading frame 46 [Source:HGNC Symbol;Acc:HGNC:26294] -1.04 0.00
62 ENSG00000139793 MBNL2 muscleblind-like splicing regulator 2 [Source:HGNC Symbol;Acc:HGNC:16746] -1.04 0.00
63 ENSG00000148204 CRB2 crumbs family member 2 [Source:HGNC Symbol;Acc:HGNC:18688] -1.04 0.00
64 ENSG00000177181 RIMKLA ribosomal modiﬁcation protein rimK-like family member A [Source:HGNC Sym-
bol;Acc:HGNC:28725]
-1.03 0.00
65 ENSG00000128872 TMOD2 tropomodulin 2 [Source:HGNC Symbol;Acc:HGNC:11872] -1.03 0.00
66 ENSG00000157851 DPYSL5 dihydropyrimidinase like 5 [Source:HGNC Symbol;Acc:HGNC:20637] -1.02 0.00
67 ENSG00000168453 HR hair growth associated [Source:HGNC Symbol;Acc:HGNC:5172] -1.02 0.00
68 ENSG00000143643 TTC13 tetratricopeptide repeat domain 13 [Source:HGNC Symbol;Acc:HGNC:26204] -1.02 0.00
69 ENSG00000162426 SLC45A1 solute carrier family 45 member 1 [Source:HGNC Symbol;Acc:HGNC:17939] -1.01 0.00
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70 ENSG00000021300 PLEKHB1 pleckstrin homology domain containing B1 [Source:HGNC Symbol;Acc:HGNC:19079] -1.00 0.00
71 ENSG00000025708 TYMP thymidine phosphorylase [Source:HGNC Symbol;Acc:HGNC:3148] -0.99 0.00
72 ENSG00000105376 ICAM5 intercellular adhesion molecule 5 [Source:HGNC Symbol;Acc:HGNC:5348] -0.99 0.00
73 ENSG00000152804 HHEX hematopoietically expressed homeobox [Source:HGNC Symbol;Acc:HGNC:4901] -0.98 0.00
74 ENSG00000204934 ATP6V0E2-AS1 ATP6V0E2 antisense RNA 1 [Source:HGNC Symbol;Acc:HGNC:44180] -0.98 0.00
75 ENSG00000185561 TLCD2 TLC domain containing 2 [Source:HGNC Symbol;Acc:HGNC:33522] -0.97 0.00
76 ENSG00000095752 IL11 interleukin 11 [Source:HGNC Symbol;Acc:HGNC:5966] -0.97 0.00
77 ENSG00000102003 SYP synaptophysin [Source:HGNC Symbol;Acc:HGNC:11506] -0.97 0.00
78 ENSG00000182134 TDRKH tudor and KH domain containing [Source:HGNC Symbol;Acc:HGNC:11713] -0.97 0.00
79 ENSG00000068976 PYGM phosphorylase, glycogen, muscle [Source:HGNC Symbol;Acc:HGNC:9726] -0.97 0.00
80 ENSG00000171533 MAP6 microtubule associated protein 6 [Source:HGNC Symbol;Acc:HGNC:6868] -0.96 0.00
81 ENSG00000132436 FIGNL1 ﬁdgetin-like 1 [Source:HGNC Symbol;Acc:HGNC:13286] -0.96 0.00
82 ENSG00000212978 AC016747.3 -0.96 0.00
83 ENSG00000183773 AIFM3 apoptosis inducing factor, mitochondria associated 3 [Source:HGNC Sym-
bol;Acc:HGNC:26398]
-0.95 0.01
84 ENSG00000215271 HOMEZ homeobox and leucine zipper encoding [Source:HGNC Symbol;Acc:HGNC:20164] -0.95 0.00
85 ENSG00000187583 PLEKHN1 pleckstrin homology domain containing N1 [Source:HGNC Symbol;Acc:HGNC:25284] -0.95 0.01
86 ENSG00000121454 LHX4 LIM homeobox 4 [Source:HGNC Symbol;Acc:HGNC:21734] -0.94 0.00
87 ENSG00000112561 TFEB transcription factor EB [Source:HGNC Symbol;Acc:HGNC:11753] -0.94 0.00
88 ENSG00000090530 P3H2 prolyl 3-hydroxylase 2 [Source:HGNC Symbol;Acc:HGNC:19317] -0.94 0.00
89 ENSG00000099282 TSPAN15 tetraspanin 15 [Source:HGNC Symbol;Acc:HGNC:23298] -0.94 0.00
90 ENSG00000178233 TMEM151B transmembrane protein 151B [Source:HGNC Symbol;Acc:HGNC:21315] -0.93 0.00
91 ENSG00000162572 SCNN1D sodium channel, non voltage gated 1 delta subunit [Source:HGNC Sym-
bol;Acc:HGNC:10601]
-0.93 0.00
92 ENSG00000159733 ZFYVE28 zinc ﬁnger, FYVE domain containing 28 [Source:HGNC Symbol;Acc:HGNC:29334] -0.92 0.00
93 ENSG00000185269 NOTUM notum pectinacetylesterase homolog (Drosophila) [Source:HGNC Sym-
bol;Acc:HGNC:27106]
-0.92 0.00
94 ENSG00000105251 SHD Src homology 2 domain containing transforming protein D [Source:HGNC Sym-
bol;Acc:HGNC:30633]
-0.90 0.00
95 ENSG00000180425 C11orf71 chromosome 11 open reading frame 71 [Source:HGNC Symbol;Acc:HGNC:25937] -0.90 0.00
96 ENSG00000177570 SAMD12 sterile alpha motif domain containing 12 [Source:HGNC Symbol;Acc:HGNC:31750] -0.90 0.00
97 ENSG00000149599 DUSP15 dual speciﬁcity phosphatase 15 [Source:HGNC Symbol;Acc:HGNC:16236] -0.90 0.00
98 ENSG00000163617 CCDC191 coiled-coil domain containing 191 [Source:HGNC Symbol;Acc:HGNC:29272] -0.90 0.00
99 ENSG00000185386 MAPK11 mitogen-activated protein kinase 11 [Source:HGNC Symbol;Acc:HGNC:6873] -0.90 0.00
100 ENSG00000139800 ZIC5 Zic family member 5 [Source:HGNC Symbol;Acc:HGNC:20322] -0.89 0.00
101 ENSG00000273045 C2orf15 chromosome 2 open reading frame 15 [Source:HGNC Symbol;Acc:HGNC:28436] -0.89 0.00
102 ENSG00000125945 ZNF436 zinc ﬁnger protein 436 [Source:HGNC Symbol;Acc:HGNC:20814] -0.89 0.00
103 ENSG00000228594 C1orf233 chromosome 1 open reading frame 233 [Source:HGNC Symbol;Acc:HGNC:42951] -0.89 0.00
104 ENSG00000175414 ARL10 ADP ribosylation factor like GTPase 10 [Source:HGNC Symbol;Acc:HGNC:22042] -0.88 0.00
105 ENSG00000113648 H2AFY H2A histone family member Y [Source:HGNC Symbol;Acc:HGNC:4740] -0.88 0.00
106 ENSG00000228889 UBAC2-AS1 UBAC2 antisense RNA 1 [Source:HGNC Symbol;Acc:HGNC:42502] -0.88 0.00
107 ENSG00000185621 LMLN leishmanolysin-like (metallopeptidase M8 family) [Source:HGNC Sym-
bol;Acc:HGNC:15991]
-0.88 0.00
108 ENSG00000101417 PXMP4 peroxisomal membrane protein 4 [Source:HGNC Symbol;Acc:HGNC:15920] -0.88 0.00
109 ENSG00000109832 DDX25 DEAD (Asp-Glu-Ala-Asp) box helicase 25 [Source:HGNC Symbol;Acc:HGNC:18698] -0.88 0.00
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110 ENSG00000164885 CDK5 cyclin-dependent kinase 5 [Source:HGNC Symbol;Acc:HGNC:1774] -0.88 0.00
111 ENSG00000198208 RPS6KL1 ribosomal protein S6 kinase like 1 [Source:HGNC Symbol;Acc:HGNC:20222] -0.87 0.00
112 ENSG00000168490 PHYHIP phytanoyl-CoA 2-hydroxylase interacting protein [Source:HGNC Sym-
bol;Acc:HGNC:16865]
-0.87 0.00
113 ENSG00000107014 RLN2 relaxin 2 [Source:HGNC Symbol;Acc:HGNC:10027] -0.87 0.00
114 ENSG00000129654 FOXJ1 forkhead box J1 [Source:HGNC Symbol;Acc:HGNC:3816] -0.87 0.00
115 ENSG00000102109 PCSK1N proprotein convertase subtilisin/kexin type 1 inhibitor [Source:HGNC Sym-
bol;Acc:HGNC:17301]
-0.86 0.00
116 ENSG00000136274 NACAD NAC alpha domain containing [Source:HGNC Symbol;Acc:HGNC:22196] -0.86 0.00
117 ENSG00000078487 ZCWPW1 zinc ﬁnger, CW type with PWWP domain 1 [Source:HGNC Sym-
bol;Acc:HGNC:23486]
-0.86 0.00
118 ENSG00000133794 ARNTL aryl hydrocarbon receptor nuclear translocator like [Source:HGNC Sym-
bol;Acc:HGNC:701]
-0.85 0.00
119 ENSG00000118513 MYB v-myb avian myeloblastosis viral oncogene homolog [Source:HGNC Sym-
bol;Acc:HGNC:7545]
-0.84 0.00
120 ENSG00000079974 RABL2B RAB, member of RAS oncogene family-like 2B [Source:HGNC Sym-
bol;Acc:HGNC:9800]
-0.84 0.00
121 ENSG00000148926 ADM adrenomedullin [Source:HGNC Symbol;Acc:HGNC:259] -0.83 0.00
122 ENSG00000185567 AHNAK2 AHNAK nucleoprotein 2 [Source:HGNC Symbol;Acc:HGNC:20125] -0.83 0.00
123 ENSG00000241360 PDXP pyridoxal (pyridoxine, vitamin B6) phosphatase [Source:HGNC Sym-
bol;Acc:HGNC:30259]
-0.83 0.00
124 ENSG00000213963 AC074286.1 -0.83 0.00
125 ENSG00000043355 ZIC2 Zic family member 2 [Source:HGNC Symbol;Acc:HGNC:12873] -0.83 0.00
126 ENSG00000130287 NCAN neurocan [Source:HGNC Symbol;Acc:HGNC:2465] -0.83 0.00
127 ENSG00000160460 SPTBN4 spectrin, beta, non-erythrocytic 4 [Source:HGNC Symbol;Acc:HGNC:14896] -0.83 0.00
128 ENSG00000167711 SERPINF2 serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived
factor), member 2 [Source:HGNC Symbol;Acc:HGNC:9075]
-0.82 0.00
129 ENSG00000154930 ACSS1 acyl-CoA synthetase short-chain family member 1 [Source:HGNC Sym-
bol;Acc:HGNC:16091]
-0.82 0.00
130 ENSG00000166796 LDHC lactate dehydrogenase C [Source:HGNC Symbol;Acc:HGNC:6544] -0.81 0.00
131 ENSG00000245498 RP11-677M14.7 -0.81 0.00
132 ENSG00000173175 ADCY5 adenylate cyclase 5 [Source:HGNC Symbol;Acc:HGNC:236] -0.80 0.00
133 ENSG00000106013 ANKRD7 ankyrin repeat domain 7 [Source:HGNC Symbol;Acc:HGNC:18588] -0.80 0.00
134 ENSG00000166780 C16orf45 chromosome 16 open reading frame 45 [Source:HGNC Symbol;Acc:HGNC:19213] -0.80 0.00
135 ENSG00000185761 ADAMTSL5 ADAMTS like 5 [Source:HGNC Symbol;Acc:HGNC:27912] -0.80 0.00
136 ENSG00000132881 RSG1 REM2 and RAB-like small GTPase 1 [Source:HGNC Symbol;Acc:HGNC:28127] -0.79 0.00
137 ENSG00000243449 C4orf48 chromosome 4 open reading frame 48 [Source:HGNC Symbol;Acc:HGNC:34437] -0.79 0.00
138 ENSG00000170231 FABP6 fatty acid binding protein 6, ileal [Source:HGNC Symbol;Acc:HGNC:3561] -0.79 0.00
139 ENSG00000133640 LRRIQ1 leucine-rich repeats and IQ motif containing 1 [Source:HGNC Sym-
bol;Acc:HGNC:25708]
-0.79 0.00
140 ENSG00000156253 RWDD2B RWD domain containing 2B [Source:HGNC Symbol;Acc:HGNC:1302] -0.79 0.00
141 ENSG00000271601 LIX1L limb and CNS expressed 1 like [Source:HGNC Symbol;Acc:HGNC:28715] -0.78 0.00
142 ENSG00000041880 PARP3 poly(ADP-ribose) polymerase family member 3 [Source:HGNC Sym-
bol;Acc:HGNC:273]
-0.78 0.00
143 ENSG00000160471 COX6B2 cytochrome c oxidase subunit VIb polypeptide 2 (testis) [Source:HGNC Sym-
bol;Acc:HGNC:24380]
-0.78 0.00
182
144 ENSG00000139266 MARCH9 membrane associated ring-CH-type ﬁnger 9 [Source:HGNC Sym-
bol;Acc:HGNC:25139]
-0.78 0.00
145 ENSG00000169258 GPRIN1 G protein regulated inducer of neurite outgrowth 1 [Source:HGNC Sym-
bol;Acc:HGNC:24835]
-0.78 0.00
146 ENSG00000147117 ZNF157 zinc ﬁnger protein 157 [Source:HGNC Symbol;Acc:HGNC:12942] -0.78 0.00
147 ENSG00000161860 SYCE2 synaptonemal complex central element protein 2 [Source:HGNC Sym-
bol;Acc:HGNC:27411]
-0.77 0.00
148 ENSG00000088876 ZNF343 zinc ﬁnger protein 343 [Source:HGNC Symbol;Acc:HGNC:16017] -0.77 0.00
149 ENSG00000149548 CCDC15 coiled-coil domain containing 15 [Source:HGNC Symbol;Acc:HGNC:25798] -0.77 0.00
150 ENSG00000183570 PCBP3 poly(rC) binding protein 3 [Source:HGNC Symbol;Acc:HGNC:8651] -0.77 0.00
151 ENSG00000161940 BCL6B B-cell CLL/lymphoma 6, member B [Source:HGNC Symbol;Acc:HGNC:1002] -0.76 0.00
152 ENSG00000065717 TLE2 transducin like enhancer of split 2 [Source:HGNC Symbol;Acc:HGNC:11838] -0.76 0.00
153 ENSG00000173409 ARV1 ARV1 homolog, fatty acid homeostasis modulator [Source:HGNC Sym-
bol;Acc:HGNC:29561]
-0.76 0.00
154 ENSG00000179546 HTR1D 5-hydroxytryptamine (serotonin) receptor 1D, G protein-coupled [Source:HGNC
Symbol;Acc:HGNC:5289]
-0.76 0.00
155 ENSG00000214595 EML6 echinoderm microtubule associated protein like 6 [Source:HGNC Sym-
bol;Acc:HGNC:35412]
-0.76 0.00
156 ENSG00000144134 RABL2A RAB, member of RAS oncogene family-like 2A [Source:HGNC Sym-
bol;Acc:HGNC:9799]
-0.76 0.00
157 ENSG00000001561 ENPP4 ectonucleotide pyrophosphatase/phosphodiesterase 4 (putative) [Source:HGNC Sym-
bol;Acc:HGNC:3359]
-0.76 0.00
158 ENSG00000108439 PNPO pyridoxamine 5'-phosphate oxidase [Source:HGNC Symbol;Acc:HGNC:30260] -0.76 0.00
159 ENSG00000196391 ZNF774 zinc ﬁnger protein 774 [Source:HGNC Symbol;Acc:HGNC:33108] -0.75 0.00
160 ENSG00000099958 DERL3 derlin 3 [Source:HGNC Symbol;Acc:HGNC:14236] -0.75 0.00
161 ENSG00000116014 KISS1R KISS1 receptor [Source:HGNC Symbol;Acc:HGNC:4510] -0.75 0.00
162 ENSG00000253716 MINCR MYC-induced long noncoding RNA [Source:HGNC Symbol;Acc:HGNC:51653] -0.74 0.00
163 ENSG00000142875 PRKACB protein kinase, cAMP-dependent, beta catalytic subunit [Source:HGNC Sym-
bol;Acc:HGNC:9381]
-0.74 0.00
164 ENSG00000273604 C17orf96 chromosome 17 open reading frame 96 [Source:HGNC Symbol;Acc:HGNC:34493] -0.74 0.01
165 ENSG00000116667 C1orf21 chromosome 1 open reading frame 21 [Source:HGNC Symbol;Acc:HGNC:15494] -0.73 0.00
166 ENSG00000117477 CCDC181 coiled-coil domain containing 181 [Source:HGNC Symbol;Acc:HGNC:28051] -0.73 0.00
167 ENSG00000142530 FAM71E1 family with sequence similarity 71 member E1 [Source:HGNC Sym-
bol;Acc:HGNC:25107]
-0.73 0.00
168 ENSG00000004948 CALCR calcitonin receptor [Source:HGNC Symbol;Acc:HGNC:1440] -0.73 0.00
169 ENSG00000113522 RAD50 RAD50 homolog, double strand break repair protein [Source:HGNC Sym-
bol;Acc:HGNC:9816]
-0.73 0.00
170 ENSG00000227640 SOX21-AS1 SOX21 antisense RNA 1 (head to head) [Source:HGNC Symbol;Acc:HGNC:39807] -0.73 0.00
171 ENSG00000161544 CYGB cytoglobin [Source:HGNC Symbol;Acc:HGNC:16505] -0.73 0.00
172 ENSG00000161905 ALOX15 arachidonate 15-lipoxygenase [Source:HGNC Symbol;Acc:HGNC:433] -0.72 0.01
173 ENSG00000103260 METRN meteorin, glial cell diﬀerentiation regulator [Source:HGNC Symbol;Acc:HGNC:14151] -0.72 0.00
174 ENSG00000204923 FBXO48 F-box protein 48 [Source:HGNC Symbol;Acc:HGNC:33857] -0.72 0.00
175 ENSG00000189057 FAM111B family with sequence similarity 111 member B [Source:HGNC Sym-
bol;Acc:HGNC:24200]
-0.72 0.00
176 ENSG00000160716 CHRNB2 cholinergic receptor, nicotinic beta 2 [Source:HGNC Symbol;Acc:HGNC:1962] -0.72 0.00
183
177 ENSG00000130489 SCO2 SCO2 cytochrome c oxidase assembly protein [Source:HGNC Sym-
bol;Acc:HGNC:10604]
-0.71 0.00
178 ENSG00000018236 CNTN1 contactin 1 [Source:HGNC Symbol;Acc:HGNC:2171] -0.71 0.00
179 ENSG00000124074 ENKD1 enkurin domain containing 1 [Source:HGNC Symbol;Acc:HGNC:25246] -0.71 0.00
180 ENSG00000163888 CAMK2N2 calcium/calmodulin-dependent protein kinase II inhibitor 2 [Source:HGNC Sym-
bol;Acc:HGNC:24197]
-0.70 0.00
181 ENSG00000197261 C6orf141 chromosome 6 open reading frame 141 [Source:HGNC Symbol;Acc:HGNC:21351] -0.70 0.00
182 ENSG00000138111 MFSD13A major facilitator superfamily domain containing 13A [Source:HGNC Sym-
bol;Acc:HGNC:26196]
-0.70 0.00
183 ENSG00000104953 TLE6 transducin like enhancer of split 6 [Source:HGNC Symbol;Acc:HGNC:30788] -0.70 0.00
184 ENSG00000198105 ZNF248 zinc ﬁnger protein 248 [Source:HGNC Symbol;Acc:HGNC:13041] -0.69 0.00
185 ENSG00000163584 RPL22L1 ribosomal protein L22 like 1 [Source:HGNC Symbol;Acc:HGNC:27610] -0.69 0.00
186 ENSG00000267640 CTD-2554C21.2 -0.69 0.00
187 ENSG00000167971 CASKIN1 CASK interacting protein 1 [Source:HGNC Symbol;Acc:HGNC:20879] -0.69 0.00
188 ENSG00000197557 TTC30A tetratricopeptide repeat domain 30A [Source:HGNC Symbol;Acc:HGNC:25853] -0.69 0.00
189 ENSG00000204839 MROH6 maestro heat-like repeat family member 6 [Source:HGNC Symbol;Acc:HGNC:27814] -0.69 0.00
190 ENSG00000188690 UROS uroporphyrinogen III synthase [Source:HGNC Symbol;Acc:HGNC:12592] -0.69 0.00
191 ENSG00000103034 NDRG4 NDRG family member 4 [Source:HGNC Symbol;Acc:HGNC:14466] -0.68 0.00
192 ENSG00000114646 CSPG5 chondroitin sulfate proteoglycan 5 [Source:HGNC Symbol;Acc:HGNC:2467] -0.68 0.00
193 ENSG00000113763 UNC5A unc-5 netrin receptor A [Source:HGNC Symbol;Acc:HGNC:12567] -0.68 0.00
194 ENSG00000112562 SMOC2 SPARC related modular calcium binding 2 [Source:HGNC Symbol;Acc:HGNC:20323] -0.68 0.00
195 ENSG00000158106 RHPN1 rhophilin, Rho GTPase binding protein 1 [Source:HGNC Symbol;Acc:HGNC:19973] -0.68 0.00
196 ENSG00000185697 MYBL1 v-myb avian myeloblastosis viral oncogene homolog-like 1 [Source:HGNC Sym-
bol;Acc:HGNC:7547]
-0.68 0.00
197 ENSG00000110076 NRXN2 neurexin 2 [Source:HGNC Symbol;Acc:HGNC:8009] -0.68 0.00
198 ENSG00000138769 CDKL2 cyclin-dependent kinase-like 2 (CDC2-related kinase) [Source:HGNC Sym-
bol;Acc:HGNC:1782]
-0.68 0.00
199 ENSG00000141040 ZNF287 zinc ﬁnger protein 287 [Source:HGNC Symbol;Acc:HGNC:13502] -0.67 0.00
200 ENSG00000166963 MAP1A microtubule associated protein 1A [Source:HGNC Symbol;Acc:HGNC:6835] -0.67 0.00
201 ENSG00000138380 CARF calcium responsive transcription factor [Source:HGNC Symbol;Acc:HGNC:14435] -0.67 0.00
202 ENSG00000102007 PLP2 proteolipid protein 2 (colonic epithelium-enriched) [Source:HGNC Sym-
bol;Acc:HGNC:9087]
-0.67 0.00
203 ENSG00000174137 FAM53A family with sequence similarity 53 member A [Source:HGNC Sym-
bol;Acc:HGNC:31860]
-0.67 0.00
204 ENSG00000121486 TRMT1L tRNA methyltransferase 1 like [Source:HGNC Symbol;Acc:HGNC:16782] -0.67 0.00
205 ENSG00000180543 TSPYL5 TSPY-like 5 [Source:HGNC Symbol;Acc:HGNC:29367] -0.67 0.00
206 ENSG00000132321 IQCA1 IQ motif containing with AAA domain 1 [Source:HGNC Symbol;Acc:HGNC:26195] -0.67 0.00
207 ENSG00000196177 ACADSB acyl-CoA dehydrogenase, short/branched chain [Source:HGNC Sym-
bol;Acc:HGNC:91]
-0.67 0.00
208 ENSG00000101180 HRH3 histamine receptor H3 [Source:HGNC Symbol;Acc:HGNC:5184] -0.67 0.01
209 ENSG00000168803 ADAL adenosine deaminase-like [Source:HGNC Symbol;Acc:HGNC:31853] -0.67 0.00
210 ENSG00000169169 CPT1C carnitine palmitoyltransferase 1C [Source:HGNC Symbol;Acc:HGNC:18540] -0.66 0.00
211 ENSG00000185818 NAT8L N-acetyltransferase 8-like (GCN5-related, putative) [Source:HGNC Sym-
bol;Acc:HGNC:26742]
-0.66 0.00
212 ENSG00000168056 LTBP3 latent transforming growth factor beta binding protein 3 [Source:HGNC Sym-
bol;Acc:HGNC:6716]
-0.66 0.00
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213 ENSG00000142961 MOB3C MOB kinase activator 3C [Source:HGNC Symbol;Acc:HGNC:29800] -0.66 0.00
214 ENSG00000135740 SLC9A5 solute carrier family 9, subfamily A (NHE5, cation proton antiporter 5), member 5
[Source:HGNC Symbol;Acc:HGNC:11078]
-0.66 0.00
215 ENSG00000115226 FNDC4 ﬁbronectin type III domain containing 4 [Source:HGNC Symbol;Acc:HGNC:20239] -0.66 0.00
216 ENSG00000189046 ALKBH2 alkB homolog 2, alpha-ketoglutarate-dependent dioxygenase [Source:HGNC Sym-
bol;Acc:HGNC:32487]
-0.66 0.00
217 ENSG00000116254 CHD5 chromodomain helicase DNA binding protein 5 [Source:HGNC Sym-
bol;Acc:HGNC:16816]
-0.66 0.00
218 ENSG00000008056 SYN1 synapsin I [Source:HGNC Symbol;Acc:HGNC:11494] -0.66 0.00
219 ENSG00000140104 C14orf79 chromosome 14 open reading frame 79 [Source:HGNC Symbol;Acc:HGNC:20126] -0.66 0.00
220 ENSG00000119703 ZC2HC1C zinc ﬁnger, C2HC-type containing 1C [Source:HGNC Symbol;Acc:HGNC:20354] -0.65 0.00
221 ENSG00000127585 FBXL16 F-box and leucine-rich repeat protein 16 [Source:HGNC Symbol;Acc:HGNC:14150] -0.65 0.00
222 ENSG00000068831 RASGRP2 RAS guanyl releasing protein 2 (calcium and DAG-regulated) [Source:HGNC Sym-
bol;Acc:HGNC:9879]
-0.65 0.00
223 ENSG00000100360 IFT27 intraﬂagellar transport 27 [Source:HGNC Symbol;Acc:HGNC:18626] -0.65 0.00
224 ENSG00000149557 FEZ1 fasciculation and elongation protein zeta 1 [Source:HGNC Symbol;Acc:HGNC:3659] -0.65 0.00
225 ENSG00000180616 SSTR2 somatostatin receptor 2 [Source:HGNC Symbol;Acc:HGNC:11331] -0.65 0.00
226 ENSG00000166199 ALKBH3 alkB homolog 3, alpha-ketoglutarate-dependent dioxygenase [Source:HGNC Sym-
bol;Acc:HGNC:30141]
-0.65 0.00
227 ENSG00000126882 FAM78A family with sequence similarity 78 member A [Source:HGNC Sym-
bol;Acc:HGNC:25465]
-0.65 0.00
228 ENSG00000139160 METTL20 methyltransferase like 20 [Source:HGNC Symbol;Acc:HGNC:28739] -0.65 0.00
229 ENSG00000196544 BORCS6 BLOC-1 related complex subunit 6 [Source:HGNC Symbol;Acc:HGNC:25939] -0.65 0.00
230 ENSG00000248746 ACTN3 actinin, alpha 3 (gene/pseudogene) [Source:HGNC Symbol;Acc:HGNC:165] -0.65 0.00
231 ENSG00000280780 JAKMIP2-AS1 JAKMIP2 antisense RNA 1 [Source:HGNC Symbol;Acc:HGNC:27203] -0.64 0.00
232 ENSG00000156973 PDE6D phosphodiesterase 6D [Source:HGNC Symbol;Acc:HGNC:8788] -0.64 0.00
233 ENSG00000068971 PPP2R5B protein phosphatase 2 regulatory subunit B', beta [Source:HGNC Sym-
bol;Acc:HGNC:9310]
-0.64 0.00
234 ENSG00000047634 SCML1 sex comb on midleg-like 1 (Drosophila) [Source:HGNC Symbol;Acc:HGNC:10580] -0.64 0.00
235 ENSG00000105136 ZNF419 zinc ﬁnger protein 419 [Source:HGNC Symbol;Acc:HGNC:20648] -0.64 0.00
236 ENSG00000100346 CACNA1I calcium channel, voltage-dependent, T type, alpha 1I subunit [Source:HGNC Sym-
bol;Acc:HGNC:1396]
-0.64 0.00
237 ENSG00000204248 COL11A2 collagen, type XI, alpha 2 [Source:HGNC Symbol;Acc:HGNC:2187] -0.63 0.00
238 ENSG00000172733 PURG purine-rich element binding protein G [Source:HGNC Symbol;Acc:HGNC:17930] -0.63 0.00
239 ENSG00000131437 KIF3A kinesin family member 3A [Source:HGNC Symbol;Acc:HGNC:6319] -0.63 0.00
240 ENSG00000188760 TMEM198 transmembrane protein 198 [Source:HGNC Symbol;Acc:HGNC:33704] -0.63 0.00
241 ENSG00000171130 ATP6V0E2 ATPase, H+ transporting V0 subunit e2 [Source:HGNC Symbol;Acc:HGNC:21723] -0.63 0.00
242 ENSG00000115318 LOXL3 lysyl oxidase like 3 [Source:HGNC Symbol;Acc:HGNC:13869] -0.63 0.00
243 ENSG00000180347 CCDC129 coiled-coil domain containing 129 [Source:HGNC Symbol;Acc:HGNC:27363] -0.63 0.00
244 ENSG00000204642 HLA-F major histocompatibility complex, class I, F [Source:HGNC Symbol;Acc:HGNC:4963] -0.62 0.00
245 ENSG00000089723 OTUB2 OTU deubiquitinase, ubiquitin aldehyde binding 2 [Source:HGNC Sym-
bol;Acc:HGNC:20351]
-0.62 0.00
246 ENSG00000198440 ZNF583 zinc ﬁnger protein 583 [Source:HGNC Symbol;Acc:HGNC:26427] -0.62 0.00
247 ENSG00000059915 PSD pleckstrin and Sec7 domain containing [Source:HGNC Symbol;Acc:HGNC:9507] -0.62 0.00
248 ENSG00000103507 BCKDK branched chain ketoacid dehydrogenase kinase [Source:HGNC Sym-
bol;Acc:HGNC:16902]
-0.62 0.00
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249 ENSG00000169598 DFFB DNA fragmentation factor, 40kDa, beta polypeptide (caspase-activated DNase)
[Source:HGNC Symbol;Acc:HGNC:2773]
-0.62 0.00
250 ENSG00000135439 AGAP2 ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 [Source:HGNC
Symbol;Acc:HGNC:16921]
-0.62 0.01
251 ENSG00000105270 CLIP3 CAP-Gly domain containing linker protein 3 [Source:HGNC Sym-
bol;Acc:HGNC:24314]
-0.62 0.00
252 ENSG00000182405 PGBD4 piggyBac transposable element derived 4 [Source:HGNC Symbol;Acc:HGNC:19401] -0.62 0.00
253 ENSG00000153982 GDPD1 glycerophosphodiester phosphodiesterase domain containing 1 [Source:HGNC Sym-
bol;Acc:HGNC:20883]
-0.61 0.00
254 ENSG00000139364 TMEM132B transmembrane protein 132B [Source:HGNC Symbol;Acc:HGNC:29397] -0.61 0.00
255 ENSG00000117280 RAB29 RAB29, member RAS oncogene family [Source:HGNC Symbol;Acc:HGNC:9789] -0.61 0.00
256 ENSG00000256546 AC156455.1 -0.61 0.00
257 ENSG00000169026 MFSD7 major facilitator superfamily domain containing 7 [Source:HGNC Sym-
bol;Acc:HGNC:26177]
-0.61 0.00
258 ENSG00000119547 ONECUT2 one cut homeobox 2 [Source:HGNC Symbol;Acc:HGNC:8139] -0.61 0.00
259 ENSG00000249992 TMEM158 transmembrane protein 158 (gene/pseudogene) [Source:HGNC Sym-
bol;Acc:HGNC:30293]
-0.61 0.00
260 ENSG00000142459 EVI5L ecotropic viral integration site 5-like [Source:HGNC Symbol;Acc:HGNC:30464] -0.60 0.00
261 ENSG00000148814 LRRC27 leucine rich repeat containing 27 [Source:HGNC Symbol;Acc:HGNC:29346] -0.60 0.00
262 ENSG00000173673 HES3 hes family bHLH transcription factor 3 [Source:HGNC Symbol;Acc:HGNC:26226] -0.60 0.00
263 ENSG00000273274 ZBTB8B zinc ﬁnger and BTB domain containing 8B [Source:HGNC Symbol;Acc:HGNC:37057] -0.59 0.00
264 ENSG00000205213 LGR4 leucine-rich repeat containing G protein-coupled receptor 4 [Source:HGNC Sym-
bol;Acc:HGNC:13299]
-0.59 0.00
265 ENSG00000176022 B3GALT6 Beta-1,3-galactosyltransferase 6 [Source:HGNC Symbol;Acc:HGNC:17978] -0.59 0.00
266 ENSG00000163945 UVSSA UV stimulated scaﬀold protein A [Source:HGNC Symbol;Acc:HGNC:29304] -0.59 0.00
267 ENSG00000141576 RNF157 ring ﬁnger protein 157 [Source:HGNC Symbol;Acc:HGNC:29402] -0.59 0.00
268 ENSG00000100299 ARSA arylsulfatase A [Source:HGNC Symbol;Acc:HGNC:713] -0.59 0.00
269 ENSG00000120784 ZFP30 ZFP30 zinc ﬁnger protein [Source:HGNC Symbol;Acc:HGNC:29555] -0.59 0.00
270 ENSG00000115255 REEP6 receptor accessory protein 6 [Source:HGNC Symbol;Acc:HGNC:30078] -0.58 0.00
271 ENSG00000186300 ZNF555 zinc ﬁnger protein 555 [Source:HGNC Symbol;Acc:HGNC:28382] -0.58 0.00
272 ENSG00000109618 SEPSECS Sep (O-phosphoserine) tRNA:Sec (selenocysteine) tRNA synthase [Source:HGNC
Symbol;Acc:HGNC:30605]
-0.58 0.00
273 ENSG00000166997 CNPY4 canopy FGF signaling regulator 4 [Source:HGNC Symbol;Acc:HGNC:28631] -0.58 0.00
274 ENSG00000115257 PCSK4 proprotein convertase subtilisin/kexin type 4 [Source:HGNC Sym-
bol;Acc:HGNC:8746]
-0.58 0.00
275 ENSG00000247516 MIR4458HG MIR4458 host gene [Source:HGNC Symbol;Acc:HGNC:49008] -0.58 0.00
276 ENSG00000100604 CHGA chromogranin A [Source:HGNC Symbol;Acc:HGNC:1929] -0.58 0.00
277 ENSG00000145439 CBR4 carbonyl reductase 4 [Source:HGNC Symbol;Acc:HGNC:25891] -0.58 0.00
278 ENSG00000153093 ACOXL acyl-CoA oxidase-like [Source:HGNC Symbol;Acc:HGNC:25621] -0.58 0.00
279 ENSG00000151093 OXSM 3-oxoacyl-ACP synthase, mitochondrial [Source:HGNC Symbol;Acc:HGNC:26063] -0.58 0.00
280 ENSG00000100078 PLA2G3 phospholipase A2 group III [Source:HGNC Symbol;Acc:HGNC:17934] -0.57 0.00
281 ENSG00000137720 C11orf1 chromosome 11 open reading frame 1 [Source:HGNC Symbol;Acc:HGNC:1163] -0.57 0.00
282 ENSG00000131370 SH3BP5 SH3-domain binding protein 5 (BTK-associated) [Source:HGNC Sym-
bol;Acc:HGNC:10827]
-0.56 0.00
283 ENSG00000269404 SPIB Spi-B transcription factor (Spi-1/PU.1 related) [Source:HGNC Sym-
bol;Acc:HGNC:11242]
-0.56 0.00
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284 ENSG00000091592 NLRP1 NLR family, pyrin domain containing 1 [Source:HGNC Symbol;Acc:HGNC:14374] -0.56 0.00
285 ENSG00000163013 FBXO41 F-box protein 41 [Source:HGNC Symbol;Acc:HGNC:29409] -0.56 0.00
286 ENSG00000006283 CACNA1G calcium channel, voltage-dependent, T type, alpha 1G subunit [Source:HGNC Sym-
bol;Acc:HGNC:1394]
-0.56 0.00
287 ENSG00000127419 TMEM175 transmembrane protein 175 [Source:HGNC Symbol;Acc:HGNC:28709] -0.56 0.00
288 ENSG00000178053 MLF1 myeloid leukemia factor 1 [Source:HGNC Symbol;Acc:HGNC:7125] -0.56 0.00
289 ENSG00000149929 HIRIP3 HIRA interacting protein 3 [Source:HGNC Symbol;Acc:HGNC:4917] -0.56 0.00
290 ENSG00000187867 PALM3 paralemmin 3 [Source:HGNC Symbol;Acc:HGNC:33274] -0.55 0.00
291 ENSG00000076258 FMO4 ﬂavin containing monooxygenase 4 [Source:HGNC Symbol;Acc:HGNC:3772] -0.55 0.00
292 ENSG00000205269 TMEM170B transmembrane protein 170B [Source:HGNC Symbol;Acc:HGNC:34244] -0.55 0.00
293 ENSG00000171456 ASXL1 additional sex combs like 1, transcriptional regulator [Source:HGNC Sym-
bol;Acc:HGNC:18318]
-0.55 0.00
294 ENSG00000105357 MYH14 myosin, heavy chain 14, non-muscle [Source:HGNC Symbol;Acc:HGNC:23212] -0.55 0.00
295 ENSG00000173442 EHBP1L1 EH domain binding protein 1 like 1 [Source:HGNC Symbol;Acc:HGNC:30682] -0.55 0.00
296 ENSG00000005020 SKAP2 src kinase associated phosphoprotein 2 [Source:HGNC Symbol;Acc:HGNC:15687] -0.55 0.00
297 ENSG00000018625 ATP1A2 ATPase, Na+/K+ transporting, alpha 2 polypeptide [Source:HGNC Sym-
bol;Acc:HGNC:800]
-0.54 0.00
298 ENSG00000099949 LZTR1 leucine-zipper-like transcription regulator 1 [Source:HGNC Symbol;Acc:HGNC:6742] -0.54 0.00
299 ENSG00000172086 KRCC1 lysine-rich coiled-coil 1 [Source:HGNC Symbol;Acc:HGNC:28039] -0.54 0.00
300 ENSG00000167716 WDR81 WD repeat domain 81 [Source:HGNC Symbol;Acc:HGNC:26600] -0.54 0.00
301 ENSG00000063854 HAGH hydroxyacylglutathione hydrolase [Source:HGNC Symbol;Acc:HGNC:4805] -0.54 0.00
302 ENSG00000073464 CLCN4 chloride channel, voltage-sensitive 4 [Source:HGNC Symbol;Acc:HGNC:2022] -0.54 0.00
303 ENSG00000135617 PRADC1 protease-associated domain containing 1 [Source:HGNC Symbol;Acc:HGNC:16047] -0.54 0.00
304 ENSG00000165215 CLDN3 claudin 3 [Source:HGNC Symbol;Acc:HGNC:2045] -0.54 0.00
305 ENSG00000152133 GPATCH11 G-patch domain containing 11 [Source:HGNC Symbol;Acc:HGNC:26768] -0.53 0.00
306 ENSG00000136052 SLC41A2 solute carrier family 41 (magnesium transporter), member 2 [Source:HGNC Sym-
bol;Acc:HGNC:31045]
-0.53 0.01
307 ENSG00000130558 OLFM1 olfactomedin 1 [Source:HGNC Symbol;Acc:HGNC:17187] -0.53 0.00
308 ENSG00000081377 CDC14B cell division cycle 14B [Source:HGNC Symbol;Acc:HGNC:1719] -0.53 0.00
309 ENSG00000246089 RP11-115C21.2 -0.53 0.00
310 ENSG00000103460 TOX3 TOX high mobility group box family member 3 [Source:HGNC Sym-
bol;Acc:HGNC:11972]
-0.53 0.00
311 ENSG00000099625 CBARP calcium channel, voltage-dependent, beta subunit associated regulatory protein
[Source:HGNC Symbol;Acc:HGNC:28617]
-0.53 0.00
312 ENSG00000133460 SLC2A11 solute carrier family 2 (facilitated glucose transporter), member 11 [Source:HGNC
Symbol;Acc:HGNC:14239]
-0.53 0.00
313 ENSG00000135473 PAN2 PAN2 poly(A) speciﬁc ribonuclease subunit [Source:HGNC Sym-
bol;Acc:HGNC:20074]
-0.53 0.00
314 ENSG00000130707 ASS1 argininosuccinate synthase 1 [Source:HGNC Symbol;Acc:HGNC:758] -0.52 0.00
315 ENSG00000164169 PRMT9 protein arginine methyltransferase 9 [Source:HGNC Symbol;Acc:HGNC:25099] -0.52 0.00
316 ENSG00000164187 LMBRD2 LMBR1 domain containing 2 [Source:HGNC Symbol;Acc:HGNC:25287] -0.52 0.00
317 ENSG00000138185 ENTPD1 ectonucleoside triphosphate diphosphohydrolase 1 [Source:HGNC Sym-
bol;Acc:HGNC:3363]
-0.52 0.00
318 ENSG00000110328 GALNT18 polypeptide N-acetylgalactosaminyltransferase 18 [Source:HGNC Sym-
bol;Acc:HGNC:30488]
-0.52 0.00
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319 ENSG00000108384 RAD51C RAD51 paralog C [Source:HGNC Symbol;Acc:HGNC:9820] -0.52 0.00
320 ENSG00000215375 MYL5 myosin light chain 5 [Source:HGNC Symbol;Acc:HGNC:7586] -0.51 0.00
321 ENSG00000120860 CCDC53 coiled-coil domain containing 53 [Source:HGNC Symbol;Acc:HGNC:24256] -0.51 0.00
322 ENSG00000162576 MXRA8 matrix-remodelling associated 8 [Source:HGNC Symbol;Acc:HGNC:7542] -0.51 0.00
323 ENSG00000241472 PTPRG-AS1 PTPRG antisense RNA 1 [Source:HGNC Symbol;Acc:HGNC:44638] -0.51 0.00
324 ENSG00000099953 MMP11 matrix metallopeptidase 11 [Source:HGNC Symbol;Acc:HGNC:7157] -0.51 0.01
325 ENSG00000183044 ABAT 4-aminobutyrate aminotransferase [Source:HGNC Symbol;Acc:HGNC:23] -0.51 0.00
326 ENSG00000137133 HINT2 histidine triad nucleotide binding protein 2 [Source:HGNC Symbol;Acc:HGNC:18344] -0.51 0.00
327 ENSG00000196372 ASB13 ankyrin repeat and SOCS box containing 13 [Source:HGNC Sym-
bol;Acc:HGNC:19765]
-0.51 0.00
328 ENSG00000164252 AGGF1 angiogenic factor with G-patch and FHA domains 1 [Source:HGNC Sym-
bol;Acc:HGNC:24684]
-0.51 0.00
329 ENSG00000008516 MMP25 matrix metallopeptidase 25 [Source:HGNC Symbol;Acc:HGNC:14246] -0.51 0.00
330 ENSG00000025156 HSF2 heat shock transcription factor 2 [Source:HGNC Symbol;Acc:HGNC:5225] -0.50 0.00
331 ENSG00000077150 NFKB2 nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)
[Source:HGNC Symbol;Acc:HGNC:7795]
-0.50 0.00
332 ENSG00000169683 LRRC45 leucine rich repeat containing 45 [Source:HGNC Symbol;Acc:HGNC:28302] -0.50 0.00
333 ENSG00000163626 COX18 COX18 cytochrome c oxidase assembly factor [Source:HGNC Sym-
bol;Acc:HGNC:26801]
-0.50 0.00
334 ENSG00000188827 SLX4 SLX4 structure-speciﬁc endonuclease subunit [Source:HGNC Sym-
bol;Acc:HGNC:23845]
-0.50 0.00
335 ENSG00000137941 TTLL7 tubulin tyrosine ligase like 7 [Source:HGNC Symbol;Acc:HGNC:26242] -0.50 0.00
336 ENSG00000121057 AKAP1 A-kinase anchoring protein 1 [Source:HGNC Symbol;Acc:HGNC:367] -0.50 0.00
337 ENSG00000120256 LRP11 LDL receptor related protein 11 [Source:HGNC Symbol;Acc:HGNC:16936] -0.50 0.00
338 ENSG00000196263 ZNF471 zinc ﬁnger protein 471 [Source:HGNC Symbol;Acc:HGNC:23226] -0.50 0.00
339 ENSG00000126259 KIRREL2 kin of IRRE like 2 (Drosophila) [Source:HGNC Symbol;Acc:HGNC:18816] -0.50 0.01
340 ENSG00000149476 TKFC triokinase/FMN cyclase [Source:HGNC Symbol;Acc:HGNC:24552] -0.50 0.00
341 ENSG00000186104 CYP2R1 cytochrome P450 family 2 subfamily R member 1 [Source:HGNC Sym-
bol;Acc:HGNC:20580]
-0.50 0.00
342 ENSG00000162755 KLHDC9 kelch domain containing 9 [Source:HGNC Symbol;Acc:HGNC:28489] -0.50 0.00
343 ENSG00000156860 FBRS ﬁbrosin [Source:HGNC Symbol;Acc:HGNC:20442] -0.49 0.00
344 ENSG00000107872 FBXL15 F-box and leucine-rich repeat protein 15 [Source:HGNC Symbol;Acc:HGNC:28155] -0.49 0.00
345 ENSG00000178882 FAM101A family with sequence similarity 101 member A [Source:HGNC Sym-
bol;Acc:HGNC:27051]
-0.49 0.00
346 ENSG00000178882 FAM101A family with sequence similarity 101 member A [Source:HGNC Sym-
bol;Acc:HGNC:27051]
-0.49 0.00
347 ENSG00000107890 ANKRD26 ankyrin repeat domain 26 [Source:HGNC Symbol;Acc:HGNC:29186] -0.49 0.00
348 ENSG00000092051 JPH4 junctophilin 4 [Source:HGNC Symbol;Acc:HGNC:20156] -0.49 0.00
349 ENSG00000109084 TMEM97 transmembrane protein 97 [Source:HGNC Symbol;Acc:HGNC:28106] -0.48 0.00
350 ENSG00000099910 KLHL22 kelch like family member 22 [Source:HGNC Symbol;Acc:HGNC:25888] -0.48 0.00
351 ENSG00000140718 FTO fat mass and obesity associated [Source:HGNC Symbol;Acc:HGNC:24678] -0.48 0.00
352 ENSG00000168280 KIF5C kinesin family member 5C [Source:HGNC Symbol;Acc:HGNC:6325] -0.48 0.00
353 ENSG00000183837 PNMA3 paraneoplastic Ma antigen 3 [Source:HGNC Symbol;Acc:HGNC:18742] -0.48 0.00
354 ENSG00000012822 CALCOCO1 calcium binding and coiled-coil domain 1 [Source:HGNC Symbol;Acc:HGNC:29306] -0.48 0.00
355 ENSG00000205643 CDPF1 cysteine rich, DPF motif domain containing 1 [Source:HGNC Sym-
bol;Acc:HGNC:33710]
-0.48 0.00
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356 ENSG00000141736 ERBB2 erb-b2 receptor tyrosine kinase 2 [Source:HGNC Symbol;Acc:HGNC:3430] -0.48 0.00
357 ENSG00000161267 BDH1 3-hydroxybutyrate dehydrogenase, type 1 [Source:HGNC Symbol;Acc:HGNC:1027] -0.48 0.00
358 ENSG00000185129 PURA purine-rich element binding protein A [Source:HGNC Symbol;Acc:HGNC:9701] -0.48 0.00
359 ENSG00000164989 CCDC171 coiled-coil domain containing 171 [Source:HGNC Symbol;Acc:HGNC:29828] -0.47 0.00
360 ENSG00000099365 STX1B syntaxin 1B [Source:HGNC Symbol;Acc:HGNC:18539] -0.47 0.00
361 ENSG00000167740 CYB5D2 cytochrome b5 domain containing 2 [Source:HGNC Symbol;Acc:HGNC:28471] -0.47 0.00
362 ENSG00000141540 TTYH2 tweety family member 2 [Source:HGNC Symbol;Acc:HGNC:13877] -0.47 0.00
363 ENSG00000010626 LRRC23 leucine rich repeat containing 23 [Source:HGNC Symbol;Acc:HGNC:19138] -0.47 0.00
364 ENSG00000101210 EEF1A2 eukaryotic translation elongation factor 1 alpha 2 [Source:HGNC Sym-
bol;Acc:HGNC:3192]
-0.47 0.00
365 ENSG00000006757 PNPLA4 patatin like phospholipase domain containing 4 [Source:HGNC Sym-
bol;Acc:HGNC:24887]
-0.47 0.00
366 ENSG00000173264 GPR137 G protein-coupled receptor 137 [Source:HGNC Symbol;Acc:HGNC:24300] -0.47 0.00
367 ENSG00000004455 AK2 adenylate kinase 2 [Source:HGNC Symbol;Acc:HGNC:362] -0.47 0.00
368 ENSG00000176055 MBLAC2 metallo-beta-lactamase domain containing 2 [Source:HGNC Sym-
bol;Acc:HGNC:33711]
-0.47 0.00
369 ENSG00000173705 SUSD5 sushi domain containing 5 [Source:HGNC Symbol;Acc:HGNC:29061] -0.47 0.00
370 ENSG00000114473 IQCG IQ motif containing G [Source:HGNC Symbol;Acc:HGNC:25251] -0.47 0.00
371 ENSG00000128185 DGCR6L DiGeorge syndrome critical region gene 6-like [Source:HGNC Sym-
bol;Acc:HGNC:18551]
-0.46 0.00
372 ENSG00000018510 AGPS alkylglycerone phosphate synthase [Source:HGNC Symbol;Acc:HGNC:327] -0.46 0.00
373 ENSG00000166562 SEC11C SEC11 homolog C, signal peptidase complex subunit [Source:HGNC Sym-
bol;Acc:HGNC:23400]
-0.46 0.00
374 ENSG00000197763 TXNRD3 thioredoxin reductase 3 [Source:HGNC Symbol;Acc:HGNC:20667] -0.46 0.00
375 ENSG00000197763 TXNRD3 thioredoxin reductase 3 [Source:HGNC Symbol;Acc:HGNC:20667] -0.46 0.00
376 ENSG00000185483 ROR1 receptor tyrosine kinase-like orphan receptor 1 [Source:HGNC Sym-
bol;Acc:HGNC:10256]
-0.46 0.00
377 ENSG00000072818 ACAP1 ArfGAP with coiled-coil, ankyrin repeat and PH domains 1 [Source:HGNC Sym-
bol;Acc:HGNC:16467]
-0.46 0.00
378 ENSG00000204104 TRAF3IP1 TRAF3 interacting protein 1 [Source:HGNC Symbol;Acc:HGNC:17861] -0.46 0.00
379 ENSG00000214655 ZSWIM8 zinc ﬁnger, SWIM-type containing 8 [Source:HGNC Symbol;Acc:HGNC:23528] -0.46 0.00
380 ENSG00000204852 TCTN1 tectonic family member 1 [Source:HGNC Symbol;Acc:HGNC:26113] -0.46 0.00
381 ENSG00000144749 LRIG1 leucine-rich repeats and immunoglobulin-like domains 1 [Source:HGNC Sym-
bol;Acc:HGNC:17360]
-0.46 0.00
382 ENSG00000163344 PMVK phosphomevalonate kinase [Source:HGNC Symbol;Acc:HGNC:9141] -0.46 0.00
383 ENSG00000177239 MAN1B1 mannosidase, alpha, class 1B, member 1 [Source:HGNC Symbol;Acc:HGNC:6823] -0.46 0.00
384 ENSG00000138604 GLCE glucuronic acid epimerase [Source:HGNC Symbol;Acc:HGNC:17855] -0.46 0.00
385 ENSG00000196507 TCEAL3 transcription elongation factor A (SII)-like 3 [Source:HGNC Sym-
bol;Acc:HGNC:28247]
-0.45 0.00
386 ENSG00000166965 RCCD1 RCC1 domain containing 1 [Source:HGNC Symbol;Acc:HGNC:30457] -0.45 0.00
387 ENSG00000022976 ZNF839 zinc ﬁnger protein 839 [Source:HGNC Symbol;Acc:HGNC:20345] -0.45 0.00
388 ENSG00000175175 PPM1E protein phosphatase, Mg2+/Mn2+ dependent 1E [Source:HGNC Sym-
bol;Acc:HGNC:19322]
-0.45 0.00
389 ENSG00000168806 LCMT2 leucine carboxyl methyltransferase 2 [Source:HGNC Symbol;Acc:HGNC:17558] -0.45 0.00
390 ENSG00000175854 SWI5 SWI5 homologous recombination repair protein [Source:HGNC Sym-
bol;Acc:HGNC:31412]
-0.45 0.00
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391 ENSG00000204682 CASC10 cancer susceptibility candidate 10 [Source:HGNC Symbol;Acc:HGNC:31448] -0.45 0.00
392 ENSG00000167114 SLC27A4 solute carrier family 27 (fatty acid transporter), member 4 [Source:HGNC Sym-
bol;Acc:HGNC:10998]
-0.45 0.00
393 ENSG00000167702 KIFC2 kinesin family member C2 [Source:HGNC Symbol;Acc:HGNC:29530] -0.45 0.00
394 ENSG00000143578 CREB3L4 cAMP responsive element binding protein 3-like 4 [Source:HGNC Sym-
bol;Acc:HGNC:18854]
-0.45 0.00
395 ENSG00000196456 ZNF775 zinc ﬁnger protein 775 [Source:HGNC Symbol;Acc:HGNC:28501] -0.44 0.00
396 ENSG00000130635 COL5A1 collagen, type V, alpha 1 [Source:HGNC Symbol;Acc:HGNC:2209] -0.44 0.00
397 ENSG00000137821 LRRC49 leucine rich repeat containing 49 [Source:HGNC Symbol;Acc:HGNC:25965] -0.44 0.00
398 ENSG00000145029 NICN1 nicolin 1 [Source:HGNC Symbol;Acc:HGNC:18317] -0.44 0.00
399 ENSG00000128228 SDF2L1 stromal cell-derived factor 2-like 1 [Source:HGNC Symbol;Acc:HGNC:10676] -0.44 0.00
400 ENSG00000182325 FBXL6 F-box and leucine-rich repeat protein 6 [Source:HGNC Symbol;Acc:HGNC:13603] -0.44 0.00
401 ENSG00000083123 BCKDHB branched chain keto acid dehydrogenase E1, beta polypeptide [Source:HGNC Sym-
bol;Acc:HGNC:987]
-0.44 0.00
402 ENSG00000184905 TCEAL2 transcription elongation factor A (SII)-like 2 [Source:HGNC Sym-
bol;Acc:HGNC:29818]
-0.44 0.00
403 ENSG00000180921 FAM83H family with sequence similarity 83 member H [Source:HGNC Sym-
bol;Acc:HGNC:24797]
-0.44 0.00
404 ENSG00000196975 ANXA4 annexin A4 [Source:HGNC Symbol;Acc:HGNC:542] -0.44 0.00
405 ENSG00000180902 D2HGDH D-2-hydroxyglutarate dehydrogenase [Source:HGNC Symbol;Acc:HGNC:28358] -0.44 0.00
406 ENSG00000131849 ZNF132 zinc ﬁnger protein 132 [Source:HGNC Symbol;Acc:HGNC:12916] -0.43 0.00
407 ENSG00000187097 ENTPD5 ectonucleoside triphosphate diphosphohydrolase 5 [Source:HGNC Sym-
bol;Acc:HGNC:3367]
-0.43 0.00
408 ENSG00000105255 FSD1 ﬁbronectin type III and SPRY domain containing 1 [Source:HGNC Sym-
bol;Acc:HGNC:13745]
-0.43 0.00
409 ENSG00000111879 FAM184A family with sequence similarity 184 member A [Source:HGNC Sym-
bol;Acc:HGNC:20991]
-0.43 0.00
410 ENSG00000169621 APLF aprataxin and PNKP like factor [Source:HGNC Symbol;Acc:HGNC:28724] -0.43 0.00
411 ENSG00000169621 APLF aprataxin and PNKP like factor [Source:HGNC Symbol;Acc:HGNC:28724] -0.43 0.00
412 ENSG00000160767 FAM189B family with sequence similarity 189 member B [Source:HGNC Sym-
bol;Acc:HGNC:1233]
-0.43 0.00
413 ENSG00000160216 AGPAT3 1-acylglycerol-3-phosphate O-acyltransferase 3 [Source:HGNC Sym-
bol;Acc:HGNC:326]
-0.43 0.00
414 ENSG00000130751 NPAS1 neuronal PAS domain protein 1 [Source:HGNC Symbol;Acc:HGNC:7894] -0.43 0.00
415 ENSG00000134901 KDELC1 KDEL motif containing 1 [Source:HGNC Symbol;Acc:HGNC:19350] -0.43 0.00
416 ENSG00000139579 NABP2 nucleic acid binding protein 2 [Source:HGNC Symbol;Acc:HGNC:28412] -0.43 0.00
417 ENSG00000204946 ZNF783 zinc ﬁnger family member 783 [Source:HGNC Symbol;Acc:HGNC:27222] -0.43 0.00
418 ENSG00000054282 SDCCAG8 serologically deﬁned colon cancer antigen 8 [Source:HGNC Symbol;Acc:HGNC:10671] -0.43 0.00
419 ENSG00000146350 TBC1D32 TBC1 domain family member 32 [Source:HGNC Symbol;Acc:HGNC:21485] -0.43 0.00
420 ENSG00000176058 TPRN taperin [Source:HGNC Symbol;Acc:HGNC:26894] -0.42 0.00
421 ENSG00000151338 MIPOL1 mirror-image polydactyly 1 [Source:HGNC Symbol;Acc:HGNC:21460] -0.42 0.00
422 ENSG00000164114 MAP9 microtubule associated protein 9 [Source:HGNC Symbol;Acc:HGNC:26118] -0.42 0.00
423 ENSG00000153094 BCL2L11 BCL2-like 11 (apoptosis facilitator) [Source:HGNC Symbol;Acc:HGNC:994] -0.42 0.00
424 ENSG00000008300 CELSR3 cadherin, EGF LAG seven-pass G-type receptor 3 [Source:HGNC Sym-
bol;Acc:HGNC:3230]
-0.42 0.00
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425 ENSG00000147955 SIGMAR1 sigma non-opioid intracellular receptor 1 [Source:HGNC Symbol;Acc:HGNC:8157] -0.42 0.00
426 ENSG00000235106 LINC00094 long intergenic non-protein coding RNA 94 [Source:HGNC Symbol;Acc:HGNC:24742] -0.42 0.00
427 ENSG00000103150 MLYCD malonyl-CoA decarboxylase [Source:HGNC Symbol;Acc:HGNC:7150] -0.42 0.00
428 ENSG00000091844 RGS17 regulator of G-protein signaling 17 [Source:HGNC Symbol;Acc:HGNC:14088] -0.42 0.00
429 ENSG00000140545 MFGE8 milk fat globule-EGF factor 8 protein [Source:HGNC Symbol;Acc:HGNC:7036] -0.42 0.00
430 ENSG00000100592 DAAM1 dishevelled associated activator of morphogenesis 1 [Source:HGNC Sym-
bol;Acc:HGNC:18142]
-0.42 0.00
431 ENSG00000134207 SYT6 synaptotagmin 6 [Source:HGNC Symbol;Acc:HGNC:18638] -0.42 0.00
432 ENSG00000229544 NKX1-2 NK1 homeobox 2 [Source:HGNC Symbol;Acc:HGNC:31652] -0.41 0.00
433 ENSG00000159921 GNE glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase
[Source:HGNC Symbol;Acc:HGNC:23657]
-0.41 0.00
434 ENSG00000060642 PIGV phosphatidylinositol glycan anchor biosynthesis class V [Source:HGNC Sym-
bol;Acc:HGNC:26031]
-0.41 0.00
435 ENSG00000122512 PMS2 PMS1 homolog 2, mismatch repair system component [Source:HGNC Sym-
bol;Acc:HGNC:9122]
-0.41 0.00
436 ENSG00000176473 WDR25 WD repeat domain 25 [Source:HGNC Symbol;Acc:HGNC:21064] -0.41 0.00
437 ENSG00000151445 VIPAS39 VPS33B interacting protein, apical-basolateral polarity regulator, spe-39 homolog
[Source:HGNC Symbol;Acc:HGNC:20347]
-0.41 0.00
438 ENSG00000172731 LRRC20 leucine rich repeat containing 20 [Source:HGNC Symbol;Acc:HGNC:23421] -0.41 0.00
439 ENSG00000080709 KCNN2 potassium channel, calcium activated intermediate/small conductance subfamily N
alpha, member 2 [Source:HGNC Symbol;Acc:HGNC:6291]
-0.41 0.00
440 ENSG00000164087 POC1A POC1 centriolar protein A [Source:HGNC Symbol;Acc:HGNC:24488] -0.41 0.00
441 ENSG00000179195 ZNF664 zinc ﬁnger protein 664 [Source:HGNC Symbol;Acc:HGNC:25406] -0.41 0.00
442 ENSG00000182093 WRB tryptophan rich basic protein [Source:HGNC Symbol;Acc:HGNC:12790] -0.41 0.00
443 ENSG00000157911 PEX10 peroxisomal biogenesis factor 10 [Source:HGNC Symbol;Acc:HGNC:8851] -0.40 0.00
444 ENSG00000095321 CRAT carnitine O-acetyltransferase [Source:HGNC Symbol;Acc:HGNC:2342] -0.40 0.00
445 ENSG00000167925 GHDC GH3 domain containing [Source:HGNC Symbol;Acc:HGNC:24438] -0.40 0.00
446 ENSG00000167654 ATCAY ataxia, cerebellar, Cayman type [Source:HGNC Symbol;Acc:HGNC:779] -0.40 0.00
447 ENSG00000116198 CEP104 centrosomal protein 104kDa [Source:HGNC Symbol;Acc:HGNC:24866] -0.40 0.00
448 ENSG00000144792 ZNF660 zinc ﬁnger protein 660 [Source:HGNC Symbol;Acc:HGNC:26720] -0.40 0.00
449 ENSG00000158019 BRE brain and reproductive organ-expressed (TNFRSF1A modulator) [Source:HGNC
Symbol;Acc:HGNC:1106]
-0.40 0.00
450 ENSG00000101166 PRELID3B PRELI domain containing 3B [Source:HGNC Symbol;Acc:HGNC:15892] -0.40 0.00
451 ENSG00000166105 GLB1L3 galactosidase beta 1 like 3 [Source:HGNC Symbol;Acc:HGNC:25147] -0.40 0.00
452 ENSG00000025039 RRAGD Ras-related GTP binding D [Source:HGNC Symbol;Acc:HGNC:19903] -0.40 0.00
453 ENSG00000129473 BCL2L2 BCL2-like 2 [Source:HGNC Symbol;Acc:HGNC:995] -0.40 0.00
454 ENSG00000185437 SH3BGR SH3 domain binding glutamate-rich protein [Source:HGNC Sym-
bol;Acc:HGNC:10822]
-0.40 0.00
455 ENSG00000162065 TBC1D24 TBC1 domain family member 24 [Source:HGNC Symbol;Acc:HGNC:29203] -0.40 0.00
456 ENSG00000163867 ZMYM6 zinc ﬁnger, MYM-type 6 [Source:HGNC Symbol;Acc:HGNC:13050] -0.40 0.00
457 ENSG00000171608 PIK3CD phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta [Source:HGNC
Symbol;Acc:HGNC:8977]
-0.40 0.00
458 ENSG00000131697 NPHP4 nephronophthisis 4 [Source:HGNC Symbol;Acc:HGNC:19104] -0.40 0.00
459 ENSG00000171766 GATM glycine amidinotransferase (L-arginine:glycine amidinotransferase) [Source:HGNC
Symbol;Acc:HGNC:4175]
-0.40 0.00
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460 ENSG00000153012 LGI2 leucine-rich repeat LGI family member 2 [Source:HGNC Symbol;Acc:HGNC:18710] -0.40 0.00
461 ENSG00000050426 LETMD1 LETM1 domain containing 1 [Source:HGNC Symbol;Acc:HGNC:24241] -0.40 0.00
462 ENSG00000164402 SEPT8 septin 8 [Source:HGNC Symbol;Acc:HGNC:16511] -0.39 0.00
463 ENSG00000124374 PAIP2B poly(A) binding protein interacting protein 2B [Source:HGNC Sym-
bol;Acc:HGNC:29200]
-0.39 0.00
464 ENSG00000166750 SLFN5 schlafen family member 5 [Source:HGNC Symbol;Acc:HGNC:28286] -0.39 0.00
465 ENSG00000144647 POMGNT2 protein O-linked mannose N-acetylglucosaminyltransferase 2 (beta 1,4-)
[Source:HGNC Symbol;Acc:HGNC:25902]
-0.39 0.00
466 ENSG00000118855 MFSD1 major facilitator superfamily domain containing 1 [Source:HGNC Sym-
bol;Acc:HGNC:25874]
-0.39 0.00
467 ENSG00000169750 RAC3 ras-related C3 botulinum toxin substrate 3 (rho family, small GTP binding protein
Rac3) [Source:HGNC Symbol;Acc:HGNC:9803]
-0.39 0.00
468 ENSG00000134330 IAH1 isoamyl acetate-hydrolyzing esterase 1 homolog [Source:HGNC Sym-
bol;Acc:HGNC:27696]
-0.39 0.00
469 ENSG00000144426 NBEAL1 neurobeachin like 1 [Source:HGNC Symbol;Acc:HGNC:20681] -0.39 0.00
470 ENSG00000148408 CACNA1B calcium channel, voltage-dependent, N type, alpha 1B subunit [Source:HGNC Sym-
bol;Acc:HGNC:1389]
-0.38 0.00
471 ENSG00000164105 SAP30 Sin3A associated protein 30kDa [Source:HGNC Symbol;Acc:HGNC:10532] -0.38 0.00
472 ENSG00000214941 ZSWIM7 zinc ﬁnger, SWIM-type containing 7 [Source:HGNC Symbol;Acc:HGNC:26993] -0.38 0.00
473 ENSG00000137216 TMEM63B transmembrane protein 63B [Source:HGNC Symbol;Acc:HGNC:17735] -0.38 0.00
474 ENSG00000160326 SLC2A6 solute carrier family 2 (facilitated glucose transporter), member 6 [Source:HGNC
Symbol;Acc:HGNC:11011]
-0.38 0.00
475 ENSG00000172638 EFEMP2 EGF containing ﬁbulin-like extracellular matrix protein 2 [Source:HGNC Sym-
bol;Acc:HGNC:3219]
-0.38 0.00
476 ENSG00000198707 CEP290 centrosomal protein 290kDa [Source:HGNC Symbol;Acc:HGNC:29021] -0.38 0.00
477 ENSG00000131584 ACAP3 ArfGAP with coiled-coil, ankyrin repeat and PH domains 3 [Source:HGNC Sym-
bol;Acc:HGNC:16754]
-0.38 0.00
478 ENSG00000079432 CIC capicua transcriptional repressor [Source:HGNC Symbol;Acc:HGNC:14214] -0.38 0.00
479 ENSG00000155016 CYP2U1 cytochrome P450 family 2 subfamily U member 1 [Source:HGNC Sym-
bol;Acc:HGNC:20582]
-0.38 0.00
480 ENSG00000188130 MAPK12 mitogen-activated protein kinase 12 [Source:HGNC Symbol;Acc:HGNC:6874] -0.38 0.00
481 ENSG00000099940 SNAP29 synaptosome associated protein 29kDa [Source:HGNC Symbol;Acc:HGNC:11133] -0.38 0.00
482 ENSG00000008869 HEATR5B HEAT repeat containing 5B [Source:HGNC Symbol;Acc:HGNC:29273] -0.38 0.00
483 ENSG00000196700 ZNF512B zinc ﬁnger protein 512B [Source:HGNC Symbol;Acc:HGNC:29212] -0.38 0.00
484 ENSG00000161091 MFSD12 major facilitator superfamily domain containing 12 [Source:HGNC Sym-
bol;Acc:HGNC:28299]
-0.37 0.00
485 ENSG00000163001 CFAP36 cilia and ﬂagella associated protein 36 [Source:HGNC Symbol;Acc:HGNC:30540] -0.37 0.00
486 ENSG00000133138 TBC1D8B TBC1 domain family member 8B [Source:HGNC Symbol;Acc:HGNC:24715] -0.37 0.00
487 ENSG00000071859 FAM50A family with sequence similarity 50 member A [Source:HGNC Sym-
bol;Acc:HGNC:18786]
-0.37 0.00
488 ENSG00000196922 ZNF252P zinc ﬁnger protein 252, pseudogene [Source:HGNC Symbol;Acc:HGNC:13046] -0.37 0.00
489 ENSG00000081177 EXD2 exonuclease 3'-5' domain containing 2 [Source:HGNC Symbol;Acc:HGNC:20217] -0.37 0.00
490 ENSG00000014138 POLA2 polymerase (DNA directed), alpha 2, accessory subunit [Source:HGNC Sym-
bol;Acc:HGNC:30073]
-0.37 0.00
491 ENSG00000108465 CDK5RAP3 CDK5 regulatory subunit associated protein 3 [Source:HGNC Sym-
bol;Acc:HGNC:18673]
-0.37 0.00
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492 ENSG00000147813 NAPRT nicotinate phosphoribosyltransferase [Source:HGNC Symbol;Acc:HGNC:30450] -0.37 0.00
493 ENSG00000100116 GCAT glycine C-acetyltransferase [Source:HGNC Symbol;Acc:HGNC:4188] -0.37 0.00
494 ENSG00000159423 ALDH4A1 aldehyde dehydrogenase 4 family member A1 [Source:HGNC Symbol;Acc:HGNC:406] -0.37 0.00
495 ENSG00000047188 YTHDC2 YTH domain containing 2 [Source:HGNC Symbol;Acc:HGNC:24721] -0.36 0.00
496 ENSG00000166347 CYB5A cytochrome b5 type A (microsomal) [Source:HGNC Symbol;Acc:HGNC:2570] -0.36 0.00
497 ENSG00000253738 OTUD6B-AS1 OTUD6B antisense RNA 1 (head to head) [Source:HGNC Symbol;Acc:HGNC:50466] -0.36 0.00
498 ENSG00000184207 PGP phosphoglycolate phosphatase [Source:HGNC Symbol;Acc:HGNC:8909] -0.36 0.00
499 ENSG00000141971 MVB12A multivesicular body subunit 12A [Source:HGNC Symbol;Acc:HGNC:25153] -0.36 0.00
500 ENSG00000114388 NPRL2 NPR2-like, GATOR1 complex subunit [Source:HGNC Symbol;Acc:HGNC:24969] -0.36 0.00
501 ENSG00000159363 ATP13A2 ATPase type 13A2 [Source:HGNC Symbol;Acc:HGNC:30213] -0.36 0.00
502 ENSG00000074211 PPP2R2C protein phosphatase 2 regulatory subunit B, gamma [Source:HGNC Sym-
bol;Acc:HGNC:9306]
-0.36 0.00
503 ENSG00000254685 FPGT fucose-1-phosphate guanylyltransferase [Source:HGNC Symbol;Acc:HGNC:3825] -0.36 0.00
504 ENSG00000146834 MEPCE methylphosphate capping enzyme [Source:HGNC Symbol;Acc:HGNC:20247] -0.36 0.00
505 ENSG00000168243 GNG4 guanine nucleotide binding protein (G protein), gamma 4 [Source:HGNC Sym-
bol;Acc:HGNC:4407]
-0.36 0.00
506 ENSG00000172915 NBEA neurobeachin [Source:HGNC Symbol;Acc:HGNC:7648] -0.36 0.00
507 ENSG00000151500 THYN1 thymocyte nuclear protein 1 [Source:HGNC Symbol;Acc:HGNC:29560] -0.36 0.00
508 ENSG00000132406 TMEM128 transmembrane protein 128 [Source:HGNC Symbol;Acc:HGNC:28201] -0.36 0.00
509 ENSG00000234787 LINC00458 long intergenic non-protein coding RNA 458 [Source:HGNC Sym-
bol;Acc:HGNC:42807]
-0.36 0.00
510 ENSG00000155850 SLC26A2 solute carrier family 26 (anion exchanger), member 2 [Source:HGNC Sym-
bol;Acc:HGNC:10994]
-0.35 0.00
511 ENSG00000101220 C20orf27 chromosome 20 open reading frame 27 [Source:HGNC Symbol;Acc:HGNC:15873] -0.35 0.00
512 ENSG00000160284 SPATC1L spermatogenesis and centriole associated 1-like [Source:HGNC Sym-
bol;Acc:HGNC:1298]
-0.35 0.00
513 ENSG00000141759 TXNL4A thioredoxin like 4A [Source:HGNC Symbol;Acc:HGNC:30551] -0.35 0.00
514 ENSG00000033627 ATP6V0A1 ATPase, H+ transporting, lysosomal V0 subunit a1 [Source:HGNC Sym-
bol;Acc:HGNC:865]
-0.35 0.00
515 ENSG00000117408 IPO13 importin 13 [Source:HGNC Symbol;Acc:HGNC:16853] -0.35 0.00
516 ENSG00000143224 PPOX protoporphyrinogen oxidase [Source:HGNC Symbol;Acc:HGNC:9280] -0.35 0.00
517 ENSG00000131844 MCCC2 methylcrotonoyl-CoA carboxylase 2 [Source:HGNC Symbol;Acc:HGNC:6937] -0.35 0.00
518 ENSG00000155876 RRAGA Ras-related GTP binding A [Source:HGNC Symbol;Acc:HGNC:16963] -0.35 0.00
519 ENSG00000064687 ABCA7 ATP binding cassette subfamily A member 7 [Source:HGNC Symbol;Acc:HGNC:37] -0.35 0.00
520 ENSG00000169189 NSMCE1 NSE1 homolog, SMC5-SMC6 complex component [Source:HGNC Sym-
bol;Acc:HGNC:29897]
-0.35 0.00
521 ENSG00000090971 NAT14 N-acetyltransferase 14 (GCN5-related, putative) [Source:HGNC Sym-
bol;Acc:HGNC:28918]
-0.35 0.00
522 ENSG00000150867 PIP4K2A phosphatidylinositol-5-phosphate 4-kinase, type II, alpha [Source:HGNC Sym-
bol;Acc:HGNC:8997]
-0.35 0.00
523 ENSG00000188811 NHLRC3 NHL repeat containing 3 [Source:HGNC Symbol;Acc:HGNC:33751] -0.35 0.00
524 ENSG00000153406 NMRAL1 NmrA-like family domain containing 1 [Source:HGNC Symbol;Acc:HGNC:24987] -0.35 0.00
525 ENSG00000103494 RPGRIP1L RPGRIP1-like [Source:HGNC Symbol;Acc:HGNC:29168] -0.35 0.00
526 ENSG00000067836 ROGDI rogdi homolog [Source:HGNC Symbol;Acc:HGNC:29478] -0.35 0.00
527 ENSG00000091542 ALKBH5 alkB homolog 5, RNA demethylase [Source:HGNC Symbol;Acc:HGNC:25996] -0.35 0.00
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528 ENSG00000135924 DNAJB2 DnaJ heat shock protein family (Hsp40) member B2 [Source:HGNC Sym-
bol;Acc:HGNC:5228]
-0.35 0.00
529 ENSG00000117758 STX12 syntaxin 12 [Source:HGNC Symbol;Acc:HGNC:11430] -0.35 0.00
530 ENSG00000143314 MRPL24 mitochondrial ribosomal protein L24 [Source:HGNC Symbol;Acc:HGNC:14037] -0.34 0.00
531 ENSG00000255302 EID1 EP300 interacting inhibitor of diﬀerentiation 1 [Source:HGNC Sym-
bol;Acc:HGNC:1191]
-0.34 0.00
532 ENSG00000186416 NKRF NFKB repressing factor [Source:HGNC Symbol;Acc:HGNC:19374] -0.34 0.00
533 ENSG00000088888 MAVS mitochondrial antiviral signaling protein [Source:HGNC Symbol;Acc:HGNC:29233] -0.34 0.00
534 ENSG00000159079 C21orf59 chromosome 21 open reading frame 59 [Source:HGNC Symbol;Acc:HGNC:1301] -0.34 0.00
535 ENSG00000159753 RLTPR RGD motif, leucine rich repeats, tropomodulin domain and proline-rich containing
[Source:HGNC Symbol;Acc:HGNC:27089]
-0.34 0.00
536 ENSG00000162066 AMDHD2 amidohydrolase domain containing 2 [Source:HGNC Symbol;Acc:HGNC:24262] -0.34 0.00
537 ENSG00000111652 COPS7A COP9 signalosome subunit 7A [Source:HGNC Symbol;Acc:HGNC:16758] -0.34 0.00
538 ENSG00000142528 ZNF473 zinc ﬁnger protein 473 [Source:HGNC Symbol;Acc:HGNC:23239] -0.34 0.00
539 ENSG00000014824 SLC30A9 solute carrier family 30 (zinc transporter), member 9 [Source:HGNC Sym-
bol;Acc:HGNC:1329]
-0.34 0.00
540 ENSG00000103148 NPRL3 NPR3-like, GATOR1 complex subunit [Source:HGNC Symbol;Acc:HGNC:14124] -0.34 0.00
541 ENSG00000149809 TM7SF2 transmembrane 7 superfamily member 2 [Source:HGNC Symbol;Acc:HGNC:11863] -0.34 0.00
542 ENSG00000107874 CUEDC2 CUE domain containing 2 [Source:HGNC Symbol;Acc:HGNC:28352] -0.34 0.00
543 ENSG00000149499 EML3 echinoderm microtubule associated protein like 3 [Source:HGNC Sym-
bol;Acc:HGNC:26666]
-0.33 0.00
544 ENSG00000101443 WFDC2 WAP four-disulﬁde core domain 2 [Source:HGNC Symbol;Acc:HGNC:15939] -0.33 0.00
545 ENSG00000169738 DCXR dicarbonyl/L-xylulose reductase [Source:HGNC Symbol;Acc:HGNC:18985] -0.33 0.00
546 ENSG00000101350 KIF3B kinesin family member 3B [Source:HGNC Symbol;Acc:HGNC:6320] -0.33 0.00
547 ENSG00000183010 PYCR1 pyrroline-5-carboxylate reductase 1 [Source:HGNC Symbol;Acc:HGNC:9721] -0.33 0.01
548 ENSG00000198690 FAN1 FANCD2/FANCI-associated nuclease 1 [Source:HGNC Symbol;Acc:HGNC:29170] -0.33 0.00
549 ENSG00000100418 DESI1 desumoylating isopeptidase 1 [Source:HGNC Symbol;Acc:HGNC:24577] -0.33 0.00
550 ENSG00000169992 NLGN2 neuroligin 2 [Source:HGNC Symbol;Acc:HGNC:14290] -0.33 0.00
551 ENSG00000116406 EDEM3 ER degradation enhancer, mannosidase alpha-like 3 [Source:HGNC Sym-
bol;Acc:HGNC:16787]
-0.33 0.00
552 ENSG00000189060 H1F0 H1 histone family member 0 [Source:HGNC Symbol;Acc:HGNC:4714] -0.33 0.00
553 ENSG00000128524 ATP6V1F ATPase, H+ transporting, lysosomal 14kDa, V1 subunit F [Source:HGNC Sym-
bol;Acc:HGNC:16832]
-0.33 0.00
554 ENSG00000136436 CALCOCO2 calcium binding and coiled-coil domain 2 [Source:HGNC Symbol;Acc:HGNC:29912] -0.33 0.00
555 ENSG00000170876 TMEM43 transmembrane protein 43 [Source:HGNC Symbol;Acc:HGNC:28472] -0.33 0.00
556 ENSG00000182963 GJC1 gap junction protein gamma 1 [Source:HGNC Symbol;Acc:HGNC:4280] -0.33 0.00
557 ENSG00000009780 FAM76A family with sequence similarity 76 member A [Source:HGNC Sym-
bol;Acc:HGNC:28530]
-0.33 0.00
558 ENSG00000133612 AGAP3 ArfGAP with GTPase domain, ankyrin repeat and PH domain 3 [Source:HGNC
Symbol;Acc:HGNC:16923]
-0.33 0.00
559 ENSG00000158079 PTPDC1 protein tyrosine phosphatase domain containing 1 [Source:HGNC Sym-
bol;Acc:HGNC:30184]
-0.32 0.00
560 ENSG00000205060 SLC35B4 solute carrier family 35 (UDP-xylose/UDP-N-acetylglucosamine transporter), mem-
ber B4 [Source:HGNC Symbol;Acc:HGNC:20584]
-0.32 0.00
561 ENSG00000069998 CECR5 cat eye syndrome chromosome region, candidate 5 [Source:HGNC Sym-
bol;Acc:HGNC:1843]
-0.32 0.00
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562 ENSG00000129317 PUS7L pseudouridylate synthase 7-like [Source:HGNC Symbol;Acc:HGNC:25276] -0.32 0.00
563 ENSG00000153130 SCOC short coiled-coil protein [Source:HGNC Symbol;Acc:HGNC:20335] -0.32 0.00
564 ENSG00000140105 WARS tryptophanyl-tRNA synthetase [Source:HGNC Symbol;Acc:HGNC:12729] -0.32 0.00
565 ENSG00000227372 TP73-AS1 TP73 antisense RNA 1 [Source:HGNC Symbol;Acc:HGNC:29052] -0.32 0.00
566 ENSG00000135317 SNX14 sorting nexin 14 [Source:HGNC Symbol;Acc:HGNC:14977] -0.32 0.00
567 ENSG00000137601 NEK1 NIMA-related kinase 1 [Source:HGNC Symbol;Acc:HGNC:7744] -0.32 0.00
568 ENSG00000094916 CBX5 chromobox 5 [Source:HGNC Symbol;Acc:HGNC:1555] -0.32 0.00
569 ENSG00000198056 PRIM1 primase, DNA, polypeptide 1 (49kDa) [Source:HGNC Symbol;Acc:HGNC:9369] -0.31 0.00
570 ENSG00000110060 PUS3 pseudouridylate synthase 3 [Source:HGNC Symbol;Acc:HGNC:25461] -0.31 0.00
571 ENSG00000188428 BLOC1S5 biogenesis of lysosomal organelles complex-1, subunit 5, muted [Source:HGNC Sym-
bol;Acc:HGNC:18561]
-0.31 0.00
572 ENSG00000064545 TMEM161A transmembrane protein 161A [Source:HGNC Symbol;Acc:HGNC:26020] -0.31 0.00
573 ENSG00000196976 LAGE3 L antigen family member 3 [Source:HGNC Symbol;Acc:HGNC:26058] -0.31 0.00
574 ENSG00000132024 CC2D1A coiled-coil and C2 domain containing 1A [Source:HGNC Symbol;Acc:HGNC:30237] -0.30 0.00
575 ENSG00000126391 FRMD8 FERM domain containing 8 [Source:HGNC Symbol;Acc:HGNC:25462] -0.30 0.00
576 ENSG00000153767 GTF2E1 general transcription factor IIE subunit 1 [Source:HGNC Symbol;Acc:HGNC:4650] -0.30 0.00
577 ENSG00000116984 MTR 5-methyltetrahydrofolate-homocysteine methyltransferase [Source:HGNC Sym-
bol;Acc:HGNC:7468]
-0.30 0.00
578 ENSG00000162600 OMA1 OMA1 zinc metallopeptidase [Source:HGNC Symbol;Acc:HGNC:29661] -0.30 0.00
579 ENSG00000170100 ZNF778 zinc ﬁnger protein 778 [Source:HGNC Symbol;Acc:HGNC:26479] -0.30 0.00
580 ENSG00000185115 NSMCE3 NSE3 homolog, SMC5-SMC6 complex component [Source:HGNC Sym-
bol;Acc:HGNC:7677]
-0.30 0.00
581 ENSG00000068885 IFT80 intraﬂagellar transport 80 [Source:HGNC Symbol;Acc:HGNC:29262] -0.29 0.00
582 ENSG00000082146 STRADB STE20-related kinase adaptor beta [Source:HGNC Symbol;Acc:HGNC:13205] -0.29 0.00
583 ENSG00000151498 ACAD8 acyl-CoA dehydrogenase family member 8 [Source:HGNC Symbol;Acc:HGNC:87] -0.29 0.00
584 ENSG00000197879 MYO1C myosin IC [Source:HGNC Symbol;Acc:HGNC:7597] -0.29 0.00
585 ENSG00000163832 ELP6 elongator acetyltransferase complex subunit 6 [Source:HGNC Sym-
bol;Acc:HGNC:25976]
-0.29 0.00
586 ENSG00000154124 OTULIN OTU deubiquitinase with linear linkage speciﬁcity [Source:HGNC Sym-
bol;Acc:HGNC:25118]
-0.29 0.00
587 ENSG00000129003 VPS13C vacuolar protein sorting 13 homolog C (S. cerevisiae) [Source:HGNC Sym-
bol;Acc:HGNC:23594]
-0.29 0.00
588 ENSG00000196437 ZNF569 zinc ﬁnger protein 569 [Source:HGNC Symbol;Acc:HGNC:24737] -0.28 0.00
589 ENSG00000147162 OGT O-linked N-acetylglucosamine (GlcNAc) transferase [Source:HGNC Sym-
bol;Acc:HGNC:8127]
-0.28 0.00
590 ENSG00000158457 TSPAN33 tetraspanin 33 [Source:HGNC Symbol;Acc:HGNC:28743] -0.28 0.00
591 ENSG00000128294 TPST2 tyrosylprotein sulfotransferase 2 [Source:HGNC Symbol;Acc:HGNC:12021] -0.28 0.00
592 ENSG00000105419 MEIS3 Meis homeobox 3 [Source:HGNC Symbol;Acc:HGNC:29537] -0.28 0.00
593 ENSG00000056097 ZFR zinc ﬁnger RNA binding protein [Source:HGNC Symbol;Acc:HGNC:17277] 0.30 0.00
594 ENSG00000164611 PTTG1 pituitary tumor-transforming 1 [Source:HGNC Symbol;Acc:HGNC:9690] 0.30 0.00
595 ENSG00000214113 LYRM4 LYR motif containing 4 [Source:HGNC Symbol;Acc:HGNC:21365] 0.30 0.00
596 ENSG00000168615 ADAM9 ADAM metallopeptidase domain 9 [Source:HGNC Symbol;Acc:HGNC:216] 0.31 0.00
597 ENSG00000148672 GLUD1 glutamate dehydrogenase 1 [Source:HGNC Symbol;Acc:HGNC:4335] 0.31 0.00
598 ENSG00000060339 CCAR1 cell division cycle and apoptosis regulator 1 [Source:HGNC Symbol;Acc:HGNC:24236] 0.31 0.00
599 ENSG00000100625 SIX4 SIX homeobox 4 [Source:HGNC Symbol;Acc:HGNC:10890] 0.31 0.00
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600 ENSG00000092068 SLC7A8 solute carrier family 7 (amino acid transporter light chain, L system), member 8
[Source:HGNC Symbol;Acc:HGNC:11066]
0.31 0.00
601 ENSG00000175061 LRRC75A-AS1 LRRC75A antisense RNA 1 [Source:HGNC Symbol;Acc:HGNC:28619] 0.31 0.00
602 ENSG00000269893 SNHG8 small nucleolar RNA host gene 8 [Source:HGNC Symbol;Acc:HGNC:33098] 0.31 0.00
603 ENSG00000134755 DSC2 desmocollin 2 [Source:HGNC Symbol;Acc:HGNC:3036] 0.31 0.00
604 ENSG00000112306 RPS12 ribosomal protein S12 [Source:HGNC Symbol;Acc:HGNC:10385] 0.32 0.00
605 ENSG00000001036 FUCA2 fucosidase, alpha-L- 2, plasma [Source:HGNC Symbol;Acc:HGNC:4008] 0.32 0.00
606 ENSG00000150471 ADGRL3 adhesion G protein-coupled receptor L3 [Source:HGNC Symbol;Acc:HGNC:20974] 0.32 0.00
607 ENSG00000113140 SPARC secreted protein, acidic, cysteine-rich (osteonectin) [Source:HGNC Sym-
bol;Acc:HGNC:11219]
0.32 0.00
608 ENSG00000064115 TM7SF3 transmembrane 7 superfamily member 3 [Source:HGNC Symbol;Acc:HGNC:23049] 0.32 0.00
609 ENSG00000139112 GABARAPL1 GABA(A) receptor-associated protein like 1 [Source:HGNC Symbol;Acc:HGNC:4068] 0.32 0.00
610 ENSG00000186767 SPIN4 spindlin family member 4 [Source:HGNC Symbol;Acc:HGNC:27040] 0.33 0.00
611 ENSG00000167671 UBXN6 UBX domain protein 6 [Source:HGNC Symbol;Acc:HGNC:14928] 0.33 0.00
612 ENSG00000087586 AURKA aurora kinase A [Source:HGNC Symbol;Acc:HGNC:11393] 0.33 0.00
613 ENSG00000196646 ZNF136 zinc ﬁnger protein 136 [Source:HGNC Symbol;Acc:HGNC:12920] 0.33 0.00
614 ENSG00000145247 OCIAD2 OCIA domain containing 2 [Source:HGNC Symbol;Acc:HGNC:28685] 0.33 0.00
615 ENSG00000114450 GNB4 guanine nucleotide binding protein (G protein), beta polypeptide 4 [Source:HGNC
Symbol;Acc:HGNC:20731]
0.33 0.00
616 ENSG00000183077 AFMID arylformamidase [Source:HGNC Symbol;Acc:HGNC:20910] 0.33 0.00
617 ENSG00000166130 IKBIP IKBKB interacting protein [Source:HGNC Symbol;Acc:HGNC:26430] 0.34 0.00
618 ENSG00000130340 SNX9 sorting nexin 9 [Source:HGNC Symbol;Acc:HGNC:14973] 0.34 0.00
619 ENSG00000175581 MRPL48 mitochondrial ribosomal protein L48 [Source:HGNC Symbol;Acc:HGNC:16653] 0.34 0.00
620 ENSG00000110811 P3H3 prolyl 3-hydroxylase 3 [Source:HGNC Symbol;Acc:HGNC:19318] 0.34 0.00
621 ENSG00000213626 LBH limb bud and heart development [Source:HGNC Symbol;Acc:HGNC:29532] 0.34 0.00
622 ENSG00000145390 USP53 ubiquitin speciﬁc peptidase 53 [Source:HGNC Symbol;Acc:HGNC:29255] 0.34 0.00
623 ENSG00000171604 CXXC5 CXXC ﬁnger protein 5 [Source:HGNC Symbol;Acc:HGNC:26943] 0.35 0.00
624 ENSG00000122644 ARL4A ADP ribosylation factor like GTPase 4A [Source:HGNC Symbol;Acc:HGNC:695] 0.35 0.00
625 ENSG00000163166 IWS1 IWS1 homolog (S. cerevisiae) [Source:HGNC Symbol;Acc:HGNC:25467] 0.35 0.00
626 ENSG00000122861 PLAU plasminogen activator, urokinase [Source:HGNC Symbol;Acc:HGNC:9052] 0.35 0.00
627 ENSG00000152818 UTRN utrophin [Source:HGNC Symbol;Acc:HGNC:12635] 0.35 0.00
628 ENSG00000167565 SERTAD3 SERTA domain containing 3 [Source:HGNC Symbol;Acc:HGNC:17931] 0.35 0.00
629 ENSG00000102316 MAGED2 MAGE family member D2 [Source:HGNC Symbol;Acc:HGNC:16353] 0.35 0.00
630 ENSG00000100154 TTC28 tetratricopeptide repeat domain 28 [Source:HGNC Symbol;Acc:HGNC:29179] 0.35 0.00
631 ENSG00000134247 PTGFRN prostaglandin F2 receptor inhibitor [Source:HGNC Symbol;Acc:HGNC:9601] 0.35 0.00
632 ENSG00000197905 TEAD4 TEA domain family member 4 [Source:HGNC Symbol;Acc:HGNC:11717] 0.35 0.00
633 ENSG00000132434 LANCL2 LanC lantibiotic synthetase component C-like 2 (bacterial) [Source:HGNC Sym-
bol;Acc:HGNC:6509]
0.36 0.00
634 ENSG00000124588 NQO2 NAD(P)H dehydrogenase, quinone 2 [Source:HGNC Symbol;Acc:HGNC:7856] 0.36 0.00
635 ENSG00000102349 KLF8 Kruppel-like factor 8 [Source:HGNC Symbol;Acc:HGNC:6351] 0.36 0.00
636 ENSG00000198915 RASGEF1A RasGEF domain family member 1A [Source:HGNC Symbol;Acc:HGNC:24246] 0.36 0.00
637 ENSG00000182621 PLCB1 phospholipase C beta 1 [Source:HGNC Symbol;Acc:HGNC:15917] 0.36 0.00
638 ENSG00000196683 TOMM7 translocase of outer mitochondrial membrane 7 homolog (yeast) [Source:HGNC Sym-
bol;Acc:HGNC:21648]
0.36 0.00
639 ENSG00000197608 ZNF841 zinc ﬁnger protein 841 [Source:HGNC Symbol;Acc:HGNC:27611] 0.36 0.00
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640 ENSG00000154122 ANKH ANKH inorganic pyrophosphate transport regulator [Source:HGNC Sym-
bol;Acc:HGNC:15492]
0.36 0.00
641 ENSG00000144677 CTDSPL CTD small phosphatase like [Source:HGNC Symbol;Acc:HGNC:16890] 0.36 0.00
642 ENSG00000120686 UFM1 ubiquitin-fold modiﬁer 1 [Source:HGNC Symbol;Acc:HGNC:20597] 0.37 0.00
643 ENSG00000253276 CCDC71L coiled-coil domain containing 71-like [Source:HGNC Symbol;Acc:HGNC:26685] 0.37 0.00
644 ENSG00000151136 BTBD11 BTB (POZ) domain containing 11 [Source:HGNC Symbol;Acc:HGNC:23844] 0.37 0.00
645 ENSG00000100353 EIF3D eukaryotic translation initiation factor 3 subunit D [Source:HGNC Sym-
bol;Acc:HGNC:3278]
0.37 0.00
646 ENSG00000121005 CRISPLD1 cysteine-rich secretory protein LCCL domain containing 1 [Source:HGNC Sym-
bol;Acc:HGNC:18206]
0.37 0.00
647 ENSG00000101004 NINL ninein like [Source:HGNC Symbol;Acc:HGNC:29163] 0.37 0.00
648 ENSG00000198408 MGEA5 meningioma expressed antigen 5 (hyaluronidase) [Source:HGNC Sym-
bol;Acc:HGNC:7056]
0.38 0.00
649 ENSG00000143333 RGS16 regulator of G-protein signaling 16 [Source:HGNC Symbol;Acc:HGNC:9997] 0.38 0.00
650 ENSG00000154040 CABYR calcium binding tyrosine-(Y)-phosphorylation regulated [Source:HGNC Sym-
bol;Acc:HGNC:15569]
0.38 0.00
651 ENSG00000182704 TSKU tsukushi, small leucine rich proteoglycan [Source:HGNC Symbol;Acc:HGNC:28850] 0.38 0.00
652 ENSG00000071205 ARHGAP10 Rho GTPase activating protein 10 [Source:HGNC Symbol;Acc:HGNC:26099] 0.38 0.00
653 ENSG00000172456 FGGY FGGY carbohydrate kinase domain containing [Source:HGNC Sym-
bol;Acc:HGNC:25610]
0.38 0.00
654 ENSG00000151388 ADAMTS12 ADAM metallopeptidase with thrombospondin type 1 motif 12 [Source:HGNC Sym-
bol;Acc:HGNC:14605]
0.39 0.00
655 ENSG00000007384 RHBDF1 rhomboid 5 homolog 1 (Drosophila) [Source:HGNC Symbol;Acc:HGNC:20561] 0.39 0.00
656 ENSG00000116678 LEPR leptin receptor [Source:HGNC Symbol;Acc:HGNC:6554] 0.39 0.00
657 ENSG00000198938 MT-CO3 mitochondrially encoded cytochrome c oxidase III [Source:HGNC Sym-
bol;Acc:HGNC:7422]
0.39 0.00
658 ENSG00000163520 FBLN2 ﬁbulin 2 [Source:HGNC Symbol;Acc:HGNC:3601] 0.39 0.00
659 ENSG00000185340 GAS2L1 growth arrest speciﬁc 2 like 1 [Source:HGNC Symbol;Acc:HGNC:16955] 0.39 0.00
660 ENSG00000169093 ASMTL acetylserotonin O-methyltransferase-like [Source:HGNC Symbol;Acc:HGNC:751] 0.39 0.00
661 ENSG00000136826 KLF4 Kruppel-like factor 4 (gut) [Source:HGNC Symbol;Acc:HGNC:6348] 0.39 0.00
662 ENSG00000186468 RPS23 ribosomal protein S23 [Source:HGNC Symbol;Acc:HGNC:10410] 0.39 0.00
663 ENSG00000135333 EPHA7 EPH receptor A7 [Source:HGNC Symbol;Acc:HGNC:3390] 0.40 0.00
664 ENSG00000105193 RPS16 ribosomal protein S16 [Source:HGNC Symbol;Acc:HGNC:10396] 0.40 0.00
665 ENSG00000137193 PIM1 Pim-1 proto-oncogene, serine/threonine kinase [Source:HGNC Sym-
bol;Acc:HGNC:8986]
0.40 0.00
666 ENSG00000137955 RABGGTB Rab geranylgeranyltransferase, beta subunit [Source:HGNC Sym-
bol;Acc:HGNC:9796]
0.40 0.00
667 ENSG00000080546 SESN1 sestrin 1 [Source:HGNC Symbol;Acc:HGNC:21595] 0.40 0.00
668 ENSG00000136732 GYPC glycophorin C (Gerbich blood group) [Source:HGNC Symbol;Acc:HGNC:4704] 0.40 0.00
669 ENSG00000204387 C6orf48 chromosome 6 open reading frame 48 [Source:HGNC Symbol;Acc:HGNC:19078] 0.40 0.00
670 ENSG00000150593 PDCD4 programmed cell death 4 (neoplastic transformation inhibitor) [Source:HGNC Sym-
bol;Acc:HGNC:8763]
0.40 0.00
671 ENSG00000114948 ADAM23 ADAM metallopeptidase domain 23 [Source:HGNC Symbol;Acc:HGNC:202] 0.41 0.00
672 ENSG00000076685 NT5C2 5'-nucleotidase, cytosolic II [Source:HGNC Symbol;Acc:HGNC:8022] 0.41 0.00
673 ENSG00000107518 ATRNL1 attractin like 1 [Source:HGNC Symbol;Acc:HGNC:29063] 0.41 0.00
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674 ENSG00000146242 TPBG trophoblast glycoprotein [Source:HGNC Symbol;Acc:HGNC:12004] 0.41 0.00
675 ENSG00000196352 CD55 CD55 molecule, decay accelerating factor for complement (Cromer blood group)
[Source:HGNC Symbol;Acc:HGNC:2665]
0.41 0.00
676 ENSG00000175215 CTDSP2 CTD small phosphatase 2 [Source:HGNC Symbol;Acc:HGNC:17077] 0.41 0.00
677 ENSG00000006194 ZNF263 zinc ﬁnger protein 263 [Source:HGNC Symbol;Acc:HGNC:13056] 0.41 0.00
678 ENSG00000100916 BRMS1L breast cancer metastasis-suppressor 1-like [Source:HGNC Symbol;Acc:HGNC:20512] 0.41 0.00
679 ENSG00000134324 LPIN1 lipin 1 [Source:HGNC Symbol;Acc:HGNC:13345] 0.41 0.00
680 ENSG00000166025 AMOTL1 angiomotin like 1 [Source:HGNC Symbol;Acc:HGNC:17811] 0.41 0.00
681 ENSG00000077044 DGKD diacylglycerol kinase delta [Source:HGNC Symbol;Acc:HGNC:2851] 0.42 0.00
682 ENSG00000158710 TAGLN2 transgelin 2 [Source:HGNC Symbol;Acc:HGNC:11554] 0.42 0.00
683 ENSG00000172197 MBOAT1 membrane bound O-acyltransferase domain containing 1 [Source:HGNC Sym-
bol;Acc:HGNC:21579]
0.42 0.00
684 ENSG00000112559 MDFI MyoD family inhibitor [Source:HGNC Symbol;Acc:HGNC:6967] 0.42 0.00
685 ENSG00000136010 ALDH1L2 aldehyde dehydrogenase 1 family member L2 [Source:HGNC Sym-
bol;Acc:HGNC:26777]
0.42 0.00
686 ENSG00000128335 APOL2 apolipoprotein L2 [Source:HGNC Symbol;Acc:HGNC:619] 0.42 0.00
687 ENSG00000176204 LRRTM4 leucine rich repeat transmembrane neuronal 4 [Source:HGNC Sym-
bol;Acc:HGNC:19411]
0.43 0.00
688 ENSG00000122863 CHST3 carbohydrate (chondroitin 6) sulfotransferase 3 [Source:HGNC Sym-
bol;Acc:HGNC:1971]
0.43 0.00
689 ENSG00000134574 DDB2 damage-speciﬁc DNA binding protein 2 [Source:HGNC Symbol;Acc:HGNC:2718] 0.43 0.00
690 ENSG00000146409 SLC18B1 solute carrier family 18, subfamily B, member 1 [Source:HGNC Sym-
bol;Acc:HGNC:21573]
0.43 0.00
691 ENSG00000148426 PROSER2 proline and serine rich 2 [Source:HGNC Symbol;Acc:HGNC:23728] 0.43 0.00
692 ENSG00000167981 ZNF597 zinc ﬁnger protein 597 [Source:HGNC Symbol;Acc:HGNC:26573] 0.43 0.00
693 ENSG00000170899 GSTA4 glutathione S-transferase alpha 4 [Source:HGNC Symbol;Acc:HGNC:4629] 0.43 0.00
694 ENSG00000164932 CTHRC1 collagen triple helix repeat containing 1 [Source:HGNC Symbol;Acc:HGNC:18831] 0.44 0.00
695 ENSG00000156140 ADAMTS3 ADAM metallopeptidase with thrombospondin type 1 motif 3 [Source:HGNC Sym-
bol;Acc:HGNC:219]
0.44 0.00
696 ENSG00000048052 HDAC9 histone deacetylase 9 [Source:HGNC Symbol;Acc:HGNC:14065] 0.44 0.00
697 ENSG00000130066 SAT1 spermidine/spermine N1-acetyltransferase 1 [Source:HGNC Sym-
bol;Acc:HGNC:10540]
0.44 0.00
698 ENSG00000120833 SOCS2 suppressor of cytokine signaling 2 [Source:HGNC Symbol;Acc:HGNC:19382] 0.44 0.00
699 ENSG00000197324 LRP10 LDL receptor related protein 10 [Source:HGNC Symbol;Acc:HGNC:14553] 0.44 0.00
700 ENSG00000111057 KRT18 keratin 18, type I [Source:HGNC Symbol;Acc:HGNC:6430] 0.44 0.00
701 ENSG00000185088 RPS27L ribosomal protein S27 like [Source:HGNC Symbol;Acc:HGNC:18476] 0.44 0.00
702 ENSG00000156869 FRRS1 ferric-chelate reductase 1 [Source:HGNC Symbol;Acc:HGNC:27622] 0.45 0.00
703 ENSG00000067177 PHKA1 phosphorylase kinase, alpha 1 (muscle) [Source:HGNC Symbol;Acc:HGNC:8925] 0.45 0.00
704 ENSG00000105327 BBC3 BCL2 binding component 3 [Source:HGNC Symbol;Acc:HGNC:17868] 0.45 0.00
705 ENSG00000183696 UPP1 uridine phosphorylase 1 [Source:HGNC Symbol;Acc:HGNC:12576] 0.45 0.00
706 ENSG00000127955 GNAI1 guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide
1 [Source:HGNC Symbol;Acc:HGNC:4384]
0.45 0.00
707 ENSG00000080573 COL5A3 collagen, type V, alpha 3 [Source:HGNC Symbol;Acc:HGNC:14864] 0.45 0.00
708 ENSG00000089472 HEPH hephaestin [Source:HGNC Symbol;Acc:HGNC:4866] 0.45 0.00
709 ENSG00000257315 ZBED6 zinc ﬁnger, BED-type containing 6 [Source:HGNC Symbol;Acc:HGNC:33273] 0.45 0.00
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710 ENSG00000136098 NEK3 NIMA-related kinase 3 [Source:HGNC Symbol;Acc:HGNC:7746] 0.46 0.00
711 ENSG00000072422 RHOBTB1 Rho-related BTB domain containing 1 [Source:HGNC Symbol;Acc:HGNC:18738] 0.46 0.00
712 ENSG00000136156 ITM2B integral membrane protein 2B [Source:HGNC Symbol;Acc:HGNC:6174] 0.46 0.00
713 ENSG00000170421 KRT8 keratin 8, type II [Source:HGNC Symbol;Acc:HGNC:6446] 0.47 0.00
714 ENSG00000115414 FN1 ﬁbronectin 1 [Source:HGNC Symbol;Acc:HGNC:3778] 0.47 0.00
715 ENSG00000177311 ZBTB38 zinc ﬁnger and BTB domain containing 38 [Source:HGNC Symbol;Acc:HGNC:26636] 0.47 0.00
716 ENSG00000164687 FABP5 fatty acid binding protein 5 (psoriasis-associated) [Source:HGNC Sym-
bol;Acc:HGNC:3560]
0.47 0.00
717 ENSG00000197702 PARVA parvin alpha [Source:HGNC Symbol;Acc:HGNC:14652] 0.47 0.00
718 ENSG00000145536 ADAMTS16 ADAM metallopeptidase with thrombospondin type 1 motif 16 [Source:HGNC Sym-
bol;Acc:HGNC:17108]
0.47 0.00
719 ENSG00000179046 TRIML2 tripartite motif family like 2 [Source:HGNC Symbol;Acc:HGNC:26378] 0.47 0.00
720 ENSG00000115112 TFCP2L1 transcription factor CP2-like 1 [Source:HGNC Symbol;Acc:HGNC:17925] 0.48 0.00
721 ENSG00000101850 GPR143 G protein-coupled receptor 143 [Source:HGNC Symbol;Acc:HGNC:20145] 0.48 0.00
722 ENSG00000160145 KALRN kalirin, RhoGEF kinase [Source:HGNC Symbol;Acc:HGNC:4814] 0.48 0.00
723 ENSG00000082397 EPB41L3 erythrocyte membrane protein band 4.1-like 3 [Source:HGNC Sym-
bol;Acc:HGNC:3380]
0.48 0.00
724 ENSG00000166250 CLMP CXADR-like membrane protein [Source:HGNC Symbol;Acc:HGNC:24039] 0.48 0.00
725 ENSG00000069869 NEDD4 neural precursor cell expressed, developmentally down-regulated 4, E3 ubiquitin pro-
tein ligase [Source:HGNC Symbol;Acc:HGNC:7727]
0.48 0.00
726 ENSG00000242125 SNHG3 small nucleolar RNA host gene 3 [Source:HGNC Symbol;Acc:HGNC:10118] 0.48 0.00
727 ENSG00000154783 FGD5 FYVE, RhoGEF and PH domain containing 5 [Source:HGNC Sym-
bol;Acc:HGNC:19117]
0.49 0.00
728 ENSG00000133121 STARD13 StAR related lipid transfer domain containing 13 [Source:HGNC Sym-
bol;Acc:HGNC:19164]
0.49 0.00
729 ENSG00000112984 KIF20A kinesin family member 20A [Source:HGNC Symbol;Acc:HGNC:9787] 0.49 0.00
730 ENSG00000116741 RGS2 regulator of G-protein signaling 2 [Source:HGNC Symbol;Acc:HGNC:9998] 0.49 0.00
731 ENSG00000027075 PRKCH protein kinase C, eta [Source:HGNC Symbol;Acc:HGNC:9403] 0.49 0.00
732 ENSG00000137672 TRPC6 transient receptor potential cation channel, subfamily C, member 6 [Source:HGNC
Symbol;Acc:HGNC:12338]
0.49 0.00
733 ENSG00000163359 COL6A3 collagen, type VI, alpha 3 [Source:HGNC Symbol;Acc:HGNC:2213] 0.49 0.00
734 ENSG00000173559 NABP1 nucleic acid binding protein 1 [Source:HGNC Symbol;Acc:HGNC:26232] 0.49 0.00
735 ENSG00000169570 DTWD2 DTW domain containing 2 [Source:HGNC Symbol;Acc:HGNC:19334] 0.49 0.00
736 ENSG00000123131 PRDX4 peroxiredoxin 4 [Source:HGNC Symbol;Acc:HGNC:17169] 0.49 0.00
737 ENSG00000228526 MIR34AHG MIR34A host gene [Source:HGNC Symbol;Acc:HGNC:51913] 0.49 0.00
738 ENSG00000026508 CD44 CD44 molecule (Indian blood group) [Source:HGNC Symbol;Acc:HGNC:1681] 0.50 0.00
739 ENSG00000139117 CPNE8 copine VIII [Source:HGNC Symbol;Acc:HGNC:23498] 0.50 0.00
740 ENSG00000184384 MAML2 mastermind like transcriptional coactivator 2 [Source:HGNC Sym-
bol;Acc:HGNC:16259]
0.50 0.00
741 ENSG00000101665 SMAD7 SMAD family member 7 [Source:HGNC Symbol;Acc:HGNC:6773] 0.51 0.00
742 ENSG00000173482 PTPRM protein tyrosine phosphatase, receptor type, M [Source:HGNC Sym-
bol;Acc:HGNC:9675]
0.51 0.00
743 ENSG00000128283 CDC42EP1 CDC42 eﬀector protein (Rho GTPase binding) 1 [Source:HGNC Sym-
bol;Acc:HGNC:17014]
0.51 0.00
744 ENSG00000115350 POLE4 polymerase (DNA-directed), epsilon 4, accessory subunit [Source:HGNC Sym-
bol;Acc:HGNC:18755]
0.51 0.00
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745 ENSG00000145681 HAPLN1 hyaluronan and proteoglycan link protein 1 [Source:HGNC Symbol;Acc:HGNC:2380] 0.51 0.00
746 ENSG00000107104 KANK1 KN motif and ankyrin repeat domains 1 [Source:HGNC Symbol;Acc:HGNC:19309] 0.51 0.00
747 ENSG00000161513 FDXR ferredoxin reductase [Source:HGNC Symbol;Acc:HGNC:3642] 0.52 0.00
748 ENSG00000127241 MASP1 mannan-binding lectin serine peptidase 1 (C4/C2 activating component of Ra-
reactive factor) [Source:HGNC Symbol;Acc:HGNC:6901]
0.52 0.00
749 ENSG00000151892 GFRA1 GDNF family receptor alpha 1 [Source:HGNC Symbol;Acc:HGNC:4243] 0.52 0.00
750 ENSG00000112343 TRIM38 tripartite motif containing 38 [Source:HGNC Symbol;Acc:HGNC:10059] 0.52 0.00
751 ENSG00000113448 PDE4D phosphodiesterase 4D [Source:HGNC Symbol;Acc:HGNC:8783] 0.52 0.00
752 ENSG00000134802 SLC43A3 solute carrier family 43 member 3 [Source:HGNC Symbol;Acc:HGNC:17466] 0.52 0.00
753 ENSG00000120549 KIAA1217 KIAA1217 [Source:HGNC Symbol;Acc:HGNC:25428] 0.52 0.00
754 ENSG00000112186 CAP2 CAP, adenylate cyclase-associated protein, 2 (yeast) [Source:HGNC Sym-
bol;Acc:HGNC:20039]
0.52 0.00
755 ENSG00000115380 EFEMP1 EGF containing ﬁbulin-like extracellular matrix protein 1 [Source:HGNC Sym-
bol;Acc:HGNC:3218]
0.52 0.00
756 ENSG00000171055 FEZ2 fasciculation and elongation protein zeta 2 (zygin II) [Source:HGNC Sym-
bol;Acc:HGNC:3660]
0.52 0.00
757 ENSG00000139926 FRMD6 FERM domain containing 6 [Source:HGNC Symbol;Acc:HGNC:19839] 0.53 0.00
758 ENSG00000010539 ZNF200 zinc ﬁnger protein 200 [Source:HGNC Symbol;Acc:HGNC:12993] 0.53 0.00
759 ENSG00000050767 COL23A1 collagen, type XXIII, alpha 1 [Source:HGNC Symbol;Acc:HGNC:22990] 0.53 0.00
760 ENSG00000136960 ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase 2 [Source:HGNC Sym-
bol;Acc:HGNC:3357]
0.53 0.00
761 ENSG00000122507 BBS9 Bardet-Biedl syndrome 9 [Source:HGNC Symbol;Acc:HGNC:30000] 0.53 0.00
762 ENSG00000132274 TRIM22 tripartite motif containing 22 [Source:HGNC Symbol;Acc:HGNC:16379] 0.53 0.00
763 ENSG00000115828 QPCT glutaminyl-peptide cyclotransferase [Source:HGNC Symbol;Acc:HGNC:9753] 0.53 0.00
764 ENSG00000103740 ACSBG1 acyl-CoA synthetase bubblegum family member 1 [Source:HGNC Sym-
bol;Acc:HGNC:29567]
0.54 0.00
765 ENSG00000175832 ETV4 ets variant 4 [Source:HGNC Symbol;Acc:HGNC:3493] 0.54 0.00
766 ENSG00000060140 STYK1 serine/threonine/tyrosine kinase 1 [Source:HGNC Symbol;Acc:HGNC:18889] 0.54 0.00
767 ENSG00000150394 CDH8 cadherin 8, type 2 [Source:HGNC Symbol;Acc:HGNC:1767] 0.54 0.00
768 ENSG00000169116 PARM1 prostate androgen-regulated mucin-like protein 1 [Source:HGNC Sym-
bol;Acc:HGNC:24536]
0.54 0.00
769 ENSG00000189184 PCDH18 protocadherin 18 [Source:HGNC Symbol;Acc:HGNC:14268] 0.54 0.00
770 ENSG00000152377 SPOCK1 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1
[Source:HGNC Symbol;Acc:HGNC:11251]
0.54 0.00
771 ENSG00000135917 SLC19A3 solute carrier family 19 (thiamine transporter), member 3 [Source:HGNC Sym-
bol;Acc:HGNC:16266]
0.55 0.00
772 ENSG00000179542 SLITRK4 SLIT and NTRK like family member 4 [Source:HGNC Symbol;Acc:HGNC:23502] 0.55 0.00
773 ENSG00000075651 PLD1 phospholipase D1 [Source:HGNC Symbol;Acc:HGNC:9067] 0.55 0.00
774 ENSG00000154734 ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif 1 [Source:HGNC Sym-
bol;Acc:HGNC:217]
0.55 0.00
775 ENSG00000082781 ITGB5 integrin subunit beta 5 [Source:HGNC Symbol;Acc:HGNC:6160] 0.55 0.00
776 ENSG00000173267 SNCG synuclein gamma [Source:HGNC Symbol;Acc:HGNC:11141] 0.55 0.00
777 ENSG00000053747 LAMA3 laminin subunit alpha 3 [Source:HGNC Symbol;Acc:HGNC:6483] 0.56 0.00
778 ENSG00000104611 SH2D4A SH2 domain containing 4A [Source:HGNC Symbol;Acc:HGNC:26102] 0.56 0.00
779 ENSG00000104419 NDRG1 N-myc downstream regulated 1 [Source:HGNC Symbol;Acc:HGNC:7679] 0.56 0.00
200
780 ENSG00000007237 GAS7 growth arrest speciﬁc 7 [Source:HGNC Symbol;Acc:HGNC:4169] 0.56 0.00
781 ENSG00000115290 GRB14 growth factor receptor bound protein 14 [Source:HGNC Symbol;Acc:HGNC:4565] 0.56 0.00
782 ENSG00000101938 CHRDL1 chordin-like 1 [Source:HGNC Symbol;Acc:HGNC:29861] 0.56 0.00
783 ENSG00000100031 GGT1 gamma-glutamyltransferase 1 [Source:HGNC Symbol;Acc:HGNC:4250] 0.56 0.00
784 ENSG00000100031 GGT1 gamma-glutamyltransferase 1 [Source:HGNC Symbol;Acc:HGNC:4250] 0.56 0.00
785 ENSG00000100031 GGT1 gamma-glutamyltransferase 1 [Source:HGNC Symbol;Acc:HGNC:4250] 0.56 0.00
786 ENSG00000100031 GGT1 gamma-glutamyltransferase 1 [Source:HGNC Symbol;Acc:HGNC:4250] 0.56 0.00
787 ENSG00000100031 GGT1 gamma-glutamyltransferase 1 [Source:HGNC Symbol;Acc:HGNC:4250] 0.56 0.00
788 ENSG00000164292 RHOBTB3 Rho-related BTB domain containing 3 [Source:HGNC Symbol;Acc:HGNC:18757] 0.57 0.00
789 ENSG00000112414 ADGRG6 adhesion G protein-coupled receptor G6 [Source:HGNC Symbol;Acc:HGNC:13841] 0.57 0.00
790 ENSG00000145431 PDGFC platelet derived growth factor C [Source:HGNC Symbol;Acc:HGNC:8801] 0.58 0.00
791 ENSG00000158125 XDH xanthine dehydrogenase [Source:HGNC Symbol;Acc:HGNC:12805] 0.58 0.00
792 ENSG00000164070 HSPA4L heat shock protein family A (Hsp70) member 4 like [Source:HGNC Sym-
bol;Acc:HGNC:17041]
0.58 0.00
793 ENSG00000158828 PINK1 PTEN induced putative kinase 1 [Source:HGNC Symbol;Acc:HGNC:14581] 0.59 0.00
794 ENSG00000172380 GNG12 guanine nucleotide binding protein (G protein), gamma 12 [Source:HGNC Sym-
bol;Acc:HGNC:19663]
0.59 0.00
795 ENSG00000187676 B3GLCT beta 3-glucosyltransferase [Source:HGNC Symbol;Acc:HGNC:20207] 0.59 0.00
796 ENSG00000158089 GALNT14 polypeptide N-acetylgalactosaminyltransferase 14 [Source:HGNC Sym-
bol;Acc:HGNC:22946]
0.59 0.00
797 ENSG00000047617 ANO2 anoctamin 2, calcium activated chloride channel [Source:HGNC Sym-
bol;Acc:HGNC:1183]
0.59 0.00
798 ENSG00000117069 ST6GALNAC5 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide
alpha-2,6-sialyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:19342]
0.59 0.00
799 ENSG00000103196 CRISPLD2 cysteine-rich secretory protein LCCL domain containing 2 [Source:HGNC Sym-
bol;Acc:HGNC:25248]
0.59 0.00
800 ENSG00000120708 TGFBI transforming growth factor beta induced [Source:HGNC Symbol;Acc:HGNC:11771] 0.59 0.00
801 ENSG00000140092 FBLN5 ﬁbulin 5 [Source:HGNC Symbol;Acc:HGNC:3602] 0.60 0.00
802 ENSG00000130830 MPP1 membrane protein, palmitoylated 1 [Source:HGNC Symbol;Acc:HGNC:7219] 0.60 0.00
803 ENSG00000104324 CPQ carboxypeptidase Q [Source:HGNC Symbol;Acc:HGNC:16910] 0.60 0.00
804 ENSG00000178538 CA8 carbonic anhydrase VIII [Source:HGNC Symbol;Acc:HGNC:1382] 0.60 0.00
805 ENSG00000172986 GXYLT2 glucoside xylosyltransferase 2 [Source:HGNC Symbol;Acc:HGNC:33383] 0.60 0.00
806 ENSG00000147465 STAR steroidogenic acute regulatory protein [Source:HGNC Symbol;Acc:HGNC:11359] 0.61 0.00
807 ENSG00000131080 EDA2R ectodysplasin A2 receptor [Source:HGNC Symbol;Acc:HGNC:17756] 0.61 0.00
808 ENSG00000150722 PPP1R1C protein phosphatase 1 regulatory inhibitor subunit 1C [Source:HGNC Sym-
bol;Acc:HGNC:14940]
0.61 0.00
809 ENSG00000074527 NTN4 netrin 4 [Source:HGNC Symbol;Acc:HGNC:13658] 0.61 0.00
810 ENSG00000163219 ARHGAP25 Rho GTPase activating protein 25 [Source:HGNC Symbol;Acc:HGNC:28951] 0.61 0.00
811 ENSG00000187475 HIST1H1T histone cluster 1, H1t [Source:HGNC Symbol;Acc:HGNC:4720] 0.62 0.00
812 ENSG00000134762 DSC3 desmocollin 3 [Source:HGNC Symbol;Acc:HGNC:3037] 0.62 0.00
813 ENSG00000118523 CTGF connective tissue growth factor [Source:HGNC Symbol;Acc:HGNC:2500] 0.62 0.00
814 ENSG00000188984 AADACL3 arylacetamide deacetylase-like 3 [Source:HGNC Symbol;Acc:HGNC:32037] 0.62 0.00
815 ENSG00000109452 INPP4B inositol polyphosphate-4-phosphatase type II B [Source:HGNC Sym-
bol;Acc:HGNC:6075]
0.62 0.00
816 ENSG00000124762 CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) [Source:HGNC Sym-
bol;Acc:HGNC:1784]
0.63 0.00
201
817 ENSG00000138821 SLC39A8 solute carrier family 39 (zinc transporter), member 8 [Source:HGNC Sym-
bol;Acc:HGNC:20862]
0.63 0.00
818 ENSG00000134954 ETS1 v-ets avian erythroblastosis virus E26 oncogene homolog 1 [Source:HGNC Sym-
bol;Acc:HGNC:3488]
0.63 0.00
819 ENSG00000188517 COL25A1 collagen, type XXV, alpha 1 [Source:HGNC Symbol;Acc:HGNC:18603] 0.63 0.00
820 ENSG00000165591 FAAH2 fatty acid amide hydrolase 2 [Source:HGNC Symbol;Acc:HGNC:26440] 0.64 0.00
821 ENSG00000102547 CAB39L calcium binding protein 39 like [Source:HGNC Symbol;Acc:HGNC:20290] 0.64 0.00
822 ENSG00000166736 HTR3A 5-hydroxytryptamine (serotonin) receptor 3A, ionotropic [Source:HGNC Sym-
bol;Acc:HGNC:5297]
0.65 0.00
823 ENSG00000091428 RAPGEF4 Rap guanine nucleotide exchange factor 4 [Source:HGNC Symbol;Acc:HGNC:16626] 0.65 0.00
824 ENSG00000164237 CMBL carboxymethylenebutenolidase homolog (Pseudomonas) [Source:HGNC Sym-
bol;Acc:HGNC:25090]
0.66 0.00
825 ENSG00000151617 EDNRA endothelin receptor type A [Source:HGNC Symbol;Acc:HGNC:3179] 0.66 0.00
826 ENSG00000177398 UMODL1 uromodulin like 1 [Source:HGNC Symbol;Acc:HGNC:12560] 0.67 0.00
827 ENSG00000258545 RHOXF1-AS1 RHOXF1 antisense RNA 1 [Source:HGNC Symbol;Acc:HGNC:51582] 0.67 0.00
828 ENSG00000163071 SPATA18 spermatogenesis associated 18 [Source:HGNC Symbol;Acc:HGNC:29579] 0.67 0.00
829 ENSG00000183508 FAM46C family with sequence similarity 46 member C [Source:HGNC Sym-
bol;Acc:HGNC:24712]
0.68 0.00
830 ENSG00000134042 MRO maestro [Source:HGNC Symbol;Acc:HGNC:24121] 0.68 0.00
831 ENSG00000164136 IL15 interleukin 15 [Source:HGNC Symbol;Acc:HGNC:5977] 0.69 0.00
832 ENSG00000127084 FGD3 FYVE, RhoGEF and PH domain containing 3 [Source:HGNC Sym-
bol;Acc:HGNC:16027]
0.69 0.00
833 ENSG00000150540 HNMT histamine N-methyltransferase [Source:HGNC Symbol;Acc:HGNC:5028] 0.69 0.00
834 ENSG00000175445 LPL lipoprotein lipase [Source:HGNC Symbol;Acc:HGNC:6677] 0.69 0.00
835 ENSG00000135298 ADGRB3 adhesion G protein-coupled receptor B3 [Source:HGNC Symbol;Acc:HGNC:945] 0.69 0.00
836 ENSG00000153071 DAB2 Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila) [Source:HGNC
Symbol;Acc:HGNC:2662]
0.70 0.00
837 ENSG00000183230 CTNNA3 catenin alpha 3 [Source:HGNC Symbol;Acc:HGNC:2511] 0.70 0.00
838 ENSG00000049130 KITLG KIT ligand [Source:HGNC Symbol;Acc:HGNC:6343] 0.71 0.00
839 ENSG00000164946 FREM1 FRAS1 related extracellular matrix 1 [Source:HGNC Symbol;Acc:HGNC:23399] 0.71 0.00
840 ENSG00000205730 ITPRIPL2 inositol 1,4,5-trisphosphate receptor interacting protein-like 2 [Source:HGNC Sym-
bol;Acc:HGNC:27257]
0.71 0.00
841 ENSG00000146592 CREB5 cAMP responsive element binding protein 5 [Source:HGNC Sym-
bol;Acc:HGNC:16844]
0.71 0.00
842 ENSG00000049192 ADAMTS6 ADAM metallopeptidase with thrombospondin type 1 motif 6 [Source:HGNC Sym-
bol;Acc:HGNC:222]
0.71 0.00
843 ENSG00000110799 VWF von Willebrand factor [Source:HGNC Symbol;Acc:HGNC:12726] 0.72 0.00
844 ENSG00000168772 CXXC4 CXXC ﬁnger protein 4 [Source:HGNC Symbol;Acc:HGNC:24593] 0.72 0.00
845 ENSG00000118785 SPP1 secreted phosphoprotein 1 [Source:HGNC Symbol;Acc:HGNC:11255] 0.72 0.00
846 ENSG00000198756 COLGALT2 collagen beta(1-O)galactosyltransferase 2 [Source:HGNC Symbol;Acc:HGNC:16790] 0.72 0.00
847 ENSG00000174564 IL20RB interleukin 20 receptor subunit beta [Source:HGNC Symbol;Acc:HGNC:6004] 0.72 0.00
848 ENSG00000182645 CCDC172 coiled-coil domain containing 172 [Source:HGNC Symbol;Acc:HGNC:30524] 0.73 0.00
849 ENSG00000143318 CASQ1 calsequestrin 1 [Source:HGNC Symbol;Acc:HGNC:1512] 0.74 0.00
850 ENSG00000138772 ANXA3 annexin A3 [Source:HGNC Symbol;Acc:HGNC:541] 0.74 0.00
851 ENSG00000069535 MAOB monoamine oxidase B [Source:HGNC Symbol;Acc:HGNC:6834] 0.75 0.00
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852 ENSG00000133135 RNF128 ring ﬁnger protein 128, E3 ubiquitin protein ligase [Source:HGNC Sym-
bol;Acc:HGNC:21153]
0.75 0.00
853 ENSG00000180801 ARSJ arylsulfatase family member J [Source:HGNC Symbol;Acc:HGNC:26286] 0.76 0.00
854 ENSG00000075213 SEMA3A sema domain, immunoglobulin domain (Ig), short basic domain, secreted,
(semaphorin) 3A [Source:HGNC Symbol;Acc:HGNC:10723]
0.76 0.00
855 ENSG00000182326 C1S complement component 1, s subcomponent [Source:HGNC Symbol;Acc:HGNC:1247] 0.77 0.00
856 ENSG00000155511 GRIA1 glutamate receptor, ionotropic, AMPA 1 [Source:HGNC Symbol;Acc:HGNC:4571] 0.78 0.00
857 ENSG00000115468 EFHD1 EF-hand domain family member D1 [Source:HGNC Symbol;Acc:HGNC:29556] 0.79 0.00
858 ENSG00000107954 NEURL1 neuralized E3 ubiquitin protein ligase 1 [Source:HGNC Symbol;Acc:HGNC:7761] 0.79 0.00
859 ENSG00000204262 COL5A2 collagen, type V, alpha 2 [Source:HGNC Symbol;Acc:HGNC:2210] 0.79 0.00
860 ENSG00000091986 CCDC80 coiled-coil domain containing 80 [Source:HGNC Symbol;Acc:HGNC:30649] 0.80 0.00
861 ENSG00000108375 RNF43 ring ﬁnger protein 43 [Source:HGNC Symbol;Acc:HGNC:18505] 0.80 0.00
862 ENSG00000123700 KCNJ2 potassium channel, inwardly rectifying subfamily J, member 2 [Source:HGNC Sym-
bol;Acc:HGNC:6263]
0.81 0.00
863 ENSG00000116711 PLA2G4A phospholipase A2 group IVA [Source:HGNC Symbol;Acc:HGNC:9035] 0.81 0.00
864 ENSG00000147174 ACRC acidic repeat containing [Source:HGNC Symbol;Acc:HGNC:15805] 0.82 0.00
865 ENSG00000176076 KCNE5 potassium channel, voltage gated subfamily E regulatory beta subunit 5
[Source:HGNC Symbol;Acc:HGNC:6241]
0.82 0.00
866 ENSG00000145632 PLK2 polo-like kinase 2 [Source:HGNC Symbol;Acc:HGNC:19699] 0.82 0.00
867 ENSG00000102287 GABRE gamma-aminobutyric acid (GABA) A receptor, epsilon [Source:HGNC Sym-
bol;Acc:HGNC:4085]
0.82 0.00
868 ENSG00000198838 RYR3 ryanodine receptor 3 [Source:HGNC Symbol;Acc:HGNC:10485] 0.82 0.00
869 ENSG00000118515 SGK1 serum/glucocorticoid regulated kinase 1 [Source:HGNC Symbol;Acc:HGNC:10810] 0.83 0.00
870 ENSG00000125414 MYH2 myosin, heavy chain 2, skeletal muscle, adult [Source:HGNC Sym-
bol;Acc:HGNC:7572]
0.83 0.00
871 ENSG00000173535 TNFRSF10C tumor necrosis factor receptor superfamily member 10c [Source:HGNC Sym-
bol;Acc:HGNC:11906]
0.83 0.00
872 ENSG00000104321 TRPA1 transient receptor potential cation channel, subfamily A, member 1 [Source:HGNC
Symbol;Acc:HGNC:497]
0.83 0.00
873 ENSG00000186451 SPATA12 spermatogenesis associated 12 [Source:HGNC Symbol;Acc:HGNC:23221] 0.83 0.00
874 ENSG00000173404 INSM1 insulinoma associated 1 [Source:HGNC Symbol;Acc:HGNC:6090] 0.84 0.00
875 ENSG00000163053 SLC16A14 solute carrier family 16 member 14 [Source:HGNC Symbol;Acc:HGNC:26417] 0.85 0.00
876 ENSG00000130513 GDF15 growth diﬀerentiation factor 15 [Source:HGNC Symbol;Acc:HGNC:30142] 0.86 0.00
877 ENSG00000145642 FAM159B family with sequence similarity 159 member B [Source:HGNC Sym-
bol;Acc:HGNC:34236]
0.86 0.00
878 ENSG00000236581 STARD13-AS STARD13 antisense RNA [Source:HGNC Symbol;Acc:HGNC:40873] 0.87 0.00
879 ENSG00000109255 NMU neuromedin U [Source:HGNC Symbol;Acc:HGNC:7859] 0.87 0.00
880 ENSG00000174343 CHRNA9 cholinergic receptor, nicotinic alpha 9 [Source:HGNC Symbol;Acc:HGNC:14079] 0.88 0.00
881 ENSG00000118733 OLFM3 olfactomedin 3 [Source:HGNC Symbol;Acc:HGNC:17990] 0.88 0.00
882 ENSG00000104327 CALB1 calbindin 1 [Source:HGNC Symbol;Acc:HGNC:1434] 0.89 0.00
883 ENSG00000115758 ODC1 ornithine decarboxylase 1 [Source:HGNC Symbol;Acc:HGNC:8109] 0.89 0.00
884 ENSG00000243064 ABCC13 ATP binding cassette subfamily C member 13, pseudogene [Source:HGNC Sym-
bol;Acc:HGNC:16022]
0.90 0.00
885 ENSG00000170961 HAS2 hyaluronan synthase 2 [Source:HGNC Symbol;Acc:HGNC:4819] 0.90 0.00
886 ENSG00000111452 ADGRD1 adhesion G protein-coupled receptor D1 [Source:HGNC Symbol;Acc:HGNC:19893] 0.91 0.00
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887 ENSG00000014257 ACPP acid phosphatase, prostate [Source:HGNC Symbol;Acc:HGNC:125] 0.92 0.00
888 ENSG00000162374 ELAVL4 ELAV like neuron-speciﬁc RNA binding protein 4 [Source:HGNC Sym-
bol;Acc:HGNC:3315]
0.93 0.00
889 ENSG00000101977 MCF2 MCF.2 cell line derived transforming sequence [Source:HGNC Sym-
bol;Acc:HGNC:6940]
0.95 0.00
890 ENSG00000130052 STARD8 StAR related lipid transfer domain containing 8 [Source:HGNC Sym-
bol;Acc:HGNC:19161]
0.97 0.00
891 ENSG00000129538 RNASE1 ribonuclease, RNase A family, 1 (pancreatic) [Source:HGNC Sym-
bol;Acc:HGNC:10044]
0.97 0.00
892 ENSG00000273036 FAM95C family with sequence similarity 95 member C [Source:HGNC Sym-
bol;Acc:HGNC:45272]
0.97 0.00
893 ENSG00000108691 CCL2 chemokine (C-C motif) ligand 2 [Source:HGNC Symbol;Acc:HGNC:10618] 0.98 0.00
894 ENSG00000138696 BMPR1B bone morphogenetic protein receptor type IB [Source:HGNC Sym-
bol;Acc:HGNC:1077]
0.98 0.00
895 ENSG00000187546 AGMO alkylglycerol monooxygenase [Source:HGNC Symbol;Acc:HGNC:33784] 0.99 0.00
896 ENSG00000137948 BRDT bromodomain, testis-speciﬁc [Source:HGNC Symbol;Acc:HGNC:1105] 1.02 0.00
897 ENSG00000168754 FAM178B family with sequence similarity 178 member B [Source:HGNC Sym-
bol;Acc:HGNC:28036]
1.03 0.00
898 ENSG00000157542 KCNJ6 potassium channel, inwardly rectifying subfamily J, member 6 [Source:HGNC Sym-
bol;Acc:HGNC:6267]
1.05 0.00
899 ENSG00000143119 CD53 CD53 molecule [Source:HGNC Symbol;Acc:HGNC:1686] 1.05 0.00
900 ENSG00000232224 LINC00202-1 long intergenic non-protein coding RNA 202-1 [Source:HGNC Sym-
bol;Acc:HGNC:24672]
1.06 0.00
901 ENSG00000076356 PLXNA2 plexin A2 [Source:HGNC Symbol;Acc:HGNC:9100] 1.07 0.00
902 ENSG00000138798 EGF epidermal growth factor [Source:HGNC Symbol;Acc:HGNC:3229] 1.08 0.00
903 ENSG00000166292 TMEM100 transmembrane protein 100 [Source:HGNC Symbol;Acc:HGNC:25607] 1.09 0.00
904 ENSG00000280639 RP11-96C21.2 1.09 0.00
905 ENSG00000269964 MEI4 meiotic double-stranded break formation protein 4 [Source:HGNC Sym-
bol;Acc:HGNC:43638]
1.10 0.00
906 ENSG00000100867 DHRS2 dehydrogenase/reductase (SDR family) member 2 [Source:HGNC Sym-
bol;Acc:HGNC:18349]
1.10 0.00
907 ENSG00000178031 ADAMTSL1 ADAMTS like 1 [Source:HGNC Symbol;Acc:HGNC:14632] 1.13 0.00
908 ENSG00000111348 ARHGDIB Rho GDP dissociation inhibitor (GDI) beta [Source:HGNC Symbol;Acc:HGNC:679] 1.13 0.00
909 ENSG00000162949 CAPN13 calpain 13 [Source:HGNC Symbol;Acc:HGNC:16663] 1.14 0.00
910 ENSG00000057657 PRDM1 PR domain containing 1, with ZNF domain [Source:HGNC Symbol;Acc:HGNC:9346] 1.15 0.00
911 ENSG00000243709 LEFTY1 left-right determination factor 1 [Source:HGNC Symbol;Acc:HGNC:6552] 1.16 0.00
912 ENSG00000165092 ALDH1A1 aldehyde dehydrogenase 1 family member A1 [Source:HGNC Symbol;Acc:HGNC:402] 1.17 0.00
913 ENSG00000150347 ARID5B AT-rich interaction domain 5B [Source:HGNC Symbol;Acc:HGNC:17362] 1.17 0.00
914 ENSG00000225383 SFTA1P surfactant associated 1, pseudogene [Source:HGNC Symbol;Acc:HGNC:18383] 1.19 0.01
915 ENSG00000143006 DMRTB1 DMRT like family B with proline rich C-terminal 1 [Source:HGNC Sym-
bol;Acc:HGNC:13913]
1.20 0.00
916 ENSG00000182261 NLRP10 NLR family, pyrin domain containing 10 [Source:HGNC Symbol;Acc:HGNC:21464] 1.20 0.00
917 ENSG00000228592 D21S2088E D21S2088E [Source:EntrezGene;Acc:266917] 1.22 0.01
918 ENSG00000168621 GDNF glial cell derived neurotrophic factor [Source:HGNC Symbol;Acc:HGNC:4232] 1.22 0.00
919 ENSG00000163565 IFI16 interferon, gamma-inducible protein 16 [Source:HGNC Symbol;Acc:HGNC:5395] 1.23 0.00
204
920 ENSG00000243978 RGAG1 retrotransposon gag domain containing 1 [Source:HGNC Symbol;Acc:HGNC:29245] 1.25 0.00
921 ENSG00000198774 RASSF9 Ras association (RalGDS/AF-6) domain family (N-terminal) member 9
[Source:HGNC Symbol;Acc:HGNC:15739]
1.31 0.00
922 ENSG00000138449 SLC40A1 solute carrier family 40 (iron-regulated transporter), member 1 [Source:HGNC Sym-
bol;Acc:HGNC:10909]
1.33 0.00
923 ENSG00000146047 HIST1H2BA histone cluster 1, H2ba [Source:HGNC Symbol;Acc:HGNC:18730] 1.35 0.00
924 ENSG00000110195 FOLR1 folate receptor 1 (adult) [Source:HGNC Symbol;Acc:HGNC:3791] 1.39 0.00
925 ENSG00000125931 CITED1 Cbp/p300-interacting transactivator, with Glu/Asp rich carboxy-terminal domain, 1
[Source:HGNC Symbol;Acc:HGNC:1986]
1.47 0.00
926 ENSG00000231918 AC007682.1 1.49 0.00
927 ENSG00000205221 VIT vitrin [Source:HGNC Symbol;Acc:HGNC:12697] 1.61 0.00
928 ENSG00000235268 KDM4E lysine (K)-speciﬁc demethylase 4E [Source:HGNC Symbol;Acc:HGNC:37098] 1.93 0.00
929 ENSG00000156466 GDF6 growth diﬀerentiation factor 6 [Source:HGNC Symbol;Acc:HGNC:4221] 2.05 0.00
930 ENSG00000121858 TNFSF10 tumor necrosis factor superfamily member 10 [Source:HGNC Sym-
bol;Acc:HGNC:11925]
2.09 0.00
931 ENSG00000164508 HIST1H2AA histone cluster 1, H2aa [Source:HGNC Symbol;Acc:HGNC:18729] 2.09 0.00
932 ENSG00000105967 TFEC transcription factor EC [Source:HGNC Symbol;Acc:HGNC:11754] 2.33 0.01
933 ENSG00000231944 PHKA1-AS1 PHKA1 antisense RNA 1 [Source:HGNC Symbol;Acc:HGNC:40446] 4.35 0.00
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A.1.2. Gene ontology enrichment
Table (A.2) GO Component
term id term description proteins hits p-value
1 GO:0005578 proteinaceous extracellular matrix 323 32 0.00000
2 GO:0031012 extracellular matrix 354 33 0.00000
3 GO:0044420 extracellular matrix component 116 16 0.00001
4 GO:0005588 collagen type V trimer 3 3 0.00006
5 GO:0005783 endoplasmic reticulum 1466 86 0.00012
6 GO:0005604 basement membrane 88 12 0.00017
7 GO:0043005 neuron projection 803 52 0.00031
8 GO:0005815 microtubule organizing center 557 39 0.00039
9 GO:0015630 microtubule cytoskeleton 938 58 0.00046
10 GO:0019867 outer membrane 174 17 0.00053
11 GO:0097458 neuron part 1026 62 0.00053
12 GO:0005741 mitochondrial outer membrane 146 15 0.00065
13 GO:0005813 centrosome 443 32 0.00075
14 GO:0044463 cell projection part 796 50 0.00079
15 GO:0036477 somatodendritic compartment 578 39 0.00079
16 GO:0043025 neuronal cell body 389 29 0.00080
17 GO:0031968 organelle outer membrane 168 16 0.00100
18 GO:0044297 cell body 436 31 0.00116
19 GO:0005788 endoplasmic reticulum lumen 189 17 0.00133
20 GO:0044429 mitochondrial part 826 50 0.00173
21 GO:0031233 intrinsic component of external side of
plasma membrane
23 5 0.00174
22 GO:0044432 endoplasmic reticulum part 1014 59 0.00175
Table (A.3) GO Biological Process
term id term description proteins hits p-value
1 GO:0022008 neurogenesis 1283 89 0.00000
2 GO:0048699 generation of neurons 1218 85 0.00000
3 GO:0030030 cell projection organization 910 69 0.00000
4 GO:0030198 extracellular matrix organization 341 36 0.00000
5 GO:0043062 extracellular structure organization 342 36 0.00000
6 GO:0044712 single-organism catabolic process 814 63 0.00000
7 GO:0048468 cell development 1470 96 0.00000
8 GO:0032989 cellular component morphogenesis 945 69 0.00000
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9 GO:0000902 cell morphogenesis 869 65 0.00000
10 GO:2000026 regulation of multicellular organis-
mal development
1400 90 0.00000
11 GO:0048858 cell projection morphogenesis 692 54 0.00000
12 GO:0031175 neuron projection development 617 49 0.00000
13 GO:0032990 cell part morphogenesis 711 54 0.00000
14 GO:0048646 anatomical structure formation in-
volved in morphogenesis
914 64 0.00000
15 GO:0030182 neuron diﬀerentiation 901 63 0.00000
16 GO:0048666 neuron development 744 54 0.00000
17 GO:0006928 movement of cell or subcellular com-
ponent
1211 77 0.00000
18 GO:0042325 regulation of phosphorylation 1162 74 0.00000
19 GO:0051094 positive regulation of developmental
process
1018 67 0.00000
20 GO:0022603 regulation of anatomical structure
morphogenesis
798 56 0.00000
21 GO:1902531 regulation of intracellular signal
transduction
1267 79 0.00000
22 GO:0010647 positive regulation of cell communi-
cation
1439 87 0.00000
23 GO:0001932 regulation of protein phosphoryla-
tion
1083 70 0.00000
24 GO:0019220 regulation of phosphate metabolic
process
1377 84 0.00000
25 GO:0040011 locomotion 1091 70 0.00001
26 GO:0051174 regulation of phosphorus metabolic
process
1390 84 0.00001
27 GO:0009719 response to endogenous stimulus 1285 79 0.00001
28 GO:0044283 small molecule biosynthetic process 366 32 0.00001
29 GO:0048812 neuron projection morphogenesis 510 40 0.00001
30 GO:0051240 positive regulation of multicellular
organismal process
1232 76 0.00001
31 GO:0000904 cell morphogenesis involved in diﬀer-
entiation
615 45 0.00001
32 GO:0035295 tube development 544 41 0.00001
33 GO:1901565 organonitrogen compound catabolic
process
298 27 0.00002
34 GO:0045597 positive regulation of cell diﬀerentia-
tion
746 51 0.00002
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35 GO:0010243 response to organonitrogen com-
pound
728 50 0.00002
36 GO:0031399 regulation of protein modiﬁcation
process
1448 84 0.00003
37 GO:0023056 positive regulation of signaling 1320 78 0.00003
38 GO:0019752 carboxylic acid metabolic process 736 50 0.00003
39 GO:0000003 reproduction 862 56 0.00003
40 GO:0006082 organic acid metabolic process 864 56 0.00003
41 GO:0016053 organic acid biosynthetic process 243 23 0.00004
42 GO:0046394 carboxylic acid biosynthetic process 243 23 0.00004
43 GO:0033554 cellular response to stress 1487 85 0.00004
44 GO:0043436 oxoacid metabolic process 848 55 0.00004
45 GO:0034405 response to ﬂuid shear stress 36 8 0.00004
46 GO:0044703 multi-organism reproductive process 830 54 0.00004
47 GO:0071498 cellular response to ﬂuid shear stress 19 6 0.00005
48 GO:0051241 negative regulation of multicellular
organismal process
895 57 0.00005
49 GO:0043085 positive regulation of catalytic activ-
ity
1302 76 0.00005
50 GO:0032504 multicellular organism reproduction 719 48 0.00006
51 GO:0044711 single-organism biosynthetic process 1206 71 0.00007
52 GO:1901575 organic substance catabolic process 1385 79 0.00008
53 GO:1901700 response to oxygen-containing com-
pound
1214 71 0.00009
54 GO:0009967 positive regulation of signal trans-
duction
1194 70 0.00009
55 GO:0071495 cellular response to endogenous
stimulus
938 58 0.00009
56 GO:0070555 response to interleukin-1 75 11 0.00009
57 GO:0010212 response to ionizing radiation 130 15 0.00009
58 GO:0061564 axon development 477 35 0.00010
59 GO:0007409 axonogenesis 459 34 0.00011
60 GO:0071417 cellular response to organonitrogen
compound
459 34 0.00011
61 GO:0048667 cell morphogenesis involved in neu-
ron diﬀerentiation
498 36 0.00011
62 GO:2000425 regulation of apoptotic cell clearance 8 4 0.00012
63 GO:0006942 regulation of striated muscle con-
traction
90 12 0.00012
64 GO:1901698 response to nitrogen compound 800 51 0.00012
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65 GO:0044702 single organism reproductive process 970 59 0.00013
66 GO:0044248 cellular catabolic process 1317 75 0.00013
67 GO:0016054 organic acid catabolic process 180 18 0.00013
68 GO:0046395 carboxylic acid catabolic process 180 18 0.00013
69 GO:0086004 regulation of cardiac muscle cell con-
traction
42 8 0.00013
70 GO:0048609 multicellular organismal reproduc-
tive process
701 46 0.00013
71 GO:2000241 regulation of reproductive process 92 12 0.00015
72 GO:0019953 sexual reproduction 684 45 0.00015
73 GO:0030334 regulation of cell migration 564 39 0.00015
74 GO:0022414 reproductive process 1083 64 0.00015
75 GO:0034616 response to laminar ﬂuid shear stress 15 5 0.00015
76 GO:0055117 regulation of cardiac muscle contrac-
tion
79 11 0.00015
77 GO:0009887 organ morphogenesis 809 51 0.00015
78 GO:0051345 positive regulation of hydrolase ac-
tivity
769 49 0.00016
79 GO:0055114 oxidation-reduction process 917 56 0.00017
80 GO:0051336 regulation of hydrolase activity 1154 67 0.00017
81 GO:0051270 regulation of cellular component
movement
669 44 0.00017
82 GO:1901564 organonitrogen compound metabolic
process
1465 81 0.00018
83 GO:0060341 regulation of cellular localization 1092 64 0.00019
84 GO:0031667 response to nutrient levels 397 30 0.00019
85 GO:0060322 head development 652 43 0.00019
86 GO:0043547 positive regulation of GTPase activ-
ity
455 33 0.00020
87 GO:0051130 positive regulation of cellular compo-
nent organization
1057 62 0.00023
88 GO:0045595 regulation of cell diﬀerentiation 1343 75 0.00023
89 GO:1901699 cellular response to nitrogen com-
pound
500 35 0.00025
90 GO:1903115 regulation of actin ﬁlament-based
movement
46 8 0.00025
91 GO:0009991 response to extracellular stimulus 425 31 0.00028
92 GO:0009063 cellular amino acid catabolic process 99 12 0.00029
93 GO:0008016 regulation of heart contraction 160 16 0.00030
94 GO:0007283 spermatogenesis 466 33 0.00030
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95 GO:0033280 response to vitamin D 26 6 0.00031
96 GO:0048232 male gamete generation 467 33 0.00032
97 GO:0040012 regulation of locomotion 647 42 0.00032
98 GO:0048585 negative regulation of response to
stimulus
1202 68 0.00032
99 GO:0071305 cellular response to vitamin D 10 4 0.00033
100 GO:1902547 regulation of cellular response to vas-
cular endothelial growth factor stim-
ulus
10 4 0.00033
101 GO:1901652 response to peptide 432 31 0.00036
102 GO:0051046 regulation of secretion 612 40 0.00038
103 GO:0009083 branched-chain amino acid catabolic
process
18 5 0.00039
104 GO:0010563 negative regulation of phosphorus
metabolic process
473 33 0.00040
105 GO:0045936 negative regulation of phosphate
metabolic process
473 33 0.00040
106 GO:0007584 response to nutrient 164 16 0.00040
107 GO:0097305 response to alcohol 303 24 0.00041
108 GO:0070848 response to growth factor 614 40 0.00041
109 GO:0071363 cellular response to growth factor
stimulus
595 39 0.00043
110 GO:0071377 cellular response to glucagon stimu-
lus
38 7 0.00043
111 GO:0031960 response to corticosteroid 149 15 0.00043
112 GO:0048514 blood vessel morphogenesis 361 27 0.00045
113 GO:2000427 positive regulation of apoptotic cell
clearance
5 3 0.00048
114 GO:2000145 regulation of cell motility 599 39 0.00049
115 GO:0044057 regulation of system process 401 29 0.00049
116 GO:0001822 kidney development 236 20 0.00052
117 GO:1903530 regulation of secretion by cell 561 37 0.00053
118 GO:0043087 regulation of GTPase activity 501 34 0.00053
119 GO:0007417 central nervous system development 792 48 0.00058
120 GO:1901342 regulation of vasculature develop-
ment
204 18 0.00060
121 GO:0044282 small molecule catabolic process 240 20 0.00064
122 GO:0060429 epithelium development 903 53 0.00064
123 GO:0032963 collagen metabolic process 79 10 0.00065
124 GO:0006935 chemotaxis 588 38 0.00066
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125 GO:0042330 taxis 588 38 0.00066
126 GO:0051960 regulation of nervous system devel-
opment
630 40 0.00068
127 GO:0003012 muscle system process 242 20 0.00071
128 GO:0007411 axon guidance 373 27 0.00075
129 GO:0097485 neuron projection guidance 373 27 0.00075
130 GO:0051384 response to glucocorticoid 141 14 0.00075
131 GO:0007276 gamete generation 572 37 0.00076
132 GO:0009081 branched-chain amino acid
metabolic process
21 5 0.00085
133 GO:0044782 cilium organization 176 16 0.00086
134 GO:0022617 extracellular matrix disassembly 112 12 0.00090
135 GO:0010811 positive regulation of cell-substrate
adhesion
97 11 0.00091
136 GO:0042326 negative regulation of phosphoryla-
tion
359 26 0.00092
137 GO:0032226 positive regulation of synaptic trans-
mission, dopaminergic
6 3 0.00093
138 GO:0060385 axonogenesis involved in innervation 6 3 0.00093
139 GO:0072001 renal system development 248 20 0.00096
140 GO:0010810 regulation of cell-substrate adhesion 161 15 0.00096
141 GO:0044087 regulation of cellular component bio-
genesis
601 38 0.00098
142 GO:0043434 response to peptide hormone 401 28 0.00104
143 GO:0034612 response to tumor necrosis factor 114 12 0.00106
144 GO:0044259 multicellular organismal macro-
molecule metabolic process
84 10 0.00106
145 GO:0030574 collagen catabolic process 70 9 0.00107
146 GO:0001933 negative regulation of protein phos-
phorylation
326 24 0.00114
147 GO:0051248 negative regulation of protein
metabolic process
949 54 0.00116
148 GO:0072330 monocarboxylic acid biosynthetic
process
164 15 0.00116
149 GO:0007420 brain development 609 38 0.00125
150 GO:0010927 cellular component assembly in-
volved in morphogenesis
236 19 0.00130
151 GO:0050804 modulation of synaptic transmission 236 19 0.00130
152 GO:0031669 cellular response to nutrient levels 183 16 0.00131
153 GO:0042594 response to starvation 183 16 0.00131
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154 GO:0009725 response to hormone 802 47 0.00132
155 GO:0035513 oxidative RNA demethylation 2 2 0.00137
156 GO:0035552 oxidative single-stranded DNA
demethylation
2 2 0.00137
157 GO:0035553 oxidative single-stranded RNA
demethylation
2 2 0.00137
158 GO:0042822 pyridoxal phosphate metabolic pro-
cess
2 2 0.00137
159 GO:1900623 regulation of monocyte aggregation 2 2 0.00137
160 GO:1900625 positive regulation of monocyte ag-
gregation
2 2 0.00137
161 GO:1901074 regulation of engulfment of apoptotic
cell
2 2 0.00137
162 GO:2000243 positive regulation of reproductive
process
34 6 0.00140
163 GO:0014070 response to organic cyclic compound 740 44 0.00141
164 GO:0000724 double-strand break repair via ho-
mologous recombination
73 9 0.00145
165 GO:0090257 regulation of muscle system process 185 16 0.00146
Table (A.4) GO Molecular Function
term id term description proteins hits p-value
1 GO:0016491 oxidoreductase activity 638 44 0.00000
2 GO:0032559 adenyl ribonucleotide binding 1450 79 0.00000
3 GO:0030554 adenyl nucleotide binding 1456 79 0.00000
4 GO:0030234 enzyme regulator activity 841 51 0.00001
5 GO:0005524 ATP binding 1415 75 0.00001
6 GO:0005539 glycosaminoglycan binding 190 19 0.00001
7 GO:0050839 cell adhesion molecule binding 128 15 0.00002
8 GO:0098772 molecular function regulator 1094 61 0.00002
9 GO:0004222 metalloendopeptidase activity 104 13 0.00003
10 GO:0035514 DNA demethylase activity 3 3 0.00003
11 GO:0043734 DNA-N1-methyladenine dioxygenase
activity
3 3 0.00003
12 GO:0008047 enzyme activator activity 423 30 0.00005
13 GO:0005509 calcium ion binding 663 41 0.00005
14 GO:0050660 ﬂavin adenine dinucleotide binding 70 10 0.00008
15 GO:0030695 GTPase regulator activity 274 22 0.00008
16 GO:0060589 nucleoside-triphosphatase regulator
activity
296 23 0.00009
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17 GO:0005178 integrin binding 74 10 0.00012
18 GO:0005096 GTPase activator activity 245 20 0.00014
19 GO:0008201 heparin binding 144 14 0.00023
20 GO:0005102 receptor binding 1038 54 0.00034
21 GO:0005518 collagen binding 43 7 0.00040
22 GO:0005215 transporter activity 1055 54 0.00050
23 GO:0016462 pyrophosphatase activity 715 40 0.00051
24 GO:0016818 hydrolase activity, acting on acid
anhydrides, in phosphorus-containing
anhydrides
718 40 0.00055
25 GO:0016817 hydrolase activity, acting on acid an-
hydrides
719 40 0.00056
26 GO:0008762 UDP-N-acetylmuramate dehydroge-
nase activity
6 3 0.00061
27 GO:0017111 nucleoside-triphosphatase activity 679 38 0.00069
28 GO:0016772 transferase activity, transferring
phosphorus-containing groups
849 45 0.00072
29 GO:0016301 kinase activity 705 39 0.00073
30 GO:0001071 nucleic acid binding transcription fac-
tor activity
973 50 0.00074
31 GO:0003700 transcription factor activity,
sequence-speciﬁc DNA binding
973 50 0.00074
32 GO:0022892 substrate-speciﬁc transporter activity 902 47 0.00080
33 GO:0008753 NADPH dehydrogenase (quinone) ac-
tivity
2 2 0.00103
34 GO:0035515 oxidative RNA demethylase activity 2 2 0.00103
35 GO:0051747 cytosine C-5 DNA demethylase activ-
ity
2 2 0.00103
36 GO:0097363 protein O-GlcNAc transferase activity 2 2 0.00103
37 GO:0016788 hydrolase activity, acting on ester
bonds
625 35 0.00109
38 GO:0051213 dioxygenase activity 82 9 0.00125
39 GO:0031267 small GTPase binding 154 13 0.00143
40 GO:0048037 cofactor binding 253 18 0.00144
41 GO:0005525 GTP binding 362 23 0.00157
42 GO:0016773 phosphotransferase activity, alcohol
group as acceptor
640 35 0.00163
43 GO:0003840 gamma-glutamyltransferase activity 8 3 0.00164
44 GO:0008289 lipid binding 594 33 0.00170
45 GO:1901681 sulfur compound binding 199 15 0.00199
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46 GO:0016887 ATPase activity 347 22 0.00201
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A.1.3. R code for RNAseq analysis
RNAseq analysis
Required packages: Bioconductor, edgeR, STRINGdb, biomaRT, pylr
Differential gene expression with edgeR
Making the “wide”-object that can be used for DEG with EdgeR:
setwd("D:/Dropbox/Tanja's PhD/lab stuff/RNAseq ChiPS4 GNS/RNAseq analysis/Analysis Tanja")
full<-read.csv("fullResults.csv", header=T, sep=";")
colnames(full)
fullu<-unique(full[, -c(1, which(colnames(full)=="entrezgene"))])
wide<-fullu[,5:16]
#View(wide)
rownames(wide)<-fullu$ensembl_gene_id
#View(wide)
These commands are used to run the differential gene expression analysis:
library(edgeR)
dge <- DGEList(wide,group=as.factor(substr(colnames(wide),1,2))
+ )
design <- model.matrix(~dge$samples$group -1)
colnames(design) <- levels(dge$samples$group)
dge <- calcNormFactors(dge)
dge <- estimateDisp(dge,design)
fit <- glmFit(dge,design)
lrt <- glmLRT(fit,contrast=c(-1,1))
ttn<-topTags(lrt,100000)$table
StringDB & biomaRT
This frist chunk generates the environment:
StringDB analysis:
#biocLite("STRINGdb")
require(STRINGdb)
string_db <- STRINGdb$new( version="10", species=9606) #Builds the environment
rl<-read.csv("sorted_hits_Stringdb_TD.csv", header=T, sep=",", stringsAsFactors = FALSE)
rl<-unique(rl)
rl<-na.omit(rl)
string_db <- STRINGdb$new( version="10", species=9606)
1
rl_mapped <- string_db$map(rl, "entrezgene", removeUnmappedRows = TRUE )
rl_mapped_sig<-string_db$add_diff_exp_color(rl_mapped, logFcColStr = "logFC")
#to only get proteins with FDR<0.05:
rl_mapped_sig<-string_db$add_diff_exp_color(subset(rl_mapped, FDR<0.05,
logFcColStr = "logFC")
#in the end I used these settings: abs(logFC)>0.85
rl_mapped_sig<-string_db$add_diff_exp_color(subset (rl_mapped, abs(logFC)>0.85),
logFcColStr = "logFC")
payload_id <- string_db$post_payload(rl_mapped_sig$STRING_id, colors=rl_mapped_sig$color)
string_db$plot_network(rl_mapped_sig$STRING_id[1:200], #show 200 proteins
payload_id=payload_id )
Gene ontology analysis
The code below allows to retrieve the genes within a GO hit that are in our DEG list. Alternatively, the web
version of GO can be used.
rl <- read.csv("topAnnotatedhitsR.csv", header=T, sep=";", stringsAsFactors = FALSE)
goGenes <- getBM(attributes=c("ensembl_gene_id","external_gene_name"),
filters="go_parent_term",
values="GO:0048699", #put the desired GO term id here
mart=ens)
goGenes<-getBM(attributes=c("ensembl_gene_id","external_gene_name"),
filters=c("go_parent_term","go_evidence_code"),
values=list("GO:0007417","IEA"), mart=ens)
hitsProcess<-merge(goGenes, rl, by="ensembl_gene_id")
write.xlsx(hitsProcess, "hits in GO terms/GO0007417.xlsx")
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Elevated O-GlcNAc Levels Activate Epigenetically
Repressed Genes and Delay Mouse ESC
Differentiation Without Affecting Na€ıve to Primed
Cell Transition
CHRISTOPHER M. SPEAKMAN,a TANJA C.E. DOMKE,a WIKROM WONGPAIBOONWATTANA,a
KELLY SANDERS,b MANIKHANDAN MUDALIAR,c,d DAAN M.F. VAN AALTEN,b GEOFFREY J. BARTON,c
MARIOS P. STAVRIDISa
Key Words. Embryonic stem cells • Cell differentiation • O-GlcNAc • Post-translational protein
modiﬁcation • Signal transduction • Oligonucleotide microarrays
ABSTRACT
The differentiation of mouse embryonic stem cells (ESCs) is controlled by the interaction of multi-
ple signaling pathways, typically mediated by post-translational protein modiﬁcations. The addi-
tion of O-linked N-acetylglucosamine (O-GlcNAc) to serine and threonine residues of nuclear and
cytoplasmic proteins is one such modiﬁcation (O-GlcNAcylation), whose function in ESCs is only
now beginning to be elucidated. Here, we demonstrate that the speciﬁc inhibition of O-GlcNAc
hydrolase (Oga) causes increased levels of protein O-GlcNAcylation and impairs differentiation of
mouse ESCs both in serum-free monolayer and in embryoid bodies (EBs). Use of reporter cell lines
demonstrates that Oga inhibition leads to a reduction in the number of Sox1-expressing neural
progenitors generated following induction of neural differentiation as well as maintained expres-
sion of the ESC marker Oct4 (Pou5f1). In EBs, expression of mesodermal and endodermal markers
is also delayed. However, the transition of na€ıve cells to primed pluripotency indicated by Rex1
(Zfp42), Nanog, Esrrb, and Dppa3 downregulation and Fgf5 upregulation remains unchanged.
Finally, we demonstrate that increased O-GlcNAcylation results in upregulation of genes normally
epigenetically silenced in ESCs, supporting the emerging role for this protein modiﬁcation in the
regulation of histone modiﬁcations and DNA methylation. STEM CELLS 2014;32:2605–2615
INTRODUCTION
Over the last decade there have been major
advances in our understanding of the mecha-
nisms controlling embryonic stem cell (ESC)
behavior in response to the changing extracellu-
lar environment [1]. These mechanisms largely
involve engagement of signal transduction
relays that operate by post-translational modiﬁ-
cations of proteins. Under standard conditions,
ESCs grow as a mixture of “na€ıve” and “primed”
cells. Signaling mediated by Erk1/2 target phos-
phorylation has recently been implicated in reg-
ulating the transition between these two states
and initiation of differentiation [2]. Reversible
protein modiﬁcation by addition of O-linked N-
acetylglucosamine to serine or threonine resi-
dues (O-GlcNAcylation) was ﬁrst described 30
years ago [3] and occurs with similar time
scales, dynamics, and stoichiometry as protein
phosphorylation, with which it sometimes com-
petes. O-GlcNAcylation is found in all higher
eukaryotes tested to date and has been impli-
cated in development, epigenetic regulation,
and diseases such as diabetes and Alzheimer’s
[4]. Its addition and removal are catalyzed by
one transferase (Ogt) and one hydrolase (Oga;
also known as Mgea5), respectively.
To date there have been very few studies
on O-GlcNAc function in ESCs, although accu-
mulating evidence suggests a critical role for
this modiﬁcation. Elimination of Ogt in mouse
ESCs or conditional deletion in somatic cells
leads to death, consistent with an essential role
in all cell types [5, 6]. Ogt has recently been
identiﬁed as a protein partner of the essential
ESC transcription factor Oct4 (Pou5f1) by three
independent studies [7–9]. Furthermore, Oct4
has been shown to be modiﬁed by O-GlcNAc
[10], and this was demonstrated to be impor-
tant for regulation of a subset of its targets in
ESCs and during reprogramming [11]. A previ-
ous study has suggested that increased O-
GlcNAcylation in ESCs prevents differentiation
along the cardiac lineage in spontaneously dif-
ferentiating embryoid bodies (EBs) [12]; how-
ever, the mechanism for this or the stage at
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which differentiation stalled was not determined. Ogt is a mam-
malian homolog of the Drosophila super sex combs (scx) gene,
a member of the Polycomb group of transcriptional repressors
[13, 14] and has established roles in gene repression [15]. Fur-
thermore, recent studies implicate O-GlcNAc transferase in the
regulation of the Tet epigenetic modiﬁers [16–18], suggesting
that the O-GlcNAc modiﬁcation and the enzymes controlling it
regulate chromatin in pluripotent cells by multiple
mechanisms.
In this study, we investigate in detail the effects of
increased O-GlcNAcylation on neural differentiation of mouse
ESCs. Our results show that Oga inhibition leads to delayed
onset of differentiation although the transition of na€ıve cells
to primed pluripotency proceeds unhindered. We also present
a genome-wide gene expression analysis of ESCs and differen-
tiating cells treated with a highly speciﬁc Oga inhibitor, reveal-
ing that increased O-GlcNAc levels control the expression of
distinct groups of genes in ESCs associated with a recently
described subpopulation resembling the two-cell-stage
embryo. Upregulation of these gene sets is consistent with a
disruption of the normal transcriptional repression pro-
gramme operating in pluripotent cells.
MATERIALS AND METHODS
ESC Culture and Differentiation
Mouse ESCs were cultured without feeders on 0.1% gelatin-
coated plastics in Glasgow Minimal Essential Medium with
10% serum and Leukemia Inhibitory Factor (LIF) [19] and dif-
ferentiation was performed according to our previous protocol
[20]. The cell lines used were derivatives of E14Tg2aIV (46C
[21], OCRG9 [22]) or Oct4GiP [23]. GlcNAcstatin C (GNS) was
obtained from GlycoBioChem (Dundee, UK; www.glycobio
chem.com) and used at 1 mM unless otherwise speciﬁed. For
ﬂow cytometry, cells were dissociated using Accutase (Milli-
pore, Billerica, MA; www.emdmillipore.com) and resuspended
in PBS/1% bovine serum albumin (BSA) containing 1 mg/ml
propidium iodide (PI; Sigma, St. Louis, MO; www.sigmaaldrich.
com). Cellular debris and PI-positive cells were excluded from
analysis. For clonal analysis, 600/100 cells were plated per
10 cm dish/well of six-well plate and cultured for 6–8 days,
then ﬁxed, and stained using an Alkaline phosphatase staining
kit (Sigma).
siRNA Induced Knockdown of Oga and Ogt
Cells were seeded into six-well dishes (2 3 105 cells/well).
While still in suspension, cells were transfected with Smart-
Pool siRNAs targeting Oga or Ogt or with a nontargeting
siRNA pool (50 pmol per well, Thermo Scientiﬁc, Waltham,
MA; www.thermoscientiﬁc.com) using Lipofectamine RNAiMAX
(Life Technologies, Carlsbad, CA; www.lifetechnologies.com) (5
ml per well). Cells were transfected again after 24 hours.
Western Blotting
Cells were cultured or differentiated in 9 cm dishes and treat-
ments were for 24 hours unless otherwise speciﬁed. Lysis was
performed on ice in whole-cell lysis buffer (150 mM sodium
chloride, 1.0% Nonidet P40, 50 mM Tris, pH 8.0 with 1 mM
GNS, Complete protease inhibitor, and PhosStop phosphatase
inhibitor cocktail tablets from Roche, Basel, Switzerland; www.
roche.com). For nuclear/cytoplasmic fractionation, cells were
lysed on ice in Buffer A (10 mM HEPES, 1.5 mM MgCl2,
10 mM KCl, 0.5 mM Dithiothreitol (DTT), 0.05% Nonidet P40
pH 7.9) for 10 minutes and centrifuged for 10 minutes at
3,000 rpm in a microfuge at 4C. The supernatant was
removed as a cytoplasmic fraction and the pellet was resus-
pended in Buffer B (5 mM HEPES, 1.5 mM MgCl2, 0.2 mM
EDTA, 0.5 mM DTT, 26% glycerol [vol/vol], pH 7.9) by micro-
pestle homogenization, NaCl added to 300 mM, and incu-
bated on ice for 30 minutes. A ﬁnal spin at 12,000g was
performed to separate insoluble material from the nuclear
fraction. Protein concentration was determined by Coomassie
protein assay (Thermo Scientiﬁc) and 10–30 mg of protein was
loaded per lane of Life Technologies NuPage gels and trans-
ferred to Polyvinylidene ﬂuoride membrane (Millipore). Mem-
branes were blocked in either 5% Milk (Marvel, Premier
Foods, St. Albans, UK; www.premierfoods.co.uk) in TBST or
1%–5% BSA (Millipore) in TBST (all other chemicals from
Sigma). Antibodies were incubated in blocking buffer over-
night: anti-O-GlcNAc, CTD110.6 (Covance, Princeton, NJ; www.
covance.com, 1/5,000), or RL-2 (Santa Cruz Biotechnology,
Dallas, TX; www.scbt.com, 1/1,000); beta actin (Abcam,
Cambridge, UK; www.abcam.co.uk, 1/2,000); phosphoErk1/2
(Cell Signaling Technologies, Beverly, MA; www.cellsignal.com,
1/1,000); Gsk3a and phosphoGsk3a/b (Cell Signaling,
1/1,000); phospho-Serine and phospho-Threonine (Cell Signal-
ing, 1/1,000); Oct4 (Abcam 1/1,000); Sox2 (Abcam 1/1,000).
For the phospho-kinase antibody array (R&D Systems, Minne-
apolis, MN; www.rndsystems.com) 500 mg of total cell lysate
was used according to manufacturers instructions and the
arrays were developed using LumiGLO from Cell Signaling and
imaged on a Fuji LAS3000 mini scanner. Densitometry was
performed with ImageJ.
Immunoprecipitation
Whole cell lysate (500 mg) was incubated overnight with a
mixture of succinylated wheat germ agglutinin-agarose and
protein A sepharose beads in the presence of antibody RL-2
(anti-O-GlcNAc). After washing the bound proteins were
eluted in 25 ml of 23 LDS loading buffer (Life Technologies),
boiled for 5 minutes, and analyzed by Western blotting.
Immunocytochemistry
Cells were ﬁxed in 4% paraformaldehyde (PFA) for 15 minutes,
permeabilized in PBS, 0.1% Tween (PBST), and incubated in
PBST 15% BSA (blocking buffer). Primary antibody (goat anti-
Oct4, Santa Cruz) was diluted in blocking buffer at 1/50 and
incubated overnight at 4C. Subsequently, cells were incu-
bated in ﬂuorescent secondary antibody (AlexaFluor conju-
gate, Life Technologies, 1/1,000) and 300 nM 40,6-diamidino-
2-phenylindole for 1 hour.
Two-Dimensional-PAGE
Nuclear samples extracted from ESCs treated with LIF, or 1–4
days treatment with N2B27, were enzymatically labeled using
Click-IT O-GlcNAc labeling system (Life Technologies) according
to the manufacturers instructions. Samples were chloroform-
methanol precipitated and resuspended in 7 M urea, 2 M thi-
ourea, 4% CHAPS, 1% ASB-14, and 0.5% ampholytes. Passive
rehydration was performed overnight followed by isoelectric
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focusing using pH 3–10 NL IPG strips for 4,200 vh. Preceding
equilibration, samples were separated by SDS-PAGE using
4%–12% bis/tris gels and transferred to Polyvinylidene ﬂuo-
ride for detection by streptavidin-HRP. Ten prominent spots
were excised from duplicate gels and analyzed by MALDI-TOF
mass spectrometry.
Quantitative RT-PCR
RNA was extracted from cells grown in six-well plates using
Nucleospin II RNA kit (Macherey-Nagel, Dueren, Germany;
www.mn-net.com). DNase treatment was performed on-
column during RNA extraction. One microgram of RNA was
reverse transcribed with the qScript cDNA synthesis kit
(Quanta Biosciences, Gaithersburg, MD; www.quantabio.com).
PCR was performed on a BioRad iCycler or an AB 7500 using
PerfeCTa SYBR Green FastMix for iQ or PerfeCTa SYBR Green
FastMix Low Rox (both Quanta Biosciences), respectively.
Primer sequences are shown in Supporting Information Table
S1. Relative quantitation was performed using the method by
Pfafﬂ [24] and b-actin as a reference gene from technical dupli-
cates or triplicates of at least three independent experiments.
Microarray Analysis
RNA samples (from four independent experiments) were proc-
essed and hybridized to Affymetrix Gene 1.1ST arrays by Ark
Genomics (www.ark-genomics.org) and the raw array expression
data were obtained as CEL ﬁles. For quality control and probe
sets annotations, the annotations ﬁles (Release 32, dated 23-06-
2011) downloaded from Affymetrix (Santa Clara, CA; www.affy
metrix.com) were used. Background noise control (Detected
Above Background), Robust Multi-array Average normalization,
and summarization of probe set level data into transcript clus-
ters were carried out using Affymetrix Power Tools. Quality anal-
ysis and differential expression analyses were performed in
Partek GS 6.5 (version 6.11.0321) software and R (version
2.13.1)—Bioconductor using Limma [25], and RankProd [26]
packages [27]. The microarray data have been deposited in EBI
ArrayExpress under accession number E-MEXP-3593. For gene
set enrichment analysis (GSEA) GSEA v2.0.13 was used, along
with gene sets from MSigDB, GenesigDB, or custom made ones
from the literature (Supporting Information Table S5). Genes
were ranked by the Signal2Noise metric and the weighted2
enrichment statistic was used over 1,000 gene set permutations.
A false discovery rate q-value cut-off of 0.05 was applied.
RESULTS
Protein O-GlcNAcylation Delays Mouse ESC
Differentiation
We decided to investigate the changes in O-GlcNAc signal-
ing during ESC neural differentiation. Global O-GlcNAc levels
decline slightly during the ﬁrst few days of differentiation,
as measured by Western blotting with the O-GlcNAc-speciﬁc
antibody CTD110.6 (Fig. 1A). However, this method may
miss changes in the O-GlcNAcylation of lower abundance
proteins. To test for more subtle changes in protein
O-GlcNAcylation, we performed a two-dimensional-PAGE-
Western blot analysis of nuclear extracts of ESCs and cells
during the ﬁrst 4 days of monolayer differentiation using
chemoenzymatic labeling of O-GlcNAcylated proteins (Fig.
1B and Supporting Information Fig. S1A). The results
revealed a dynamic pattern of nuclear O-GlcNAcylated pro-
teins, with a dramatic change during the ﬁrst 24 hours of
differentiation. As the O-GlcNAcylation on the majority of
the nuclear proteins disappeared following 24 hours of dif-
ferentiation, we hypothesized that removal of the O-GlcNAc
modiﬁcation from some ESC protein(s) may be required for
differentiation onset. We also picked 10 spots showing dra-
matic regulation from the Day 1 gel and identiﬁed them
by mass spectrometry. Our analysis identiﬁed 26 unique
proteins. Although we were not able to positively identify
O-GlcNAc modiﬁcation on any of these proteins due to the
instrumentation used, we note that 13 of the 26 had pre-
viously been identiﬁed as O-GlcNAc modiﬁed by other
screens (Supporting Information Table S2).
We then sought to determine whether the O-GlcNAc lev-
els in ESCs can be modulated by inhibiting the Oga enzyme
activity that removes O-GlcNAc using GNS, a highly potent
and speciﬁc small molecule Oga inhibitor that exhibits 164-
fold selectivity for Oga when tested against the closely related
lysosomal hexosaminidases HexA/B [28] and a competitive
inhibitor of the O-GlcNAc transferase Ogt (4Ac5SGlcNAc) [29].
Treatment of ESCs with GNS resulted in a dose-dependent
increase in cellular O-GlcNAc levels (Fig. 1C) including
O-GlcNAcylation of the transcription factor Sox2 on S248 (Fig.
1D), with no discernable effects on cell viability or prolifera-
tion even after prolonged treatment (Fig. 1E, 1F). Similar
results were obtained by use of siRNA (Supporting Informa-
tion Fig. S1B). Inhibition of Ogt conversely led to cell death
within 4–5 days in culture (Supporting Information Fig. S1C),
consistent with the previous observation that this protein is
essential for ESC viability [5] (Fig. 3A).
We then treated murine 46C ESCs (engineered to express
the green ﬂuorescent protein [GFP] from the endogenous
neural-speciﬁc Sox1 locus [21]) with GNS during monolayer
differentiation into neural cells [20]. Flow cytometry showed
that a signiﬁcantly smaller proportion of neural progenitors
were generated during ESC differentiation in the presence of
GNS (24.6% in GNS vs. 32.2% in DMSO at day 3, a reduction
of 23.6%; n5 4, p5 .0118) (Fig. 2A, Supporting Information
Videos S1 and S2). Similar effects were seen using a structur-
ally distinct Oga inhibitor, Thiamet G (21.4% reduction at day
3). Sox1 mRNA levels were similarly reduced (Supporting
Information Fig. S2A). This decrease in neural progenitors
could reﬂect a bias of differentiation against neural fate, or
be due to a more general effect on the onset of differentia-
tion irrespective of lineage. To test this differentiating 46C
cells were assessed for expression of the ESC marker Oct4.
GNS-treated ESCs remained Oct4 positive when vehicle-
treated control cells have largely lost Oct4 immunoreactivity
and instead expressed Sox1GFP (Fig. 2B). We obtained the
same result using the transgenic Oct4-GFP reporter ESC line
Oct4GiP (Fig. 2C), suggesting a delay in differentiation onset
in the presence of GNS. Consistently, we also observed a
decrease in endoderm (BMP2) and mesoderm (Brachyury,
Eomesodermin) markers following EB differentiation (Fig. 2D–
2F). Interestingly, primitive endoderm differentiation meas-
ured by RT-qPCR for Sox17 and Gata6 appears to be unaf-
fected by GNS (Supporting Information Fig. S2B, S2C).
ESC self-renewal can be maintained through the action of
the transcription factor Stat3, operating downstream of the
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cytokine LIF. However, we could not detect any change in
Stat3 phosphorylation in GNS-treated cells compared to con-
trols (Fig. 3A), which suggests that the effect of raised O-
GlcNAc levels on ESC differentiation is independent of Stat3
activity. Furthermore, GNS is not able to substitute for LIF and
promotes the clonal expansion of ESCs in serum (Supporting
Information Fig. S3A), nor does it affect cloning efﬁciency in
the presence of LIF (Fig. 3B), consistent with a delay rather
than a complete block in differentiation.
O-GlcNAc Levels Do Not Affect Transition of Na€ıve
Cells to a Primed State
Recent work has suggested that O-GlcNAcylation of Oct4 can
maintain ESCs by regulation of downstream na€ıve state
markers like Nanog, Rex1, Klf2, Klf5 and others [11]. When
cultured in the presence of serum and LIF, ESC populations
consist of mixed na€ıve and primed cells, but in serum-free
N2B27 monolayer differentiation conditions the transcripts for
the na€ıve markers decline sharply after 24 hours and the
cells proceed to differentiate. To test whether this early transi-
tion is affected by O-GlcNAc levels we used the OCRG9 line,
expressing GFP under the control of the endogenous Rex1
locus. Under control conditions, OCRG9 cells become GFP
negative at day 2 of differentiation (the delay between loss of
Rex1 mRNA and loss of GFP is due to the stability of the
latter). GNS-treated OCRG9 cells lost expression of Rex1-GFP
at the same rate as the control (DMSO-treated) cells (Fig. 3C).
The transition from na€ıve to primed state is mediated by the
actions of the Erk1/2 kinases downstream of ﬁbroblast growth
factor (Fgf) signaling. Recent work in Drosophila has identiﬁed
Figure 1. Global protein O-GlcNAcylation in embryonic stem cells (ESCs). (A): Whole-cell lysates of ESCs and cells at various stages of
neural differentiation were blotted for O-GlcNAc levels. No major changes are detectable in the most abundant bands. (B): Two-
dimensional gels of nuclear extracts blotted for O-GlcNAcylation. The overall level of O-GlcNAc is reduced in differentiation conditions
whereas a cluster of basic proteins is prominent in the Day 1 sample. (C): Dose-dependent increase in protein O-GlcNAcylation after 24
hours treatment with 1 mM GNS. (D): Undifferentiated and 3-day neural differentiated ESCs in DMSO or GNS were immunoprecipitated
with antibody against O-GlcNAc (RL-2) and succinylated WGA beads or antibody against Sox2 then blotted for Sox2 or Sox2 GlcNAcylated
at S248. GNS increases O-GlcNAc levels on Sox2, especially on day 3. (E): Measurement of apoptotic cells (pink) after 24 hours of vehicle
(DMSO) or 1 mM GNS treatment shows no difference in apoptosis levels. (F): ESC proliferation in vehicle (DMSO), the Oga inhibitors
Thiamet G, and GNS or its inactive stereoisomer, GalNacstatin C (all at 1 mM). Abbreviations: GNS, GlcNAcstatin C; O-GlcNAc, O-linked
N-acetylglucosamine.
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a requirement for O-GlcNAcylation for Erk1/2 signal transduc-
tion downstream of Fgf receptor [30]. However, consistent
with a normal transition to the primed state, we did not
detect any changes in the proﬁle of Erk1/2 phosphorylation in
GNS-treated cells (Supporting Information Fig. S3B), suggest-
ing that the signal regulating transition of na€ıve cells to
primed pluripotency is unaltered by increased O-GlcNAc
levels.
This is further conﬁrmed by quantitative RT-PCR for other
na€ıve cell markers Nanog, Rex1/Zfp42, Esrrb, and Dppa3
(Fig. 3D, Supporting Information Fig. S3C) as well as the tran-
sient upregulation of the epiblast marker Fgf5 in EB differen-
tiation (Fig. 3E). Taken together, these results indicate that O-
GlcNAc levels do not affect the initial events of ESC
differentiation.
In order to test this hypothesis further we performed a
microarray experiment to measure GNS’s effect on global
transcriptional changes during the transition of na€ıve pluripo-
tent cells to a primed state. We treated ESCs with DMSO or
GNS for 24 hours either in ESC media or in neural differentia-
tion conditions and compared gene expression between treat-
ments. Principal component analysis showed that the change
from self-renewal media to monolayer differentiation media
(including serum withdrawal) causes a major effect on global
gene expression (37%). This is reﬂected in the clustering of
the most signiﬁcantly regulated genes that change their
expression from ESCs to day 1 of differentiation irrespective
of GNS (Fig. 3F). We then compared the changes in gene
expression during the ﬁrst 24 hours of differentiation in the
presence of GNS or DMSO compared to undifferentiated
ESCs. This revealed that a great majority of the genes are
common to the two conditions (Fig. 3G), consistent with the
hypothesis that na€ıve-to-primed transition is unaffected by O-
GlcNAc levels. Many of the genes downregulated (fold change
>1.2, p< .05) in both vehicle and GNS samples belong to
pathways regulating ESC self-renewal (i.e., MAPK, Jak/Stat and
Tgfb superfamily; Table 1) and include Bmp4, Tgfb1 and down-
stream targets Id1, Id2, Id3; Stat3 and downstream target
Socs3 as well as transcription factors associated with na€ıve
pluripotency (Klf2, 3, 4, and 5, Nanog, Rex1/Zfp42). Common
upregulated genes include neural and mesodermal early dif-
ferentiation regulators (Otx2, Tbx4, Neurogenin3, NeuroD1,
and NeuroD4) as well as primed pluripotency epiblast marker
Fgf5, consistent with our RT-qPCR results. In total, 45 genes
from our set also belong to the Plurinet network of
pluripotency-related markers [31], 20 of which are
Figure 2. GlcNAcstatin treatment impairs embryonic stem cell (ESC) differentiation. (A): The proportion of Sox1GFP expressing neural
progenitors is decreased following GNS treatment during differentiation of 46C cells. (B): 46C cells retain expression of Oct4 when differ-
entiated in the presence of GNS while control cells differentiate into neural progenitors. Scale bar5 50 mm. (C): Oct4GiP cells retain
Oct4-GFP expression at higher levels in differentiation conditions compared to vehicle only controls. (D–F): ESCs were differentiated as
embryoid bodies in the presence of DMSO or GNS for 3 or 5 days then assayed for expression of endodermal marker BMP2 (D) or mes-
odermal markers Brachyury (E) or Eomesodermin (F) by RT-qPCR. Mean6 SEM from n5 3 experiments. Abbreviations: DAPI, 40,6-diami-
dino-2-phenylindole; GFP, green ﬂuorescent protein; GNS, GlcNAcstatin C.
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upregulated in ESCs, and 25 are upregulated in the day 1
samples (Supporting Information Tables S3 and S4, respec-
tively). This result conﬁrms that raised O-GlcNAc levels do not
affect the expression of genes controlling the onset of differ-
entiation in serum-free monolayer.
Increased Protein O-GlcNAcylation Does Not Interfere
With Phosphorylation of Major Signaling Pathways in
ESCs
O-GlcNAc is frequently attached to serine and threonine resi-
dues that can also be phosphorylated and for many proteins
this reciprocal relationship (often described as a “Yin-Yang”)
regulates their activity. To investigate whether increased O-
GlcNAc levels affect the global phosphorylation of proteins in
ESCs we compared the global phospho-serine and phospho-
threonine levels of ESC protein extracts treated with various
concentrations of GNS. Unlike global O-GlcNAc levels that
showed a dose-dependent increase, protein phosphorylation
levels remained relatively constant, suggesting that the major-
ity of ESC phosphosites are not occupied by O-GlcNAc (Sup-
porting Information Fig. S4A). This result, however, could
reﬂect a high abundance of constitutively phosphorylated pro-
teins in these cells that conceal signiﬁcant changes in less
abundant and more dynamically regulated phosphoproteins.
We therefore focused our attention on protein kinases as
these proteins are often dynamically regulated by phosphoryl-
ation and mediate numerous important cellular responses. We
analyzed kinase phosphorylation in whole-cell lysates from
ESCs treated for 24 hours with either DMSO or GNS using a
protein kinase array. However, none of the 46 kinase sites
Figure 3. Increased O-GlcNAcylation does not affect na€ıve-primed embryonic stem cell (ESC) transition. (A): 46C ESCs were cultured in
the absence of LIF overnight and then stimulated with either LIF or the LIF receptor antagonist hLIF-05 in the presence of either DMSO
or GNS, then blotted for phospho-Stat3 (Y705). GNS treatment does not interfere with the ability of LIF to stimulate Stat3 phosphoryla-
tion and does not cause Stat3 phosphorylation in the absence of LIF. (B): GNS or Oga knockdown does not affect the ability of ESCs to
form undifferentiated colonies, while inhibition or knockdown of Ogt results in cell death. 4Ac: 4-Acetyl-5S-GlcNAc (Ogt inhibitor). (C):
OCRG9 ESCs (Rex1EGFP reporter line) were differentiated in N2B27 for 2 days in vehicle or GNS and analyzed by ﬂow cytometry for
EGFP ﬂuorescence. GlcNAcstatin treatment does not affect the loss of na€ıve marker Rex1. (D): Quantitative RT-PCR analysis during
monolayer differentiation shows that expression of the na€ıve marker Nanog is lost at equivalent rates in the presence of vehicle
(DMSO; black bars) or GNS (white bars). (E): Upregulation of the primed pluripotency marker Fgf5 is unaffected by GNS treatment (D
and E, n5 3, mean6 SEM). (F): Hierarchical clustering (using Euclidean distance with complete linkage agglomeration method) of sam-
ples based on the top 31 differentially expressed genes (ranked by p-value) separates the samples according to the stage of differentia-
tion and shows clustering of genes that contribute to differentiation. (G): Pairwise comparison of genes regulated during the ﬁrst 24
hours of differentiation in vehicle (DMSO) or GNS (fold change >1.2, p< .05). Abbreviation: GNS, GlcNAcstatin C.
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proﬁled showed a signiﬁcant change in their basal level of
phosphorylation by GNS (Supporting Information Fig. S4B)
indicating that the ESC kinome is not signiﬁcantly affected by
the Yin-Yang interplay between O-GlcNAc and phosphate.
Raised O-GlcNAc Levels Affect Transcription
of Repressed Genes in ESCs
We then analyzed ESCs treated for 24 hours with DMSO or
GNS by microarrays, using Ranked Product analysis—a method
better at detecting changes in gene expression from small
number of replicates than the more commonly used Signiﬁ-
cance Analysis of Microarrays or Analysis of Variance methods
[32]. Using a Ranked Product p-value< .05 we identiﬁed 971
differentially regulated genes. Of these, 516 were upregulated
following GNS treatment and 455 were downregulated. Two
of the most signiﬁcantly regulated genes are Ogt and Oga
(Fig. 4A). Using RT-qPCR we found that Ogt expression is sig-
niﬁcantly reduced within 1 hour of treatment with GNS,
whereas Oga upregulation appears slower (Fig. 4B, 4C). The
regulation of Oga and Ogt by O-GlcNAc levels is also reﬂected
at the protein level within 24 hours of treatment with GNS
(Supporting Information Fig. S4C) or by knockdown of Ogt or
Oga using siRNA (Fig. 4D).
One other gene that stood out from this analysis is Zscan4
(Fig. 4A). This gene has previously been associated with telo-
mere maintenance in ESCs [33] and is associated with a sub-
population of cells similar to that of the recently described
“2C” state of privileged developmental plasticity, existing
within ESC cultures [34–36]. 2C cells differ in gene expression
from ESCs in that they express genes associated with zygotic
genome activation and have been demonstrated to be totipo-
tent (giving rise to extraembryonic as well as embryonic tis-
sues in chimeras) [36]. Transcripts marking this subpopulation
include retrotransposons normally repressed by epigenetic
mechanisms as well as chimeric transcripts of genes with
junctions to murine endogenous retrovirus with leucine tRNA
primer (MERVL) elements [36]. Interestingly, the number of
genes upregulated in the GNS-treated samples was much
larger than the DMSO samples, both for the genes enriched
in ESCs and for genes enriched in Day 1 differentiating cells.
We therefore performed pairwise comparisons between the
ESC and Day 1 samples in DMSO or GNS treatment for the
most regulated genes (p< .05, fold change >2). The majority
of genes with expression higher in ESCs than Day 1 (80%;
348/437) were similarly regulated both in DMSO and GNS.
However, of the remaining 20% (those that were not common
to GNS and DMSO), nearly three times more genes were
higher in the GNS sample than in DMSO (65 vs. 24; Fig. 5A).
Similarly, the majority of the genes expressed at higher level
in Day 1 samples compared to ESCs are common to GNS and
DMSO (75%; 160/214), but of those differentially regulated
between the treatments, those regulated by GNS outnum-
bered those regulated by DMSO by a factor of 3.5 (42 vs. 12;
Fig. 5A). This result suggests that GNS treatment causes a
general increase in gene expression both in ESCs and early
differentiating cells (Fig. 3G). We then turned to GSEA for fur-
ther mining of our expression data. Search of the whole
MSigDB and GeneSigDB databases using GSEA did not reveal
a signiﬁcant enrichment for any gene set so we created our
own gene sets from publicly available microarray and ChIP-
seq data as published in relevant papers. We focused our
attention to targets of the ESC core pluripotency network [37,
38] and genes regulated by the Polycomb group [39–41].
Although there was no signiﬁcant enrichment for polycomb
complex 1 or 2 targets in our dataset (Supporting Information
Table S6), a speciﬁc subset of polycomb target genes, desig-
nated as Polycomb-repressed (PRCR) [39], is highly
Table 1. KEGG pathway analysis of the genes signiﬁcantly regulated during the ﬁrst 24 hours of embryonic stem cell differentiation
irrespective of GlcNAcstatin C treatment
Regulation Term Count % of genes in group p-Value Benjamini
Up in ES Focal adhesion 57 0.3 2.30E-12 3.90E-10
Up in ES Lysosome 39 0.2 1.90E-10 1.60E-08
Up in ES ECM-receptor interaction 28 0.2 5.70E-08 3.10E-06
Up in ES Regulation of actin cytoskeleton 45 0.2 1.70E-05 7.20E-04
Up in ES TGF-beta signaling pathway 24 0.1 2.80E-05 9.20E-04
Up in ES Pathways in cancer 59 0.3 3.90E-05 1.10E-03
Up in ES Tight junction 31 0.2 6.70E-05 1.60E-03
Up in ES Leukocyte transendothelial migration 28 0.2 1.10E-04 2.20E-03
Up in ES MAPK signaling pathway 49 0.3 1.50E-04 2.70E-03
Up in ES ARVC 20 0.1 2.50E-04 4.20E-03
Up in ES Small cell lung cancer 21 0.1 5.00E-04 7.50E-03
Up in ES Other glycan degradation 8 <0.1 7.50E-04 1.00E-02
Up in ES Glycosphingolipid biosynthesis 7 <0.1 2.10E-03 2.60E-02
Up in ES Endocytosis 36 0.2 2.60E-03 3.00E-02
Up in ES Jak-STAT signaling pathway 29 0.2 2.70E-03 3.00E-02
Up in ES HCM 19 0.1 2.90E-03 3.00E-02
Up in ES Glycosphingolipid biosynthesis 7 <0.1 3.20E-03 3.10E-02
Up in ES ErbB signaling pathway 19 0.1 4.30E-03 3.90E-02
Up in ES Amino sugar and nucleotide sugar metabolism 12 0.1 5.50E-03 4.70E-02
Up in ES Galactose metabolism 9 <0.1 5.80E-03 4.70E-02
Up in ES Dorso-ventral axis formation 8 <0.1 6.30E-03 4.90E-02
Up in Day 1 Steroid biosynthesis 11 0.1 1.90E-08 3.40E-06
Up in Day 1 Terpenoid backbone biosynthesis 8 0.1 1.30E-05 1.10E-03
Up in Day 1 Biosynthesis of unsaturated fatty acids 9 0.1 2.60E-04 1.50E-02
Up in Day 1 Pathways in cancer 38 0.3 6.90E-04 3.00E-02
Abbreviations: ARVC, arrhythmogenic right ventricular cardiomyopathy; HCM, hypertrophic cardiomyopathy.
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signiﬁcantly enriched in ESCs treated with GNS compared to
the vehicle control (Fig. 5B, Table 2). Strikingly, we also
detected highly signiﬁcant enrichment in the GNS-treated
samples for the gene sets corresponding to the 2C population
(the 2C sets as described previously [36]) as well as the gene
set “2C-MERVL1” which comprises the genes from the 2C set
that contain MERVL chimeric transcripts. The enrichment of
2C transcripts is highly signiﬁcant both in undifferentiated
ESCs and in Day 1 differentiation samples treated with GNS
compared to their respective vehicle controls (Fig. 5C, 5D,
Table 2, Supporting Information Tables S6 and S7). We vali-
dated the upregulation of three 2C associated genes (Zfp352,
Tdpoz3, and Zscan4) by Oga knockdown and GNS in ESCs
using quantitative RT-PCR and show a consistent upregulation
for all three (Fig. 5C, Supporting Information Fig. S5A–S5C).
These results therefore indicate that increased O-GlcNAc lev-
els result in increased expression of epigenetically repressed
genes, including those characteristic of a totipotent 2C state.
DISCUSSION
Our results demonstrate that ESC differentiation is reduced
under conditions of increased O-GlcNAc signaling and pinpoint
the deﬁcit to a stage in differentiation after the loss of naive
pluripotency but before the deﬁnitive differentiation as
marked by the loss of Oct4 expression. Using a range of dif-
ferentiation protocols we found a delay in the onset of differ-
entiation toward embryonic lineages. We report that Oga
inhibition does not affect the upregulation or downregulation
of the genes known to be regulated early during differentia-
tion, but results in prolonged expression of the pluripotency
master regulator Oct4 and a delay in the acquisition of stable
neural differentiation marker Sox1. Therefore, our results
clearly demonstrate that Oga inhibition does not affect the
transition from the na€ıve to the primed state, indicating
instead that elevated O-GlcNAc levels affect differentiation
progression at a later stage. Taken together, our data show a
clear effect of Oga inhibition on the initiation of ESC differen-
tiation that affects multiple somatic lineages.
We also report that Oga inhibition does not interfere with
the steady-state phosphorylation levels of several key kinases,
suggesting that the main mechanism of action operates down-
stream of the signal transduction machinery. The fact that the
phosphorylation status of kinases is unaffected by GNS in this
context does not, however, preclude changes in kinase activity,
localization, or interaction with substrates. It also remains pos-
sible that the stimulated, maximal phosphorylation levels of
some of these kinases will be affected by elevated O-GlcNAc
despite no obvious effects at the basal phosphorylation levels.
An early study of Oga inhibition during ESC differentiation
identiﬁed a deﬁcit in spontaneous cardiomyocyte generation
in EBs [12]. In that study a different, less speciﬁc Oga inhibi-
tor was added to 5-day-old differentiating EBs, when ESC
markers are already lost and the cells have already committed
to differentiating, highlighting a role for Oga in the commit-
ment of mesodermal cells to the cardiomyocyte lineage. Our
data extend and reﬁne this previous observation by determin-
ing an earlier role in the exit from the pluripotent state.
More recently, a report demonstrated a role for the O-GlcNAc
modiﬁcation of Oct4 in the onset of ESC differentiation [11].
Our results are consistent with those ﬁndings, although we
ﬁnd that na€ıve ESC markers decline normally under elevated
O-GlcNAc conditions, demonstrating that the earliest events
in ESC differentiation are not O-GlcNAc dependent.
A number of recent papers have linked the O-GlcNAc
transferase to the regulation of epigenetic regulators [16–18,
42]. Our gene expression analysis has revealed that following
Oga inhibition a number of repressed genes become acti-
vated. Gene set enrichment analysis showed a signiﬁcant
enrichment for a speciﬁc subset of polycomb repressor com-
plex target genes, as well as genes associated with the early
zygotic genome activation and retrovirus-like elements. This
latter gene expression signature is thought to mark a develop-
mentally privileged ESC subpopulation capable of differentia-
tion into extraembryonic lineages [35, 36]. These genes are
Figure 4. O-linked N-acetylglucosamine levels control Ogt and
Oga levels in embryonic stem cells (ESCs). (A): Ranked product
analysis of genes regulated in ESCs by GlcNAcstatin C treatment.
Blue: signiﬁcantly upregulated genes; yellow: signiﬁcantly downre-
gulated genes. (B): Validation of Ogt regulation by RT-qPCR
(n5 4, mean6 SEM). (C): Validation of Oga expression by
RT-qPCR (n5 4, mean6 SEM). (D): RNAi knockdown of Ogt and
Oga results in a negative feedback regulation on the expression
of Oga and Ogt, respectively. *, p< .05; **, p< .01 compared to
t5 0 (t test).
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under the control of epigenetic regulators of gene expression
and their expression can be induced by interfering with histone
acetylation and methylation, either pharmacologically or by
genetic deletion of key enzymes [36]. Our ﬁndings therefore
suggest that the levels of O-GlcNAc in cells inﬂuence global
gene expression regulated by major epigenetic mechanisms
such as histone modiﬁcations and DNA methylation, and are
consistent with a differentiation delay observed in ESCs treated
with an inhibitor of histone deacetylases [43]. Intriguingly, Oga
has been shown to possess histone acetyltransferase (HAT)
activity in vitro [44] and this activity is distinct from its GlcNA-
case function. It is therefore likely that although inhibition of
Oga’s O-GlcNAcase activity by GNS raises O-GlcNAc levels and
leads to feedback Oga upregulation, it does not affect the pro-
tein’s HAT activity (as has been shown for the less speciﬁc
inhibitor Streptozotocin [44]). This could possibly lead to
increased histone acetylation and the derepression of tran-
scription we observe, although the observation that 2C genes
were upregulated even when Oga protein levels are reduced
by siRNA (Fig. 5E) indicates that this is not the main mecha-
nism in this case. The negative feedback regulation from
increased O-GlcNAc levels to a reduction in Ogt protein levels
may also contribute to the phenotypes observed, by disrupting
the formation of some of its protein complexes. O-GlcNAc can
itself modify histones [45] and promote transcriptional activa-
tion [46], so the precise mechanism by which gene expression
is regulated by O-GlcNAc levels is likely to be complex and
involve many, possibly redundant molecular players.
Figure 5. Oga inhibition results in a broad genomic transcriptional derepression. (A): Bar charts showing the number of unique genes
upregulated in ESCs or in Day 1 differentiation in the DMSO or GNS samples (p< .05, fold change >2). (B): Gene set enrichment analy-
sis (GSEA) shows that GNS treatment results in an upregulation of the “Polycomb repressed” gene set. (C): GSEA showing enrichment of
the 2C gene set in the GNS-treated ESCs. (D): The 2C gene set is also enriched in the GNS-treated Day 1 differentiating cells. (E): RT-
qPCR validation of the upregulation of three genes from the 2C cohort by knockdown of Oga (n5 3, mean6 SEM) *, p< .05. Abbrevia-
tion: GNS, GlcNAcstatin C.
Table 2. Gene sets signiﬁcantly enriched in GlcNAcstatin C or DMSO-treated embryonic stem cell or Day 1 differentiation samples
Name Size
Enrichment
score
Normalized
enrichment
score
Nominal
p-value
False discovery rate
q-value Enrichment in
2C-MERVL1 45 0.85 1.85 <.001 <0.001 ES GNS versus ES DMSO
2C 466 0.66 1.78 <.001 0.001 ES GNS versus ES DMSO
PRCR 1,331 0.47 1.31 <.001 0.038 ES GNS versus ES DMSO
2C 466 0.39 1.25 .006 0.033 Day 1 GNS versus Day 1 DMSO
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CONCLUSIONS
In conclusion, our results demonstrate that ESC differentiation
is delayed under conditions of increased O-GlcNAc signaling
and pinpoint the delay to a stage in differentiation after the
loss of naive pluripotency but before commitment to differen-
tiation as marked by the loss of Oct4 expression. We used
deﬁned media and short timescales to minimize the possibility
of multiple effects on several interacting cell types, and found a
measurable, signiﬁcant defect in the progression toward differ-
entiation. We attribute this differentiation defect to a disrup-
tion of the normal function of global activation and repression
complexes, such as the histone deacetylases, polycomb group,
and Ten-eleven translocation proteins as well as direct effects
of Oga and Ogt on chromatin.
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